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The ubiquitin proteasome system (UPS) is responsible for the degradation and 
turnover of proteins in eukaryotes. As such it is a key process that is involved in 
normal and in some cases, abnormal cellular functions. Ubiquitin conjugating 
enzymes (UBCs) are key components of the UPS and may serve as therapeutic 
targets.
The aims of this project are the structural and functional analyses of UBCs in 
eukaryotic organisms whose genomes have been fully sequenced, and also the review 
of the nomenclature of yeast and human UBCs. The main findings were:
1) The successful construction of Phylogenetic trees containing all 14 yeast UBCs and 
UBC-like proteins and their homologues in selected species whose genomes have 
been fully sequenced. The phylogenetic tree consists of 15 different branches. 
Thirteen of the branches contain a member of the yeast UBC or UBC-like family 
(MMS2) and their homologues. The remaining two branches contain firstly the human 
UBE2L proteins and secondly the TSG101 UBC like proteins, both of which branches 
do not appear to have any yeast orthologues.
2) The UBC phylogenetic study was also used to identify the previously unknown 
UBC active site of the Drosophila transcription factor, TAFn250. Using multiple 
sequence manual alignments of known TAFn250 and UBC protein sequences a 
putative UBC active site in Drosophila melanosaster and Apis mellifera TAFn250 
was successfully identified, and was shown to share approximately 70% homology to 
the known UBC PROSITE signature.
3) Using multiple sequence alignments the hitherto unknown PROSITE signature of 
the clinically important UBE2J family was identified. This PROSITE signature is 
very different from all other UBCs suggesting that this family of enzymes has 
significant structural changes at their active sites. Homology modelling proved to be a 
successful approach to obtain structural information of the UBE2J1 active site. 
Superimposition studies using the previously solved structures for human UBE2J2 
and human UBC9 were carried out. Significant differences were observed near the 
active sites of human UBE2J proteins compared to the active site for human UBC9.
I I
DECLARATION
I, Joy Mukheijee, hereby certify that this thesis has been written by me, that it is a 
record of work carried out by me and that it has not been submitted in any previous 
application for a higher degree.
Date. \ . f? .? .:. ¥  Signature of Candidate
I hereby certify that the candidate has fulfilled the conditions of the resolution and 
regulations appropriate for the degree of Doctor of Philosophy at the University of 
Abertay, Dundee and that the candidate is qualified to submit this thesis in application 
for the degree.
Date.. .1 ^  Signature of Director of studie
In submitting this thesis to the University of Abertay, Dundee I understand that I am 
giving permission for it to be made available for use in accordance with the 
regulations of the University Library for the time being in force, subject to any 
copyright vested in the work not being affected thereby.
Date. £?.%. :.£P . Signature of candidate
I I I
ACKNOWLEDGEMENTS
I would like to thank the ESF funding body for funding the first two years of my 
University tuition fees.
I would like to thank my supervisors, Dr. Douglas Lester and Dr Eldridge Buultjens, 
for sharing with me their enthusiasm for the research, and providing me with 
opportunities, encouragement, and support throughout my PhD, both with my work 
and in developing my own ideas and interests. Although the work that I had carried 
out in my research was not in any collaboration, it benefited greatly from the excellent 
help and assistance freely given by Professor Ron Hay (University of St. Andrews) 
and Dr. Dimitris Xirodimus (Post Doctorate under the supervision of Prof. Ron Hay) 
at the BMS building St Andrews University where I had carried out the 
crystallography experiments. I greatfully acknowledge their help and assistance 
throughout the time of research at the St. Andrews University. I would additionally 
like to thanks Dr Whang Ting and Dr. Steven for their kind support at the St. Andrews 
University.
I would also like to extend my gratitude to Dr. Sharon Kelly (University of Glasgow) 
and Dr. Jane Potter (of St. Andrews University) for helping me to do the CD spectrum 
analysis, which was carried out at the University of St. Andrews.
Dr. Frank Wright of the SCRI (Scottish Crop Research Institute) had guided me in the 
phylogenetic analysis, which helped me a lot to get the analysis done. I would like to 
thank him especially for that.
I would also like to extend my gratitude to my mother and second brother, for their 
support during the period of my research.
I would like to especially thank my parents in law who have treated me as their own 
son, and have supported me (both mentally and financially) during this period of my 
research.
Last but not the least I would like to say that without the strong support of my wife, I 
would not have been able to reach up to this stage. Tanima (my Wife) has gone 
through the struggle during this period along with me, and have given me all possible 
support that was required.
IV
CONTENTS PAGE
CHAPTER ONE: GENERAL INTRODUCTION TO
UBIQUITIN PROTEASOME SYSTEM (UPS)................... 1
1.1 The importance of the (UPS) in eukaryotes........................................................2
1.2 Enzymes involved in the UPS..............................................................................2
1.3 Degradation of polyubiquinated proteins by the 26S proteasome..................... 3
1.4 Mono-ubiquitination and multi-ubiquitination................................................... 5
1.5 E3 Ubiquitin ligase..............................................................................................8
1.6 The diversity of the E2 ubiquitin conjugating enzymes.....................................8
1.7 The non-catalytic homologues of ubiquitin conjugating enzymes.................. 14
1.7.1 TSG101........................................................................................................... 14
1.7.2 CROC-1 (UBE2V1)......................................................................................... 15
1.8 UBCs and ubiquitin like proteins (UBLs).........................................................18
1.8.1 The relation of ubiquitin with SUMO and their functions.............................18
1.8.2 Involvement of El, E2, E3 inNEDD8...........................................................18
1.9 UBCs and ERAD............................................................................................... 19
1.10 UBC6, PML-RARa and ERAD..................................................................... 24
1.11 UBCs, ERAD and human diseases................................................................. 24
1.12 UBC’s as potential drug targets...................................................................... 28
1-.13 Phylogenetic and structural studies to determine the
function of (E2s) UBC orthologues................................................................ 29
1.14 Structure of UBCs (E2’s)..................................................................................30
CHAPTER TWO: AIMS AND OBJECTIVES.................................................... 41
2 Research aims and objectives................  42
CHAPTER THREE: INTRODUCTION TO
PHYLOGENETIC ANALYSIS.......................................43
3.1 Multiple sequence alignment (MSA).................................................................. 44
3.1.1 Introduction of MS A.........................................................................................44
3.1.2 MSA tools.........................................................................................................44
3.1.3 Scoring matrices in sequence alignment...................................................... 48
V
CONTENTS PAGE
3.1.3.1 DAYHOFF PAM matrix.......................................................................... 48




3.2.3 Distance matrix method ( Neighbor-Joining)............................................ 56
3.2.4 Bootstrapping...............................................................................................57
3.2.5 Phylip tree plotting programs: Drawgram and Drawtree.......................... 59
3.2.6. Summary of the advantages and disadvantages
of Phylogenetic programs...........................................................................60
CHAPTER FOUR: INTRODUCTION OF CONSURF ANALYSIS........... 61
4.1 Orthologous sequence and conservation of structure..................................... 62
CHAPTER FIVE: INTRODUCTION TO STRUCTURE
PREDICTION BY X-RAY CRYSTALLOGTAPHY........................................ 63
5.1. Introduction to all crystallographic methods....................................................64
5.1.1. Cloning...........................................................................................................64
5.1.1.1. DNA cloning..............................................................................................64
5.1.1.2. Polymerase chain reaction (PCR)............................................................. 64
5.1.2. Protein purification.......................................................................................65
5.1.2.1. Gel permeation chromatography................................................................ 65
5.1.3. Crystallography in general.................   67
5.1.3.1. Properties of protein crystals....................................  68
5.1.3.2 Methods of crystallisation (Vapour diffusion techniques).......................68
5.1.3.3. Crystal growth...........................................................................................70
5.1.3.4 Factors that affect crystallization............................................................... 72
5.1.3.5 Crystal mounting for x-ray data collection.............................................. 73
5.1.3.6. Cryo-crystallography................................................................................73
5.1.3.7. X-ray diffraction......................................................................................74
5.1.3.8. The arrangement of protein molecules in a crystal.................................. 76
5.1.3.9. Diffraction of X-rays by crystals............................................................. 77
5.2. Circular Dichroism spectroscopy....................................................................79
V I
CONTENTS PAGE
5.2.1. Mechanism of CD spectroscopy................................................................... 79
5.2.2. Informations obtained from CD studies of proteins..................................... 82
CHAPTER SIX: INTRODUCTION TO COMPUTATIONAL 
STRUCTURE PREDICTION
(HOMOLOGY MODELLING)............................................ 84
6.1 The importance of 3D structures...................................................................... 85
6.2 Relationship between structure and function..................................................87
CHAPTER SEVEN: METHODOLOGY (PHYLIP ANALYSIS)................ 89
7.1. Methods of the phylogenetic analysis of the UBC and UBC like
peptide sequences............................................................................................. 90
7.2. The phylogenetic analysis of drosophila TAFn250, selected UBCs
and human CROC-1 (UBE2V1)....................................................................... 94
CHAPTER EIGHT: METHODOLOGY ON CONSURF ANALYSIS..........96
8.1 Methodology of Consurf analysis.....................................................................97
CHAPTER NINE: METHODOLOGY OF STRUCTURE
PREDICTION BY X-RAY CRYSTALLOGRAPHY........................................98
9.1. PCR reactions....................................................................................................101
9.1.1 The PCR mix..................................................................................................101
9.1.2 Calculation of annealing temperatures......................................................... 101
9.1.3 Setting of the PCR machine.........................................................................101
9.2. DNA preparation.............................................................................................102
9.3. Transformation of plasmids..............................................................................102
9.4. Plasmid preparation..........................................................................................105
9.5. Growing of the GST-HIS-TEV and HIS-TEV colonies from the
kanamycin plates...............................................................................................106
9.6. Gel electrophoresis..........................................................................................106
9.7. Digestion of the PCR product of UBE2J1
fragment and the plasmids..............................................................................106
9.8 Gel extraction...................................................................................................107
9.9 PCR product and plasmid ligation reaction.................................................... 107
V II
CONTENTS PAGE
9.10. Transformation of the ligated product in DH5a cells..................................108
9.11. Digestion of ligated product......................................................................... 108
9.12. Preparation of BL21 competant cells..........................................................108
9.13. Transformation of the ligated product into the BL21 competant cells......108
9.14. DNA sequencing to confirm the constructed primers.................................109
9.15. Protein induction.........................................................................................109
9.16. Cell lysis...................................................................................................... 109
9.17. SDS/PAGE analysis.....................................................................................110
9.18.1 Preparation of the nickel beads.................................................................110
9.18.2. Recharging of the nickel-NT A beads....................................................110
9.19. Binding with the protein...............................................................................110
9.20. Micro Bradford assay..................................................................................I l l
9.21. Quantitation of the eluted fraction containing protein............................... I l l
9.22. TEVprotease cleavage...............................................................................I l l
9.23 Concentrating the cleaved protein before gel purification............ .............112
9.24. Purification of the cloned, expressed UBE2J1
fragment by gel permeation chromatography.............................................. 112
9.25. Concentrating and desalting the protein..................................................... 112
9.26. Crystallization...............................................................................................113
9.27. X-ray diffraction of the crystal obtained..................................................... 113
9.28. Circular dichroism (CD) spectrum analysis................................................. 113
CHAPTER TEN: METHODOLOGY OF COMPUTATIONAL 
STRUCTURE PREDICTION (HOMOLOGY MODELLING).....................115
10.1 Methodology of homology modelling of UBE2 J1 by Deepview............... 116
10.2 Methodology of homology modelling of UBE2J1 by 3D-JIGSAW........... 116
CHAPTER ELEVEN: DESIGNING OF THE PROSITE 
SIGNATURE OF UBC6 FAMILY FROM THE MULTIPLE
SEQUENCE ALIGNMENT (MSA)................................................................. 117
11.1 Results and discussion of MSA & PROSITE signature............................118
V I I I
CONTENTS PAGE
CHAPTER TWELVE: RESULTS AND DISCUSSION OF 
PHYLOGENETIC ANALYSIS................................................................. 124
12.1 Results and Discussion of the phylogenetic analysis
of UBCs by phylip................................................................................129
12.2. Phylogenetic analysis of peptide sequences by consurf....................129
12.3. The overall discussion of the phylogenetic trees
obtained by Phylip and Consurf................................. ..................... 130
12.3.1. The yeast UBC6 and human UBE2J orthologous
phylogenetic branch.........................................................................132
12.3.2. Yeast UBC9 and its homologues.....................................................135
12.3.3. Yeast UBC11 and its homologues.................................................... 137
12.3.4. Yeast UBC2 and its homologues...................................................... 139
12.3.5. The yeast UBC7/ human UBE2G branch and its evolutionary
relationship to the yeast UBC3/human CDC34 branch................... 141
12.3.6. Yeast UBC10 and its homologues................................................... 144
12.3.7. Yeast UBC12 and its homologues................................................... 146
12.3.8. Yeast UBC 8 and its homologues.................................................... 148
12.3.9. Yeast UBC13 and its homologues.................................................. 150
12.3.10. YeastUBC4/UBC5 and its homologues....................................... 152
12.3.11. Yeast UBC land its homologues..................................................... 154
12.3.12. UBCs and UBE2Vs, TSG101........................................................ 156
12.3.13. An overall view of the phylogenetic analysis............................... 157
12.4. Revised nomenclature of human UBCs.............................................158
12.4.1. Yeast UBC1 and HIP2 (UBE2K)..................................................... 159
12.4.2. Yeast UBC2 and human UBE2A and UBE2B................................ 159
12.4.3. Yeast UBC3 (CDC34), human CDC34 (UBE2R1)
and UBE2R2....................................................................................159
12.4.4. Yeast UBC4/5, Human UBE2D’s and Human UBE2E’s................159
12.4.5. Human UBE2L3 and UBE2L6....................................................... 160
12.4.6. Yeast UBC7 and human UBE2G..................................................... 160
12.4.7. Yeast UBC8 and human UBE2H.................................................... 161
12.4.8. Yeast UBC9 and UBE21...................................................................161
CONTENTS PAGE
12.4.9. Yeast UBC10 and human UBE2S.................................................161
12.4.10. Yeast UBC11 and human UBE2C.............................................. 161
12.4.11. Yeast UBC12 and human UBE2M..............................................162
12.4.12. Yeast UBC13 and human UBE2N.............................................162
12.4.13. Yeast MMS2 and the human UBE2V, and the TSG101.......... 162
12.4.14. Yeast UBC6 and the human UBE2J......................................... 162
12.4.15. Conclusions from HGNC approved UBC nomenclature............ 163
12.5 Structural Conservation results from Consurf analysis................. 163
12.6 Conclusion......................................................................................... 167
12.7 Future prospects................................................................................. 167
CHAPTER THIRTEEN: RESULTS & DISCUSSION 
OF PHYLOGENETIC ANALYSIS OF TAFn250............................. 168
13.1 Results and discussion of phylogenetic analysis of TAFn250........169
13.2. Conclusion........................................................................................ 176
CHAPTER FORTEEN: RESULTS AND DISCUSSION 
OF STRUCTURE DETERMINATION BY X-RAY 
CRYSTALLOGRAPHY AND CD
SPECTROSCOPIC ANALYSIS.............................................................177
14.1. Results of the expression of UBE2J1 for X-ray crystallography 178
14.1.1. PCR of UBE2J1 fragment.............................................................178
14.1.2. Digestion by the restriction enzymes............................................ 179
14.1.3. Digestion by the restriction enzymes of the digested
UBE2J1 fragment and HISTEV30A plasmid............................... 180
14.1.4. Gel purification (by gel permeation chromatography).................184
14.1.5. Mass spectrometry........................................................................187
14.2. Results of Circular Dichroism (CD) spectrum analysis.....................189
14.3. Conclusion and future research.........................................................192
X
CONTENTS PAGE
14.4. To check the globularity and disorder domains
in the UBE2J1 fragment....................................................................192
14.4.1. Globplot......................................................................................... 192
14.4.2. RONN: to predict the disordered region of a protein................... 195
14.4.3. Trypsin proteolysis........................................................................ 197
14.4.4. Protein purification......................................................................... 198
CHAPTER FIFTEEN: RESULTS & DISCUSSION 
OF COMPUTATIONAL STRUCTURE PREDICTION 
(HOMOLOGY MODELLING)..................................................................199
15.1 Results and discussion of conputational structure prediction........200
15.1.1. Modelling, using DeepView...........................................................200
15.1.2. Obtaining the model ofUBE2Jl by DeepView............................200
15.1.3. Evaluating and optimising the model sent by SWISS PDB...........205
15.1.3.1. Colour by B-factor........................................................................ 206
15.1.3.2. The Ramachandran p lo t........................................................... 207
15.1.3.3. Force field energy.....................................................................210
15.1.3.4. Colour by force field energy........................................................ 214
15.1.3.5. Model of UBE2J1 coloured by
RMS (root mean square)............................................................ 216
15.1.3.6. Model of UBE2J1 coloured by alignment diversity................... 217
15.1.3.7. Model of UBE2J1 coloured by secondary structure..................219
15.1.3.8. Model of UBE2J1 coloured by solvent accessibility.................220
15.1.3.9. What check report comparison of the template
structure and the model of UBE2J1..........................................222
15.1.3.10. Feature of the Whatcheck report...............................................223
15.1.4. Homology modelling by 3D-JIGS AW......................................... 225
CONTENTS PAGE
15.1.4.1. What check report comparison of the model 
of UBE2J1 obtained by homology modelling 
by DeepView, with that of the UBE2J1 model
obtained from 3D-JIGSAW........................................................ 228
15.1.4.2. Interpretation of the Whatcheck report of the model 
generated by DeepView and the model
generated by 3D-JIGS A W ........................................................ 231
15.2. Structural comparisons of UBE2Js (UBE2J1 & UBE2J2)
with UBC9 protein.......................................................................... 231
15.2.1. Superimposition of UBE2J2 with UBC9.......................................235
15.2.2. Superimposition of UBE2J1 andUBC9.......................................238
15.3. Conclusion.........................................................................................240
15.4. Future research................................................................................. 240
CHAPTER SIXTEEN: OVERALL CONCLUSION
AND FUTURE RESEARCH................................................................. 241
16.1 Overall conclusion and future research.......................................... 242
16.2. The use of Grid to identify specific UBE2J inhibitors.................. 244
CHAPTER SEVENTEEN: REFERENCES.......................................245
CHAPTER EIGHTEEN: APPENDIX ,279
Figure 1.1 The ubiquitin proteasome system..................................................4
Figure 1.2 The functional domains of dTAFn250........................................... 7
Figure 1.3 Ubiquitin modifications and cellular response...............................8
Figure 1.4 Multiple sequence alignmnet of selected UBC6s with
all other yeast UBCs and their selected homologues................... 16
Figure 1.5 Trimming of sugar chains and elongation of polyubiquitin
that target the protein for degradation..............................................21
Figure 1.6 Cystic Fibrosis Transmembrane conductance
Regulator (CFTR) and its degradation pathway................................27
Figure 1.7 Multiple sequence alignment of UBC7, UBC4 and UBC1.............. 32
Figure 1.8 Stereo diagram of UBC7 on the a-carbon position.................... 33
Figure 1.9 Stereo diagram of yeast UBC7.................................... 34
Figure 1.10 Superimposed structure of UBC7 and UBC4................................35
Figure 1.11 Alignment of all 13 yeast UBCs around the
active site residue region................................................................ 37
Figure 1.12 Some UBC (E2s) whose structures have
already been determined.................................................................39
Figure 3.1 Venn diagram of the properties of the amino acid residues..............45
Figure 3.2 Example of an MSA showing different
conservation notation...................................................................... 47
Figure 3.3 Illustration of the use of gaps in MSA.............................. 48
Figure 3.4 External node and internal node of a Phylogenetic tree................... 52
Figure 3.5 Groupings of a phylogenetic tree.................................. 52
Figure 3.6 Gene duplication............................................... 54
Figure 3.7 Consensus in phylogeny......................................... 58
Figure 5.1 Gel permeation chromatography...................................66
Figure 5.2 Molecular weight selective curves for G-type sephadex................ 67
Figure 5.3 Sitting drop vapour diffusion technique............................................ 69
Figure 5.4 Hanging drop vapour diffusion technique........................... 69
Figure 5.5 Crystallization phase diagram..................................... 71
Figure 5.6 X-ray diffraction patterns........................................ 75
F IG U R E S  P A G E S
X I I I
F IG U R E S P A G E S
Figure 5.7 A triclinic unit cell............................ ........................................... 76
Figure 5.8 Diagramatic representation of Bragg’s law................................. 78
Figure 5.9 Principle of polarization of light in CD spectrometry.................. 80
Figure 5.10 The far UV CD spectrum illustrating
secondary structural features..................................................... 81
Figure 5.11 Near UV CD spectrum arising from amino acid residues..........82
Figure 6.1 Information that can be obtained from 3D
structure of UBE2J..................................................................... 85
Figure 6.2 Homology zones from percentage identity of residues..............86
Figure 9.1. Portion of the UBE2J1 peptide sequence used to
design the primers..........................................................................100
Figure 9.2.1 pHISTEV30a plasmid vector................................................... 103
Figure 9.2 .2 pHISTEV30a-GST-thrombin plasmid vector......................... 103
Figure 9.3.1 Plasmid map showing the cloning site of the
UBE2J1 fragment.......................................................................104
Figure 9.3.2 Plasmid map showing the cloning site of GST-thrombin.......... 104
Figure 11.1 Multiple sequence alignment of selected ubc6s
with all other yeast UBCs and their selected homologues................... 119
Figure 11.2 Multiple sequence alignment of selected UBCs other 
than UBC6 family, with other non-catalytic UBCs which lack
the active site residue cysteine.....................................................................121
Figure 12.1 Phylogenetic tree of all yeast UBCs and its homologues
in selected organisms generated by Phylip............................... 125
Figure 12.2 Phylogenetic tree of all UBCs and its homologues
in selected organisms generated by Consurf........................... 127
Figure 12.3 Branch of UBC6 generated by Phylip.................................132
Figure 12.4 Branch of UBC6 generated by Consurf................................. 132
Figure 12.5 UBC9 branch generated by Phylip........................................... 135
Figure 12.6 UBC9 branch generated by consurf......................................... 135
Figure 12.7 UBC11 branch generated by Phylip.........................................137
Figure 12.8 UBC11 branch generated by consurf..................................... 137
Figure 12.9 UBC2 branch generated by Phylip........................................... 139
X IV
Figurel2.10 UBC2 branch generated by consurf................................ 139
Figure 12.11 UBC7 and UBC3 branch generated by Phylip.................... 141
Figure 12.12 UBC7 and UBC3 branch generated by consurf.................. 142
Figure 12.13 UBC10 branch generated by Phylip.................................... 144
Figurel2.14 UBC10 branch generated by Consurf..................................144
Figure 12.15 UBC12 branch generated by Phylip.................................. 146
Figure 12.16 UBC12 branch generated by Consurf........................... 146
Figure 12.17 UBC8 branch generated by Phylip......................................148
Figure 12.18 UBC8 branch generated by Consurf..................................148
Figure 12.19 UBC13 branch generated by Phylip........................... 150
Figure 12.20 UBC13 branch generated by Consurf................................150
Figure 12.21 UBC4/5 branch generated by Phylip................................. 152
Figure 12.22 UBC4/5 branch generated by consurf............................... 152
Figure 12.23 UBC1 branch generated by Phylip.................................... 154
Figure 12.24 UBC1 branch generated by Consurf................................. 154
Figure 12.25.1 MMS2 and UBE2Vs branches generated by Phylip.....156
Figure 12.25.2 TSG101 and UBC9 branch generated by Phylip.......... 156
Figurel2.26 MMS2, TSG101 and UBE2V branch
generated by Consurf........................................................ 156
Figure 12.27 Evolutionary conservation on the 3D
structure the UBE2J2 protein (2F4W)............................... 164
Figure 13.1.1 TAFn250 & UBC block......................................................171
Figure 13.1.2 TAFn250 & CR0C1(UBE2V1) block...............................171
Figure 13.2 Unrooted phylogenetic tree generated from the 
MSA of TAFn250,
UBC & CROC 1 (UBE2V1)................................................172
Figure 13.3 The whole MSA of TAFn250, UBC &
CROC 1 (UBE2 V1).............................................................. 173
Figure 14.1 Gel electrophoresis of PCR reaction products
and the plasmids...................................................................178
Figure 14.2 Gel electrophoresis of the digested products..................... 179
F IG U R E S  P A G E S
X V
Figure 14.3 Gel electrophoresis of the digestion by the
restriction enzymes.............................................................. 180
Figure 14.4 TE V -protease clevage trials................................................ 182
Figure 14.5 Gel electrophoresis of the eluted protein
fractions in different stages..................................................... 183
Figure 14.6 Gel electrophoresis of the TEV protease
cleaved protein sample............................................................ 184
Figure 14.7 The chromatogram of gel permeation chromatography........185
Figure 14.8 Gel electrophoresis of gel purified fractions...................... 186
Figure 14.9 Mass spectrometric result....................................................... 187
Figure 14.10 A suspected crystal growth in one of the
crystal trial plates...................................................................188
Figure 14.11.1 Diffraction pattern of the crystal obtained......................... 188
Figure 14.11.2 An example of a typical diffraction
pattern of a protein crystal................................................ 188
Figure 14.12 Far UV CD spectrum of the protein UBE2J1..................... 189
Figure 14.13 Near UV CD of the protein UBE2J1................................ 190
Figure 14.14 Result of globplot......................................................... . ..193
Figure 14.15 Disorder prediction of UBE2J1 by RONN
prediction server...................................................................195
Figure 14.16 Disorder prediction of UBE2J2 by RONN
prediction server....................................................................196
Figure 15.1 Results obtained from Pfam domain prediction..................... 201
Figure 15.2 Secondary structural contents of UBE2J1...............................202
Figure 15.3 Alignment of UBE2J1 with the template (2F4WB)............. 203
Figure 15.4 Pairwise sequence alignment generated
by DeepView........................................................................ 204
Figure 15.5 The alignment that was generated by DeepView 
and the gap introduced manually at the region
of missing 9 amino acids......................................................... 205
Figure 15.6 Model of UBE2J1 coloured by B-factor................................206
Figure 15.7.1 Ramachandran plot of modelled UBE2J1............................208
F IG U R E S  P A G E S
F IG U R E S P A G E S
Figure 15.7.2 The Ramachandran plot of the template (2F4WB)............. 209
Figure 15.8 Force field energy of UBE2J1 model............................... 210
Figure 15.9 Model of UBE2J1 coloured by
force field energy.............................................................. 215
Figure 15.10 Colour by RMS.................................................................. 216
Figure 15.11.1 Colour by alignment diversity........................................ 217
Figure 15.11.2 Colour by alignment diversity shown
in the alignment.............................................................. 218
Figure 15.12 Colour by secondary structure..........................................219
Figure 15.13.1 Colour by solvent accessibility of
the UBE2J1 model........................................................... 220
Figure 15.13.2 Colour by solvent accessibility of
the UBE2J2 model......................................................... 220
Figure 15.14 Model of UBE2J1 obtained by homology
modelling from 3D- JIGSAW........................................226
Figure 15.15 The Ramachamdran plot of the model of 
UBE2J1, obtained from 3D-JIGSAW
homology modelling........................................................ 227
Figure 15.16 The catalytically active amino acids in UBC9.................233
Figure 15.17 Superimposition of UBE2J2 with UBC9......................... 235
Figure 15.18.1 Structural superimposition of UBE2J2 and 
UBC9 of Figure 15.17, shown at its amino
acid residue level............................................................. 236
Figure 15.18.2 Structural superimposition of UBE2J2 and 
UBC9 shown at its amino acid residue level,
continued from the previous Figure 15.18.1....................236
Figure 15.19 Superimposition of UBE2J1 and UBC9............................ 238
Figure 15.20 Structural superimposition of UBE2J1
and UBC9 along the whole length of the
peptide sequence shown in 3 blocks.................................239
X V I I
T A B L E S P A G E S
Table 1.1 Sub cellular localization and /or function(s)
of UBC (E2s)...........................................................................9
Table 1.2 Homologues of yeast UBCs that are UBC (E2)
like proteins, and their functions illustrated..............................13
Table 1.3.1 Diseases associated with defects in protein
degradation.............................................................................. 25
Table 1.3.2 Diseases associated with defects in protein aggregation......... 25
Table 3.1 Colouring schemes in the MSA...................................................46
Table 3.2 Colouring scheme according to physiochemical properties........ 46
Table 3.3.1 Main advantages of the three phylogenetic programs............. 60
Table 3.3.2 Main disadvantages of the three phylogeny programs.............60
Table 5.1 The crystal systems.......................................................................77
Table 9.1 The whole of the nucleotide sequence of UBE2J1
that was used to design the primers................................................100
Table 9.2 Experimental parameters of CD spectrum analysis......................114
Table 12.1 Methods of phylogenetic analysis by phylip 3.6 and consurf.. ...129
Table 12.2 Gene duplication in the UBC6 family........................................133
Table 12.3 Gene duplication in the UBC9 family........................................136
Tablel2.4 Gene duplication in the UBC 11 family........................................ 138
Tablel2.5 Gene duplication in the UBC2 family...........................................140
Table 12.6 Gene duplication in the UBC7 family..........................................143
Table 12.7 Gene duplication in the UBC3 family..........................................143
Table 12.8 Gene duplication in the UBC10 family........................................145
Table 12.9 Gene duplication in the UBC12 family........................................147
Table 12.10 Gene duplication in the UBC8 family........................................149
Table 12.11 Gene duplication in the UBC 13 family......................................151
Table 12.12 Gene duplication in the UBC4/5 family.....................................153
Table 12.13 Gene duplication in the UBC1 family........................................155
Table 12.14 Table of yeast human UBC nomenclature................................ 158
Table 14.1.1 Quantity of standard BSA and its O.D. at 595nm.................... 181
Table 14.1.2 Quantity of test sample taken and its O.D. at 595nm............... 181
X V I I I
Table 14.2 Result obtained from Dichroweb of the secondary
structural component, which has been calculated 
from the CD spectrum of figure 14.15.................................... 190
Table 14.3 Globular and disordered region of UBE2J1 protein............... 194
Table 14.4 Globular and disordered regions of the protein UBE2J2.......194
Table 14.5 Continuation of the disorder prediction of
UBE2J1 by RONN predicion server ....................................... 196
Table 14.6 Continuation of the disorder prediction of
UBE2J1 by RONN predicion server..........................................197
Table 15.1 Whatcheck report of the template 2F4WB structure
and the UBE2J1 model................ ...........................................222
Table 15.2 Whatcheck report comparison of the models of
UBE2J1 generated by Deepview and 3D-JIGSAW................ 230
T A B L E S  P A G E S
X IX
ATP
ABBREVIATIONS, SYMBOLS AND NOTATIONS
Adenosine Triphosphate
APL acute promyelocytic leukemia
BLOSUM Block Substitution Matrix
BLAST Basic local alignment search tool
CDC Cell division cycle




EBI European Bioinformatics Institute
ERAD Endoplasmic Reticulum Associated Degradation
ERQC
EMBOSS
Endoplasmic Reticulum quality control
The European Molecular Biology Open Software Suite.
E2 It is the abbreviation of UBE2. All yeast UBC orthologues have 
been given a nomenclature naming starting with UBE2 followed by 
the alphabet corresponding to each individual UBCs. So at times 
UBC and E2 have been used together.
FBPase Fructose-1,6-bisphosphatase
HAT Histone Acetyl Transferase
HMGCoA 3-hydroxy-3-methyl-glutaryl-Co A
HMM Hidden Markov Models
KDa Kilo Dalton
MHC Major histocompatibility complex
MSA Multiple sequence alignment
MPD 2-methyl 2,4-pentadiol
NCBI National Center for Biotechnology Information
NTK N-Terminal Kinase
NEDD8 neural precursor cell expressed developmentally downregulated gene 8
NMR Nuclear magnetic resonance
NCoR nuclear receptor corepressor
PML promyelocytic leukaemia
PAM point accepted mutation
PCR Polymerase Chain Reaction
X X
pi Isoelectric point
pH "p" stands for "potenz" (this means the potential to be) and the "H"
stands for Hydrogen 
PEGs Polyethylene glycols
PDB Protein data bank
RUB1 related to ubiquitin 1 protein
RB Retinoblastomaprotein
RAR-a retinoic acid receptor-a
SUMO Small Ubiquitin like modifier
SMRT silencing mediator of retinoic acid and thyroid hormone receptor
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
TAF TBP Associated Factor
TBP TATA Box-binding Protein
TFTTP Transcription Factor complex
TIGR The institute for genome research.
TSG101 Tumor suppressor gene 101
UPS Ubiquitin Proteasome System
UBC Ubiquitin Conjugating Enzymes
UBL Ubiquitin like
UGGT UDP-glucose glycoprotein:glucosyltransferase
Organism Latin name abbreviation name commonly used in this thesis
Anopheles gambiae Ag mosquito
Arabidopsis thaliana At same as the Latin name
Caenorhabditis elegans Ce same as the Latin name
Drosophila melanogaster Dm same as the Latin name
Homo sapiens Hs human
Mus muscuius Mm mouse
Neurospora crassa Nc same as the Latin name
Oiyza sativa Os rice
Plasmodium falciparum Pf same as the Latin name
Plasmodium yoelli yoelli Pyy same as the Latin name
Schizosaccharomyces pombe Sp pombe
Saccharomyces cerevisiae Sc yeast
X X I
The amino acids, symbols, and codons
Amino acids Symbols j Codons j
Alanine Ala I A | GCA, GCC, GCG, GCU
Aspartic acid Asp D GAC, GAU j
Asparagine ;Asn ii N AAC, AAU j
Arginine Arg ; R ! AGA, AGG, CGA, CGC,
j CGG, CGU I
i
Cysteine Cys !j c I UGC, UGU 1
Glutamine Gin | Q CAA, CAG
Glycine Gly | G GGA, GGC, GGG, GGU
Glutamic acid ! Glu I E | GAA, GAG j
Histidine His j H j CAC, CAU j
Isoleucine lie j I AUA, AUC, AUU
Lysine Lys j K AAA, AAG |
Leucine Leu | L | UUA, UUG, CUA, CUC, !j CUG, CUU I
Methionine Met j M | AUG
Proline Pro | P | CCA, CCC, CCG, CCU |
Phenylalanine ) Phe j F uuc,uuu j
Serine Ser | s 1 AGC, AGU, UCA, UCC,
ji.. 1 ) UCG, UCU j
Threonine Thr 1 T | ACA, ACC, ACG, ACU
Tryptophan Trp j W 1 UGG
Tyrosine Tyr ; Y ! UACUAU I_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _ _ _ _ _ _ J
Valine Val j V j GUA, GUC, GUG, GUU j
X X I I
CHAPTER ONE
GENERAL INTRODUCTION
TO UBIQUITIN PROTEASOME SYSTEM
(UPS)
1.1 The importance of the UPS in eukaryotes
Proteins destined for degradation by the proteasome are tagged by the covalent 
attachment of one or more molecules of the protein ubiquitin. The proteasome only 
recognizes ubiquitinated proteins and subsequently digests them into small peptides (see 
Figure 1.1). This Ubiquitin Proteasome System (UPS) is important in regulating the 
half-lives of proteins that have critical regulatory functions within the cell, such as those 
controlling gene transcription and cell cycle progression, including transcription factors, 
tumor suppressors such as p53, oncoproteins, certain cell surface receptors, cyclins and 
related proteins (Bence, Sampat and Kopito, 2001). The UPS is also responsible for the 
degradation of mutant or misfolded proteins and has been implicated in the processing 
of MHC (major histocompatibility complex) restricted class I antigens. Additionally the 
ubiquitin-proteasome pathway is responsible for antigen presentation and the 
degradation of mutant or misfolded proteins that are processed by the endoplasmic 
reticulum (ER) by a process known as Endoplasmic Reticulum Associated Degradation 
or ERAD (Kostova and Wolf, 2003; Plemper and Wolf, 1999; Bonifacino and 
Weissman, 1998; Lester et al., 2000).
Ubiquitin is a heat stable small 76 amino acid protein, which is apparently available in 
all eukaryotes. It is not, however found in eubacteria or archaebacteria. Ubiquitin is 
found in the cellular compartments such as the nucleus, the cytosol, and the cell 
membrane surface. It is either free or covalently attached to other proteins and all of its 
related functions are mediated through its linkage to cellular proteins. The post- 
translational conjugation of ubiquitin to proteins usually leads to branched ubiquitin- 
protein conjugates. This conjugate has the carboxyl C-terminus of the ubiquitin protein 
covalently attached to the s-amino group of a lysine residue in the target protein 
(Jentsch, 1992).
1.2 Enzymes involved in the UPS
Ubiquitination is a multistep process and it involves four classes of enzymes (see Figure
1.1). In the first step ubiquitin is first activated by an El or ubiquitin activating enzyme. 
This reaction requires ATP hydrolysis.
In the second step the activated ubiquitin is transferred to a conserved cysteine residue 
on one of the several ubiquitin conjugating enzymes (UBCs) or E2s (E2 is the
2
abbreviation of UBE2. All yeast UBC orthologues have been given a nomenclature 
naming starting with UBE2 followed by the alphabet corresponding to each individual 
UBCs. UBC and E2 have been used together at times). The third step involves 
participation of a third class of enzymes E3 (ubiquitin ligase), which catalyses the 
formation of an isopeptide linkage between the C-terminal glycine of the ubiquitin 
moiety and the 8-amino group of an internal lysine in the target protein. A polyubiquitin 
chain is synthesised by the successive transfer of ubiquitin molecules to lysine 29, or 
lysine 48 of the previous ubiquitin moiety. In contrast protein modification by lysine 63 
linked chains or by a single ubiquitin moiety (mono-ubiquitination), seem to trigger 
other functions like DNA repair, gene expression, and protein sorting (see Figure 1.3) 
(Plemper and Wolf, 1999; Zhang et al., 2003). In the fourth and final step, the ubiquitin 
chain is elongated by an ubiquitin-chain elongating factor (E4), which assembles the 
branched polyubiquitin chain (Hoppe, 2005; Hershko and Ciechanover, 1992; Hamilton 
et al., 2001; Ciechanover, 1994; Richly et al., 2005; Chau et al., 1989).
1.3 Degradation of polyubiquitinated proteins by the 26S proteasome
Ubiquitinated proteins are finally unfolded and degraded by the 26S proteasome (see 
Figure 1.1). The 26S proteasome is a complex of 20S core and the 19S cap or 
regulatory particles. The 20S core is composed of four stacked rings, each containing 
seven different a or (3 subunits with an overall a7p7p7a7 geometry. The function of the 
19S cap is to recognize the ubiquitinated protein, bind and unfold it, and also to regulate 
the opening of the 20S core. After the degradation of the protein, the ubiquitin is set free 
where it is again recycled as shown in the figure below, to carry out another set of 
ubiquitination reactions and the cycle is repeated. This is represented by the Figure 1.1 
(Kostova and Wolf, 2003).
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1.4 M ono-ubiqu itination  and m ulti-ubiquitination
Most proteins targeted for degradation by the UPS are polyubiquitinated by the reaction 
described in Figure 1.1. However some proteins, e.g. histones, which are not targeted 
for degradation, can be modified by monoubiquitination, resulting in a change in 
structure and function of these proteins. Monoubiquitination of protein requires the 
involvement of only the El and E2 enzyme activity. Activation of gene expression may 
be correlated with monoubiquitination of histones, however the functional connections 
between histone ubiquitination and activation of gene expression is currently unknown, 
but presumably it may involve alteration of chromatin structure allowing transcription 
factors access to the exposed DNA (Pham and Sauer, 2000).
It has been found that most histones (e.g. histone HI), are monoubiquitinated by 
conventional UBC E2s but not by E3s (Haas, Bright and Jackson, 1988). An unusual 
example of monoubiquitination activity by the Drosophila transcription factor 
TAFn250, was demonstrated by Pham and Sauer (2000).
Research was carried out by Pham and Sauer (2000) to understand the role of histone 
ubiquitination in transcriptional regulation. As a first step towards this understanding 
they had tried to identify enzymes that ubiquitinate histones in Drosophila embryonic 
nuclear extract using an activity gel assay (Acetyltransferase Activity Gel Assay- The 
crude macronuclear extracts or column purified fractions were analysed for histone 
acetyltransferase activity following electrophoresis in SDS or polyacrylamide gels 
containing calf thymus histones or bovine serum albumin). To purify the identified 
activity from the nuclear extract, gel filtration chromatography was carried out, and it 
was observed that the fractionation pattern from the activity gel assay resembled the 
pattern described for the general transcription factor TAFIID (Pham and Sauer, 2000; 
Brownell and Allis, 1995).
The TFIED transcription initiation complex is composed of TBP and multiple TAFs. It 
nucleates the assembly of RNA polymerase II and other initiation factors (TFIIA, 
TFIEB, TFEOE, TFIIF, TFEIH) at the core promoter of protein coding genes. The 
Drosophila melanogaster TFIID is composed of TBP and eight other TAFs namely 
TAF250, TAF150, TAF110, TAF80, TAF60, TAF40, TAF30a and TAF30p. TAF250 is 
the largest subunit of TAFIID, and is required for progression through Gl/S of the cell 
cycle and repression of apoptosis. TAFn250 is required for regulating the cell cycle, cell 
differentiation, cell proliferation and cell survival. TAFn250 consists of two
5
independent protein kinase domains and a HAT (histone acetyltransferase) domain 
(Wassarman et al., 2000; Jacobson et al., 2000). The binding of activator proteins to the 
enhancer region of the target genes initiates the transcriptional activation. Within the 
chromatin, the chromosomal DNA associates with histones (HI, H2A, H2B, H3, H4) to 
form nucleosomes. This can inhibit the interaction of transcriptional factors and the 
general transcriptional machinery with target genes, which activates transcription (Pham 
and Sauer, 2000; Ruppert, Wang and Tjian, 1993; Hisatake et al., 1993).
As the largest TAFII subunit is TAFU250 within the TFDD complex, the precipitated 
activity may correspond to Drosophila TAFn250. Antibodies to ubiquitin detected 
ubiquitin at a position that coincides with dTAFn250, suggesting that dTAFn250 
ubiquinates histone HI. The nuclear membrane assay and the molecular weight of 
known enzymes in the ubiquitin pathway suggest that the nuclear membrane bound 
dTAFn250 most likely does not interact with the E l, E2, or E3 enzymes. As it is known 
that monoubiquitination involves at least El and E2 activities, the result implies that 
dTAFn250 may have intrinsic El and E2 activities (Jacobson et al., 2000; Mizzen and 
Allis, 2000).
It was detected in the membrane assay that ubiquitin/Hl conjugates resisted reducing 
agents, which suggests that dTAFn250 may mediate a covalent bond between ubiquitin 
and HI by means of isopeptide linkages which indicates that dTAFn250 may have 
intrinsic E2 activity, since this reaction is characteristic for E2 enzymes.
Generally El enzymes require ATP to conjugate with ubiquitin to form the thioester 
bond. Hence to find out whether dTAFn250 has the El activity, Pham and Sauer (2000) 
investigated the capability of dTAFn250 to conjugate with ubiquitin by means of 
thioester bond. It was found that dTAFn250 conjugated with ubiquitin in an ATP 
dependent manner in the absence of a reducing agent. This suggests that dTAFn250 
may have both El and E2 activities and may therefore be a “ubac” (ubiquitin activating 
and conjugating). The E1/E2 activities for dTAFn250 are known, but the PROSITE 
signature of the E2 domain is unknown. The current view of the functional domains of 




Table 1.1 Sub cellular localization and /or function(s) of UBC (E2s)
Yeast (Sc) & 
human UBC Functions
ScUBCl It is a ubiquitin conjugating enzyme that plays a vital role in 
the vesicle biogenesis and ER-associated protein degradation 
(ERAD) and is a component of cellular stress response. It also 
mediates selective degradation of short lived and abnormal 
proteins
HIP2 HIP2 binds selectively at the N-terminus o f Huntingtin.
ScUBC2 It is a ubiquitin conjugating enzyme (E2) involved in the 
ubiquitin mediated N-end rule protein degradation (with 
Ubrlp), telomere silencing, sporulation, and in post­
replication repair (with Radl8p)
UBE2A, UBE2B The protein is strongly conserved in eukaryotic evolution, and 
plays an important role in various cellular processes.
ScUBC3 It is a ubiquitin conjugating enzyme (E2), which regulates cell 
cycle progression by targeting key substrates for degradation. 
It, together with Skplp, Rbxlp, Cdc53p, and an F-box protein, 
forms a ubiquitin protein ligase called the SCF complex
UBE2R2, CDC34 Catalyzes the covalent attachment of ubiquitin to other 
proteins.
ScUBC4 It is a ubiquitin conjugating enzyme that is a component of 
cellular stress response, interacts with many SCF ubiquitin 
protein ligases. It mediates degradation of short lived and 
abnormal proteins.
ScUBC5 It is a ubiquitin conjugating enzyme that mediates degradation 
of short-lived and abnormal proteins and is a central 
component of the cellular stress response.
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Catalyzes the covalent attachment of ubiquitin to other 
proteins and mediates the selective degradation of short-lived 
and abnormal proteins. It also functions in the E6/E6-AP- 
induced ubiquitination of p53.
ScUBC6 It is a ubiquitin conjugating enzyme that is involved in the ER 
associated degradation, which consists, of the transmembrane 
segment at the end of the C-terminus, and is a substrate of the 
ubiquitin-proteasome pathway.
UBE2J1, UBE2J2 It functions in the selective degradation of misfolded 
membrane proteins from the endoplasmic reticulum, and 
catalyzes the covalent attachment of ubiquitin to other 
proteins.
ScUBC7 It is a ubiquitin conjugating enzyme that is involved in the 
ER-associated degradation pathway, which requires Cuelp for 
recruitment to the ER membrane.
UBE2G1, UBE2G2 Catalyzes the covalent attachment of ubiquitin to other 
proteins, may be involved in degradation of muscle-specific 
proteins.
ScUBC8 It is a ubiquitin conjugating enzyme that mediates the glucose- 
induced ubiquitination of Fructose-1,6-bisphosphatase 
(FBPase) and hence negatively regulates gluconeogenesis. It 
is a cytoplasmic enzyme that catalyses the ubiquitination of 
histones in vitro.
UBE2H Catalyzes the covalent attachment of ubiquitin to other 
proteins, and is capable, in vitro, to ubiquitinate histone H2A.
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Subcellular localization and /or function(s) continued: 
Functions
ScUBC9 It is a SUMO (small ubiquitin like modifier)-conjugating 
enzyme involved in the Smt3p conjugation pathway and also 
involved in the proteolysis mediated by the anaphase- 
promoting complexcyclosome (APCC). It is a nuclear protein 
required for S- and M-phase cyclin degradation and mitotic 
control.
UBE2I Catalyzes the covalent attachment of ubiquitin-like protein 
SUMO-1 to other proteins.
ScUBCIO It is a ubiquitin conjugating enzyme, which is essential for 
peroxisome biogenesis and it catalyses the covalent 
attachment of ubiquitin to other proteins.
UBE2S Catalyzes the covalent attachment o f ubiquitin to other 
proteins.
S cU B C ll It is a ubiquitin conjugating enzyme, which catalyses the 
covalent attachment of ubiquitin to other proteins.
UBE2C Catalyzes the covalent attachment of ubiquitin to other 
proteins, and is required for the destruction of mitotic cyclins.
ScUBC12 It is a ubiquitin conjugating enzyme, which accepts the 
ubiquitin like protein NEDD8/RUB1 from the UBA3-ULA1 
E l complex and catalyses its covalent attachment to other 
proteins. The major substrate is CDC53/Cullin.
UBE2M Accepts the ubiquitin-like protein NEDD8 from the UBE1C- 
APPBP1 E l complex and catalyzes its covalent attachment to 
other proteins, and is also involved in cell proliferation.
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Subcellular localization and /or function(s) 
Functions
ScUBC13 It is a ubiquitin conjugating enzyme which is involved in the 
error free DNA postreplication repair pathway, DNA damage 
triggers distribution from the cytoplasm to the nucleus.
UBE2N Plays a role in the DNA repair pathway and contributes to the 
survival of cells after DNA damage and has a role in the 
control of progress through the cell cycle and differentiation. 
It catalyzes the synthesis of non-canonical poly-ubiquitin 
chains that are linked through Lys-63, and mediates 
transcriptional activation of target genes.
Ubiquitin-conjugating enzyme 13 (UBC 13) has a key role in 
B-cell development and is important for both B-cell and 




Catalyzes the covalent attachment of ubiquitin to other 
proteins and mediates the selective degradation of short-lived 
and abnormal proteins. It also functions in the E6/E6-AP- 
induced ubiquitination of p53.
UBE2Q1, UBE2Q2 Catalyzes the covalent attachment of ubiquitin to other 
proteins











It has no ubiquitin ligase activity on its own. It catalyzes the 
synthesis of non-canonical poly-ubiquitin chains that are linked 
through Lys-63. This type of poly-ubiquitination activates IKK 
and does not seem to involve protein degradation by the 
proteasome. It plays a role in the activation of NF-kappa-B 
mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates 
transcriptional activation of target genes. Plays a role in the 
control of progress through the cell cycle and differentiation, 
and DNA repair pathway and contributes to the survival of cells 
after DNA damage.
TSG101 TSG101 is a tumor susceptibility gene, which is important for 
growth restriction of normal cells. Mutations of the TSG101 
gene are rare events in human breast cancers, but aberrant 
products from this gene are observed quite frequently. The 
occurrence of these abnormal products seem to be correlated 
with tumor and the mutation of another important tumor- 
suppressor gene called p53.
(Data from Table 1.2 was retrieved from http://www.gene.ucl.ac.uk/cgi- 
bin/nomenclature/searchgenes.pl; Koonin and Abagyan, 1997)
Most o f these enzymes in the Table 1.1 & 1.2 mentioned, appear to have a range of 
different cellular locations and/or substrate specificities. For example, yeast UBC6 and 
UBC7 bind to the endoplasmic reticulum and have been shown to be specifically 
involved in ERAD (Plemper and Wolf, 1999). In addition, both of these enzymes 
appear to have active sites, which are different from each other, and all other UBCs, 
with respect to their PROSITE signatures. For example, an entirely different PROSITE 
signature for yeast UBC6 homologues compared to all other UBC’s has been described 
(see Figure 1.4). In multicellular organisms such as humans and plants, many of the 
homologues of the 13 different yeast UBCs appear to have been duplicated at least
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once, e.g. there are 6 different homologues o f yeast UBC4/5 in humans UBE2D1, 
UBE2D2, UBE2D3, UBE2E1, UBE2E2, UBE2E3 (see Table 1.1). In addition UBE2V1 
and UBE2V2 appear to be homologue of yeast ScMMS2 (Table 1.1). So the UBC (E2s) 
represent a divergent population of homologous proteins.
1.7 The non-catalytic homologues of ubiquitin conjugating enzymes
The so-called noncatalytic UBCs, e.g. the tumour suppressor gene TSG101 and UBE2V  
[Li and Cohen, 1996; Li et al, 1997; Xiao et al, 1998] are an unusual class of proteins, 
which contain much of the conserved UBC domain but significantly lack the cysteine 
that is found in all UBC enzymes (Figure 1.4). The function of this class of proteins has 
been predicted to be a regulatory role, where the increased expression of this class of 
protein inhibits the ubiquitination of selected proteins by competing for protein 
substrates with other active enzyme, ubiquitin conjugating enzymes (Koonin and 
Abagyan 1997). However, this class of protein may still be able to interact with E3 
ubiquitin ligases, and could therefore be actively involved in the ubiquitination process. 
In support of this latter hypothesis is the fact that, with the obvious notable exception of 
the highly conserved cysteine residue, this class of enzyme contains much of the UBC 
PROSITE signature, as well as other conserved ubiquitin domain amino acids at either 
side of the signature sequence. Therefore, activated ubiquitin may still be able to bind to 
this partial UBC active site before it is transferred to the active site of an E3 enzyme for 
catalytic addition to the target protein (Xiao et al., 1998).
1.7.1 TSG101
The tumor susceptibility gene (TSG101) contains a proline rich region and a predicted 
coiled coil domain, but the function could not be initially predicted from either the 
sequence or the structure. This suggests that TSG101 belongs to the group of apparently 
inactive homologues of ubiquitin conjugating enzymes (E2). When the protein database 
was searched at the NCBI to find the homologues of the TSG101 sequence using the 
BLAST2 program, a significant similarity to yeast and other homologues of E2 
ubiquitin conjugating enzyme was found. Cysteine, which is within the active site of the 
E2s, was replaced by tyrosine in TSG101 (Koonin and Abagyan, 1997). TSG101 
inhibits the ubiquitination and degradation of MDM2 and hence is directly involved in
14
cell cycle control by regulation of cellular p53 levels (Kloor et al., 2002). It could hence 
be concluded that TSGlOland its UBC homologues have a common evolutionary 
ancestor, but they are most unlikely to possess the same function (Ponting, Cai and 
Bork, 1997).
1.7.2 CROC-1 (UBE2V1)
CROC-1 (UBE2V1) protein was isolated from human cDNA and is a homologue of 
yeast methyl methane sulphonate (MMS2) and the human MMS2 (UBE2V2). These 
homologues share significant amino acid sequence homology with that of CROC-1 and 
hence with the UBCs. The size and the predicted secondary structure of CROC-1 and 
MMS2 also resemble E2 enzymes, but they lack the active site cysteine residue which is 
highly conserved in the UBCs. It can be said that CROC-1 and MMS2 may form a 
separate UBC like protein family because though they resemble the UBCs, at the amino 
acid sequence level they are more homologous to each other than to the UBCs (Xiao,
1998). This is demonstrated by the multiple sequence alignment shown in Figure 1.4.
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F ig u re  1 .4  sh o w s a  C L U ST A L X  a n d  G E N E D O C  g e n e ra te d  m u ltip le  seq u en ce  a lig n m en t o f  y e a s t  U BC6, i t ’s  tw o  o r th o lo g o u s hum an U B E 2J  
p e p tid e  seq u en ces a n d  a ll o th er  y e a s t  a n d  hum an U BCs. The h igh ly  co n se rv e d  cys te in e , w h ich  is e ssen tia l f o r  th is fa m ily  o f  en zym es a c tiv ity , is 
h ig h lig h ted  b y  a  rec tan g le . This a lig n m en t a lso  in c lu des tw o  hum an U B C  re la te d  p ro te in s , tu m ou r su p p re sso r  gen e 1 0 1 (T S G 1 0 1 ) a n d  U BE2V1, 
w hich  in terestin g ly , lack  the h igh ly  c o n served  cys te in e  a c tiv e  s ite  residue, b u t a s  can  be  seen  fro m  the F igure, a re  s til l  h igh ly  h o m ologou s to  a ll  
o th er  U B C ’s. F rom  th is a lig n m en t it  can  c le a r ly  b e  seen  th a t w ith  the n o ta b le  excep tion  o f  th ese  la tte r  n a m ed  p ro te in s  to g e th er  w ith  the y e a s t  
U B C 6 a n d  its r e la te d  hum an U B E 2J sequ en ces, a ll o th er  know n U B C s o b ey  the fo llo w in g  p r o s ite  s ig n a tu re  [F Y W L P S ]-H -[P C ]-[N H ]-[L IV ]~  
x (3 ,4 )-G -x -[L IV ]-C * -[L IV ]-x -[L IV ]. On a n a lysin g  a ll know n U B C 6 re la te d  seq u en ces w h ich  d o  n o t o b ey  the ty p ic a l U B C  p ro s ite  sign atu re , w e  
h ave su g g e s te d  the fo llo w in g  p ro s ite  sig n a tu re  f o r  U B C 6: T -[P A R ]-[N S ]-G -R -F -x (3 )-[K T E ]-[R K ]-[L IV ]-C -[L M S ]-[S T ]-[IM F ]-[S T ]-x (2 )-H -  
[P K ]. I t can  c le a r ly  b e  seen  fro m  f ig u re  1 .4  th a t y e a s t  U B C 6  a n d  the hum an U B E 2J seq u en ces o b ey  th is su g g e s te d  sign atu re. N o  P R O SIT E  
sig n a tu re  h as y e t  been  su g g e s te d  f o r  hum an TSG 101 a n d  its  r e la te d  p ro te in s .
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1.8.1 The relation of ubiquitin with SUMO and their functions
1.8 UBCs AND UBIQUITIN LIKE PROTEINS (UBLs)
SUMO or “small ubiquitin like modifier” are distantly related proteins to ubiquitin 
with a 20% identity, which were first identified in mammals. SUMO is a Ubiquitin- 
like protein (Ubls) that conjugate to proteins, altering the properties of the modified 
protein and thus increasing the complexity of the proteome in eukaryotic cells. The 
mechanism of the SUMO conjugation is similar to that of ubiquitin conjugation 
involving the three enzymes E l, E2, and E3. The distinguishing feature o f human 
UBC9 (UBE2I) that differentiates it from other conjugating enzymes for Ubls, is its 
ability to directly recognize substrate proteins. Hence the thioester UBC9-SUMO can 
catalyse formation of an isopeptide bond between the C-terminal carboxyl group of 
SUMO and the s-amino group of lysine in the substrate protein (Hay, 2005). UBC9 
has shown to be responsible for SUMO conjugation or sumoylation (Mo and 
Moschos, 2005). SUMO is required for DNA replication, repair and recombination 
and also to control the cell cycle progression (Hay, 2005; Desterro, Thomson and 
Hay, 1997).
1.8.2 Involvement of E l, E2, E3 in NEDD8
Another ubiquitin-like protein is NEDD8, which can be said to be the closest relative 
of ubiquitin. Although the enzymes involved in neddylation are the same as in the 
case of ubiquitin and ubiquitin-like proteins, the NEDD8 pathway involves only one 
E l, one E2 and a few E3s. Moreover NEDD8 involves only a small number of targets, 
in comparison to other ubiquitins that are involved in a greater number of targets. 
Human UBC12 (UBE2M) functions as a UBC for NEDD8, and has a 26 amino acid 
N-terminal extension upstream of its 150 amino acid residue conserved E2 core 
domain (Huang et al., 2004; Chiba, 2005).
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1.9 UBCs and ERAD
The endoplasmic reticulum (ER) is the site in eukaryotic cells at which secretory 
proteins and membrane proteins enter the central vacuolar system which is made up 
of ER, Golgi apparatus, intermediate transport compartments, endosomes, lysosomes, 
and plasma membrane. The function of the endoplasmic reticulum (ER) is to properly 
fold in their native conformation and covalently modify the proteins which are 
inserted into the ER membrane or into the lumen before they arrive at their 
destination. Major ER modifications are N-glycosylation, disulphide bond formation 
and glycosyl phosphatidyl inositol (GPI) anchoring (Buschhom et al., 2004). The 
folding process in the ER is controlled by a retention based quality control system 
consisting of ER-resident chaperones, protein disulphide isomerase (PDI), and lectins 
(Buschhom et al., 2004). At the ER only properly folded proteins are allowed to pass 
through, whereas the misfolded proteins are eliminated. These misfolded proteins 
eventually are degraded in the ER lumen itself, and is known as ERAD or 
Endoplasmic Reticulum Associated Degradation (Plemper and Wolf, 1999). ERAD 
plays a central role during active secretion, cell growth, and normal turnover in 
eukaryotic cells (Mancini, Aebi and Helenius, 2003).
The three events that ERAD comprises are 1) substrate selection, b) transport to the 
cytoplasm, c) proteasome mediated proteolysis. It had been assumed before, that 
secretory proteins were degraded by ER resident proteases. It is now known that some 
ER substrates are re-translocated back to the cytoplasm and degraded by the 
proteasome although they are selected within the ER. The folding intermediates 
should be distinguished from the aberrant proteins, and for that the degree of substrate 
selectivity during ERAD must be high. The part of action of molecular chaperones is 
to assist in protein folding and is designed to recognize solvent exposed hydrophobic 
amino acid patches in unfolded proteins. The chaperones interact with ERAD 
substrates in yeast and mammalian cells, and for a number of ERAD substrates a 
correlation between substrate release from chaperones and proteasome mediated 
degradation has been observed. Chaperones help ERAD to fold a secretory protein, 
but if  it does not fold, they retain the substrate in the soluble conformation. This 
prevents the formation of toxic aggregates and helps re-translocation through the ER 
membrane channel. If a protein folds and buries chaperone-associated hydrophobic 
patches, it will escape ERAD. If specific ER luminal chaperones are mutated in yeast,
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ERAD substrates aggregate. Some misfolded subunits of multiprotein complexes, or 
misfolded proteins can remain bound to a chaperone indefinitely and are quite stable 
(McCracken and Brodsky, 2003).
There are various ERAD substrates that are associated with a disease for example the 
substrate AiPiZ (Z variant of the a l  proteinase inhibitor) is the most common genetic 
cause of liver disease in children and emphysema in adults. AiPiZ is a secretion- 
defective, accumulates in the ER, and is destroyed by ERAD. The most common 
substrate for the disease Cystic Fibrosis is AF508 CFTR. The mechanism of ERAD 
substrate recognition is not clear. It is thought to be likely that unfolded regions of 
aberrant polypeptides serve as recognition motifs that specify degradation, and that 
molecular chaperones play a role in targeting proteins to the ERAD pathway (Brodsky 
and McCracken, 1999). Selective proteolysis is an essential process in every cell 
(Biederer, Volkwein and Sommer, 1996).
It had also been said that when the mis-folded proteins are retained in the ER by 
chaperone association, an intra-lumenal timer is activated to select a protein for ER 
degradation. The degradation of some ERAD substrates requires the time dependent, 
enzymatic trimming of a terminal mannose residue on the middle chain o f the N- 
linked core oligosaccharide. Proteins containing the shortened mannoside side chain 
(Mannose 8 instead of Mannose 9) are recognised poorly by glucosidase n , which 
trims a terminal glucose from the oligosaccharide. If the glucose residue is absent, 
calnexin binding does not occur, but if it is present, then glycoproteins bind calnexin, 
chaperones that retain mis-folded proteins in the ER and are known to play a vital role 
in ERAD. For mis-folded proteins, the decision to re-enter the calnexin cycle is made 
by the UDP-glucose: glycoprotein glucosyl transferase (UGGT), which adds glucose 
back to the oligosaccharide, which activates the calnexin re-association (McCracken 
and Brodsky, 2003). This is further illustrated in Figure 1.5.
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Figure 1.5 Trimming of sugar chains and elongation of polyubiquitin that target
the protein for degradation
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Figure 1.5 shows the step-wise trimming of mannose residues, which provides a timer 
for glycoprotein delivery to ERAD. (Stepl) The oligosaccharide gets transferred to an 
asparagine residue in the mammalian rough E R  (RER). (Step2) After that the two 
glucose residues gets trimmed which leads to binding of calnexin. (Step3-6) The 
calnexin folding cycles then starts, where trimming of the sugar residues takes place. 
(Step7) Reassociation with the calnexin takes place, followed by deglucosylation (step 
3) and again mannose trimming. During any of these cycles the glycoprotein can 
acquire proper folding leading to its release from the cycle. (Step8) Once folded, the 
glycoprotein either remains as a stable E R  resident or, (step9) is transported to the 
Golgi through the E R  exit sites, where it is transported to its final destination, with 
the help of either ERG IC53, V IP36 or other lectins.
If  even upon reaching step 6 the glycoprotein does not fold properly, the mannose-a 
residue is then removed, which leads to its release from the calnexin cycle, followed 
by the binding of the putative lectin ED EM , which leads to the E R  degradation of the 
glycoprotein. The E R Q C  (ER quality control) compartment indicated, confirms some 
of the steps (Figure adapted from Lederkremer and Glickman, 2005).
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The two ubiquitin conjugating enzymes (E2s) in yeast UBC6 and UBC7 are involved 
in the ERAD process. UBC6 is an ER membrane protein whereas UBC7 is not an 
integral membrane protein, but associates itself with an ER bound protein (see Table
1.1) called Cuel (Tiwari and Weissman, 2001). Proteasomal degradation is not 
limited to proteins located in the nucleus and the cytosol; many transmembrane and 
lumenal proteins are degraded from the ER by the proteasomes, and this process of 
the proteasomal degradation of ER associated proteins is also known as ERAD. The 
steps involved in this form of ERAD are trimming of the N linked glycans, 
ubiquination, retrograde movement through the ER membrane, deglycosylation and 
degradation in the cytosol by proteasomes. A number of ERAD substrates are 
multiubiquitinated in yeast, which include the mutant forms of sec61, 
carboxypeptidase Y (CPY) and HMGCoA-reductase. In ERAD two yeast E2s, UBC6 
and UBC7 have been implicated by genetic analysis, deletion of which stabilizes 
mutant sec61, CPY, Ssslp, Pdr5 and uracil permease. UBC7 protein associates with 
an ER bound protein, Cuel as it lacks a membrane anchor, whereas UBC6 is a 
membrane protein, whose catalytic side faces the cytosol (Tiwari and Weissman,
2001).
There are two human homologues of yeast UBC6 namely UBE2J1 (NCUBE1) and 
UBE2J2 (NCUBE2). Similiarly there are also two human homologues of yeast UBC7 
namely UBE2G1 and UBE2G2.
ER substrates can be translocated by another mechanism involving 
polyubiquitination. This involves the three ubiquitination enzymes E l (ubiquitin 
activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligases) 
(McCracken and Brodsky, 2003; Taxis et al., 2003). UBC1 and UBC7 may also 
contribute to the polyubiquination of ERAD substrates, whose activities seem to 
represent the principal ubiquitin conjugation steps in this process (Friedlander et al.,
2000). UBC6 has a central role in the ER Associated Degradation in yeast and other 
higher eukaryotes, where the misfolded protein is translocated out of the ER, 
ubiquitinated and degraded in the proteasome. This ubiquitination reaction is carried 
out by a complex, consisting of UBC6, UBC7 and Cuel a membrane bound protein 
that couples the interaction of both UBC6 and UBC7 (Lester et al., 2000).
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1.10 UBC6, PML-RARa and ERAD
PML-RARa is a fusion protein of promyelocytic leukaemia (PML) and the retinoic 
acid receptor-a (RAR-a), which causes acute promyelocytic leukemias (APL). The 
ubiquitination of N-CoR is stimulated by PML-RARa via UBC6 that is involved in 
the protein quality control. PML-RARa has two N-CoR interacting sites, which are 
required for the ERAD of N-CoR, which suggests that the abberant binding of PML- 
RARa to the N-CoR, may induce the ERAD of N-CoR (Khan et ah, 2004; Atsumi et 
al., 2006).
1.11 UBCs, ERAD and human diseases
All mutated proteins are not degraded; only those mutations that cause a problem in 
protein folding are degraded. Misfolded proteins resulting from mutations are usually 
destined for protein degradation (Alfred et al., 2003).
Endoplasmic Reticulum Associated Degradation (ERAD) is the central element o f the 
secretory pathway and also has the major implications for the generation of human 
diseases. There are two groups of disorders, the first being the result from the loss-of- 
function mutations in ERAD components that stabilize aberrant proteins which in turn 
accumulates and damages the cell, an example of it is the Parkinson’s disease (see 
Table 1.3.2). The premature degradation of secretory or membrane proteins, is the 
second group of disorder, cystic fibrosis being an example (see Table 1.3.1) (Meusser 
et al., 2005; Plemper and Wolf, 1999). The following Tables 1.3.1 and 1.3.2 provide 
examples o f diseases that are thought to result from defects in protein degradation.
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Table 1.3.1 Diseases associated with defects in protein degradation
Cystic fibrosis_____________________________________________________________




Thyroxin binding globulin deficiency_________________________________________
Protein C deficiency________________________________________________________





Nephrogenic diabetes insipidus due to mutations in AVP receptor 2 or aquaporin-2
Growth hormone receptor deficiency_________________________________________
Osteogenesis imperfecta____________________________________________________
Procollagen type I, II, IV deficiency__________________________________________
Albinism / Tyrosinase deficiency_____________________________________________
Table 1.3.2 Diseases associated with defects in protein aggregation
Autosomal dominant neurohypophyseal diabetes insipidus





(Tables 1.3.1 & 1.3.2 were adapted from Rutishauser and Spiess, 2002; Aridor and 
Hannah, 2002).
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ER associated degradation and cystic fibrosis
The Cystic Fibrosis gene encodes a large (around 168 KDa) epithelial membrane 
protein called Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Cystic 
Fibrosis is an autosomal recessive disorder affecting the lungs, pancreas, biliary tree, 
intestinal glands, reproductive organs and sweat glands (Gelman and Kopito, 2002). 
The CFTR functions as a regulator of chloride ion channel and also other ion channels.
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Figure 1.6 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
and its degradation pathway
Figure 1.6 shows the fate of the CFTR molecule synthesised on the ER associated 
ribosomes. Calnexin binds to the attached core oligosaccharide chains, and in addition 
to it the Hsp90, Hsp70 and Hdj2 binds, where ubiquitination may occur. The completely 
folded CFTR is prevented from degradation, but those molecules that are misfolded are 
degraded by the proteasome. But when degradation is prevented, extensive aggregation 
of molecules occur that are not competent to be exported (Riordan, 1999).
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The most common CFTR mutation found in most patients is a deletion of phenylalanine 
at position 508 (AF508)
(Rutishauser and Spiess, 2002; Ward, Omura and Kopito, 1995).
UBC6 and UBC7 are the E2s that function with the E3s such as gp78 and DoalO on the 
cytoplasmic face of the ER to ubiquitinate a number of substrates. Therefore it is 
possible that E2-E3 complexes that contain UBC6 and/or UBC7 cause the degradation 
of CFTR AF508 (Younger et al., 2004). Human homologues o f yeast UBC6 (UBE2J1 
and UBE2J2) have recently, both been shown to be involved in the ubiquitination and 
proteasomal degradation of the most common misfolded mutant AF508CFTR. It had 
been found that overexpression of UBC6 and not UBC7, modulates the rate of CFTR 
AF508 degradation (Lenk et al., 2002). When the effects of the dominant negative forms 
of UBC6, UBC7, UbcH5A (UBE2D1), had on CFTR and CFTR AF508 expression 
were compared, it was found that UBC6, Ubc5A (UBE2D1) drove the accumulation of 
the B form of CFTR and CFTR AF508, whereas UBC7 had no apparent effect. This 
suggests that UBC6 plays a clear role in CFTR quality control. The specific inhibition 
of the UBE2J1 and UBE2J2 enzymes may therefore have therapeutic potential in the 
treatment o f cystic fibrosis, as this would in turn inhibit the ubiquitination and 
subsequent degradation of AF508CFTR protein by the proteasome (Younger et al., 
2004; Brodsky and McCracken, 1999; Yoshida et al., 2002).
1.12 UBC’s as potential drug targets
As the ubiquitin system plays a central role in basic cellular processes, development of 
drugs that modulate the activity of the ubiquitination system, could provide a target 
oriented, highly specific approach to many diseases. The clinical importance of 
inhibiting the enzymes controlling the ubiquitination pathway (which may affect many 
processes non-specifically), may depend on striking an acceptable balance between the 
beneficial effects, the toxicity and the deviation of the treatment. The beneficial effects 
in certain diseases like Cancer, Asthma, Brain Infarct, Cystic Fibrosis, Parkinson’s, has 
been strongly suggested from experimental evidence. Overexpression of UBC6 but not 
UBC7, modulates the rate of CFTRAF508 degradation. Here UBC6 could act as a 
potential drug target in altering the degradation function of the CFTRAF508. Specific 
regulators of this proteolytic pathway should thus be valuable therapeutic tools for 
treatment of several severe human diseases (Bence, Sampat and Kopito, 2001; Mira et
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al., 2004; Kostova and W olf, 2003; Plemper and Wolf, 1999; Ciechanover and 
Schwartz, 2002; Kaiser and Huang, 2005).
The nuclear receptor corepressor (NCoR) and the related factor known as silencing 
mediator of retinoic acid and thyroid hormone receptor (SMRT) are essential 
components of multiprotein complexes, which act to repress transcription of nuclear 
hormone receptors, such as the thyroid hormone receptor (TR) and retinoic acid 
receptor, in the absence of their appropriate ligand (Ogawa et al., 2004). They play a 
crucial role in transcriptional repression by multiple classes of transcription factors, 
including some nuclear hormone receptors (Frasor et al., 2005). PML-RARa stimulates 
the ubiquitination of N-CoR via UBC6, which is involved in the protein quality control. 
As UBC6 is involved in the ER degradation and causing the disease acute 
promyelo'cytic leukaemia (APL), it is again, one of the potential drug target in the 
control o f the disease (Khan et al., 2004).
N-CoR has been seen to be regulated by ubiquitin-mediated protein degradation by an 
interaction of E3 ubiquitin ligases Siah2, which leads to the ubiquitination and 
degradation of N-CoR by the 26S proteasome. Estrogen down regulates the N-CoR 
protein levels in estrogen receptor (ER)-positive breast cancer cells without affecting N- 
CoR mRNA levels and the corepressor SMRT levels (Frasor et al., 2005). Here the 
interaction of E3 ubiquitin ligase Siah2 has been mentioned, but there could be a 
possibility of the interaction of an E2 (Ubiquitin conjugating enzyme), which by 
affecting the N-CoR level could cause breast cancer. Hence, here also UBC6 could act 
as a potential drug target in the control of breast cancer.
1.13 Phylogenetic and structural studies to determine the function of (E2s) UBC 
orthologues
As can be seen in the previous sections, UBC (E2s) are involved in diverse cellular 
processes and have been shown to possess different functions. For example yeast UBC6 
and 7 have been shown to be specifically involved in misfolded proteins that are 
targeted for ERAD (Plemper and Wolf, 1999; Kostova and Wolf, 2003) while human 
UBC9 has been shown to be involved in the specific ubiquitination of P53 helping to 
control its vital cellular function. Interestingly the active sites of yeast UBC6, yeast 
UBC7 and human UBC9 are significantly different. For example UBC6 has amino acids 
G, R, F, which is absent in all other UBCs, whereas UBC7 has 13 extra amino acids
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which are not found in any other UBCs except UBC3. Despite its possible therapeutic 
importance as mentioned in the previous section, the structure o f yeast UBC6 and its 
human orthologue (UBE2J1) remain to be determined.
1.14 Structure of UBCs (E2’s)
As the ubiquitin pathway involves the interaction of ubiquitin conjugating enzymes with 
different substrates, or other accessory proteins, distinct specificity to individual 
enzymes could be conferred by specific structural features. Hence it is essential to know 
the three dimensional structure of these ubiquitin conjugating enzymes (UBCs). There 
are 13 different yeast UBCs, each having different functions and for which some of the 
UBC structures have been resolved. Examples are the structure of Arabidopsis UBC1, 
Saccharomyces cerevisiae UBC4, Saccharomyces cerevisiae UBC7 and human UBC9 
(Cook et al., 1997). As UBC7 is thought to ubiquitinate and hence cause the degradation 
of the common mutant form of the CFTR protein (i.e. AF508), the structural 
interpretation of UBC7 is essential for a proper understanding of the disease. Before the 
elucidation of the crystal structure of UBC7, two other ubiquitin conjugating enzyme 
structures (AtUBCl and ScUBC4) had been determined (Cook et al., 1992; 1993). 
UBCs have been broadly divided into four classes of enzymes, based on amino acid 
sequence comparison. Class I enzymes consists of a relatively conserved catalytic core 
domain of around 150 amino acid residues with having at least 25 % sequence identity. 
The class II and HI enzymes have an external attachment to the core domain, of either a 
C-terminal or N-terminal extension respectively. The class IV enzymes have both the C- 
terminal and N-terminal extension. These extensions to the core domain confer 
specificity to a certain degree for enzyme-substrate recognition, or provide a 
localization signal. Residing within the core domain itself are both the specificity and 
localization signals. Either the single member substrate or the multiple member 
substrates from the same or different classes, are involved in different cellular 
processes, and hence comprise distinct functional subfamilies. (Tong et al., 1997; 
Jentsch, 1992).
The determined structures of UBC1 & UBC4 are both class I enzymes and consists 
entirely of the conserved core domain. By comparing these two structures it could be 
said that class I enzymes are highly conserved in their three-dimensional folding state. 
As most of the identical residues of the two enzymes are either buried or clustered on 
the surface that lies next to the ubiquitin accepting cysteine, variations are found (Cook
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et al., 1997). It has been speculated before that the function of the conserved surfaces is 
to help in protein-protein binding during ubiquitin thiol ester formation and may be the 
E l binding site o f all E2 enzymes. The surfaces which are not conserved may enable an 
individual Class I enzyme, to interact with its respective substrate or E3 protein.
Further structural studies have been carried out o f UBCs in order to find out whether 
any UBC contain more than the minimum core domain. The structure of UBC7, a Yeast 
UBC (E2), was determined, which contain two insertions relative to the other E2s 
(UBC1 and UBC4) (Cook et al., 1992; 1993; 1997). Yeast UBC7 has a molecular 
weight of 18521 Dalton and has 165 amino acids. Deletion of the UBC gene causes a 
cadmium hypersensitivity phenotype (Jungmann et al., 1993). UBC7 protein has 
functional implications that have been confirmed at the genetic level, as it is involved in 
the ubiquitin dependent degradation of a large group of proteins. The three dimensional 
structure of the yeast UBC7 protein has an overall folding, which is similar to the UBC1 
and UBC4, although it has 38% sequence identity to Arabidopsis UBC1 and 37% with 
that of yeast UBC4. These three structures have been compared which revealed a 
surface region that could be the E l binding site which is common to all E2 enzyme. 
There are surface regions, also which are divergent, that could enable an individual 
class I enzyme to interact with its respective substrates or E3 (Cook et al., 1997).
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Figure 1.8 Stereo diagram of UBC7 on the a-carbon position
C-terminal N-terminal Active site residue
Figure 1.8 shows the stereo diagram on the a-carbon positions. The ubiquitin accepting 
cysteine (C89) and the N -(K3) and C-(F165) terminals are labelled (Cook et al., 1997). 
UBC7 molecule has one antiparallel p-sheet like that of UBC1 and UBC4, with four 
strands (labelled SI to S4 of the Figure 1.7), bounded by four helices on each end and 
on one side (labelled A, B, C, D). On the surface of the protein there is one face of the 
p-sheet and the residues of the four P-sheets include from 24-27, 36-42, 53-59, 71-73. 
Residues 7-13, 116-128, 138-146, 148-162 are the four a-helices and there are two 
hydrogen bonds to strand S4: Phe73 N- Gly86 O and Leu 7 1 0 -  Val88 N. What is not 
present in either UBC4, nor in AtUBCl are the three short stretches of 3io helix in 
UBC7 (which are residues 91-93, 104-108, and 132-134). Located in the long extended 
stretch between the fourth strand (S4) of the P-sheet and the second a-helix (B) of the 
UBC7 molecule is Ubiquitin-accepting cysteine.
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Figure 1.9 Stereo diagram of yeast UBC7
Residues at the loop regions surrounding the active site residue cysteine (C89).
Figure 1.9 is a stereo diagram of the environment around the ubiquitin-accepting 
cysteine in yeast UBC7. The residues 68-73, 80-95, and 134-137 are shown (Cook et 
al., 1997).
Figure 1.9 shows the stereoview of the environment around the ubiquitin-accepting 
cysteine. Similar to ScUBC4 and AtUBCl, ScUBC7 also has a large insertion close to 
Cys89, the cysteine side chain is exposed and sits in a slight depression on the surface. 
Surrounding Cys89 are three loops, the closest residues are Tyr83, His94, and S eri34. 
Closer to the Ubiquitin-accepting cysteine in UBC7 is the loop containing S eri34, 
compared to the corresponding loop in yeast UBC4.
The ribbon diagram of the superimposed yeast UBC4 and UBC7, showing the 
conserved tertiary folding of class I enzymes is as follows:
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Figure 1.10 Superimposed structures of UBC7 and UBC4
Active site Ribbon structure of Ribbon structure of
residue cysteine UBC7 (in red) UBC4 (in yellow)
Figure 1.10 is the ribbon structure of yeast UBC7 molecule (in red), superimposed on 
the yeast UBC4 molecule (yellow). The ubiquitin accepting cysteine is marked in blue 
and various other residues like 3-31, 33-94, 108-164from UBC7 and residues 1-29, 30- 
91, and 92-148from UBC4 are superimposed (Cook et al., 1997). This Figure has been 
reproduced in the software called DeepView.
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The remaining a-carbon atoms of UBC7 excluding residues in the two insertion, can be 
superimposed with the corresponding atoms in UBC4 with a root mean square deviation 
of 1.8 A. The superposition of ScUBC7 with AtUBCl gave a similar root mean square 
value o f 1.8 A. As the superposition o f ScUBC4 and AtUBCl gives an RMS value of
1.6 A (Cook et al., 1993), there is not much of difference in the RMS values. The 
differences occur mostly at the loops but they are quite small. All the four strands o f the 
P-sheets in ScUBC7 are slightly shorter as compared to that of ScUBC4. Compared to 
the 27 residues in ScUBC4 there are 21 residues in the four p-strands of ScUBC7. From 
the deviations in the superposition, it can be judged that the helix A and the loop linking 
it to the first p-strand in ScUBC7 are very much similar to the corresponding regions in 
AtUBCl than in ScUBC4. Superposition at the C-terminal end of helix D compared to 
both AtUBCl and ScUBC4 shows significant deviations. Cis-Pro62 of ScUBC4 and 
cis-Pro64 of AtUBCl aligns with the cis-Pro65 of ScUBC7 as shown in the previous 
alignment Figure 1.7
The most significant difference between UBC7 and all other UBC E2s are the regions 
of extra amino acids as indicated as VI and V4 of the alignment Figure 1.7. They 
represent hypervariable surfaces in a common tertiary fold, when these three crystal 
structures are compared in these regions. By the insertion o f the extra 13 amino acids in 
the UBC7, the effect is that a large surface loop has been introduced flanking to one 
side of the Ubiquitin-accepting cysteine. This loop in UBC4 is comprised of Lys91- 
Gln93, whereas this region in UBC7 is comprised of 16 amino acid residues (His94- 
Argl09), and contains two tight turns and a short stretch of 3io helices.
Figure 1.11 shows the multiple sequence alignment of amino acids o f the 13 yeast E2s 
around the active site cysteine.
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Figure 1.11 is the alignment of all 13 yeast UBC sequences around the active site 
cysteine. The invariant residues are highlighted in black background and the identical 
ones are in gray. The secondary structural features above the alignment and the 
numbers below refer to that of UBC7 sequence. Regions marked V2, V3 and V4 are the 
variable regions of UBC7, and region marked S4 is the fourth strand and region 
marked B is the helix of the UBC7 peptide sequence (Cook et al., 1997).
Eight of the thirteen E2 sequences are similar in the loop region V4 by consisting of 3 
residues as can be seen in Figure 1.11. The remaining five sequences consist of a 
varying length of 4-16 amino acids in this loop region V4. It is evident that even though 
UBC7 has the 13 extra amino acids, the regions adjoining this loop in UBC7 are very 
much similar to that of UBC4. This loop in UBC7 is flanked on the C-terminal side by a 
tryptophan (TrpllO) and by a highly conserved leucine (Leu93) on the N-terminal side. 
When the UBC4 and UBC7 has been superimposed it is seen that the a-carbon atoms at 
the position of Leu93 and Try 110 deviate between the two molecules with values of 
0.14 and 0.30 A respectively, which is much below the root mean square deviation 
(RMSD) value of 1.8 A. Yeast UBC7 has a homologue in C. elegans, which has a 
similar 13 residue insert. A similar 12 residue insert is present in yeast UBC3 which 
also catalyses the formation of Lys48-specific ubiquitin-ubiquitin ligases. The ability of
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UBC3 to catalyse the formation of specific ubiquitin-ubiquitin linkages at Lys48 is not 
possible by any other UBCs (Banerjee et al., 1993). In the previous multiple sequence 
alignment o f Figure 1.11, the region of VI o f an extra amino acid, in the turn between 
the first two (3-strands o f UBC7 and UBC4 has the effect o f shifting the tight turn by 
two residues, which lies at the surface of the molecule and protrudes slightly. There are 
at least two other regions in yeast E2 sequences that may contain variable length 
insertions, which are located between the last (3-strand and the ubiquitin accepting 
cysteine (V2 and V3 of the alignment Figure 1.11. These insertions are absent in both 
the UBC4 and UBC7, which exhibit deviation in the superimposed structures. The four 
variable regions that are highlighted in the yeast UBC7 are not randomly distributed, 
but are located on one surface, which is quite distinct, as they are randomly distributed 
in other E2s.
From the detailed structural discussion of the yeast UBC7, its amino acid sequence 
comparison with yeast UBC4 and plant UBC1, and also its structural comparison with 
yeast UBC4, it is found that the structure of yeast UBC7 is quite distinct to that of all 
other UBCs, especially with the 13 amino acid insert in UBC7.
The structural basis by which ubiquitin conjugating enzymes (E2s) determine substrate 
specificity remains unclear. It was found that the extra 13 amino acids loop can play a 
role in substrate specificity in UBC7. When the sequences of many E2s were compared 
to this extra amino acid region, it suggests that it may represent a hypervariable surface 
in a common E2 tertiary fold (Lin and Wing, 1999). Thus a functional characterization 
was given to the yeast UBC7 from its determined structure. Figure 1.12 illustrates 
selected UBC (E2s) whose three dimensional structures had already been determined.
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Figure 1.12 Some UBC (E2s) whose structures have already been determined
Listed in Figure 1.12 are some of the UBCs (Arabidopsis thaliana UBC1, 
Saccharomyces cerevisiae UBC4, Saccharomyces cerevisiae UBC7 and human UBC9, 
whose structures had already been determined by X-ray crystallography. All of these 
UBCs have their active site residue as cysteine and consist of four Alpha helices and a 
four stranded antiparallel beta sheets (Cook et ah, 1992; 1993; 1997; Tong et al.,
1997).
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The structure of all the UBCs mentioned in the table 1.12, i.e. AtUBCl, ScUBC4, 
ScUBC7 and HsUBC9, are derived from the coordinates of their X-ray diffracted 
crystal structures.
The commonality in all these structure is that all belong to the Class I group of enzymes 
where the catalytic core domain of about 150 amino acids is conserved. All of these 
mentioned UBCs consist of four Alpha helices and a four stranded antiparallel Beta 
sheet. All have their active site residue cysteine. The overall similarity of the human 
UBC9 structure with that of the plant UBC1 and yeast UBC4 suggests that the folding 
of the catalytic domain of the family of UBC enzymes is conserved in all eukaryotes. 
Despite such similarities in the above mentioned structures, there are considerable 
differences in the catalytic active site region. There are 10 residues in UBC9 within 6A 
of the sulfhydryl group of the ubiquitin accepting cysteine. Cys93, Asn85, Tyr87, 
LyslOl, and Asp 127 are among those 10 residues that most likely mediate the catalytic 
activity. Only Asn85, Leu94, and Pro 128 are conserved compared with UBC1 and 
UBC4. Most of the difference between the two structures of UBC1 and UBC4 occurs in 
the loop region. Unlike UBC1, only the first two residues at the N-terminus are non 
helical, and there is no tight turn at the beginning of the helix. The major structural 
difference between these two structures, lie in the loop region of (14-21 and 41-46 of 
UBC4) and residues (16-23 and 43-48 of UBC1). Moreover there is greater difference at 
the amino acid sequence level of UBC6 to that of all other UBCs. The catalytic active 
site region has amino acids that are unique to UBC6, like G, R, F. To study in details 
the three dimensional structure difference of UBC6 to that of all other UBCs, it is 
necessary to derive the structure of UBC6 (human UBE2J1 and UBE2J2).
The structures of yeast UBC7 and human UBC9 have been determined and compared to 
other UBC structures. Despite its possible therapeutic importance the structure of yeast 
UBC6 and its human orthologue (UBE2J1) remain to be determined.
The X-ray crystallographic analysis procedure adopted in determining the structures of 
all the UBCs mentioned above has given a good impetus to carry out the crystal 




2. Research aims and objectives
This project firstly aimed to construct a functional phylogenetic tree for UBCs in 
selected eukaryotic species, whose genomes had been fully sequenced. All yeast UBCs 
whose functions and in some cases structures have previously been experimentally 
determined were included in this analysis in order to try to construct a phylogenetic tree, 
with different branches representing the different orthologous functions of UBCs. This 
phylogenetic tree would also importantly, help in sorting out the nomenclature naming 
of all UBCs, especially the human UBCs.
Secondly this project aimed to try to determine the 3 dimensional structure of the active 
site region of human UBE2J1, using both X-ray crystallography and by computational 
methods. It is hoped by the resolution of this structure, specific inhibitory drugs may be 
designed to stop the degradation of mutant CFTR protein and alleviate the symptoms of 
cystic fibrosis in affected patients.
Lastly this project aimed to determine the previously unknown UBC active site for the 
D ro so p h ila  transcription factor TAFn250.
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In order to carry out Phylogenetic analysis to try to statistically determine protein or 
DNA sequence evolutionary relationships, one has to first try to construct a meaningful 
multiple sequence alignment (MSA).
3.1 Multiple sequence alignment (MSA)
3.1.1 Introduction of MS A
Multiple sequence alignment is the key component of biological sequence analysis 
techniques. There are few procedures in bioinformatics that do not require at one point 
or the other the multiple sequence analysis. The multiple sequence analysis helps in 1) 
the identification of the PROSITE signature pattern of a protein, 2) the building of a 
domain profile needed for identifying the most remote member of a protein family, 3) 
structure prediction, 4) and phylogenetic analysis. Unfortunately it cannot always be 
statistically determined which particular multiple sequence alignment is the best. It is 
often preferable when carrying out an MSA to try analysing in different MSA 
algorithms to see which alignment looks most biologically correct. Following the 
automated MSA analysis, further manual alignments may be necessary to align small 
biologically significant motifs (Poirot, O'Toole and Notredame, 2003; Briffeuil et al.,
1998)
3.1.2 MSA tools
In multiple sequence alignment, a sequence is aligned with another sequence, which is 
most similar to it, and then successively aligns with the next most similar ones. There 
are a number of multiple sequence alignment programmes for example T-Coffee 
(Notredame, Higgins and Heringa, 2000), CLUSTALW (Higgins et al., 1994), 
CLUSTALX which is a graphical interface of CLUSTALW, PILEUP (Dolz, 1994), 
EMBOSS (Rice, Longden and Bleasby, 2000). Generally two basic classes of alignment 
programs are used, one is global alignment programme, which aligns the sequence 
along their whole length, and the other is local alignment programme, which aligns 
sequences only around the conserved regions. Among the two, the most accurate and 
reliable alignment of equidistant sequences, sequences of divergent families, and orphan 
sequences with a family, is the Global alignment. CLUSTALW uses the global
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alignment program to construct an alignment along the whole length of sequence 
(Thompson, Plewniak and Poch, 1999). Following the successful construction of an 
amino acid MSA (e.g. see Figure 3.2) shading of the same amino acids, or amino acids 
of similar property can help identify structurally similar protein domains. Figure 3.1 
shows the properties of the amino acid residues.
Figure 3.1 Venn diagram of the properties of the amino acid residues
F ig u re  3 .1  a d a p te d  fro m  (S tern berg , 1996). The Venn d ia g ra m  a b o v e  sh o w s the  
re la tio n sh ip s  o f  the 2 0  n a tu ra lly  o ccu rrin g  am in o  a c id s, on the b a s is  o f  th e ir  p h y s io -  
ch em ica l p ro p e r tie s . There a re  tw o  m a jo r  se ts: on e  h a v in g  am in o  a c id s  th a t h a ve  a  
p o la r  g ro u p , a n d  the o th er co n ta in in g  h yd ro p h o b ic  am in o acids. T here a re  n ine am ino  
a c id s  in the s e t  “s m a l l”, a n d  w ith in  it  th ere  is  a  sm a lle r  s e t  c a lle d  “t in y ” h a v in g  am ino  
a c id s  w h ich  h a ve  a t the m o st tw o  s id e  chain  a tom s. There a re  o th er  s e ts  c a lle d  “fu lly  
c h a r g e d ”, w h ich  has a  su b se t “p o s i t i v e ”; a n d  a lso  th ere  a re  th e  a lip h a tic  a n d  a ro m a tic  
se ts. The s in g le  le tte r  IU P A C  n om en cla tu re  f o r  am in o  a c id s  is u sed  (E idham m er, 
J o n a ssen  a n d  Taylor, 2004).
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Colour schemes:
The colour schemes of the different amino acids, helps to point out the conserved 
residues or regions. There are different colours in this colour scheme, and this is 
represented in Table 3.1.
Table 3.1 Colouring schemes in the MSA
AMINO ACIDS COLOURS PROPERTIES
A V F P M IL W R E D S m a ll (s m a ll+  h y d ro p h o b ic  ( in c l.a ro m a tic  -Y ))
D E B L U E A c id ic
R H K M A G E N T A B a s ic
S T Y H C N G Q G R E E N H y d ro x y l + A m in e  + B a s ic  - Q
O th e rs G ra y
Table 3.1 shows the colouring scheme o f the 20 naturally occurring amino acids. Table 
3.1 adapted from (htty://www. ebi. ac. uk/clustalw/#)












Table 3.2 shows the colouring scheme according to the physio-chemical properties in 
Genedoc. Figure adapted from the Genedoc Multiple sequence alignment 
(htty://www. ysc. edu/biomed/genedoc/tutorial. htm).
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A part of the MSA is shown below as an example to show the symbol and colour 
schemes as used in Figure 1.4.
Figure 3.2 Example of an MSA showing different conservation notation
OsUBCla TFVI D rH|?GGYPF0j KMQ
ncUBCl TYEVD qh p d k y p f S SMY
scUBCl KFVVD Erap m e y p f B TKMQ
OsUBClb VFLVN HgPPDYPFgE KVS
2F4WA YYHGK I § PREFPFjgE S I Y
Figure 3.2 illustrates an example o f a MSA showing different conservation notations. 
Key to symbols: *  =  which means completely conserved; : = which means highly 
conserved; and. = which means less conserved (Poirot et al., 2003).
Multiple sequence alignment can also help to identify the positions in homologous 
sequences that have descended from a common ancestor. In general the more diverged 
the sequences are to each other, the more difficult it is to align them. As multiple 
sequence alignment is the first step before phylogenetic and functional analysis, its 
errors will have broad effects on further analysis down the line. For example, different 
phylogenetic results can be obtained from different sets of multiple sequence 
alignments.
The accuracy of a multiple sequence alignment depends on the percentage of identical 
nucleotides or peptides in sequences. Generally it is known that if the sequence identity 
is more than 80%, then the aligned sites are true homologues, but as percentage identity 
decreases below 65% the probability of sequences to be correctly aligned also 
decreases. When the percentage of identical sequences further drops to below 50%, then 
the alignment becomes less accurate. The MSA algorithms set, also allow the insertion 
of gaps, so that identical nucleotides or peptides align between sequences (see Figure 
3.3). A gap occurs in an alignment when either of the contributing sequences is 
completely lacking an amino acid at an alignment position (Altschul et al., 1997).
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Figure 3.3 is a multiple sequence alignment o f few UBCs illustrating how gaps are 
introduced in order to correctly align 2F4WB (the pdb ID o f UBE2J2) with the other 
sequences. The line in red above the alignment is the gap in the multiple sequence 
alignment. Gaps are represented by a dash or a series o f dashes.
3.1.3. Scoring matrices in sequence alignment
The scoring matrices are used internally by all sequence alignment programs. There are 
many different types of scoring matrices that have been deviced for sequence 
alignments of peptide sequences. A scoring matrix is generally a tool to measure the 
relationships between sequences. Through a succession of independent point mutation 
proteins evolve. Different mutation data matrices are appropriate for different 
alignments, and sometimes there are problems which are handled by editing manually 
(http://www.lmb.uni-muenchen.de/groups/bioinformatics/04/ch 04 3.html).
There are two different substitution scoring matrices the Dayhoff PAM matrix and the 
Henikoffs BLOSUM matrix.
3.1.3.1. DAYHOFF PAM matrices:
PAM called as point accepted mutation is a widely used scoring matrix, was developed 
by Dayhoff and coworkers (Dayhoff, Schwartz and Orcutt, 1978). Multiple sequence 
alignments were used for scoring amino acid pairs, by examining global alignments of 
closely similar sequences, and observing the frequency with which amino acid 
substitutions occurred. 1PAM represents an evolutionary distance in which 1% of the 
amino acids have been changed. There are a series of PAM matrices, which are 
appropriate for use with different sets of sequences separated by different evolutionary
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distances. The different PAM matrices are PAM250, PAM120, PAM100, and PAM40. 
Among these PAM250 is the most widely used scoring matrix.
PAM250 gave a consistently higher significant score than any other PAM matrix. It is 
recommended to be used for pairwise comparison of proteins, which are known to be 
distantly related (Schwartz and Dayhoff, 1978).
PAM200 matrix is considered appropriate, when the sequences to be compared are 
thought to be related (Altschul, 1991).
PAMI20 is considered to be the best option in a situation where the relationship 
between the sequences is not known (Altschul, 1991).
3.1.3.2. HENIKOFF’S BLOSUM matrix
The BLOSUM (Block Substitution Matrix) was developed by Henikoff and Henikoff 
(Henikoff and Henikoff, 1992). The difference between the BLOSUM scoring matrix 
and the PAM matrix is that, Henikoff took the approach of analysing multiple local 
alignments of distantly related sequences. Hence the substitution was considered are 
those amino acids occurring in relatively conserved regions of the protein rather than 
over the entire length of the sequence. PAM matrix was developed on the basis of 
global alignment of very similar sequences. There are different types of BLOSUM 
matrices, for example BLOSUM90, BLOSUM80, BLOSUM62, and BLOSUM30. 
These different matrices were obtained by varying the clustering threshold, for example, 
the BLOSUM80 was derived by using a threshold of 80% identity. Local alignments of 
related sequences were used to generate a database. Within this alignment, the 
sequences were clustered into groups, where the sequences are similar at a certain 
threshold value of percentage identity. Each of these groups is then used to calculate 
substitution frequencies for all pairs of amino acids. This is used to calculate a 
BLOSUM matrix. Thus the higher BLOSUM matrices are suitable for less divergent 
sequences, and the lower numbered BLOSUM matrices are suitable for sequences that 
are highly evolutionary divergent.
When comparing the two matrices (PAM and BLOSUM), it is seen that PAM250 is 
comparable to BLOSUM45, while PAM 120 is comparable with BLOSUM80. 
BLOSUM62 is an intermediate in both clustering percentage, and is comparable to 
PAM 160. It is also seen that BLOSUM62 is tolerant to substitution involving 
hydrophobic amino acids, but not to hydrophilic amino acids. BLOSUM 62 is typically
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more tolerant to mismatches than any other matrices, especially for rare amino acids 
like cysteine and tryptophan. Hence BLOSUM62 is generally taken as a default scoring 
matrix (Henikoff and Henikoff, 1992; Barton, 1996).
It could be summarised that no single matrix is perfect for all sequence comparison. 
Substitution tables derived from structure comparison, will probably give the most 
reliable data, as more and more three dimensional structures are determined 
(Eidhammer, Jonassen and Taylor, 2004).
There is a high probability of incorrect inference of identity by an algorithm when the 
true variation among sites is very large. It may be possible to increase the percentage 
identity of sequences, by altering gaps or mismatch penalties, but these changes might 
alter the accuracy of the multiple sequence alignment. Though the sequence length does 
not affect the mean alignment accuracy, it affects the accuracy of evolutionary distance 
estimates. It is also known that the sequence length and the effect of alignment accuracy 
have no interaction on evolutionary distance estimation. Distance estimates are partially 
better with longer sequence that with short ones.
So it can be said that increased identity among sequences, helps to increase the accuracy 
of a multiple sequence alignment. Among all alignment programs, the most commonly 
used is the ClustalW, where it implements the most commonly used pair wise alignment 
method, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970). Hence it 
can be said that the use of aligned sequences, as for example, the identification of 
conserved sites, are highly dependent on the accuracy of the alignment. So, even a small 
error in it will have a large effect on the result. Evolutionary distance estimation is also 
somewhat robust to errors of multiple sequence alignment of moderate divergence 
(greater than 50% identity) (Rosenberg, 2005).
The BLOSUM62 scoring matrix, is designed by taking a big database of trusted 
alignments. The pairwise sequence identity is counted and a threshold value is taken 
into consideration of 62%. So all sequence identities falling around 62 % or less were 
considered in the BLOSUM62 target frequency; those identities falling in the higher 
region of 80% were considered in the BLOSUM80 frequency range. Similarly all 
sequence identities that are in the region of around 45%, were considered in the 
BLOSUM45 frequency range.
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For calculating a score s(a,b) for aligning two residues a and b, the equation is as 
follows:
The likelihood that the two residue a and b are correlated because they are homologous, 
is indicated by the numerator in the equation (pab)> which is the target frequency (the 
probability that is expected of the two residues a and b aligned in homologous sequence 
alignment). The denominator of the equation fafb is the likelihood of a null hypothesis, 
which indicated that these two residues a and b occurs independently and are 
uncorrelated and unrelated. Hence fa and fb are considered as the background 
frequencies, which is the probability that is expected to observe on an average amino 
acids a and b in any protein sequence. X is the scaling factor, which allows rounding off 
all terms in the scoring matrix, to sensible integers.
If residues a and b is expected to be aligned together in homologous sequences more 
often rather than occur by chance, then the score is positive otherwise negative (Eddy,
2004).
3.2 Phylogeny
Molecular phylogeny is based on the comparison of DNA or protein sequences, and is 
used in estimating the evolutionary past. Phylogeny is a major tool and seems to find a 
very broad application in research from different backgrounds (Whelan, Li and 
Goldman, 2001).
A phylogenetic tree is composed of branches, which connect to nodes and from which it 
diverges into further branches. These branches and nodes can be internal or external. 
The first node from where several branches come out is called the internal node. This 
internal node could be called the last common ancestor (LCA) as everything arises from 
it. The nodes that are at the later stages of the phylogenetic tree is known as the external 
or the terminal node.
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F ig u re  3.4 E x te rn a l node and in te rn a l node o f a Phylogenetic tree
Figure 3.4 is an unrooted phylogenetic tree, showing the internal and external nodes. 
The figure was adapted from
(httv://trishul. sci. su. edu. au/courses/ss 13bmm/phylogeny part A. doc).
The phylogenetic analysis consists of building up of a tree of multigene families where 
the internal nodes correspond to the gene duplication event, or in the case of a single 
gene from different species, the internal nodes corresponds to the speciation event, or a 
combination of both may be represented by the node. There are 3 types of groupings of 
a phylogenetic tree, the monophyletic, paraphyletic and the polyphyletic groups. When 
a group arises from a unique common ancestor, it is called a monophyletic group. When 
a group excludes some of its descendents, it is called a paraphyletic tree. When a group 
consists of members that superficially resemble each other, or have similar ancestral 
relationships, it is called as a polyphyletic group (Baldauf, 2003).




p olyp h yletic
Figure 3.5 shows the three different groupings o f a phylogenetic tree which are 
Monophyletic, Polyphyletic and Paraphyletic. (Figure 3.5 adapted from 
http.V/tolweb. org/tree/home. vases/glossary. html#polyphyletic).
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A phylogenetic tree grows and as it becomes complex, the nodes expand and turns the 
tree on to its side, where the labels are then read horizontally, which makes it easily read 
and annotated. All branches can rotate from the plane of their nodes, and are usually 
drawn with proportional branch lengths. The length of a branch between two nodes 
corresponds to the evolutionary time, so the longer the branch, the more relatively 
divergent are the sequences attached to them. Another alternative method of drawing a 
phylogenetic tree, is to display the branching patterns only (cladograms), where the 
length of branches have no meaning, but it is rarely used.
The phylogenetic tree has a base, called as a “root”, which is the oldest point of the tree. 
The root of a phylogenetic tree implies the order of branching that is, which sequence 
shares common ancestors with whom. A tree can only be rooted by keeping an external 
point as a reference called as an outgroup which is not a common member to the group 
of interest. There are two types of sequence homologues, orthologues and paralogues. 
Orthologues are genes of different species that have evolved from common ancestors 
maintaining similar function, whereas paralogues are genes with common ancestors that 
have undergone duplication resulting in a different, though related function (Nagl,
2003). Gene duplication is the prime factor to be considered when discussing 
orthologues and paralogues. Represented in Figure 3.6 is an example to illustrate gene 
duplication.
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Fig u re  3.6 Gene duplication
Figure 3.6 illustrates that gene duplication can lead to either acquiring a novel function 
or could form a pseudogene. Figure adapted from Strachan & Reid 1999. The example 
shown here is the duplication o f gene A, which results into two gene copies. In the 
presence o f selection pressure the gene copy (upper figure) has maintained the original 
function. Whereas the other gene copy (bottom) will still continue to be expressed but in 
the absence o f selection pressure will mutate (represented by vertical dotted lines). This 
mutation could be deleterious and could form a nonfunctional pseudogene, whereas in 




During the course of evolution, most nucleotide changes will occur in non-coding 
regions, as changes in the coding region will often be deleterious. In addition changes to 
regulatory or intronic splicing regions may also be deleterious as they may affect gene 
expression or correct splicing of genes. Therefore, what commonly occurs in many parts 
of the genome is heterogeneity in evolutionary rate. The phenomenon of rate 
heterogeneity is so common that it is assumed that the more conserved the sequences 
are, the more functional it is. Sequence that have changed rapidly in the course of 
evolution, have probably lost or have no function (e.g. pseudogenes). In a protein, some 
of its region evolve more rapidly than others, and is the same with different 
chromosomal regions, evolving at different rates (Schmidt, Strimmer and Haeseler,
2004). It is also known that the whole segment of the genome may evolve at different 
intrinsic rates. In carrying out a phylogenetic analysis, the effect of rate variation is 
estimated. The different parameters for estimating the rate variation are 1) “gamma” 
distributed substitution rates, 2) discretely distributed rates of variation, and 3) Hidden 
Markov Models (HMM) (Yang, 1994; Gu, Fu and Li, 1995). These tests assign different 
rates at different sites of a sequence, but they do not test for the significance of these 
differences. The reason for this is that individual sites can have different rates, whereas 
a single site is just one realization, which cannot be easily analysed. Hidden Markov 
model determines if the likelihood of variation is higher under a particular rate scheme 
(Hartmann and Golding, 1998).
In phylogenetic analysis the first criteria after the MSA is to estimate the coefficient of 
variation (CV), and in order to do that it is required to know the parameter “a ”, a is the 
index of the degree of among site rate variation (Gu and Zhang, 1997). The gamma 
distribution is used as a model for the rate variation among sites. The alpha parameter of 
gamma distribution describes degree of variation of rates across position. The 
coefficient of variation (CV) is calculated as 1/ Va (where a is the gamma distribution). 
Changing the a parameter of the rate variation, has an effect on the alignment accuracy. 
A small a  value suggests that rates differ significantly over sites, while a very large a 
value means roughly equal rates. The greater the value of a is, the weaker is the rate 
variation, and as a = a>, it implies a uniform rate among site (Gu and Zhang, 1997; 
Yang, 1993; 1996). There are two main methods of calculating the value of a from the 
peptide sequences; these are a) Maximum Likelihood and b) Maximum Parsimony. The
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Maximum likelihood method is very time consuming and very difficult to apply for 
more than five sequences. The second method which is the parsimony method, is 
computationally faster and is most used (Gu and Zhang, 1997; Yang, 1996; Goldman 
and Whelan, 2000). There are several different rate models e.g. a) Uniform rate model, 
b) discrete gamma distribution rate model, c) mixed model (gamma plus invariable 
sites) (Lio and Goldman, 1998; Zhang and Gu, 1998; Yang, 1996).
3.2.2 Phylip 3.6
Phylip is a phylogenetic package created by Joseph Felsenstein at the University of 
Washington (http://evohition.genetics.washington.edu/phvlip.html). Phylip can be run 
on the Unix platform, but windows version is also available. This program reads the 
MSA which is saved only in the phylip format (.phy). The different phylip programs run 
in a sequential manner, where the output from the first program is used as the input for 
the next program. This package has phylogenetic analysis methods such as maximum 
likelihood, distance matrix (neighbour-joining, Fitch), maximum parsimony, and 
statistical estimation tool Bootstrapping.
Maximum likelihood program in phylogenetic analysis, is the statistically most rigorous 
algorithm, but has the major disadvantage, that it is time consuming, and it only accepts 
50 sequences to do the analysis at a time. Neighbor-joining is the other most preferred 
phylip program which is used here to do the analysis (Felsenstein, 2001; Kuhner and 
Felsenstein, 1994).
3.2.3 Distance matrix method ( Neighbor-joining)
Saitou and Nei (1987) designed the Neighbor-Joining (NJ) algorithm, which works by 
clustering. The advantage of the NJ algorithm is that it is fast and fairly accurate. 
(Felsenstein, 2004). In the neighbour joining method, the phylogenetic tree is 
reconstructed, and the length of the branches of the tree is computed. The nearest nodes 
of the tree are chosen, and are defined as neighbors in the tree. This is done 





Bootstrapping was invented by Bradley Efron (1979) as a general purpose statistical 
tool and is frequently used to access the uncertainty of estimates of the phylogeny. A 
bootstrap is the statistical technique for estimating the variability of an estimate. It 
involves resampling from one’s sample with replacement, and making an assumed 
sample of the same size. It involves resampling points from ones own data, with 
replacement, to create a series of bootstrap values of the same size as the original data. 
In phylogeny the proper method of resampling is to keep all of the original species, and 
the sampling is done with replacement on the assumption that the characters have 
evolved independently. A phylogenetic tree is constructed showing all the inferred 
monophyletic groups that occurred in a majority of the bootstrap samples. It has been 
shown that if a group in the particular branch appears 95% of the time, then it is taken to 
be statistically significant (Felsenstein, 1985). In bootstrap sampling there are several 
trees with different branching, and to keep track of all is a tedious task. Hence to get a 
consensus of all the trees there is the program called m a jo rity  ru le  co n sen su s  tree, which 
summarises all the trees and plots a single tree, as illustrated in Figure 3.7.
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A. Five different phylogenetic trees with species appearing in different branches
F ig u re  3.7 Consensus in  phylogeny
A E | BCDFACE | BDF 3
ACFF 1 BD 1
A C  j BDEF ]
AEF | BCD 1
A D K F ] BC o
A BDF EC 1
ABCH DF '"VJ )
C. Consensus of the five different trees
Majority-rule consensus tree of the unrooted trees:
C B
tL U\ 6 0 60 /
60 \A F
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F ig u re  3 .7  sh o w s  tre e s  o b ta in ed  in th e  p h y lo g e n e tic  an a lysis , w h ere  a ll  sp e c ie s  a p p e a r  
in se p a ra te  b ran ch es in each  trees  a s  can b e  seen  in p a r t  A  o f  the f ig u re . P a r t  B  o f  the  
f ig u r e  sh o w s the n u m ber o f  tim es each  sp e c ie s  a p p ea r in g  in the branch  c lu s te r  in the  
f i v e  d ifferen t tree s  re p re sen ted  above . P a r t C  o f  th e  f ig u r e  sh o w s th e  con sen su s  
u n ro o ted  p h y lo g e n e tic  tre e  b y  the M a jo r ity -ru le  con sen su s m ethod. The co n sen su s tree  
h a s the p e rc e n ta g e  o f  su p p o r t f o r  each  in ter io r  branch  show n. F ig u re  3 .7  a d a p te d  fro m  
(F elsen ste in , 2004).
A consensus tree is a tree that summarises a series of trees. There are three different 
types of consensus trees:
1) Strict consensus
2) Majority rule consensus
3) Adams consensus.
Margush and McMorris’s M a jo r ity  ru le  con sen su s tree is simply a tree that consists of 
those groups that occur in a majority of the trees, and it is this consensus method that is 
mostly used (Felsenstein, 2004). The majority rule consensus tree is found by tabulating 
all groups that occur on all trees and retaining those that occur on a majority of the trees. 
The result is a single tree when it is used on the bootstrap estimates. All of the groups 
that appear on it are present in more than 50% of the bootstrap estimates. The values at 
the nodes of the tree in Figure 3.7C, are the bootstrap value, indicating the percentage of 
times the groups appear together in the branch (Felsenstein, 2004).
3.2.5 Phylip tree plotting programs: Drawgram and Drawtree
Drawgram and drawtree are tree plotting programs, that read the tree description in a 
fde, and plots the phylogenetic tree. Drawgram plots a rooted tree called Cladogram and 
Phenogram, whereas drawtree plots an unrooted tree. Drawgram and drawtree plots the 
tree which can be saved in a postscript format, where this postscript fde is taken to the 
other drawing package called Adobe Illustrator where other changes, such as writing the 
bootstrap values to the individual branches, altering the font size of the names, can be 
made to get the well represented colourful tree. 
(http://evolution.genetics.washington.edu/phvlin/doc/draw.htmn
TreeView is another tool used to draw Phylogenetic trees, but are not as portable as 
DRAWGRAM and DRAWTREE.
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3.2.6. Summary of the advantages and disadvantages of Phylogenetic programs
The preceding sections introduced a range of readily available and widely used software 
tools and analytical procedures for the preparation of phylogenetic trees from multiple 
sequence alignments (MSA). The following Tables 3.3.1 & 3.3.2 summarises the main 
advantages and disadvantages of the most commonly used analytical procedures.
Table 3.3.1 Main advantages of the three phylogenetic programs
Maximum Likelihood Neighbor-joining Maximum parsimony
1 consistent consistent Rapid
2 Most accurate Rapid and analyses 
maximum number of 
sequences
Logical model




4 Responsive to 
bootstrap analysis for 
very large trees.
Table 3.3.2 Main disadvantages of the three phylogeny programs
Maximum Likelihood Neighbor-joining Maximum parsimony
1 Very slow Does not give robust tree Non-consistent
2 Can take only small 
datasets
Accuracy declines if 
datasets have finite 
sequences
Accuracy level of giving 
true tree is quite low.
3 Does not give 
unrooted tree
Discards large amount of 




INTRODUCTION OF CONSURF 
ANALYSIS
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4.1 Orthologous sequence and conservation of structure
Consurf analysis is used to identify functionally important regions of a protein of 
known three dimensional structure. It estimates the degree of conservation of the 
amino acid sites by comparing it with its close homologues. It is an automated web 
based tool, where after identifying the functionally important regions, maps it on the 
surface of the protein (Glaser et al., 2003).
The analysis in Consurf is done automatically, where the only input is the query PDB 
ID and the multiple sequence alignment of its homologues in any one of the seven 
ClustalW format. This part is optional, as the Consurf server itself finds its 
homologues of the query protein, and does a multiple sequence alignment (MSA) in 
ClustalW and finds out the conservation sites along the whole length of the protein 
sequence. It then constructs a phylogenetic tree of the MSA using the neighbour­
joining algorithm, and the position specific conservation scores are computed using 
either the Bayesian or the Maximum Likelihood algorithm. These conservation scores 
are divided into nine grades in different colours, where grade-1 indicates m o st  
v a r ia b le  p o s itio n  and is assigned the colour Turquoise, grade-5 which is the 
in te rm ed ia te  co n serva tio n , is given the colour white, and grade-9 which is the m o st  
c o n se rv e d  is assigned the colour maroon. These nine colour conservation grades are 
plotted on the three dimensional structure of the query protein (Landau et al., 2005; 
Armon, Graur and Ben-Tal, 2001).
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CHAPTER FIVE
INTRODUCTION TO STRUCTURE 
PREDICTION BY X-RAY 
CRYSTALLOGTAPHY
5.1. Introduction to all crystallographic methods
5.1.1. Cloning
5.1.1.1. DNA cloning
DNA cloning is the selective amplification of a desired fragment of DNA molecules 
with restriction endonucleases and ligases. This is used to study its structure and 
function, by DNA sequencing, in-vitro expression studies, to name a few. There are two 
different DNA cloning approaches:
1) Cell-based DNA cloning,
2) Cell-free DNA cloning.
The cell based DNA cloning is carried out in-vivo, whereas the cell-free DNA cloning 
is carried out in-vitro. The cell free DNA cloning is enzyme mediated and the reaction 
involved is called as “Polymerase Chain reaction” (PCR). In cloning, plasmids act as 
“cloning vector”. Plasmids are small circular double stranded DNA molecules. The 
plasmids provide the replicative ability to enable the cloned gene to be propagated 
inside the host cell. The plasmids have a point of replication, which is recognized by the 
DNA polymerases that normally replicate the bacterial chromosomes (Brown, 2002; 
Strachan and Read, 1999).
5.1.1.2. Polymerase chain reaction (PCR)
The rapid method of amplifying the target DNA sequences, present within a source of 
DNA, is PCR (Polymerase Chain Reaction). Two oligonucleotide primers (amplimers) 
are designed, which are specific for the target sequence. The primers are usually about 
15-25 nucleotides long.
The steps in a PCR reaction are:
1) Denaturation (usually at a temperature of 93-95°C).
2) Reannealing (at a temperature between 50-70°C, depending on the Tm. The 
annealing temperature is usually about 5°C below the Tm),
3) DNA synthesis (usually at a temperature of about 70-75°C).
The template DNA is denatured first, and the primers are added to it, which binds 
specifically to complementary DNA sequences at the target site. The initiation of 
synthesis of new DNA strands is carried out by the presence of heat stable DNA
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polymerase (Taq polymerase) and DNA precursors (dATP, dTTP, dCTP, dGTP). The 
newly synthesised DNA strands are complementary to the individual DNA strands of 
the target DNA segment, and which overlaps each other. The newly syntheised DNA 
strands acts as templates for further DNA synthesis. Hence PCR is a chain reaction and 
around 25-30 cycles are given to get around 105 copies of the specific target sequence. 
This result is visualized as a band when subjected to gel electrophoresis (Brown, 2002; 
Strachan and Read, 1999).
5.1.2. Protein purification
5.I.2.I. Gel permeation chromatography
There are several different methods of purifying a protein sample prior to its 
crystallization. These are a) Adsorption chromatography, b) Partition chromatography, 
c) Ion exchange chromatography, d) molecular exclusion chromatography, and e) 
affinity chromatography. The method used in the thesis is “molecular exclusion 
chromatography. The parameter that is taken into account in gel permeation 
chromatography is the molecular size of the protein. The parameter of elution of the 
neutral lipids from the lyophilic dextran gels, is generally in the decreasing order of 
molecular weights, but there is another factor that affect this pattern, and that is the 
polarity of the lipid or the eluent (Yip, 1997; Calderon and Baumann, 1970).
Figure 5.1 next page illustrates gel permeation chromatography.
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F ig u re  5.1 G e l perm eation chrom atography
the column
Figure 5.1 illustrates the principle of size exclusion chromatography, wherein larger 
molecules are eluted faster than the smaller molecules (Figure adapted from 
http://www.answers.com/toDic/siz.e-exclusion-chromatosraphy).
The matrix of the molecular sieve chromatography is composed of highly cross-linked 
poly-dextrans e.g. Sephadex or any other similar material like polyacrylamide, which 
are in the form of microscopic beads. At the molecular level, these beads appear to be in 
the form of a sphere, which is perforated with a network of channels. In the process of 
molecular sieve chromatography, the protein solution gets fractionated according to the 
molecular size. The macromolecules penetrate the interior of the beads depending on its 
size. The macromolecular mixture is made to flow within the column consisting of the 
beads. Those macromolecules, which are of sufficiently small size, penetrate the beads. 
As these small size macromolecules have to spend more time in migrating about the 
interior of the beads, their speed in passing from the top to the bottom of the column is 
greatly reduced. The larger size molecules are excluded from entering the interior of the 
beads due to their bigger size and hence pass through the column faster. Hence various 
size molecules are eluted and fractions collected at different rates. Larger molecules will
6 6
appear first and successively low molecular weight components eluted later. The 
effective separation in this method is of macromolecules differing in molecular weight 
of not more than 10-20%. There are exceptions to this method as well as fibrous 
molecules, or a molecule in the shape of an ellipsoid with an extreme axial ratio, also 
behave as if it were of a higher molecular weight (McPherson, 1999).
Figure 5.2 Molecular weight selective curves for G-type Sephadex
F ig u re  5 .2  sh o w s the m o le c u la r  w e ig h t se le c tiv e  cu rves f o r  G -typ e  S eph adex , a  p o p u la r  
g e l  f i ltra tio n  m edium . O n the X -a x is  is the p ro te in  m o lecu la r  w eight, a n d  on the Y-axis  
is its  m ig ra tio n  s p e e d  (M cP h erso n , 1999).
The advantage of gel permeation over ion-exchange chromatography is that gel 
permeation chromatography is gentler and faster as it does not require exposure to pH or 
ionic strengths and also does not require any gradient solution. In ion-exchange 
chromatography, a gradient is created of variable pH and ionic strength by mixing 
different buffers, where a compound is separated according to the degree of its ionic 
charge. In gel permeation chromatography, protein separation is according to its size, 
where the larger molecules are eluted first (McPherson, 1999).
5.1.3. Crystallography in general
In the early twentieth century Lawrence Bragg used the diffraction patterns from Zinc 
Sulphide, Sodium Chloride and Potassium Chloride to suggest the three dimensional 
structure of their ions in arrangements of their crystals. The principles of 
crystallography had been well understood since then. Myoglobin and Hemoglobin were
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the first three dimensional protein structures determined by M.F. Perutz and J.C. 
Kendrew in the early 1960’s (PDB codes 1MBN and 2DHB). Protein crystals include a 
large number of protein molecules arranged in a periodic manner. As crystals amplify 
the diffraction signal to a measurable level, this periodic arrangement is very essential, 
which would otherwise be weak if only a few protein molecules are available for 
analysis. The three dimensional structure of a protein molecule is built from an electron 
density map, which requires the measurement and fourier synthesis of amplitudes and 
phases from the reflections. Amplitudes are proportional to the square root of diffraction 
intensities, and are directly obtained from the diffraction measurements. The result of a 
diffraction experiment is obtained as an array of spots (reflections) that measures the 
intensities of waves scattered by the crystal. However during the diffraction experiment, 
the phase information is lost. Subsequently, there are two processes in X-ray 
crystallographic studies. Initial diffraction experiments are carried out to measure 
intensities (and ultimately amplitudes), and another set of experiments to determine the 
phases (Clegg, 1998; McPherson, 2003).
5.I.3.I. Properties of protein crystals
One or all of the following factors may influence size, quality, and X-ray diffraction 







(e) Covalent or non-covalently bound sugars, prosthetic groups, or other ligands
(f) Other, more complex layers
(g) Various defects and dislocations.
5.1.3.2 Methods of crystallisation (Vapour diffusion techniques)
This is the most important and successful method of crystallization, which produces 
very good diffraction quality crystals. The various vapour diffusion techniques are: 
Sitting drop, and hanging drop as follows:
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air saturated with precipitant solution
Figure 5.4 Hanging drop vapour diffusion technique
Reservoir with 
precipitant
Coverslip with protein 
solution (red)
High - vacuum 
grease air saturated with 
precipitant solution
Figure 5.3 represents the sitting drop method, where the protein drop sits on a base 
above the reservoir solution, as opposed to hanging drop 
(Figure 5.3 adapted from
http://www.bio.davidson.edU/Courses/Molbio/MolStudents/sprins2003/Kosov/protein.h
tml).
Figure 5.4 illustrates the hanging drop method. Reservoir solution (blue) usually 
contains buffer and precipitant. Protein solution (red) contains the same compounds, 
but in lower concentrations. The protein solution may also contain trace metals or ions 
necessary for precipitation of particular proteins. For instance, insulin is known to 
require trace amounts of zinc for crystallization (McRee, 1993; Rhodes, 1993).




In the sitting drop vapour diffusion method wells are used of a great variety of plates 
available from the Hampton
(http://www.hamptonresearch.eom/assets/products/attachments/0000000001- 
0000000073.pdf). A droplet of 5-10 pi containing the macromolecule, a buffer and a 
precipitating agent is equilibriated against a reservoir of 1-25 ml, containing a solution 
of the same precipitant but with a higher concentration then that of the drop. Solvent 
equilibriation takes place, where the evaporation of the volatile species takes place until 
the vapour pressure of the droplet equals that of the reservoir, and crystals form in the 
droplet.
The hanging drop method is the same as of the sitting drop technique, with the 
exception that in this case the drop is inverted and remains intact by surface tension 
over the precipitant reservoir. Solvent equilibriation takes place as the sitting drop 
method, and crystals grow in the droplet.
The vapour diffusion techniques use plates with either 4 X 6  wells or for microbatch 
tests of 6 X 12 wells. It allows a wide range of choice of polymers, salts, and organic 
solvents with a high range of pH (see appendix). When a crystal is obtained in any 
particular condition, a second trial is set with that same condition in order to optimise 
the crystallization conditions, to produce X-ray diffraction quality crystals.
5.I.3.3. Crystal growth
In order to carry out X-ray crystallographic analysis, crystals of the protein must first be 
grown. Crystals are an ordered arrangement of molecules. When molecules are 
precipitated very slowly from supersaturated solutions, crystals are formed. “Hanging 
drop” and “sitting drop” are the two commonly used methods for making crystals. In 
these methods, the protein solutions are brought very gradually to supersaturation by 
vapour diffusion. The protein solution is mixed with the precipitant and a drop of this 
mixture is setup in a sealed atmosphere shared with a reservoir. Due to osmotic pressure 
the movement of water out from the protein drop to the reservoir occurs. The commonly 
used precipitants are generally salts (such as ammonium sulphate), polymers (for 
example, various molecular weight polyethylene glycols, PEGs) or organic solvents (2- 
methyl 2,4-pentadiol; MPD).
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The three steps involved in crystal growth are as follows:
1) Nucleation- the formation of a “seed”, which initiates crystal growth.
2) Growth- molecules of the protein in solution build up a crystal lattice around the 
initial seed.
3) Cessation of growth- The crystal stops growing when, either the system has reached 
an equilibrium, where the number of molecules joining the crystal lattice is the same as 
the number returning to solution; or the crystal redissolves due to factors such as the 
increasing osmolarity of the protein drop causing the equilibrium to reverse or the 
crystal to shatter. Crystals can also stop growing when external or damaged molecules 
are incorporated into the growing surface, resulting in defects that interrupt the 
established regular pattern. The figure below shows a plot of a theoretical phase 
diagram, showing the transition of a protein molecule from the soluble state to 
crystalline state (McPherson, 1999).
Figure 5.5 Crystallization phase diagram
F igu re  5 .5  sh o w s the c rys ta lliza tio n  p h a se  d iagram . (A) The u n d ersa tu ra ted  zone, 
w h ere  the p ro te in  rem a in s so lu ble . (B ) The m e ta s ta b le  zon e  o f  su p ersa tu ra tio n , w h ere  
the p ro te in  is su p ersa tu ra ted  enough to su p p o r t c ry s ta l grow th , b u t n o t h igh en ou gh  to  
in itia te  the n u clea tion  p ro c e ss . (C ) The n u clea tion  zone, w h ere  p ro te in  is 
su p ersa tu ra ted  enough  to  fo rm  c ry s ta l nuclei. (D ) The p re c ip ita tio n  zon e in w h ich  the  
p ro te in  is h igh ly  su persa tu ra ted , lead in g  to p re c ip ita tio n  (A d a p ted  f r o m  D eL u ca s e t al., 
2003).
As only well-ordered crystals of the target protein are capable of producing useful X-ray 
diffraction results, the design of a crystallization process is crucial. A typical
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cry sta lliza tion  exp er im en t starts w ith  a screen in g  p ro cess , w h ich  in v o lv e s  a ltering  the  
p h y sica l and ch em ica l en v iron m en t o f  the target protein  until so m e  form  o f  crysta llin e  
m aterial is  ob ta ined . T h is is  fo llo w e d  b y  an o p tim iza tion  p ro cess , w h ich  u su a lly  
in v o lv e s  im p ro v in g  the s iz e  and d iffraction  q u ality  o f  the crystal. D ifferen t crysta ls  
b eh a v e  in  d ifferen t w a y s , w h ere  so m e  m ay  b e  stab le  for years, w h ile  others are n o t and  
p rov id e o n ly  v ery  lim ited  op portu n ities to  gather its  d iffraction  pattern.
5.1.3.4 Factors that affect crystallization
C rysta llisa tion  is  a co m p lex  p rocess . For ex a m p le  m an y  factors can  a ffect  
crysta lliza tion , e .g . the pH  o f  the protein  drop, the precip itant typ e and con cen tration  
u sed , the tem perature at w h ich  th e exp er im en t is  carried out, and the ad d ition  o f  c o ­
factors. A  m in ute ch an ge in any o f  th ese  param eters can  m ak e the d ifferen ce  b etw een  
w h eth er a crysta l is  form ed  or not. T here is no particular w a y  to d eterm in e w h ich  set o f  
co n d itio n s w ill  produce crysta ls for a particular protein. T herefore variou s p oten tia l 
con d itio n s h a v e to b e  tried in  order to obtain  a crysta l. T he purity o f  a p rotein  sam p le  is  
the m o st im portant factor for  its crysta lliza tion  as im p urities m ay  in trod uce  
im p erfection s, w h ich  are harm ful for the grow th  o f  d iffraction  q u ality  crysta ls.
D ifferen t d eg rees o f  supersaturation  are created  to d eterm ine the con cen tration  o f  the  
protein  required to produce X -ray  q u ality  crysta ls. S a lts e .g . am m on iu m  su lphate; h igh  
m olecu lar  w e ig h t straight-chain  p o lym ers, e .g . P o ly e th y len e  g ly c o ls  (P E G s), and 2 -  
m e th y l-2 ,4  p en tan e d io l (M P D ); and organ ic so lv en ts  lik e  ethan ol are so m e  o f  the  
ch em ica l precip itants u sed  to a ch iev e  supersaturation  o f  m o lecu le s .
N o w a d a y s pentaerythrito l p rop oxy la te  and pentaerythritol e th o x y la te  are u sed  as n ew er  
precip itants (G u lick  et a l., 2 0 0 2 ) . T h e  m o st su cce ssfu l salt reported  in  crysta lliza tion  
exp er im en t is  so d iu m  m alon ate, w h ich  in v o lv e d  23  proteins and com pared  12 sa lts  
in c lu d in g  am m on iu m  su lphate, the con v en tio n a l sa lt u sed  for crysta lliza tion . M alon ate  
is  an organ ic acid  w ith  tw o  n eg a tiv e  ch arges at neutral pH . T h e ro le  o f  th ese  precip itan ts  
is  to co m p ete  for w ater w ith  p rote in s lea d in g  to in term olecu lar in teractions that 
favou red  the form ation  o f  crysta ls. pH  o f  the protein  so lu tio n  is a lso  an im portant factor  
for its crysta lliza tio n  as it a ffects the net charge on  the protein  m o le c u le  and the charged  
state o f  the e x p o sed  am ino acid s. W h ere a protein  is  le s s  so lu b le , ad justm ent o f  its pH  
can  lead  to the form ation  o f  crysta ls. In m o st ca se s  crysta lliza tion  occur o v er  a narrow  
range (<1 pH  un it), but in so m e  ca se s  it occurs ov er  a broad range o f  pH  a lso . U su a lly
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th e pH  around w h ich  protein  crysta lliza tion  o ccu rs is  the Iso e lec tr ic  p o in t o f  the protein , 
w h ere the net charge on  the protein  is  zero.
T em perature has an im portant ro le  on  protein  so lu b ility  and the b eh av io u r  o f  the other  
co m p o n en ts  d iscu ssed  before. T he rate o f  eq u ilib ration  is  gen era lly  s lo w e r  at lo w er  
tem peratures. T em perature ranges from  0 -4 °C  and 2 0 -2 4 °C  are su itab le  to  obta in  m o st  
protein  crysta ls. T here are ex c ep tio n s  w h ere a fe w  proteins h a v e  cry sta lliz ed  at 
tem peratures lo w er  than 0 °C  and a b o v e  4 0 °C . In recen t tim es crysta llisa tio n  is  carried  
ou t in  a robot w h ere m u lti-w e ll p lates are set, w ith  each  w e ll co n ta in in g  a d ifferen t 
con d ition .
5.1.3.5 Crystal mounting for x-ray data collection
In order to  obtain  the X -ray  d iffraction  pattern o f  the protein  crysta l, the crysta l m u st b e  
rem o v ed  from  the drop and p laced  in  the path o f  the X -ray  beam . G en era lly  a lo o p  o f  
n y lo n  is  u sed  to “fish ” ou t the crystal from  the protein  drop. O n ce the crysta l is  in  the  
lo o p , the b a se  is  attached m a g n etica lly  to the gon io m eter , w h ich  a llo w s  the crysta l to  b e  
a lign ed  and rotated a lo n g  the path o f  the X -ray  b eam . S urface ten sio n  h e lp s the crystal 
to b e attached in  the lo o p  during th is p rocess. T h e life tim e  o f  a crystal m ay  range from  a 
fe w  m in u tes to severa l d ays under norm al laboratory con d ition s. B u t w h en  the crystal is  
ex p o se d  to h igh  in ten sity  X -ray , th e l ife  tim e o f  the crystal u su a lly  d ecrea ses  d rastically . 
In order to p revent th is denaturation  o f  the protein  crystal, a p ro cess  ca lled  as “C ryo- 
cry sta lliza tio n ” is  u sed  (S tu m  et al., 2 0 0 4 ).
5.I.3.6. Cryo-crystallography
In th is p ro cess  the tem perature o f  the protein  crysta l is  lo w ered  b y  rap id ly  p a ssin g  a 
stream  o f  co ld  liq u id  n itrogen  through the m ou n ted  crystal. A ls o  the lo w er in g  o f  the  
tem perature o f  the crysta l ca u ses  the lo w er in g  o f  the therm al m o tio n  o f  th e con stitu en t  
atom s, and the X -ray  d iffraction  pattern is  im p roved  b oth  in in ten sity  and reso lu tion . T o  
a v o id  the freez in g  o f  the w ater in  the crystal and other so lu tio n s, a ch em ica l that acts as 
a “cryoprotectant” is  m ix ed  w ith  it b efore  the crysta l is  m ounted . T h is a llo w s the w ater  
to freeze  as a g lass. C h em ica ls  co m m o n ly  u sed  as cryoprotectan ts are G ly cero l m ak ing  
up to a con centration  o f  10 -  30%  o f  the fin a l so lu tio n . O ther ch em ica ls  u sed  are lo w  
m olecu lar  w e ig h t P E G s, e th y len e  g ly c o l and so d iu m  m alon ate (R o se  and W an g, 1997)
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5.I.3.7. X-ray diffraction
X -rays are a form  o f  e lec tro m a g n etic  radiation  w ith  a w a v e len g th  in  the range o f  10'9 m
Q
-  10' m . F or protein  crysta llograph y , there are tw o  m ain  sou rces o f  X -ra y s, “in - h o u se” 
sy stem s and synchrotron . T h e in -h o u se  sy ste m  is  re la tively  sm aller  than th e synchrotron  
system . T he synchrotron  sy stem  is  a particular storage ring, w h ich  a ccelera tes  e lectron s  
around a circular track (w h ich  is ca lled  th e b ea m  lin e) in  a h ig h  v a cu u m  at c lo se  to the  
v e lo c ity  o f  ligh t. T h e e lec tro n s em it an in ten se  con tin u ou s sp ectru m  o f  X -rays. T h is is  
cau sed  b y  u sin g  m a g n etic  fie ld s  to steer the e lec tron s around the ring. T h e in -h o u se  
sy stem  p rod uces X -ra y s b y  fo c u s in g  a b eam  o f  e lectron s on  a sm a ll area o f  m etal. T h e  
d esig n  o f  the in -h o u se  sy ste m  is  a “rotating an od e X -ray  generator”, w h ere the e lectron s  
are fo c u se d  on  a sm all area o f  a rotating cop p er cylin der. X -ra y  p rod uced  from  
synchrotrons, are m u ch  m ore in ten se  than that produced  from  the in -h o u se  sou rce and  
th ey  h a v e m u ch  better op tion a l properties. A s  there are very  fe w  synchrotrons in the  
w orld , the early  exp er im en ts  are carried ou t in -h o u se  to d eterm in e factors lik e  the b est  
cryoprotectant (D renth , 1999; M cP h erson , 2 0 0 3 ).
D iffra ctio n  is  a p h en o m en o n  that occurs w h en  a w a v e  p asses  through a s lit  or a ser ies o f  
sm all op en in gs, w h ere th e s iz e  o f  the s lit  is  com parab le to the w a v e len g th . X -rays are 
u sed  to  create “d iffraction  patterns” from  the p rotein  crystals.
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F ig u re  5.6 X -ra y  d iffractio n  patterns
Figure 5.6 illustrate the patterns obtained by X-ray diffraction of an object. The sphere 
in the top left, gives the diffraction pattern shown in the top right. The bottom part of the 
figure depicts diffraction by a crystalline array of spheres, where to the bottom left is a 
cross section of the crystal, and its diffraction pattern to its right (figure adapted from 
Rhodes, 2000).
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T h e la ttice  sp acin g  o f  the crysta l is  sm aller  vertica lly  (sh ow n  b ottom  left), and the  
d iffraction  sp acin g  is  sm aller h or izo n ta lly  (sh o w n  b ottom  right). T here is  the in v erse  
relationsh ip  b etw een  the sp acin g  o f  u nit c e lls  in  the crysta llin e  la ttice  (real la ttice )  
w h ich  is ind icated  in  the b o tto m  le ft part o f  the figure ab ove, and the sp a c in g  o f  
re flectio n s in  the la ttice  on  the f ilm  (recip rocal la ttice) as in d icated  in  the b o ttom  right 
(R h od es, 2 0 0 0 ; M cP h erson , 2 0 0 3 ).
5.I.3.8. The arrangement of protein molecules in a crystal
F rom  the d iffraction  pattern, the m olecu la r  arrangem ent o f  the d iffractin g  ob ject can  b e  
estim ated . T h e d iffraction  pattern can  be u sed  to determ ine the sh ape o f  the protein  and  
its arrangem ent w ith in  the crystal. A  crysta l is  b u ilt up o f  a large num ber o f  id en tica l 
units, ca lled  the “unit c e l ls ” . T he unit c e lls  con ta in  on e  or m ore “asym m etric  u n its” , the  
sm a llest unit o f  the crysta l w h ich  can  b e  u sed  to generate the unit, and then in turn the  
co m p le te  crystal.
T h e crystal con ta in s the unit c e lls  in  three d im en sio n s, the len gth s o f  three u n iq ue e d g es  
are a, b, and c, and three unique an g les  a , p, and y illustrated  in  F igu re 5 .7 .
Figure 5.7 A triclinic unit cell
Figure 5.7 shows a general triclinic unit cell, with edges a, b, and c, and angles a, /?, 
and y (Figure adapted from Rhodes, 2000).
A  crystal con ta in s unit c e lls  in three d im en sio n s. T h e transform ation  o f  on e  unit c e ll  
into  another is  a pure translation , and is a form  o f  sym m etry . T here are d ifferen t ty p es o f
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crysta ls w ith  re la tion sh ip s b e tw een  the c e ll  ed g es  and the a n g les  b e tw een  th e e d g e s , as 
g iv e n  in  T a b le  5 .1 .
Table 5.1 The crystal systems




T riclin ic b ^ c
M o n o c lin ic b ^ c a = y = 90°; P > 90°









T rigon al/rh om b oh ed ral a = b ^ c a  = y =  9 0 ° ; P =  120°
H ex a g o n a l a = b^ c a  = P = 90°; y = 120°
C u b ic a = b = c a  = p = y = 90°
Table 5.1 has been created with reference to Rhodes, 2000; Blow, 2002 and 
McPherson, 2003.
It is  im portant to d eterm ine the crysta l sym m etry , as the m easurem en t o f  X -ray  
scattering  b y  the crysta l during the in itia l stages o f  the ex p er im en t can  b e  determ ined . 
T h e sym m etry  o f  the crystal at the fin a l stages o f  data interpretation is a lso  s ig n ifica n t, 
w h ich  w o u ld  lead  to the d eterm ination  o f  crysta l structure.
5.1.3.9 Diffraction of X-rays by crystals 
Bragg’s law
T h e d iffraction  pattern ob ta ined  from  a crystal in  a g iv en  orien tation  is  determ in ed  b y  
B ra g g ’s la w . A  crysta l is  c o m p o se d  o f  m an y  parallel m irrors, w h ich  is referred to as 
B ra g g  p lan es, w h ich  reflect X -rays. H o w  rays scattered  at the la ttice  p oin ts in  o n e  p lane, 
all travel th e sam e d istan ce  to the scattered  w a v e  front, is  g iv en  in  the first part o f  
B ra g g ’s exp lan ation . A n y  p lan e o f  la ttice  p o in ts o f  a crystal acts as a mirror. M an y  
parallel la ttice  p lan es are created  b y  the crysta l lattice . T h e three q uan tities that are 
d ep en dent o n  for  tw o  p lan es to scatter in  p h ase  are:
-T h e w a v e len g th  X o f  the X -rays,
-T h e sp a c in g  d b etw een  the p lan es,
-T h e g la n c in g  a n g le  0.
T h e p lan es are represented  b y  a se t o f  in tegers, h k  1, referred to as la ttice  in d ices . 
A cco rd in g  to the B ra g g ’s la w , w h en  X -ra y s o f  w a v e len g th  X co m es  in  con tact w ith  a set
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o f  parallel p lan es w ith  the d istan ce b etw een  the tw o  p lan es d, at an a n g le  0 , and are 
re flected  at the sam e an g le , d iffraction  occurs.
T he eq u ation  is as:
tih= 2 d sin 0
(n is  an in teger, w h ich  d en otes  the path len gth  b etw een  adjacent p la n es) (P alm er, 20 0 1 ;  
B lo w , 2 0 0 2 ) .
Figure 5.8 Diagramatic representation of Bragg’s law
Figure 5.8 shows the conditions that produce diffracted rays according to B ra gg ’s Law. 
The parallel horizontal lines represent two parallel planes with interplanar spacing dm. 
The shaded circles on the horizontal lines represent atoms. The incident (7/ and f )  and 
reflected (Rj and R 2) rays make an angle 0 with the planes. Since two angles are equal, 
provided corresponding sides are perpendicular, the angle CAB  also equals 6 (figure 
adapted from Rhodes, 2000; Palmer, 2001).
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5.2. Circular Dichroism spectroscopy
A  v ery  im portant to o l for  in v estig a tin g  the structural properties o f  a p rotein  is  the  
C ircular D ich ro ism  (C D ) sp ectro sco p y . T h e seco n d a ry  structure con ten t o f  a protein , its 
tertiary structure, and fo ld  reco g n itio n  can  b e  a n a lysed  b y  C D  sp ectro sco p y . T he reason  
w h y  circu lar d ich ro ism  sp ectro sco p y  has b e c o m e  the m eth od  o f  c h o ic e  is  its rela tive  
sp eed  o f  a n a lysis , the sm a ll am ount o f  sam p le  required, and th e in form ation  about the  
overa ll structure o f  a p rotein  that can  b e  ob ta in ed  (A n d ersson , C arlsson  and Freskgard,
2001).
In the recen t tim e, a h igh  num ber o f  re so lv ed  p rotein  structures h a v e b een  su bm itted  to  
the protein  data bank (P D B ). X -ray  crysta llograp h y  or N M R , are the tw o  im portant 
m eth od s for structure p red iction  o f  a p rotein , b ut as th ey  are v ery  e x p e n s iv e  and tim e  
co n su m in g , circular d ich ro ism  sp ectro sco p y  has b eco m e  in crea sin g ly  reco g n ized  as a 
structural an a ly sis  tech n iq ue. T he m ain  ad vantage in  C D  sp ectro sco p y  is that the  
a n a ly sis  can  b e  p erform ed  under the co n d itio n s , in  w h ich  p rotein s actu a lly  operate, that 
is  gen era lly  in  so lu tio n  (K elly , Jess and P rice, 2 0 0 5 ) .
5.2.1. Mechanism of CD spectroscopy
C D  sp ectro sco p y  can  b e  ob serv ed  for o p tica lly  a ctive  m o le c u le s  or in  the ca se  o f  
m o lec u le -lig a n d  b in d in g  or i f  at lea st o n e  o f  the in teracting sp e c ie s  is  o p tica lly  activ e  
(D rake, 2 0 0 1 ). P lan e p o lar ised  ligh t is  co m p o sed  o f  tw o  circu larly  p o lar ised  
co m p o n en ts  o f  equal m agn itu d e, o n e  rotating c lo c k w ise  (right h anded  R ) and the other  
cou n ter c lo c k w ise  (le ft handed  L ). T he p rin c ip le  b eh in d  the circu lar d ich ro ism  is a lso  
b ased  on  the d ifferen tia l absorption  o f  th ese  tw o  (L  and R ) com p o n en ts . I f  the L  and R  
co m p o n en ts  are absorbed  to equal ex ten t w h en  a ray o f  lig h t is  p a ssed  through a sam p le, 
the recom b in ation  o f  L  and R  w o u ld  regenerate radiation  p o lar ised  in  the orig in al p lane. 
T h e resultant radiation  w o u ld  b e  said  to p o sse ss  e llip tica l p olarization  i f  the L  and R  are 
absorbed  to d ifferen t ex ten ts  (D rake, 2 0 0 1 ;
h ttp ://w w w .n ew a rk .ru tg ers.ed u /ch em istrv /g ra d /ch em 5 8 5 /lec tu re l.h tm l) .
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Figure 5.9 Principle of polarization of light in CD spectrometry
A . O rdinary ligh t B . R igh t circu larly  p o lar ised  C. L eft c ircu lar ly  p olarised
Figure 5.9 shows the ordinary light, the right circularly polarised and the left circularly 
polarised light in a C D  spectroscopy (figure adapted from Drake, 2001).
W h en  a ch rom oph ore is  o p tica lly  active , a C D  sign a l is ob served . T h e  C D  instrum ent 
m easures the d ifferen ce  in  absorbance b e tw e en  the L and R c ircu lar ly  p o lar ised  
com p o n en ts  (A A  =  A l - A r ) , and is  reported in  term s o f  the e llip tic ity  (0 ) in d egrees  
(D rake, 2 0 0 1 ).
T h e far u ltrav io let spectral range, ranges from  about 190 -  2 5 0  nm , and it p rov id es  
in form ation  on  the secon d ary  structural con ten ts o f  proteins. Spectral an a ly sis  o f  b e lo w  
190 nm  p rov id es further in form ation  about the protein  con form ation s and fo ld in g . T h is  
is  u su a lly  p o ss ib le  b y  u sin g  the C D  sp ectrom eters, u sin g  synchrotron  radiation  w h ich  
can  go  to as lo w  as 160 n m  w a v e len g th . (Sreeram a and W o o d y , 2 0 0 0 ; W a lla ce  and  
Janes, 2 0 0 1 ). T h e tertiary structure o f  a p rotein  can  b e an a lysed  from  the near U V  
circular d ich ro ism  w h o se  w a v e len g th  is  in  the range o f  2 6 0  -  3 2 0  nm . T h e spectra in  
th is reg ion  arises from  the arom atic am in o acid s, lik e  tryptophan sh o w s a p eak  b etw een  
2 9 0  and 3 0 5  nm , tyrosin e  b etw een  2 7 5  and 2 8 2  nm , and p hen y la lan in e b etw een  2 5 5  and  
2 7 0  nm .
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Figure 5.10 Far UV CD spectrum illustrating secondary structural features
Figure 5.10 shows the far U V  C D  spectrum obtained in the range of 160 -  260 nm 
wavelength. The secondary structural features have been illustrated as marked in the 
figure (Kelly, Jess and Price, 2005).
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Figure 5.11 Near UV CD spectrum arising from amino acid residues
The range of spectrum 
of the aromatic 
amino acids(Phe, Tyr & 
Trp)
Figure 5.11 shows the near U V  C D  spectrum obtained within the range o f260 -  320 nm 
wavelength of type I I  dehydroquinase from Streptomyces coelicolor as an example. The 
peaks represents the U V  signals of the absorbance of Phenyl alanine (255-270 nm), 
Tyrosine (275-282 nm), and Tryptophan (290-305 run) at different wavelength ranges 
(Kelly, Jess and Price, 2005).
5.2.2. Information obtained from CD studies of proteins
1) S econ d ary  structure c o m p o sitio n  (%  a -h e lix . [3-sheets, turns): T he absorption  in  th is  
ca se  is  in  the reg ion  o f  far U V  o f  b e lo w  2 4 0  nm , m ain ly  due to the p ep tid e  bond . T h e  
appearance o f  C D  spectra in  the far U V  is  contributed  b y  the d ifferen t ty p es o f  regular  
secon d ary  structures fou n d  in  proteins. S econ d ary  structure co m p o sitio n  o f  a protein  
can  b e  estim ated  b y  a num ber o f  a lgorithm s that u ses  the data from  far U V  C D  spectra. 
T he a lgorith m s u sed  are S E L C O N , V A R S L C , C D S S T R , C O N T IN . In m o st o f  the 
procedures, b a sic  datasets co m p rises  the C D  spectra o f  p rote in s w h o se  structure has 
b een  so lv e d  b y  X -ray  crysta llograph y. R ecen tly  an o n lin e  server ca lled  the  
D IC H R O W E B  has b een  d ev e lo p ed  to an a lyse  various C D  spectra.
2) T ertiary structure determ ination: A m in o  acid s tend  to h ave a characteristic  
w a v e len g th  p rofile . P h en y la la n in e  sh o w s a band b etw een  2 5 5  and 2 7 0  nm , tyrosin e  has  
a p eak  b etw een  2 7 5  and 2 8 8  nm , w hereas tryptophan has a peak  b etw een  2 9 0  and 30 5  
nm . T h e near U V  C D  spectrum  o f  a protein  d ep en d s on  various param eters lik e  the
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num ber o f  each  typ e o f  arom atic am in o acid s present, their m o b ility , the nature o f  their  
en v iron m en t ( H -b on d in g , polar groups and p olarisab ility ).
3 ) In form ation  about the o vera ll structural featu res o f  proteins: T h e far U V  C D  an a lysis  
g iv e s  quantitative estim a tio n  o f  secon d ary  structure and can  b e  com p ared  w ith  th ose  
from  X -ra y  crysta llograp h y  and N M R . T h e structural re lationsh ips b e tw e en  n ative and  
recom b in an t protein s, w ild  ty p e  and m utant p rote in s can  b e a sse ssed  fro m  the d ifferent 
C D  spectral reg ion s. A ls o  the in tegrity  o f  the ex p ressed  d om ain s o f  a m u lti-d om ain  
protein  can  b e  con firm ed  from  a C D  data. T h e  quantitative estim ation  o f  th e stab ility  o f  
the fo ld ed  state o f  a protein  can  b e  a ssessed , b y  the lo ss  o f  C D  s ig n a ls  either on  
in creasin g  the tem perature or b y  addition  o f  denaturing agents.
4 ) C on firm ationa l ch a n g es in  proteins: L igan d  b in d in g  cau ses structural ch an ges in  a 
p rotein , and is an im portant part in  the m ech a n ism  o f  action  and regu la tion  o f  b io lo g ic a l  
activ ity . C D  sp ectro sco p ic  an a ly sis  p rov id es a m ean  o f  estim atin g  su ch  ch a n g es from  its 
s ig n a ls  in  d ifferen t spectral reg ion s. T h e range o f  ligand  con cen tration s o v er  w h ich  the  
structural ch a n g es take p la ce , the ex ten t o f  ch a n g es in  the protein  o f  in terest, and the 
sp eed  at w h ich  su ch  ch a n g es  occu r  all can  b e  a ssessed  from  C D . W h en  X -ray  
crysta llograp h ic a n a lysis  is  n ot p o ss ib le , C D  can  b e  u sed  as an in v a lu a b le  m eth od  in  the  
stu d y o f  protein  structure.
C D  is  a d em an d in g  tech n iq u e in  term s o f  quantity o f  sam p le required fo r  an a lysis  or 
tim e  o f  an a lysis . G o o d  q uality  C D  spectra can  b e  obta ined  from  le s s  than 0 .1  m g  o f  
protein  sam p le  (for far U V ) and 1 m g  (for the near U V ). T h e tech n iq u e  is non  
d estru ctive and tim e o f  an a ly sis  is  3 0  m in u tes or le s s  (K e lly , Jess and P rice , 2 0 0 5 ).
A n  o n lin e  server fa c ilita tin g  the a n a lysis  o f  circu lar d ich ro ism  sp ectro sco p ic  data is  the  
D IC H R O W E B . T h is is  a very  popular server and u ses  f iv e  im portant datab ases, and  
accep ts the input data in  a w id e  range o f  form ats. It ca lcu la tes the seco n d a ry  structure  
con ten ts  and graphical an a ly ses , com p arin g  ca lcu la ted  stm ctures and exp er im en ta l data  








6.1 The importance of 3D structures
The desire to understand biological processes at the molecular level, had led to the 
prediction of three dimensional protein structures from amino acid sequences, and hence 
the importance of protein homology modelling in addition to those of X-ray 
crystallography and NMR (Adams, Grosse-Kunstleve and Brunger, 2003). The structure 
prediction of a protein is essential for structure-based drug design, analysis of protein 
function and protein interactions. A fundamental principle in protein science is that 
“protein structure leads to protein function” (Scheef and Fink, 2003;
http://www.biophvsics.org/education/ellis.pdf).
Figure 6.1 Information that can be obtained from 3D structure of UBE2J
EVOLUTIONARY RELATIONSHIPS OF UBC FAMILY
LOCATION OF CONSERVED RESIDUES OF UBCs (UBE2Js)
3D STRUCTURE OF UBE2JS
LIGAND BINDING SITES OF UBCs
FUNCTIONAL SITES AND FUNCTIONS OF UBC FAMILY
\STRUCTURAL AND FUNCTIONAL MOTIFS OF UBCs
(This figure is adapted from Bartlett, Todd and Thornton, 2003)
Figure 6.1 summarises the biological information that can be obtained from an actual 
or predicted three dimensional protein structure.
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T h e b est m eth od  to fin d  out the structure o f  a protein  is either b y  N M R  or b y  X -ray  
crysta llograph y, but th ese  m eth od s h ave their lim ita tion s. S o m e p rote in s are eith er too  
large fo r  carrying ou t its N M R  an a lysis , or the protein  is d ifficu lt to  cry sta llize . B o th  o f  
th ese  m eth od s are v ery  d em an d in g , and the in v o lv e m en t o f  m ore than o n e  ex p ertise , and  
it m ay  not a lw a y s b e  ab le  to carry out the exp erim en ts ec o n o m ic a lly . In th ese  
circu m stan ces, the b est m eth od  o f  structure pred iction  is  com p u tation a l h o m o lo g y  
m o d ellin g . T h e num ber o f  proteins in  the P D B  database is in creasin g  every d a y , b y  the 
con stan t input o f  N M R  and X -ray  pred icted  structures. T herefore to fin d  h o m o lo g y  o f  
the seq u en ce  o f  protein  w h o se  structure n eed s to b e predicted , to  the d esired  p ercen tage  
iden tity  is not a p rob lem . T h eoretica lly  the p ercen tage identity  o f  the tw o  h o m o lo g u e s  
(the tem p late and the protein  w h o se  structure n eed s to be p red icted) sh o u ld  b e  m ore  
than 30%  (R od rigu ez et al., 1998; H un g and Sam udrala, 2 0 0 3 ).
Figure 6.2 Homology zones from percentage identity of residues
P ercen tage  
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Figure 6.2 shows the safe homology modelling zone and the twilight zone. Two 
sequences are practically guaranteed to adopt a similar structure if the length of the 
two sequences and the percentage identity fall in the region marked as safe. This 
relationship was first identified by Chotia and Lesk (1986) (Figure adapted from  
Krieger, Nabuurs and Vriend, 2003).
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T herefore, there is  a h igh  p rob ab ility  o f  trading a re lative stringent w a tch  b etw een  a 
k n ow n  structure (tem p late seq u en ce) and that o f  a subject seq u en ce . T h e  p red icted  
structure gen erated  b y  h o m o lo g y  m o d e llin g  has to b e  treated ca u tio u sly  but its u tility  
can  b e  d em on strated  b y  the su c c e ss  o f  its  u se  in  other structure-dependent fu n ction s  
su ch  as, d o ck in g  o f  a cc esso ry  m o le c u le s . In other w a y s, the p red icted  structure can  
serve  as a u se fu l starting p o in t for trial-and-error in vestigation .
6.2. Relationship between structure and function
T he re la tion sh ip  b etw een  structure and fu n ction  can  b e  ex a m in ed  on  d ifferen t le v e ls  lik e  
c la ss , fo ld , h o m o lo g y , and an a logy .
Protein structural class and enzyme function:
Structural c la sse s  o f  proteins form  e n zy m es , o f  w h ich  a /p  fo ld s  are o v er  ex p ressed  in  
en zy m es com p ared  w ith  a norm al d istribution . T his ov er  ex p ress io n  is d u e to the large  
num ber o f  n u c leo tid e  b in d in g  d om ain  in  en zy m es . A sso c ia te d  w ith  n o n -en zy m e s  are the  
a ll- a  and sm a ll fo ld s. T he transferases and h yd ro lases are particu larly co m m o n  am on g  
the a /p  fo ld s  w h ich  reflect evo lu tio n a ry  se lec tio n .
Protein folds and function:
P roteins w ith  sim ilar structure can  h ave to ta lly  d ifferen t fu n ction s. T h is is  b eca u se  the  
num ber o f  fo ld s  is  lim ited , and there are m u ltip le  su p er-fam ilies w ith in  ea ch  fo ld  group. 
T he m o st c o m m o n ly  fou n d  fo ld  is  the (p /a )s  barrel, w h ich  has reoccurred  a num ber o f  
tim es in  ev o lu tio n  and has m an y  d iv erse  fu n ction s. T h e f iv e  m o st v ersa tile  fo ld s  in  all 
proteins are the T IM  barrel fo ld , A lp h a /b eta  h yd ro lase  fo ld , N A D  b in d in g  d om ain , P- 
lo o p  N T P  h y d ro la se  fo ld , F errod oxin  lik e  fo ld . T h ey  all are a /p  or a  +  p fo ld s , and each  
h ave d ifferen t fu n ction s a ssocia ted  w ith  it.
Homologous families and functions:
W ith in  the h o m o lo g o u s  protein  fa m ilie s  it is  ex p ec ted  that fa m ily  m em b ers w ill  h ave  
related  fu n ctio n s, but th is is  n ot a lw ays th e case . C on siderab le d iv ersity  h as b een  seen  
w ith in  h o m o lo g o u s  su p er-fam ilies. T w o  p rote in s h a v in g  h igh  seq u en ce  id en tity  b e tw een  
th em  co u ld  vary in  their fu n ction . O n the other hand during ev o lu tio n , a p rote in  fa m ily
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Analogues:
T here are proteins that are a n a lo g o u s to o n e  another sharing structural sim ilarity  but no  
seq u en ce  identity . S u ch  a n a lo g u es are ex a m p les  o f  co n v erg en t e v o lu tio n  (B artlett, T od d  
and T hornton, 2 0 0 3 ).
might have been subjected to m ultiple amino acid changes, but their function has
remained unchanged.
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7.1. Methods of the phylogenetic analysis of the UBC and UBC like peptide 
sequences.
Sequence data mining
R etr iev in g  all k n ow n  13 y ea st U B C s (U B C 1 -U B C 1 3 ) p ep tid e  seq u en ces  from  the  
E X P A S Y  site  fw w w .e x p a sv .o r g ) . B L A S T  (B a s ic  L o ca l A lig n m en t S earch  T o o l)  search  
u sin g  each  o f  the 13 y ea st  U B C  p ep tid e  seq u en ces  to find  its h o m o lo g u e s  in  d ifferen t 
o rgan ism s w h o se  g e n o m e  w a s fu lly  seq u en ced  in  appropriate databases N C B I, 
E N S E M B L , E B I, T IG R
(w w w .n c b i.n lm .n ih .g o v , w w w .e n se m b l.o r g , w w w .e b i.a c .u k , w w w .tig r .o rg ) . T he  
d ifferen t organ ism s w h o se  h o m o lo g u e s  w ere  retrieved  w ere Homo sapiens, M us 
musculus, Arabidopsis thaliana, Oryza sativa, Drosophila melanogaster, 
Caenorhabditis elegans, Plasmodium falciparum, Anopheles gambaie, Neurospora 
crassa, Schizosaccharomyces pombe and Plasmodium yoelli yoelli.
A ll h o m o lo g u e s  retrieved  b y  the B L A S T  search  w ere g iv en  arbitrary n am es, as th ey  
w ere  o n ly  ind icated  b y  a cc ess io n  num bers w ith o u t any proper n om en cla tu re n am ing. 
T here w ere  o ften  repeat and partial seq u en ces that had appeared in  the database B L A S T  
search es w h ich  w ere ex c lu d ed .
M ore than o n e  h o m o lo g u e  in  on e  organ ism  w a s o ften  retrieved  from  the b last search, 
ea ch  d iffer in g  from  the oth er b y  a d ifferen t a c c e ss io n  num ber. A n  ex a m p le  to c ite  th is  
illu stration  is  u s in g  y ea st  U B C  13 p ep tid e  seq u en ce  to a B L A S T  search  to fin d  its  
h o m o lo g u e s . T hree h o m o lo g u e s  w ere  ob ta in ed  from  the B L A S T  search  for Arabidopsis 
thaliana. T h ese  h o m o lo g u e s  ca m e up w ith  d ifferen t a ccess io n  num bers, w ith  no proper  
n om en cla tu re n am ing. A rbitrary n am es w ere  th erefore g iv en  as A tU B C 1 3 a , A tU B C 1 3 b ,  
and A tU B C 1 3 c . P h y lo g en e tic  an a ly sis  o f  th o se  arbitrarily n am ed  pep tide seq u en ces  
w ere  then  carried out. It w a s from  the b ranches o f  the p h y lo g en e tic  tree, that the  
arbitrary n am in gs w ere  recon firm ed . F or ex a m p le , i f  the arbitrarily n am ed  p ep tid e  
seq u en ces  appeared in  the sam e p h y lo g en e tic  branch o f  the sa m e y ea st U B C  (e .g . 
A tU B C 1 3 a  appearing in  the sam e branch as S c U B C 1 3 ), then it w a s  con firm ed  to b e  a 
p rob ab le true h o m o lo g u e /o r th o lo g u e  o f  S c U B C 1 3 . B u t i f  A tU B C 1 3 a  appeared in  a 
d ifferen t branch a lo n g  w ith  S cU B C IO , then  the A tU B C 1 3 a  w a s renam ed  as A tU B C lO a , 
s in c e  it is  in  the sam e branch as S cU B C IO . A  p a irw ise  a lignm en t w a s a lso  carried ou t o f  
A tU B C 1 3 a , first w ith  S cU B C IO  and then  w ith  S cU B C 1 3  to recon firm  th is, w h ere the  
p ercen tage iden tity  w a s com pared . T h e ch ro m o so m a l loca tio n  search  w as carried ou t o f  
p ep tid e  seq u en ces, to  fin d  out g en e  d u p lica tion  or sp lic e  variants. From  the
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ch rom osom al lo ca tio n  search , tw o  or m ore d up lica te gen es w ere  co n firm ed  to b e  eith er  
a g en e  d u p lica tion  or a sp lic e  variant o f  a s in g le  gen e .
Multiple sequence alignment of the retrieved sequences
A  m u ltip le  seq u en ce  a lign m en t (M S A ) o f  a ll retrieved  p ep tid e seq u en ces  w ere  carried  
out. Initial a lign m en t w as carried ou t b y  the M S A  to o l C L U S T A L W  
(w w w .eb i.a c .u k /c lu sta lW ) . A s  the a lig n m en t generated  b y  C L U S T A L W  w as  
b io lo g ic a lly  n ot s ig n ifica n t, it w a s further m an u a lly  a lign ed  b y  th e a lign m en t so ftw are  
to o l G E N E D O C  to obta in  the desired  a lignm en t.
T h e  hum an T S G 1 0 1 , hum an C R O C -1 (U B E 2 V 1 ) and hum an U B E 2 V 2  are n o n -U B C  
g en es  but th ey  are U B C  lik e . T h ey  lack  the a ctiv e  s ite  resid u e c y ste in e  and the U B C  
P R O S IT E  signature. S o  th ey  w ere  a lig n ed  as accord in g  to the a lign m en ts p u b lish ed  b y  
(S an ch o  e t al., 1998; P on ting , C ai and B ork , 1997). T he co n serv ed  reg ion  o f  the  
m u ltip le  seq u en ce  a lign m en t w as then se lec ted  and transferred to the U N IX  p latform  for  
its p h y lo g en etic  an a ly sis .
Phylogenetic analysis in Phylip 3.6
T h e p h y lo g en etic  a n a ly sis  w as carried ou t in  the unix  version  o f  P h ylip  3 .6 . T here are 
tw o  typ es o f  p h y lo g en e tic  trees, rooted  and unrooted . A  rooted  tree here g a v e  the  
ancestral in form ation  (root) o f  the p ep tid e  seq u en ces stating c lea r ly  w h ich  p ep tid e  
seq u en ce  e v o lv e d  first, the h ierarchy o f  ev o lu tio n  and a lso  the re lationsh ip  o f  on e  
seq u en ce  w ith  the other. T he step s in v o lv e d  in  the p h y lo g en e tic  an a ly sis  w ere  as 
fo llo w s: T ree -p u zz le  (to  ca lcu la te  the C o e ffic ie n t o f  V ariation ), S eq b o o t (to a ssig n  a 
sta tistica l s ig n ific a n c e  to the tree), P rotdist and N e ig h b o r-jo in in g  (the d istan ce b ased  
m eth od  o f  p h y lo g en y ), co n sen se  (to d erive  a co n sen su s  o f  a ll the d ifferen t trees that had  
b een  generated  and reproduce 1 co n sen su s  tree ou t o f  it), D raw gram  (to p lo t the rooted  
tree generated  from  c o n se n se ) and A d o b e  Illustrator (p lots the rooted  p h y lo g en e tic  tree  
from  draw gram  and all ed itin g  carried out).
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Different steps in Phylip:
Tree-puzzle:
T h e “T ree -p u zz le” program m e w a s u sed  to ca lcu la te  the c o e ff ic ie n t  o f  varia tion  (C V )  
from  the invariant am in o acid s in  the m u ltip le  seq u en ce  a lignm en t.
C V =  1/ 'Ja
a  is  the gam m a d istribu tion  param eter w h ich  w a s ob ta in ed  from  the tree-p u zz le  
an a lysis .
Phylip-seqboot
T h e “S eq b o o t” a n a ly sis  w as carried ou t b y  u sin g  the M S A  in  order to ca lcu la te  
bootstrap  v a lu es fo r  the p h y lo g en etic  tree. T he num ber o f  rep lica tes u sed  w ere 100. T h e  
“o u tfile” gen erated  w a s the result o f  th e bootstrap  an a lysis , w h ich  w a s u sed  for the n ext  
step  o f  an a ly sis  ca lled  “P r o td is f’.
Phylip-protdist
“O u tfile” o f  S eq b o o t w a s u sed  for the “P ro td is f ’ an a lysis  and 100 d atasets w ere  asked  
to  b e  an a lysed  h ere, a lso  the C V  v a lu e  (that w a s  ca lcu la ted  b y  the tree-p u zz le  a n a lysis)  
w a s entered  here in  th is an a lysis . T h e  resu lt ob ta ined  w a s th e “o u tfile” w h ich  w a s u sed  
to  carry out the n ex t step  o f  a n a lysis  ca lled  “N e ig h b o r” (n eigh b ou r-jo in in g  m eth od ).
Phylip-neighbor
“O u tfile” o f  P rotd ist w a s  u sed  for the “N e ig h b o r-jo in in g ” an a ly sis , w h ere  100  datasets  
w ere  a lso  ask ed  to b e  an alysed . T h e  resu lts ob ta ined  from  it w a s as “o u tfile  and  
ou ttree”, w h ere the “ou ttree” w as u sed  to p erform  the c o n se n se  (co n sen su s  o f  the 100  
trees generate in  th e n e igh b ou r-jo in in g  step).
Phylip-consense
“O uttree” o f  N e ig h b o r-jo in in g  a n a ly sis  w a s u sed  for the “c o n se n se ” an a ly sis . T h e result 
ob ta in ed  from  it w a s  as “o u tfile  and outtree” , w h ere the “o u tfile” co n s is ted  o f  the  
u nrooted  p h y lo g en e tic  tree w ith  the bootstrap  va lu es and the “outtree” w as the other  
resu lt w h ich  w a s u sed  to draw the rooted  p h y lo g en etic  tree.
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Drawgram:
“D raw gram ” w a s then  u sed  to p lo t the rooted  p h y lo g en etic  tree from  the p rev iou s  
p h y lip -co n sen se  an a ly sis  resu lt “outtree” . T h e  ed ited  p h y lo g en etic  tree w a s  then  saved  
as a p ostscrip t file . T h is p o st script f i le  w a s then  u sed  to p lo t the rooted  p h y lo g en etic  
tree in any o f  the p h oto  ed itin g  so ftw ares.
Editing of the generated phylogenetic tree 
Adobe-Illustrator:
T he p ost-scr ip t f i le  that w as gen erated  in  the p rev iou s D raw gram  a n a ly sis  w a s fin a lly  
u sed  in  the A d ob e-Illustrator p rogram m e to p lo t the rooted  tree for further d iagram m atic  
represen tation s and incorp oratin g  the bootstrap  va lu es at each  n od e o f  the p h y lo g en etic  
tree, w h ic h  w a s  f in a lly  sa v ed  as a P D F  f i le  w ith  the h elp  o f  the ad ob e Illustrator  
program .
Annotation of the phylogenetic tree
T he arbitrary n am es that w ere  g iv en  in it ia lly  w ere  then con firm ed  from  its appearance  
in  the re sp ectiv e  branches o f  the p h y lo g en e tic  tree. T he d isp la y ed  p h y lo g en e tic  tree 
branches in  the “A d o b e  Illustrator” w ere  then annotated  in to  fu n ction a l and  
evo lu tio n a ry  groups, and a lso  the n om en clatu re n am in g  o f  all y east and h um an U B C s  
w ere rev iew ed .
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7.2. The phylogenetic analysis of drosophila TAFn250, selected UBCs and 
human CROC-1 (UBE2V1)
Sequence data mining
T h e Drosophila T A F n 2 5 0  seq u en ce  w a s retrieved  from  the N C B I  p rotein  database  
(h ttp ://w w w .n cb i.n lm .n ih .g o v /) . T h is seq u en ce  w a s u sed  to carry ou t b oth  a B L A S T P  
and a T B L A S T N  search  (h ttp ://w w w .n cb i.n lm .n ih .g o v /B L A S T /) to  id en tify  its  
h o m o lo g u e s  in d ifferen t organ ism s in c lu d in g  so m e  o f  the in sec ts , vertebrates and  
n em atod es. U s in g  the k n o w n  U B C  a ctiv e  site , P R O S IT E  signature pattern  
('h ttp ://w w w .ex p a sv .o rg /p ro site /) . a m anual search  w a s carried ou t in  the Drosophila 
T A F II2 5 0  seq u en ce  for a ll cy ste in e  resid u es s im p ly  b y  u sin g  the fin d  fu n ction  in  
notepad. T he U B C  a ctiv e  s ite  w as then lo ca te d  in  all h o m o lo g u e s  o f  Drosophila 
T A F n 2 5 0 , but w as o n ly  fou n d  to b e  p resent in  Drosophila pseudoobscura and Apis 
mellifera.
Multiple sequence alignment
F o llo w in g  the id en tifica tio n  o f  U B C  a ctive  s ite  in  Drosophila T A F n 2 5 0  and fe w  o f  its
h o m o lo g u e s , a m u ltip le  seq u en ce  a lign m en t (M S A ) w a s carried out in  C L U S T A L W
(h ttp ://w w w .eb i.a c .u k /c lu sta lw /in d ex .h tm l) u s in g  both  com p lete  and partial TAFn250 
seq u en ces  from  d ifferen t other sp ec ie s  and a lso  in c lu d in g  hum an C R O C -1 . T he  
Drosophila TAFn250, togeth er  w ith  all its h o m o lo g o u s  p ep tid e  seq u en ces, a lso  
in c lu d in g  the hum an C R 0 C 1  (U B E 2 V 1 ) p ep tid e  seq u en ce and so m e  o f  the U B C (E 2 s)  
w h o se  3D  structure is  k n ow n , w ere  then tak en  togeth er in  the “FASTA” form at (the  
form at w h ich  is  required for  MSA) and a m u ltip le  seq u en ce a lign m en t (MSA) w as  
carried  ou t in  C lu sta lW . T h e p utative TAFn250 U B C  active  s ite  reg io n  o f  th e C lu sta lW  
gen erated  MSA, w a s then m an u ally  a lign ed  to  the U B C  active  s ite  u s in g  the m anual 
a lign m en t so ftw are G E N E D O C
(h ttp ://w w w .p sc .ed u /b io m ed /g en ed o c /) . In ad d ition  C R O C -1 w as a lso  m an u ally  a lign ed  
u sin g  p rev iou s U B C , C R O C -1 and TAFn250 a lig n m en ts  p u b lish ed  b y  P on tin g , C ai and  
B ork  (1 9 9 7 )  and R o th o fsk y  and L in  (1 9 9 7 ).
A ls o , the am in o acid  reg ion  1 9 1 - 2 1 4  o f  C R 0 C 1  and the am ino acid  reg io n  1 2 2 5 - 1248  
o f  T A F n 2 5 0  has 41 .7%  id en tity  as ind icated  in  th e paper b y  R o th o fsk y  and L in  (1 9 9 7 ) .
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H en ce  th ese  co n serv ed  reg io n s w ere a lso  m an u a lly  a ligned  in th e G E N E D O C  a lign m en t  
program . T h e co n ser v ed  reg io n s w ere  th en  u sed  to  carry out its p h y lo g e n e tic  an a lysis .
Phylogenetic analysis
T h e m anual a lign m en t gen erated  in  G E N E D O C , w as then sa v ed  in  P h y lip  form at for  
N eig h b o r-jo in in g  p h y lo g en e tic  an a lysis  u s in g  P h y lip  3 .6 , as d eta iled  in  p rev iou s sec tio n
7.1  (h ttp ://ev o lu tio n .g en etics .w a sh in g to n .ed u /p h v lip .h tm l) .
P h ylip  3 .6  program  w a s u sed  to carry ou t the p h y lo g en etic  a n a ly sis , u s in g  the N e ig h b o r ­
jo in in g  algorith m , and D R A W T R E E  w a s  u sed  to p lo t the u nrooted  p h y lo g en etic  tree. 
T h e A d o b e  Illustrator w a s then  u sed  to  co m p le te  all the ed itin g  to  reproduce a w e ll  
p resentab le p h y lo g en e tic  tree w ith  its b ootstrap  va lu es. D raw tree and not D raw gram  
w as used  to p lo t the unrooted  tree, b eca u se  here the o b jec tiv e  w a s to see  th e  
rela tion sh ip s o f  the p ep tid e  seq u en ces, and n ot the root or the ancestral in feren ce o f  the  
p ep tid e  seq u en ces.
Phylogenetic tree annotation
T h e evo lu tio n a ry  and fu n ction a l re la tion sh ip  o f  all T A F n 2 5 0 s , U B C s  and U B C  lik e  





8.1 Methodology of consurf analysis
In the a n a ly sis  o f  C on su rf (h ttp ://co n seq .b io in fo .ta u .a c .il/) P D B  ID  2 F 4 W B  (w h ich  is  
the structure o f  U B E 2 J 2 ), w a s taken  as the input for the query protein .
T h e n ex t “op tio n a l” criterion o f  the a n a lysis  procedure w a s, to  eith er le t the C on su rf  
fin d  its  h o m o lo g o u s  p ep tid e  seq u en ces , or the m u ltip le  seq u en ce  a lign m en t o f  its  
h o m o lo g u e s  co u ld  b e  su bm itted  beforehand . H ere the p rea lign ed  193 p ep tid e  seq u en ces  
(that w a s u sed  for the p h y lo g en e tic  an a lysi in  p h y lip ) w a s su b m itted  to the database for  
an a lysis . A  p h y lo g en etic  tree w a s con structed  b y  C onsurf, o f  the M S A  u sin g  the  
n eigh b o r-jo in in g  algorithm . T h e con servation  o f  the query p ep tid e  seq u en ce  w a s  
ca lcu la ted  and th ese  con servation  scores that w ere  p lo tted  on  the 3 D  structure o f  the  
query protein . T h e con servation s w ere  represented  in  d ifferen t co lo u rs, d iv id ed  into  n in e  
grades, w h ere  G ra d e-1 is  the m o st variab le p o sit io n  and is  a ss ig n ed  the co lo u r  
T urqu oise. G rade-5 is the in term ed iate co n servation , w ith  a co lo u r  a ssig n ed  w h ite , and  
G rade-9 w h ich  is the m o st co n serv ed  is  a ssig n ed  the co lo u r  M aroon  (L andau, 2 0 0 5 ;  
A rm on , Graur and B en -T a l, 2 0 0 1 ).
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CHAPTER NINE
METHODOLOGY OF STRUCTURE 
PREDICTION BY X-RAY 
CRYSTALLOGRAPHY
A  sum m ary o f  the variou s steps that w ere  in v o lv e d  in  the p rod u ction  o f  protein  fo r  X -  
ray crysta llograp h ic  determ in ation  o f  structure w e re  as fo llo w s:
Cloning
D e sig n  o f  prim ers to a m p lify  the U B E 2 J 1 fragm ent,
Preparation o f  p la sm id s and P C R  am p lifica tion  o f  U B E 2 J 1 ,
D ig e s t io n  and lig a tio n  o f  P C R  a m p lified  fragm ent,
T ransform ation , purifica tion  o f  p lasm id  o f  E. coli B L 2 1 ,
S eq u en c in g  o f  the c lo n e d  sam p le  to con firm  id en tity  o f  sam p le,
Protein production and purification 
P rotein  ind u ction  o f  transform ed c e lls ,
C e ll rupture to re lea se  recom b in an t fu s io n  protein ,
N ic k e l b in d in g  o f  fu sio n  protein  to N i-N T A  co lu m n  
P rotein  e lu tion  from  N i-N T A  co lu m n ,
P u rifica tion  o f  th e e lu ted  and con centrated  protein  b y  s iz e  e x c lu s io n  chrom atography, 
Protein analysis
M a ss sp ectrom etric an a ly sis  o f  the p urified  protein ,
C D  spectrum  o f  the p urified  protein ,
Crystallization
C rysta lliza tion  o f  the p urified  protein ,
X-ray diffraction
X -ray  d iffraction  o f  the crysta l ob ta ined .
A  hum an h o m o lo g u e  o f  y ea st U B C 6 , ca lled  U B E 2J1  w as u sed  for crysta lliza tion . T h e  
w h o le  o f  the protein  w a s  n o t u sed  as there is  a transm em brane d om ain  reg ion , w h ich  
w o u ld  b e  very  d ifficu lt to  cr y sta lliz e  (T u snad y, D o sz ta n y i and S im o n , 2 0 0 5 ). M u ltip le  
seq u en ce  a lign m en t o f  U B E 2 J 1 and a ll its h o m o lo g u e s  w ere carried  out u sin g  C lu sta lW . 
T he m o st co n serv ed  reg ion  around the activ e  s ite  w a s  se lec ted  to crysta llize . T he reg io n  
o f  U B E 2J1  that w a s u sed  is  as sh o w n  in  F igu re 9 .1 . T h e p ep tid e fragm en t co n ta in s 17 0  
am in o acid s and has a m olecu lar  w e ig h t o f  19 K D a.
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Figure 9.1. Portion of the UBE2J1 peptide sequence used to design the primers
METRYNLKSPAVKRLMKEAA ELKDPTDHYH AQPLEDNLFE
WHFT VRGPPDSDFD GG VYHGRIVLPPE YPMKPPSIILLT AN GRFE V GKKI
CLSISGHHPETWOPSWSIRTALLAIIGFMPTKGEGAIGSLDYTPEERRAL
AKKSQDFCCEGCGSAMKDVLLPLKSGSDSSQADQEAKELARQISFKAEV
N S S G K T IS E S D L N H S F S L T D L Q D D IP T T F Q G A T A S T S Y G L Q N S S A A S F H Q P T Q P  
V A K N T S M S P R O R R A O O Q S O R R L S T S P D V IO G H O P R D N H T D H G G S A V L IV IL T  
L A L A A L IF R R IY L A N  E Y IF D F E L
Figure 9.1 is the whole UBE2J1 peptide sequence, with the transmembrane domain 
SA V L IV ILT LA LA A L IF  and the U BC 6  P R O S IT E  domain T-[PAR]-[NS]-G -R-F-x(3)- 
[K T E ]-[R K ]-[L IV ]-C -[LM S ]-[ST ]-[ IM F ]-[S  T]-x(2 )-H -[PK ] underlined in bold. The 
peptide fragment that had been used to crystallise, is in bold. UBE2J1 was cloned in 
between the 5 ’ BarnHl and 3 ’ E coR l restriction sites of pH ISTEV30aplasm id vector.
Table 9.1 The whole of the nucleotide sequence of UBE2J1 that was used to 
design the primers.
1 AAGAGTCCGG CTGTTAAACG TTTAATGAAA GAAGCGGCAG AATTGAAAGA 
51 TCCAACAGAT CATTACCATG CGCAGCCTTT AGAGGATAAC CTTTTTGAAT  
101 GGCACTTCAC GGTTAGAGGG CCCCCAGACT CCGATTTTGA TGGAGGAGTT  
151 TATCACGGGC GGATAGTACT GCCACCAGAG TATCCCATGA AACCACCAAG  
201  CATTATTCTC CTAACGGCTA ATGGTCGATT TGAAGTGGGC AAGAAAATCT 
251 GTTTGAGCAT CTCAGGCCAT CATCCTGAAA CTTGGCAGCC TTCG TGGAGT  
301 ATAAGGACAG CATTATTAGC CATCATTGGG TTTATGCCAA CAAAAGGAGA  
351 GGGAGCCATA GGTTCTCTAG ATTACACTCC TGAGGAAAGA AGAGCACTTG  
4 0 1  CCAAAAAATC ACAAGATTTC TGTTGTGAAG GATGTGGCTC TGCCATGAAG  
451  GATGTCCTGT TGCCTTTAAA ATCTGGAAGC GATTCAAGCC AAGCTGACCA  
501  AGAAGCCAAA GAACTG
Prim ers w ere u sed  to incorporate Bam H l at the 5 ’ end  and E c o R l at the 3 ’ end . T he  
forw ard prim er w a s d esig n ed  to incorporate a Bam H l restriction  en zy m e  as fo llo w s:
3 extra n u c leo tid es (C G C ) w ere added to gen erate a B a m H l site.
N o te  that the 3 extra n u cleo tid es w ere added  to the 21 n u c leo tid es  o f  U B E 2J1  to  
incorporate a Bam H l site.
1 0 0
5’ CGCGGATCCAAGAGTCCGGCTGTTAAACGT 3’
In the reverse  prim er a lso  3 extra n u c leo tid es w ere added  to the 21 n u c leo tid es  o f  
U B E 2 J 1 to incorporate an E coR l site .
G A C C A A G A A G C C A A A G A A C T G  —  is  the 21 n u c leo tid e  seq u en ce  in  the 5 ’ to 3 ’ 
w ith  the ad d ition  o f  3 stop  co d o n s (T A A  T A G  T G A ) and 3 extra n u c le o tid es  (C C G ) to  
gen erate  an E coR l site .
5’ CCGGAATTCTCACTATTACAGTTCTTTGGCTTCTTGGTC 3’
9.1. PCR reactions
9.1.1 The PCR mix
A s  the con cen tration s o f  the prim ers w ere 100 p m o l/p l, th ey  w ere d ilu ted  to 10 p m o l/p l  
for  the P C R  reaction . T h e c D N A , p urchased  from  B ioC h ain  Institu te, U S A , w as  
iso la ted  from  the hum an brain tissu e .
T h e  P C R -m ix  in c lu d es 12 .5  |Lil P C R  M aster m ix  2 X  (5 0  u n its .m l T a q D N A  p o lym erase , 
4 0 0  p M  each  o f  d A T P , d G T P , dC T P, dT T P  and 3m M  M G C L 2), 2 .5  p i U B E 2J1  
(Forw ard), 2 .5  p i U B E 2J1  (R ev erse ), lp l  c D N A  and 6 .5  p i N u c le a se  free w ater.
A  con tro l P C R  m ix  w a s a lso  prepared w ith ou t the c D N A .
9.1.2. Calculation of annealing temperatures
T o  ca lcu la te  the an n ea lin g  tem peratures, the m e ltin g  tem peratures (tm) o f  b oth  the  
forw ard  and the reverse  prim ers w ere  ca lcu la ted  separately . A ll  G  and C n u c leo tid es  
w ere  g iv en  4 °C  and 2 °C  for ev ery  A  and T. F rom  the ca lcu la ted  tm, 5°  w a s subtracted, 
w h ich  w a s u sed  as the an n ea lin g  tem perature for  the first 10 c y c le s . In the n ex t 2 0  
c y c le s  the tem perature w a s in creased  so  as to  a llo w  the further b in d in g  o f  the PC R  
products and n ot a llo w  further b in d in g  o f  the P C R  product to  the c D N A .
9.1.3 Setting of the PCR machine
T h e lid  o f  the P C R  m ach in e w a s preheated  fo r  4  m in utes at 105°C . T h is  w as fo llo w e d  
b y  an in itia l denaturation  se t for  2  m in u tes at 9 4 °C . T h e sam p le  w a s then  p laced  in to  the 
P C R  m ach in e w ith  the first 10 c y c le s  o f  the fo llo w in g : 9 4 °C  for 3 0  sec o n d s, 5 0 °C  for  
3 0  seco n d s and 7 2 °C  for 3 0  seco n d s. T he n ex t 2 0  c y c le s  o f  the fo llo w in g  w ere repeated  
as: 9 4 °C  for 3 0  seco n d s, 5 9 °C  for 3 0  seco n d s, 7 2 °C  for 3 0  seco n d s. T h e reaction  w a s
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co m p leted  b y  a fin a l ch a in  ex ten s io n  step  for 5 m in u tes at 7 2 °C  fo llo w e d  b y  a h o ld in g  
step  at 10°C .
A fter  the co m p le t io n  o f  the P C R  reaction  the products w ere an a lysed  b y  agarose  g e l  
electrop h oresis .
9.2. DNA preparation
T he D N A  preparations (m ax i-p rep s, m in i-p rep s, and g e l ex traction s) u sed  for  c lo n in g  
w ere  carried  ou t w ith  Q ia g en ™  k its, in  accord ance w ith  the m anufactures instru ction s. 
D N A  restriction s en zy m es  w ere  ob ta ined  from  b oth  P rom ega™  and N e w  E n glan d  
B io la b s™  (N E B ).
Preparation of LB media:
T o m ak e 1 litre o f  L B  m edia , 1% w /v  b acto-tryp ton e, 0.5%  w /v  b a cto -y ea st extract and
0.5%  w /v  N a C l w ere added  to 8 0 0  m l w ater. T h e pH  w as adjusted  to 7 .5  w ith  N aO H , 
then 1% w /v  o f  A g a ro se  w a s added  to the m ixture and the fin a l v o lu m e  m ad e to 1 litre  
and then  a u toclaved  to ster ilise . T h e au toclaved  m ed iu m  w a s a llo w ed  to c o o l to 55° C  
and fin a lly  k an am ycin  5 0  jug m l'1 w as added.
9.3. Transformation of plasmids
T he p lasm id s w ere  k in d ly  su p p lied  b y  Dr. D im itr is  X erod im u s o f  Prof. R on  H a y ’s 
laboratory o f  the U n iv ers ity  o f  St. A n d rew s.
p H IS T E V 3 0 a  is  d eta iled  in  F igu re 9 .2 a  and p H IS T E V 30a-G S T -th rom b in  is  d eta iled  in  
F igu re 9 .2b .
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F ig u re  9.2.1 p H IS T E V 3 0 a  plasm id vector
Figure 9.2.2 pHISTEV30a-GST-thrombin plasmid vector
Figure 9.2.1 is the plasmid vector pHISTEV30a where the UBE2J1 fragment was 
inserted between the BamFIl and EcoRl which lies within Ncol and Xhol of the 
plasmid vector.
Figure 9.2.2 the plasmid vector pHISTEV30a-GST-thrombin where GST-thrombin has 
been cloned in the Ncol and Xhol region of the plasmid vector.
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Figure 9.3.1 Plasm id m ap showing the cloning site of the U BE2J1  fragm ent
T7 Pro seq primer
T7 promoter lac operator Xba [
! ■■ATCCCQCGAAATTAATACGACTCAC TATAGGGj^TTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTG
rbs N d e  I
TTf AACTTTAAjGAA'jGAGATATACAT ATG TCG 7AC TAC CAT CAC Cj ,T CAC CAT CAT l»AT TAc- SAT AT'
M S Y Y H H f j H H K D  Y D I P
UBE2J1
TEV protease site ^  ,vco I rvtmH I £coft : Sac I
Ac::; ACC GAA AAC CTG TAT TTT CAG GGC SCC ATG GCT GAT JJfC  GGA TCC GAA TTC SAG CTC CGT
T T F 0' G M O O
Sal T Hind III Not I XAc I
CGA LAA K f  TOC GGC CGC ACT CGA OCA CCA CCA CCA CCA
R A P ? P PR V J-I R
opullC'21
A;»C C C C AAA GGAAGC TGAGTTGGCTO^T-V ■ A ■.. Li I.C. AGCAATAAC TA^tCA
T~ Tor see prrmer
GGTTTTTTGCTGAA
t ft
CA CTG AGA *CC 3GC TGC TAA CAA 




Figure 9.3.1 above is an expansion of the plasmid map of figure 9.2.1, which shows the 
site into which UBE2J1 fragment was cloned in between the BamHl and EcoRl.
Figure 9.3.2 Plasmid map showing the cloning site of GST-thrombin
T7 Pro seq primer 
---------------------------- ►
T7 promoter lac operator Xba I
ATCGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTG
rbs Aide I
TTT AAC T T TAAGAAGGAGATATACAT ATG TCG TAC TAC CAT CAC CAT CAC CAT CAC GAT TAC GAT ATC CC.
M S Y Y H H H H H H D Y D I
GST THROMBIN UBE2J1
TEV protease site * Nco I T | tianiH I EcoR 1 SdC IACG S n li AAC CTG TAT TTT CAG GGC GCC ATG GCT GAT ATC GGA TCC GAA TTC GAG CTC CGT
T T E N L Y F Q* G A M D D I G S E F E L R
5a i I Hind III Not I Xho T
CGA CAA GCT TGC GGC CGC ACT CGA GCA CCA CCA CCA CCA CCA CTG AGA TCC GGC TGC TAA CAA
R Q A C G R T R A P P P P P L R S G C end
BpullQ2I T7 terminator
AGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
„ T7 Ter seq primer
GGTTTTTTGCTGAA
Figure 9.3.2 above is an expansion of the plasmid map of figure 9.2.2, which shows the 
site into which GST-Thrombin was cloned by Prof. Ron Hay’s group in between the 
Ncol and the BamHl, which is just before the UBE2J1 cloned site.
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Plasmid GST-HIS-TEV or HIS-TEV (lpl) and 50 pi of JM109 competent cells were 
mixed, then incubated on ice for 20 minutes. Heat shock was applied to the cells at 
42°C for 45 -  50 seconds and the mixture was then again placed on ice for 2 minutes. 
SOC medium 950 pi [2% w/v Bacto-tryptone, 0.5% w/v bacto-yeast extract, 0.0ImM 
NaCl, 0.0025mM KC1, 0.005mM Mg2+ stock and 0.005mM glucose., adjusted to pH 7 
and volume made up to 100 ml. After autoclaving, a final concentration of Mg 
(0.005mM) and glucose (0.005mM) were added] was added with gentle mixing and 
incubated at 37°C for VA hours. An aliquot (100 pi) of this mixture was applied to a 
kanamycin plate and spread using the sterile glass rod and incubated at 37°C for 18 -  24 
hours.
9.4. Plasmid preparation
One colony each of GST and HIS-TEV plasmids was grown at 37°C overnight in 5ml 
LB media with Kanamycin (50 pg ml"1). 2ml of this overnight growth was inoculated 
into 500ml LB media with 500 pi Kanamycin(50 pg ml"1) in a 1 litre flask. This was 
incubated at 37°C overnight. The bacterial cells were then harvested by centrifugation 
for 5 minutes at 4000 x g and plasmids isolated using the “QIAGEN MAXI PREP.” 
protocol and kit. Plasmid DNA was quantified spectrophotometrically.
QIAGEN MAXI PREP procedure:
The bacterial cells were harvested by centrifugation at 4000 x g at 4°C for 15 minutes 
and resuspended in 10 ml. buffer PI (50 mM Tris HC1 pH 8.0, 10 mM EDTA and 10 
ug.ml RNASE A). Buffer P2 (10 ml) (200mM NaOH, 1% SDS, 1M NaOH 200 ml, 
10% SDS 100 ml, water 700 ml) was added, mixed gently but thoroughly by inverting
4-6 times and incubated at room temperature for 5 minutes.
Chilled buffer P3 10 ml [3.0 M KOAc (potassium acetate) pH 5.5 (29.5% w/v in water)] 
was added, mixed immediately but gently by inverting 4-6 times and incubated on ice 
for 20 minutes. The mixture was centrifuged at 3000 x g for 15 minutes at 4°C and 
supernatant containing plasmid DNA was removed promptly,
A QIAGEN-tip 500 was equilibriated by applying 10 ml buffer QBT (4.38% w/v NaCl, 
1.04% w/v MOPS dissolved in 800 ml distilled water, pH adjusted to 7 with NaOH, 
15%v/v ml isopropanol and 15 ml 10% Triton X-100 solution added and volume
Procedure for the transformation of plasm ids
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adjusted to 1 litre with distilled water) and the column was allowed to empty by gravity 
flow. A filter was put on top of the QIAGEN tip and the supernatant was applied to pass 
through the filter and allowed to enter the resin by gravity flow.
The QIAGEN tip was washed with 2 x 30 ml buffer QC (5.84% w/v NaCl, 1.04% w/v 
MOPS dissolved in 800 ml distilled water, pH adjusted to 7 with NaOH and then 15% 
v/v isopropanol added. Finally distilled water was added to adjust the volume to 1 litre). 
DNA was eluted with 15 ml buffer QF (7.30% w/v NaCl and 0.60% w/v Tris base, pH
8.5 with the addition of 15% v/v isopropanol) and was precipitated by adding 10.5 ml 
room temperature isopropanol to the elutant. The mixture was centrifuged at 4°C for 30 
minutes at 10,000 x g. The removed pellets were washed with 5 ml of room temperature 
70 %  v/v ethanol and centrifuged at 10,000 x g for 10 minutes. The supernatant was 
decanted without disturbing the pellets, which were air dried for 5-10 minutes and the 
DNA redissolved in a suitable volume of distilled water.
9.5. Growing of the GST-HIS-TEV and HIS-TEV colonies from the kanamycin 
plates
Kanamycin 50 mg ml"1 (5 pi) was added to 10ml of LB media and inoculated with a 
single colony from the kanamycin plate (using a micro-pipette tip) then incubated at 
37°C for 12 -  16 hours. Cell growth was checked visually, and the plasmids were 
purified using the QIAGEN maxi prep detailed in section 9.4 and stored in 70% 
glycerol at -70°C.
9.6. Gel electrophoresis
Agarose gel 1.2 % w/v was prepared with 1 X TBE and 10 pi of 0.0005% w/v ethidium 
bromide. DNA marker (10 pi of a lOObp DNA ladder) was loaded onto the first lane 
and 60 pi (50 pi of each of the two PCR product and control + 10 pi of loading dye) of 
the experimental mix was loaded onto the other lanes. 1 X TBE (Tris-Borate-EDTA) 
buffer was used for running the gel.
9.7. Digestion of the PCR product of UBE2J1 fragment and the plasmids
PCR products and the plasmids were both digested with BamHl and EcoRl using the 
following incubation mixture: 5pl of 10 X Buffer H (composition of 900mM TrisHCL 
pH 7.5, 500mM NaCl, and 100 mM MgCl2 at 37°C), 0.5 pi BSA (0.5% w/v), 1.5 pi
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EcoRl (lOmM Tris-HCl (pH 7.4), 400mM NaCl, O.lmM EDTA, ImM DTT, 0.15% 
TritonX-100, 0.5mg/ml BSA, 50% glycerol), 1.5pl BamHl (lOmM Tris-HCl (pH 7.4), 
300mM KC1, 5mM MgCl2, O.lmM EDTA, ImM DTT, 0.5% w/v BSA, 50% v/v 
glycerol), 10 pi DNA (PCR product), 31.5 pi nuclease free water. This reaction mixture 
was incubated at 37°C for 4 hours for complete digestion.
9.8. Gel extraction
The digested PCR product and the plasmids were cut from the gel bands and the DNA 
extracted using the QIAGEN kit. After cutting the band from the gel containing the 
DNA the gel slice was weighed. To 1 volume (weight) of the gel slice 3 volumes of QG 
buffer
(http://wwwl.aiagen.eom/literature/handbooks/PDF/DNACleanupAndConcentration/Q 
O Spin/1021422 HBQOSpin 072002WW.pdf) was added and resuspended by 
vortexing for 30 seconds. It was then incubate for 10 minutes at 50°C and 1 gel volume 
of isopropanol was added and mixed. The sample was then centrifuged for 1 minute, the 
supernatant was removed and 0.5 ml of buffer QG was added to the spin column and 
centrifuged for 1 minute. The cells in the column was then washed by adding 0.75 ml of 
buffer PE
fhttp://wwwl.qiagen.com/literature/handbooks/PDF/DNACleanupAndConcentration/Q 
0  Spin/1021422 HBOOSpin 072002WW.pdfh centrifuged for 1 minute. The 
supernatant was again removed and was centrifuging for an additional 1 minute at 
17,900 x g. Finally the DNA was eluted by adding 50 pi of water and centrifuging for 1 
minute. As the buffers QG and PE are company patents, its ingredients were not known.
9.9. PCR product and plasmid ligation reaction
The digested PCR product and the plasmids were ligated, the reaction mixture is as 
follows: 13pi PCR product, 13pi plasmid Vector, 3pi 2X Rapid ligation Buffer (60mM 
Tris-HCl (pH 7.8), 20mM MgC12, 20mM DTT, 2mM ATP, 10% polyethylene glycol), 
lpl T4 DNA Ligase (concentration is 3 weiss units/pl in 50mM Tris-Hcl, lOmM 
MgCl2, lOmM DTT, ImM ATP & 25 pg/ml BSA at pH 7.5 and 25°C). This ligation 
reaction was incubated overnight at 4°C for complete ligation.
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9.10. Transformation of the ligated product in DH5a cells
The transformation reaction was carried out on ice for 30 minutes in 15 ml falcon tubes 
using the following incubation mix: 20pl Ligated product, 20pl 5X KCM [lx KCM is 
(100 mM KC1, 30mM of CaCl2, 50 mM MgCl2)], 60pl Water and lOOpl of DH5a cells. 
After incubation LB media (1ml) was added to the mix and incubated at 37°C on an 
orbital shaker for 1 hour. Finally lOOpl of this mix was spread on kanamycin plates that 
were incubated at 37°C overnight.
Single colonies were selected from the kanamycin plate and incubated in 10 ml LB 
kanamycin (50 pg ml"1) overnight at 37°C with agitation. Cells were harvested by 
centrifugation for 15 minutes at 6000 x g and plasmid DNA extracted using the 
QIAGEN MAXI PREP as in section 9.4.
9.11. Digestion of ligated product
Both the PCR products and the plasmids were digested with the restriction enzymes 
BamHl and EcoRl which is as follows: 5 pi 10 X Buffer H, 0.5 pi BSA, 1.5 pi EcoRl, 
1.5pl BamHl, 10 pi DNA & 31.5 pi NF water. This was incubated at 37°C for 4 hours 
for complete digestion.
9.12. Preparation of BL21 competent cells
BL21 competent cells were required for the transformation of the ligated products. The 
BL21 competant cell were streaked out from the glycerol stock into agar plates to grow 
at 37°C overnight. A single colony was used to innoculate 10 ml LB media and this was 
incubated at 37°C overnight. The overnight culture (5ml) was used to inoculate 500 ml 
LB in a 2 litre baffled flask and was incubated at 37°C until OD600 approx. 0.6. The 
cells were centrifuged (2000 x g) for 5min at 4°C, were gently resuspend in 25ml cold 
TSB (LB pH 6.1 with HC1, 5% DMSO v/v, 10 mM MgCl2 & 10 mM MgS04), 
incubated on ice for 10 min and was aliquoted into several eppendorfs, stored at -70°C.
9.13. Transformation of the ligated product into the BL21 competent cells
The ligated sample was transformed into the BL21 strain by mixing 9 pi IX KCM, lpl 
DNA & lOpl BL21 cells. A control transformation was carried out to test the BL21 
competant cells for any contamination. The test and the control were incubated on ice 
for 10 minutes and then at room temperature for 10 minutes, and finally plated out into
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kanamycin plates, then incubated at 37°C overnight. A colony of each growth plate was 
inoculated into 10ml of LB media having kanamycin and allowed to grow at 37°C 
overnight.
9.14. DNA sequencing to confirm the constructed primers
The designed primers and the double stranded plasmids were sent for sequencing to the 
University of Dundee. The nucleotide sequences that were obtained from the 
chromatogram sent by the sequencing department were transcribed to the peptide 
sequence which was found correct (data not shown).
9.15. Protein induction
Overnight growth culture (10ml) of the BL21 transformed ligation product was 
inoculated each into a 1 litre LB media which had the required antibiotic kanamycin. A 
total amount of 3 litres was allowed to grow at 37°C, until an Optical Density (OD at 
595 nm) of 0.6 -  0.8 was obtained. The solution was then cooled on ice and 0.25mM 
IPTG was added into the protein sample for induction at room temperature with 
constant orbital shaking for 5 to 6 hours. The culture was then centrifuged at 15,000 x g 
for 10 minutes to collect the cells separated from the supernatant, resuspended in 10ml 
of PBSA buffer, further centrifuged at 15,000 x g for 10 minutes and cells stored at 
-20°C.
9.16. Cell lysis
The induced cells were resuspended in 100ml of lysis buffer (50mM Tris pH 7.5, 0.5 M 
NaCl, 1%  Triton 10 % & 1 Protease Inhibitor cocktail tablet in PBSA). The cell 
membranes were ruptured and the protein released 
thttp://www.promega.com/pnotes/86 /l 1217 23/11217 23.pdf).
The re-suspended cells in the lysis buffer were sonicated 4 times 15 seconds each at an 
amplitude of 15 and were then centrifuged for 15 minutes at 40,000 x g twice, so as to 
get a clear supernatant, which was then collected and a final volume concentration of 
lOmM p-mercaptoethanol was added.
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Protein samples were resuspended in disruption buffer (IX: 20mM Tris/Hcl pH 6 .8 , 2% 
w/v SDS, 5% w/v p- mercaptoethanol, glycerol and 2.5% w/v bromophenol blue) and 
denatured at 100°C for 5 minutes, before loading on the SDS polyacrylamide gel 
(acrylamide percentage appropriate for the size of proteins to be separated). New 
England Biolabs™ prestained molecular weight markers were used as standards to 
establish the apparent molecular weights of proteins resolved on SDS- polyacrylamide 
gels. Separated polypeptides were stained with Coomassie Brilliant Blue (0.2 % w/v 
Coomassie Brilliant Blue R250; 50% v/v methanol; 10% v/v acetic acid) for thirty 
minutes and then destained ( 2 0 % v/v methanol; 10% v/v acetic acid) overnight.
Procedure for gel preparation for SDS-PAGE
Running gel (12 %  w/v) was prepared by adding 3.3ml H2O, 4.0ml 30 %  w/v 
Acrylamide mix, 2.5ml 1.5 M Tris (pH 8 .8), 0.1ml 10% w/v SDS, 0.1ml 10% w/v APS 
& 0.004ml TEMED. Stacking gel was prepared by adding 6 .8ml H2O, 1.7ml 30 %  w/v 
Acrylamide mix, 1.25ml 1.0 M Tris (pH 6 .8), 0.1ml 10% w/v SDS, 0.1ml 10% w/v APS 
& 0.02ml TEMED.
9.18.1. Preparation of nickel beads
Ni-NTA Magnetic Agarose Beads were stored as a 5% w/v suspension in 30% v/v 
ethanol at 2-8°C. Prior to use beads were washed with 10 column volumes of (50 mM 
Tris (pH 7.5), 0.25M NaCl & 30 mM Imidazole in PBS A buffer).
9.18.2. Recharging of the nickel- NTA beads
The column was washed 3 times the column volume with water, then it was washed 3 
times the column volume with 6 M GuHCl and 0.2 M Acetic acid. It was then washed 
with 3 times the column volume with 100 mM NiSC>4. The nickel-NTA beads were 
again washed with water and then with 6M GuHCl and 0.2 M Acetic acid and finally 
stored at 4°C in 30% v/v ethanol.
9.19. Binding with the protein
The protein supernatant obtained in 9.16 was suspended with nickel beads and lOmM 
Imidazole and incubated with gentle agitation for 2 hours. The supernatant-nickel beads
9.17. S D S -P A G E  analysis
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mixture was then decanted into a column (approx 25 cm), and the supernatant eluted 
and the flow collected and stored at 4°C. The column was washed in 3 column volumes 
of wash buffer (50 mM Tris pH 7.5, 0.25M NaCl & 30 mM Imidazole in PBSA) and the 
flow-through retained and stored at 4°C. Elution buffer 8 ml (50mM Tris-pH 8.0, 
500mM NaCl and 250mM Imidizole in PBSA) was applied to the nickel column and 
left for 10 minutes at room temperature. The first 5 ml fraction was collected and further 
elution buffer was run through and further 5 ml fractions were collected and assayed for 
the presence of protein (using a micro Bradford assay) until no more protein was eluted. 
The eluted fraction containing protein was dialyzed in 4 litre dialysis buffer overnight 
(50mM Tris pH 8.0 and 500mM NaCl in water) to remove Imidazole. The dialysed 
fraction was then centrifuged at 700 x g to remove any precipitate and DTT (ImM) was 
added.
9.20. Micro Bradford assay
Bradford reagent (lOOpl) was placed on each well of an Elisa plate. A drop was 
collected from the eluted fractions at regular intervals and mixed thoroughly with the 
Bradford reagent contained in the wells of the Elisa plate. A change in colour from 
reddish brown to blue indicated the presence of protein.
9.21. Quantitation of the eluted fraction containing protein
Protein concentration was determined using Bradford’s method (Bradford, 1976). 
Protein samples were mixed with Bradford’s (Biorad™) and the absorbance at 595 nm 
was measured on a spectrophotometer (Hitachi U-1100). Protein absorbance was 
calculated to mg/ml concentrations using a standard bovine serum albumin (BSA). 
Absorbance (at 595nm) of the mixture of 800 pi water, 20 pi BIORAD reagent and each 
of 2pg, 5pg and lOpg final concentration quantities of the standard (BSA) were taken 
and 2pl, 5pl and lOpl of the eluted fraction were taken and analysed, to estimate the 
amount of protein.
9.22. TEV protease clevage
After the quantification of the eluted protein as in section 9.19, typically a range of TEV 
protease concentration was incubated with 2 pl protein (6 .6  mg/ml) and the level of 
digestion determined using SDS-PAGE. The most effective concentration for complete
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HIS-tag cleavage was taken to carry out TEV-protease cleavage of the whole batch of 
the eluted protein. The required amount of TEV protease was incubated for 5 hours with 
the protein, which was further for 2  hours with nickel beads and finally passed through 
the column, where the His-tag was retained with the nickel and the His-tag cleaved 
protein was collected as a flow through.
9.23 Concentrating the cleaved protein before gel purification
The cleaved protein was concentrated by centrifuging at 2647 x g using a Centricon 
Plus-20 centrifugal membrane filter which had a molecular weight cut off limit of 
10,000.
9.24. Purification of the cloned, expressed UBE2J1 fragment by gel permeation 
chromatography
The buffer used for gel filtration chromatography contains 50mM Tris (pH 8.0), 500 
mM NaCl in final volume in water, to which (ImM) DTT final concentration was 
added.
Column used for the gel permeation chromatography was Superdex 75, of 60 cm in 
length and 1.6 cm in diameter, Flow rate of the buffer 1.5 (ml/min), Peak fraction 
volume is 2.0 ml. Before the purification step, the column was equilibrated with the 
buffer.
9.25. Concentrating and desalting the protein
The gel purified protein was then concentrated to a final volume of 700pi by 
centrifuging at 2647 x g using the Centricon Plus-20 membrane filter which had a 
molecular weight cut off limit of 10,0 0 0 .
As 500mM NaCl (in final concentration) generally interferes in the crystallization 
process, its final concentration was brought down to 100 mM by adding 10 ml of the 
dialysis buffer used as in section 9.24 (with the exception of the salt concentration being 
lOOmM in the final volume) to the concentrator, while concentrating the protein. 
Typically 5 dilutions and centrifugations were used.
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9.26. Crystallization
Crystal trials were carried out in the Robot (Hampton research crystal robot). For crystal 
trial 17 plates were set, each plate consisting of 96 wells were set for the crystallization 
of the protein UBE2J1. Around 200 pi (15.7 mg/ml) of the purified protein sample was 
used, where the machine aliquoted 100 nano-litres of the sample into each well for 
crystal trial. The various precipitants that were used are given in the appendix.
After aliquoting the precipitants by the machine, the plates were set in the incubator, for 
the crystal growth. Each of the plates were photographed by the machine everyday to 
check for the crystal growth.
9.27. X-ray diffraction of the crystal obtained
Theoretically the crystal grown should be optimised in the same condition the crystal 
was obtained, to get a much better crystal in size and form. In this case as the crystal 
obtained was suspected to be a salt crystal, the optimization procedure was not carried 
out, but the ciystal was set for its x-ray diffraction. The crystal was first separated by a 
loop, and then mixed with the cryo-protectant consisting of PEG (polyethelene glycol) 
solution and mounted onto the goniometer, where a continuous stream of liquid nitrogen 
was passed through the loop having the crystal, so as to freeze the crystal and prevent it 
from denaturation by the X-ray beam. Finally the diffraction pattern was obtained, 
which confirmed that it was actually the crystal of the salt, and upon checking the 
precipitant used for that particular condition, it was found to be an ammonium sulphate 
crystal.
9.28. Circular dichroism (CD) spectrum analysis
The circular dichroism spectrum analysis was carried out at the St. Andrews University, 
the spectroscopic data obtained from the CD spectral analysis was then fed into the 
online server called as DICHROWEB, for the analysis of its secondary structure.
1 1 3
0.5 mg/ml concentration of the protein sample was required for the Far UV using a cell 
of pathlength 0.02 cm. 1 mg/ml concentration was used for the near UV using a cell of
0.5 cm.
The wavelength range of the far UV used was 190 -  260 nm, and that used for near UV 
was 250 -  320.
P A R A M E T E R S  U S E D  in C D  spectrum analysis
Table 9.2
Experimental parameters of CD spectrum analysis
Parameters Far UV Near UV
Concentration of the 
protein sample
0.5 mg/ml 1 mg/ml
Cell path length 0 .0 2 cm 0.5cm
Wavelength range 190-260 nm 250 -  320nm
Number of scans 3 3
CD supports various algorithms like SELCON3, CONTINLL, CDSSTR VARSLC, 
K2d. The CDSSTR algorithm was used presently for the analysis. The data-files of the 
CD spectrum required for the input into the DICHROWEB are Aviv, Jasco, free format, 
Brookhaven SRCD, DRS, wherein Jasco was used here in the analysis. The data inputs 
are either in delta epsilon (which was used here), mean residue ellipticity, theta 
(machine units), or SRCD counts. The various wavelength intervals of the input data are








10.1 Methodology of homology modelling of UBE2J1 by DeepYiew
The Swiss-model server was developed by (Guex and Peitsch, 1997), and is one of the 
most preferred online homology modelling server (http://www.expasv.org/swissmod/). 
The Swiss-PDB viewer enables the analysis of proteins like homology modelling, 
where proteins can be superimposed to generate structural alignment, which compares 
relevant parts like active sites, amino acid mutations, hydrogen bonds, bond angles and 
distance between atoms, which are displayed by graphics and menu interfaces.
Here structural templates could be either given by the user or Swiss-PBD has the inbuilt 
option where it finds out the best template of the protein whose model needs to be 
generated. After the identification of the most suitable template, the next step was to 
superimpose the template structure to the target sequence. Following the 
superimposition a multiple sequence alignment of the template with that of the target 
sequence was generated. The best aligned template and the query sequence were then 
submitted to the Swis-PDB server for generation of the 3D structure. After obtaining the 
model from the Swiss-model server, an energy minimization step was carried out. The 
quality of the model was verified by the WHATCHECK report that was provided by 
DeepView. The model quality check was also obtained from various other parameters 
like colouring the model by B- factor, secondary structure, alignment diversity, and 
solvent accessibility (BBSRC Bioscience IT Services. 2003; 
http://www.usm.maine.edu/~rhodes/SPVTut/index.html).
10.2 Methodology of homology modelling of UBE2J1 by 3D-JIGS AW
The model of UBE2J1 generated by the online homology modelling server called 3D- 
JIGSAW was obtained by submitting the peptide sequence of UBE2J1 online to the 
server (http://www.bmm.icnet.uk/servers/3diigsaw/) and the model was generated by 
3D-JIGSAW. The generated model file was opened up in Deepview and seen in 
Deepview and its Ramachandran plot obtained. The Whatcheck report was also 
obtained by submitting the model to Whatif database 
(http://swift.cmbi.ru.nl/WIWWWI/).
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11.1 Results and discussion of MSA & PROSITE signature
Thirteen distinct UBCs have been identified in yeast and 24 in humans (excluding all 
possible splice variants and those lacking a cysteine at the active site). All known UBCs 
have a core domain of around 150 amino acids. This so-called UBC domain contains 
the highly conserved UBC motif, which contains a highly conserved cysteine residue 
involved in thioester formation. The primary structure around the active site is highly 
conserved and has the consensus [FYWLPS]-H-[PC]-[NH]-[LIV]-x(3,4)-G-x-[LIV]-C- 
[LIV]-x-[LIV] in virtually all UBCs, and forms the basis for the PROSITE signature for 
this class of enzyme (Figure 11.1). All UBCs containing this PROSITE signature 
contain the active site residue as cysteine. Two notable UBC families exist that do not 
conform to this canonical PROSITE signature. The first example is a family of so-called 
non-catalytic UBCs, which significantly lack the highly conserved cysteine at the UBC 
active site to which the ubiquitin molecule is attached, they are TSG101 and CROC-1 
(UBE2V1) (Koonin and Abagyan, 1997; Xiao et al, 1998).
Secondly, there exists a family of yeast UBC6 enzymes and their homologues (Lester et 
al., 2 0 0 0 ), which while having the highly conserved cysteine, found in most other 
UBC’s, have a very different sequence from the existing UBC PROSITE signature. For 
example UBC6  lack the invariant histidine and glycine residues and has the extra amino 
acids G, R, F, which is not present in any other UBCs (Figure 11.1).
The PROSITE signature of all UBCs except UBC6 family is available in the database, 
but to date no PROSITE signature of the UBC6 family is available in the database 
(www.expasv.org). Therefore in order to create a PROSITE signature for the UBC6  
family, an MSA was carried out of selected peptide sequences of few non UBC6 s and 
selected UBC6 s. From the MSA it was possible to predict a proposed PROSITE 
signature of the UBC6 family and was submitted to EBI, which is as follows: 
T -[P A R J-[N S ]-G -R -F -x (3 )-[K T E J-[R K J-[L IV ]-C -[L M S ]-[S T J-[IM F J-[S T ]-x (2 )-H -  
[P K ].
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Figure 11.1 Multiple sequence alignment of selected ubc6 s with all other yeast UBCs and their selected homologues
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F igu re  11.1 rep resen ts  the m u ltip le  seq u en ce  a lign m en t o f  s e le c te d  U B C 6  fa m ily  p e p tid e  seq u en ces a lo n g  w ith  the o th er UBCs. R ep resen ted  on  
the top  a n d  the bo tto m  o f  the M SA a re  the p r o s i te  s ig n a tu res o f  the U B C 6 fa m ily  a n d  the p r o s i te  s ig n a tu res  o f  the U B C s o th er than U B C 6 fa m ily . 
This m u ltip le  sequ en ce  a lign m en t is a  sm a ll p a r t  o f  the w h o le  a lig n m en t o f  a ll  13 y e a s t  U B C s a n d  its  h o m o lo g u es in th ose  s e le c te d  organ ism s. A s  
the to ta l nu m ber o f  seq u en ce  is 193, on ly  a  sm a ll p a r t  o f  the m u ltip le  seq u en ce  has been  sh o w n  h ere  h igh ligh tin g  the a c tiv e  s ite  resid u e  
“C yste in e ” a n d  f e w  am in o a c id s  a ro u n d  it  w hich  co vers  the P R O S IT E  s ig n a tu re  o f  UBCs.
Figure 11.2 Multiple sequence alignment of selected UBCs other than UBC6 family, with other non-catalytic UBCs which lack 
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F igu re  11 .2  rep resen ts  the m u ltip le  seq u en ce  a lign m en t o f  s e le c te d  U B C s o th er  than U B C 6 fa m ily , a lo n g  w ith  
the o th er non ca ta ly tic  U BCs, a s  T SG 101 a n d  UBE2Vs. R ep resen ted  a t  the b o tto m  o f  the M SA is aga in  the  
P R O SIT E  sig n a tu re  o f  a ll  U B C s o th er than U B C 6  (figure generated in GENEDOC using BLOSUM62 matrix).
P R O S IT E  sig n a tu re  o f  a ll  U B C ’s  ex cep t U B C 6 ’s:~ 
[F Y W L P S ]-H -[P C ]-[N H ]-[L IV ]-x (3 ,4 )-G -x -[L IV ]-C * -[L IV ]-x -[L IV ]
The su g g e s te d  P R O S IT E  sig n a tu re  f o r  U B C 6  is:
T -[P A R ]-[N S ]-G -R -F -x (3 )-[K T E ]-[R K ]-[L IV ]-C -[L M S ]-[S T J -[IM F ]-[S T ]-x (2 )-H -
[P K ]
It can be seen from the UBCs and the UBC6 family PROSITE signatures, that as well as 
containing the conserved active site residue cysteine, a neighbouring [LIV] residue is 
also highly conserved. Other than these conserved residues, the PROSITE signature for 
UBCs and the UBC6 family are very different.
Using the PROSITE signature in a PHI BLAST
('http://www.ncbi.nlm.nih.gov/BLAST). all known yeast UBC6 orthologues are 
retained. This implies that our predicted UBC6 (UBE2J) PROSITE signature is correct.
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Figure 12.1 Phylogenetic tree of all yeast UBCs and its homologues in selected organisms generated by Phylip.
NAM ES OF ALL SELECTED  
ORGANISM S IN THEIR  
RESPECTIVE COLOURS:
ag- Anopheles gambiae 
at - Arabidopsis thaliana 
ce- Caenorhabditis elegans
hs- Homo sapiens 
mm -Mus muscuius 
nc - Neurospora crassa 
os- Oryza sativa 
pf- Plasmodium falciparum 
pvv- Plasmodium yoelli yoelli 
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F ig u re  12.1  sh o w s a  P h y lip  3 .6  n eig h b o u r-jo in in g  p h y lo g e n e tic  tree  f o r  a ll  13 y e a s t  
U B C s a n d  th e ir  h o m o lo g u es in 11 o th er s e le c te d  organ ism s, w h o se  g en o m es  h ave been  
fu l ly  seq u en ced  (a d iffe ren t co lo u r h as been  a ss ig n e d  to each organ ism ). In a d d itio n  to  
the 13 y e a s t  U B C ’s, the hum an U BE2Ls (U B E 2L 3 &  U B E 2L6) w h ich  d o es  n o t h ave its  
y e a s t  o rth o lo g u e  w e re  in c lu d ed  in the an a lysis . The d is ta n t U B C  re la tiv e  y e a s t  M M S2, 
w h ich  lacks a cy s te in e  a c tiv e  s ite  (L ew is e t  al., 2006), a n d  its  hum an h om ologu es  
U B E 2V 1 (C R O C 1) a n d  U BE2V2, w ere  a lso  in c lu d ed  (R othofsky a n d  Lin, 1997). The 
hum an a n d  m ou se  TSG 101 p ro te in s  (K oon in  a n d  A bagyan , 1997) w h ich  a re  d ifferen t 
d is ta n t re la tiv e s  o f  U BCs, th a t a lso  la ck  an a c tiv e  s i te  cysteine, w e re  a lso  in c lu d ed  in 
the p h y lo g e n e tic  an a lysis .
F ro m  th is f ig u r e  i t  can  c le a r ly  b e  seen  th a t w ith  the n o ta b le  ex cep tio n  o f  y e a s t  U B C 4  
a n d  5, a ll  o th er  y e a s t  U B C s a p p e a r  to  h ave  e v o lv e d  sep a ra te ly , a s  th ey  fo rm  th e ir  ow n  
unique evo lu tio n a ry  bran ch es. These c lea r ly  d is tin c t bran ch es th a t con ta in  p ro b a b le  
fu n c tio n a l orth o logu es, h a ve  been  a n n o ta ted  w ith  both  the y e a s t  U B C  nam e a n d  an y  
a lte rn a te  nam es. The a ccess io n  num bers, o f  each  o f  the a b b re v ia te d  n am es o f  the  
p e p tid e  seq u en ces  o f  the p h y lo g e n e tic  tree  can  be  fo u n d  in T ab le-1  o f  the ap p en d ix  
sec tion .
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Figure 12.2 Phylogenetic tree of all UBCs and its homologues of selected organisms generated by Consurf
YEAST FAMILY NAMES AND 
THEIR HGNC&ALIASE 
NAMES IN BRACKETS
NAMES OF ALL SELECTED 
ORGANISMS IN THEIR 
RESPECTIVE COLOURS:
ag- Anopheles gamhiae 
at - Arabidopsis thaliana 
cc- Caenorhabditis elegans
hs- Homo sapiens 
mm - Mus musculus 
nc - Neurospora crassa 
os- Orvza saliva 
pf- Plasmodium falciparum 
pyy- Plasmodium yoelli voelli 
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F ig u re  12 .2  is the p h y lo g e n e tic  tree  o b ta in ed  b y  the C o n su rf  an a lysis . The p e p tid e  
seq u en ce  o f  the p r e d ic te d  s tru c tu re  o fU B E 2 J 2  (2F 4W B ) w a s  taken as the tem p la te  a n d  
a ll  its  h o m o lo g u es (193  p e p tid e  seq u en ces) h ave been  a n a ly sed  in Consurf. The tree  is  
p a r tic u la r ly  usefu l in th a t it  sh o w s s tru c tu ra l co n serva tio n s  o f  the h om o lo g u es o f  
UBE2J2.
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12.1 Results and Discussion of the phylogenetic analysis of UBCs by Phylip
As can be seen from the phylogenetic trees generated by the two different programs 
(Phylip 3.6 and Consurf), the tree generated by Phylip 3.6 has 15 different branches of 
which there are 12 branches that contain 13 out of a total of 14 yeast UBCs. Yeast 
UBC4 and yeast UBC5 and their respective homologues appear in the same branch of 
the tree presumably because of the high degree of identity (93%) between the yeast 
UBC4 and UBC5. The other yeast UBC-like protein, MMS2, occupies a separate 
branch of the tree with its human homologues, UBE2V1 and UBE2V2. The remaining 
branches of the tree contain the human UBE2L homologues and human & mouse 
TSG101 homologues respectively.
12.2. Phylogenetic analysis of peptide sequences by Consurf
A phylogenetic analysis of the same 193 peptide sequences, were also carried out using 
Consurf (http://conseq.bioinfo.tau.ac.il/). The phylogenetic tree generated by Consurf 
(shown in Figure 12.2) helped to compare and contrast the findings of the relationships 
of all UBCs shown by the phylogenetic tree generated by Phylip.
The phylogenetic tree generated by Consurf had also reproduced similar results as that 
of the Phylip tree, with the only difference that yeast UBC4 and yeast UBC5 and its 
homologues have been placed in two different branches. The Phylip generated tree has 
the yeast UBC4, yeast UBC5 and its homologues appearing in the same branch. The 
probable reason for the difference could be due to the difference in the method of 
analysis of the two programs Phylip and Consurf.
Table 12.1 Methods of phylogenetic analysis by Phylip 3.6 and Consurf
Methods of analysis Phylip 3.6 Consurf
Tree-puzzle analysis 
(Gu and Zhang, 1997)
Tree-puzzle analysis is 
carried out to.calculate 
the rate heterogeniety




Bootstrapping analysis is 
carried out




Neighbor-joining is used to 
compute the tree
Neighbor-joining is also used to 
compute the tree
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From the comparative study of the method of analysis of the two programs, it can be 
said that the method of analysis used by Phylip 3.6 appears to be more rigorous than 
Consurf. The various steps mentioned in the Table 12.1 used by Phylip to generate the 
phylogenetic tree are some of the essential features which are required in the analysis of 
generating a statistically significant phylogenetic tree. In Consurf the method of 
analysis appears not to be as rigorous as Phylip, but nevertheless it had reproduced a 
phylogenetic tree which is very similar to that of Phylip. This might have some 
biological implications, but can be considered at present to be debatable. The Consurf 
tree as a whole, with the exception of UBC4/5 branch supports the branching of the 
Phylip tree.
12.3. The overall discussion of the phylogenetic trees generated by Phylip and 
Consurf
The Phylogenetic trees obtained by Phylip and Consurf, is a perfect example of how 
each UBCs have segregated themselves into each individual branches. 13 different yeast 
UBCs (UBC1- UBC13) have been used to find their homologues in 11 different 
organisms whose genomes have been fully sequenced. The 11 different organisms used 
are A n o p h e les  g a m b ia e , A ra b id o p s is  th a lian a , C a en o rh a b d itis  e leg a n s, D ro so p h ila  
m ela n o g a ster , H om o sa p ien s, M u s m usculus, N eu ro sp o ra  crassa , O ryza  sa tiva , 
P la sm o d iu m  fa lc ip a ru m , P la sm o d iu m  y o e ll i  y o e lli, S ch izo sa cch a ro m yces  p o m b e .
•  As appears in both the phylogenetic trees, UBC7 and UBC3 are in the adjacent 
branches appearing in the same node. This was previously indicated in the 
multiple sequence alignment as UBC7 and UBC3 have 13 extra amino acids in 
common which are not found in any other UBCs.
• Interestingly, the yeast MMS2 appears on its own in a separate branch, with its 
human orthologues UBE2Vs appearing in the adjacent branches in the Phylip 
generated phylogenetic tree.
• The phylogenetic tree obtained by Phylip has TSG101 in adjacent branches to 
UBC9, whereas in the Consurf tree TSG101 appears in adjacent branches to yeast 
MMS2 and UBE2Vs.
• In the phylogenetic tree generated by Phylip, UBC4/UBC5 appears in a single 
branch which is furthest away from the main node of the tree. The phylogenetic 
tree generated by Consurf has the yeast UBC4/5 and its homologues in separate
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branches and are the first among all other UBC to have diverged from the main 
node.
• UBC 13 and UBC1 appear to be in adjacent branches in both the phylogenetic 
trees, which illustrates that UBC 13 & UBC1 may share some common 
evolutionary and functional similarity.
• UBC2 and UBC11 appear to be in adjacent branches in both the phylogenetic 
trees, which indicate some commonality in their evolution.
• UBC8 and UBC10 are in the adjacent branches of both the phylogenetic trees.
• In the phylogenetic tree obtained by Phylip, UBC6 have diverged from a common 
node to that of UBC7 and UBC3, whereas in the phylogenetic tree obtained by 
Consurf UBC9 appears to be in the adjacent branch to that of UBC7 and UBC3.
From the phylogenetic study both evolutionary and functional relationships can be 
estimated. These relationships are on the basis of the amino acid sequences, but more 
elaborate functional relationship can be assumed on the basis of 3-dimensional 
structures. Many of the UBC structures have been elucidated by X-ray crystallography, 
like A ra b id o p s is  th a lian a  UBC1, yeast UBC4, yeast UBC7, and human UBC9. The 
structure of one of the human homologue of yeast UBC6 has also been found recently,
i.e. UBE2J2. As the peptide sequence of the other human homologue of yeast UBC6 
which is UBE2J1, is quite different from that of UBE2J2, and as its 3-dimensional 
structure is not known, it was essential to elucidate the structure of UBE2J1 mainly for 
its clinical implications.
Illustrated in the following pages are all the branches of the two phylogenetic trees, 
which have been cut out and inferred individually, so as to compare and contrast the 
relationships of each UBCs as appearing in the two phylogenetic trees.
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12.3.1. The yeast UBC6  and human UBE2J orthologous phylogenetic branch 
Figure 12.3 Branch of UBC6  generated by Phylip
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Figures 12.3 and 12.4 illustrate sections of the two phylogenetic trees (Figure 12.1 & 
12.2) the branch of yeast UBC6 and its homologues in different organisms from the 
Phylip and the Consurf generated trees respecti vely.
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Table 12.2 Gene duplication in the UBC6 family
Different UBC6 s Number of genes Different splice /start variants
H om o sa p ien s (2) UBE2J1, UBE2J2 UBE2J2 vl, UBE2J2 v2
O ryza  sa tiv a 0
A ra b id o p s is  th a lian a (3) UBC6 a, UBC6b, UBC6 c *
M us m uscu lus (2) UBE2J1, UBE2J2
C. e leg a n s (3)UBC6a, UBC6b, UBC6 c UBC6 c vl,UBC 6 c v2
P. fa lc ip a ru m 0
A n o p h eles g a m b a ie 1
N eu ro sp o ra  c ra ssa (2) UBC6a, UBC6b
S .pom be 1
D. m e la n o g a s te r 1
S .cerev is ia e 1
P. y o e l l i  y o e l l i 0
From the Figures 12.3, 12.4, it can clearly be seen that yeast UBC6 and its 
homologues/orthologues have branched out very distinctly on its own, in both the 
phylogenetic trees generated. Only one each of yeast, p o m b e , d ro so p h ila , an oph eles  
UBC6 gene is present in contrast to most other multicellular organisms which have 
undergone duplication of this gene at least once e.g. there are two homologues in H om o  
sa p ien s  a n d  M us m usculus, three in A. th a lian a  and three in C. eleg a n s. A notable 
exception to this finding, are the two insects D . m e la n o g a ste r  and A. g a m b ia e , which 
like the yeasts have only one homologue of this gene in their genomes. This latter 
finding may either be due to the common ancestor of insects having only one yeast 
UBC6 homologous gene, or that there has been complete loss of a previously duplicated 
gene in this ancestral species.
All the enzymes in this branch contain an ER transmembrane domain at their carboxy 
terminus and have or are putatively been shown to be involved in the ER associated 
degradation of misfolded proteins. Moreover all the enzymes on this branch have the 
PROSITE signature:
T-[PAR]-[NS]-G-R-F-x(3)-[KTE]-[RK]-[LIV]-C-[LMS]-[ST]-[IMF]-[ST]-x(2)-H- 
[PK], where the conserved C is active site cysteine, for this subfamily of UBC’s. 
Bootstrap values have been obtained from the phylogenetic tree generated by P h ylip , 
but no bootstrap values have been obtained by the other tree that had been generated by 
C onsurf. The reason for not having the bootstrap values for the Consurf generated 
phylogenetic tree is that Consurf generated only the phylogenetic tree and plotted the 
conservation of the amino acids of UBCs onto the structure of UBE2J1. It does not 
estimate the bootstrap values.
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There are bootstrap values in the tree generated by Phylip, ranging from very low of 
10% to a high of 97%. Bootstrap values of 90% and above considered as very confident 
assumptions that the branching has been evolved and the rate of appearance of these 
same species in the same branch in any circumstance is very high. But bootstrap values 
less than 50% are not considered as confident assumptions. Irrespective of the bootstrap 
values, as yeast UBC6 and all its homologues in all different species have segregated 
themselves into one single branch apart from all other UBCs, is a clear indication that 
UBC6s are evolutionarily and functionally distinct from all other UBCs.
What is more interesting in the Consurf generated phylogenetic tree, is that the other 
UBC homologues which lack the UBC active site cysteine i.e. TSG101 and UBE2V1 
(CROC-1) & UBE2V2 are in the adjacent branches of UBC6. This shows that TSG101, 
though it lacks the active site, could be very much related to the UBC6 evolutionarily 
and functionally. This also indicates that there might have been a common ancestor to 
these genes and might have diverged in the time of evolution. There are two types of 
evolution, convergent evolution and divergent evolution. Divergent evolution is two or 
more related species becoming more and more dissimilar. Convergent evolution on the 
other hand is unrelated species becoming more and more similar to each other in the 
course of evolution. Here the appearance of TSG101 and UBE2V1 (CROC-1) indicates 
a convergent evolution.
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12.3.2. Yeast UBC9 and its homologues











i .—  osubc9a 
fosUBC9b
osUBC9c
Figures 12.5 and 12.6 illustrates a section taken from the Phylip and the Consurf 
generated trees respectively, highlighting the yeast UBC9 and its homologues.
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As evident from the above figures that yeast UBC9 and all its homologues have also 
appeared in a single branch. Both the phylogenetic trees look very similar, which gives 
a confidence of how well UBC9 has segregated into a single branch, distinct from all 
other UBCs.
Table 12.3 Gene duplication in the UBC9 family
Different UBC9s Number of genes Different splice /start 
variants
Homo sapiens (2), UBE2I, Q9BQ25











P. yoelli yoelli 0
From Table 12.3 it can be clearly seen that other than Homo sapiens, Oryza sativa and 
Anopheles gambaie, all other organisms appear to have appeared only once. There are 
three orthologues of Oryza sativa, two of Homo sapiens, and two in Anopheles 
gambaie.
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12.3.3. Yeast UBC11 and its homologues 
Figure 12.7 UBC11 branch generated by Phylip
Figure 12.8 UBC11 branch generated by Consurf
— [
osUBC11 
— atUBC11 b 
atUBCIIa vl 




r hsUBE2C (UBCH10) 
----- lmmUBE2cJm | JDf̂l 1
agU BC11 a
Figures 12.7 and 12.8, highlights a section taken from the main Phylip and the Consurf 
generated trees respectively, which illustrates the branching of yeast UBC11 and its 
homologues.
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The branches of this section of the phylogenetic trees above, shows the segregation of 
yeast UBC11 and its homologues from all other UBCs. They have evolved in the same 
branch with bootstrap values in the range of 100%, 95%, which are perfect 
confirmations of the assumption that the yeast UBC11 and its homologues have 
appeared in the same branch. As it appears in the UBC11, Arabidopsis have evolved 
more than once.
Tablel2.4 Gene duplication in the UBC11 family
Different UBC1 Is Number of genes Different splice /start variants
Homo sapiens 1
Oryza sativa 1
Arabidopsis thaliana (2), UBClla, 
UBCllb










P. yoelli yoelli 0
From Table 12.4 it is evident that with the exception of Arabidopsis, all other organisms 
have appeared only once in UBC11. Only Arabidopsis have duplicated as it appears to 
have two genes with three splice variants of one of the two genes as can be seen in the 
table above.
138
12.3.4. Yeast UBC2 and its homologues 
Figure 12.9 UBC2 branch generated by Phylip
Figure 12.9 shows the phylogenetic branching of yeast UBC2 and its homologues in 
different organisms generated by Phylip.
Figurel2.10 UBC2 branch generated by Consurf





















Figure 12.10 illustrates two adjacent branches of the main phylogenetic tree generated 
by Consurf, one of which is the human orthologues UBE2Ls and the other is the branch
of yeast UBC2 and its homologues. The reason for illustrating the two branches here is 
to highlight that that the UBE2L family is closer to the UBC2 family.
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The branches illustrated in Figure 12.10 of the phylogenetic tree consists of the branch 
of human orthologues UBE2L3 & UBE2L6 which is adjacent to the branch of yeast 
UBC2 and its homologues. The phylogenetic tree obtained by Phylip and Consurf has 
the yeast UBC2 and its orthologues in a single branch. The UBE2L branch of the 
Consurf tree has been shown here as it appears in the adjacent branch to UBC2 in the 
Consurf generated tree. In the phylip tree the UBE2L branch appear adjacent to UBC12 
family. Although the Phylip generated tree is more rigorous than the Consurf tree, the 
bootstrap value in the phylip tree is very poor (33%). This low bootstrap value indicates 
that it is not confirmed that the UBE2L branch and the UBC12 family branch are quite 
close to each other in evolution. It could be that the Consurf result may be right by 
illustrating the UBE2Ls being closer to the UBC2 family.
Tablel2.5 Gene duplication in the UBC2 family
Different UBC2s Number of genes Different splice /start variants
Homo sapiens 2, UBE2A, UBE2B
Oryza sativa 2, UBC2a, UBC2b UBC2a vl,UBC2a v2
Arabidopsis thaliana 2, UBC2a,UBC2b UBC2b_vl, UBC2b_v2, 
UBC2b_v3 are splice variants or 
polymorphic variant.
Mouse 2, UBE2A, UBE2B
C. elegans 1, UBC2a UBC2a vl, UBC2a v2
Plasmodium falciparum 2, UBC2a, UBC2b UBC2a vl, UBC2a v2





P. yoelli yoelli 2, UBC2a, UBC2b
It can be seen that with the exception of yeast, Neurospora crassa, S. pombe, and D. 
melanogaster, all organisms have duplicated in the UBC2 family. C. elegans has also 
one gene, but it has two splice variants.
140
12.3.5. The yeast UBC7/ human UBE2G branch and its evolutionary 
relationship to the yeast UBC3/human CDC34 branch.
Figure 12.11 UBC7 and UBC3 branch generated by Phylip
Figure 12.11 is the phylogenetic branch cut out from the main phylogenetic tree 
generated by Phylip, illustrating the close evolutionary relationship o f yeast/human 
UBC7/UBE2G and their related orthologues to yeast/human UBC3/CDC34.
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Figure 12.12 UBC7 and UBC3 branch generated by Consurf
Figure 12.12 is the phylogenetic branch cut out from the main phylogenetic tree 
generated by Consurf, illustrating the close evolutionary relationship of yeast/human 
UBC7/UBE2G and their related orthologues to ye ast/human UBC3/CDC34.
As can be seen from the multiple sequence alignment of all UBCs, all homologous 
members of yeast UBC7 and yeast UBC3 including human CDC34 have a unique, 13 
amino acid insert after the conserved UBC active site residue cysteine. This 13 amino 
acid sequence is highly conserved among the homologues of these enzymes making 
likely that they all have evolved from a single common ancestral gene. This is further 
confirmed from the phylogenetic trees, as the yeast UBC7 and UBC3 homologues 
appear to have diverged from the same evolutionary node and are in the adjacent 
branches. This evolutionary branch bifurcation into two distinct sub-branches, one 
containing the yeast UBC7 homologues, which are involved in ERAD and the other 
which includes the human CDC34, which is involved in cell cycle control, is a clear 
indication that UBC7 and UBC3 are evolutionarily and functionally related.
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Table 12.6 Gene duplication in the U B C 7  fam ily
Different UBC7s Number of genes Different splice /start variants













P. yoelli yoelli 0
From Table 12.6 it can be seen that there are 5 genes present in Arabidopsis, four genes 
in Drosophila. All other organisms have duplicated twice, with the exception of 5. 
cerevisiae, N. crassa, O. sativa and P. falciparum that appear only once.
Table 12.7 Gene duplication in the UBC3 family








Neurospora crassa 1, UBC3a UBC3a vl, UBC3a v2
S.pombe 0
D. melanogaster 1, UBC3a UBC3a_vl, UBC3a_v2, splice or 
promoter variants.
S.cerevisiae 1
P. yoelli yoelli 0
From Table 12.7 it can be seen that in UBC3, there are no O. sativa, A. thaliana, P. 
falciparum, A. gambaie, S. pombe and P. yoelli yoelli. Yeast, N. crassa, and C. elegans 
have appeared once, and only Homo sapiens and M us musculus have duplicated.
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12.3.6. Yeast U B C 1 0  and its homologues
Figure 12.13 U B C 1 0  branch generated by Phylip
Figures 12.13 and 12.14 are the sections of the main phylogenetic trees generated by 
Phylip and Consurf respectively, showing the branching of yeast UBCIO and its 
homologues in different species.
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Table 12.8 Gene duplication in the U B C 1 0  fam ily
Different UBClOs & 
UBCls












P. yoelli yoelli 1
It can be seen from the table above that all organisms have appeared only once in the 
UBC10 family with no duplication, with the exception of O. sativa, C. elegans, A. 
gambaie, and D. melanogastev which have not appeared even once.
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12.3.7. Yeast U B C 1 2  and its homologues
Figure 12.15 U B C 1 2  branch generated by Phylip
Figure 12.15 is a branch cut out from the main phylogenetic tree generated by Phylip o f 
yeast UBC12 and its homologues along with UBE2Ls
Figure 12.16 UBC12 branch generated by Consurf
Figures 12.16 show the branch portion o f the yeast UBC12 and its homologues cut out 
from the main tree generated by Consurf.
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The difference in the phylogenetic branching of the two generated trees is that the 
UBE2Ls appear to have diverged from the same node as of yeast UBC12 and its 
homologues in the tree generated by Phylip, whereas they are distant apart in the tree 
generated by Consurf.
Table 12.9 Gene duplication in the UBC12 family
Different UBC12s Number of genes Different splice /start variants
Homo sapiens 1
Oryza sativa 1









P. yoelli yoelli 0
From Table 12.9, it can be seen that there are not much duplication of genes of the 
different organisms, with the exception of A. thaliana where it has duplicated.
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12.3.8. Yeast U B C 8  and its homologues
Figure 12.17 UBC8 branch generated by Phylip
Figure 12.18 UBC8 branch generated by Consurf
—  scUBCB 
r PfUBC8
1 pyyUBCB
i cellBC8a v1 







Figures 12.17 & 12.18 illustrate the phylogenetic sub-branch o f yeast UBC8 and its 
homologues in different organisms, generated by Phylip and Consurf respectively.
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It can be seen that the branches of yeast UBC8 and its homologues in the two 
phylogenetic trees have quite distinctly segregated into a single branch. Both the 
phylogenetic branched trees confirm this fact that yeast UBC8 and its homologues 
appear to have a common evolutionary and structural similarity to each other.
Table 12.10 Gene duplication in the UBC8 family
Different UBC8s Number of genes Different splice /start variants
Homo sapiens 1
Oryza sativa 1
Arabidopsis thaliana 2, UBC8a, UBC8b UBC8a vl,UBC8a v2
Mouse 0







P. yoelli yoelli 1
From Table 12.10 above it can be seen that only Arabidopsis thaliana and Drosophila 
melanogaster has duplicated in UBC8, all other organisms have appeared only once. 
M us musculus has not appeared even once.
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12.3.9. Yeast U B C 1 3  and its homologues
Figure 12.19 UBC13 branch generated by Phylip
Figure 12.19 illustrates a section o f the whole phylogenetic tree generated by Phylip 
illustrating the branch o f yeast UBC13 and its homologues.
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Figure 12.20 illustrates a section o f the whole phylogenetic tree generated by Consurf 
illustrating the branch o f yeast UBC13 and its homologues.
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The phylogenetic trees generated by Phylip and Consurf, have very well segregated 
yeast UBC13 and its homologues into individual branches. This is evident that UBC13 
family have evolved independently and have a function distinct from all other UBCs.
Table 12.11 Gene duplication in the UBC13 family
Different UBC13s Number of genes Different splice /start variants
Homo sapiens 1
Oryza sativa 1









P. yoelli yoelli 0
The appearance of three peptide sequences of drosophila UBC13 and Arabidopsis 
UBC13 in the UBC13 branch is a clear indication that all peptide sequences of each of 
drosophila and Arabidopsis UBC13 have duplicated. There is one peptide sequence 
each of S.cerevisiae, S. pombe, N. crassa, O. sativa and M. musculus, which states that 
they have evolved only once and have not multiplied in the course of evolution.
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12.3.10. Yeast UBC4/UBC5 and its homologues 
























Figure 12.22 UBC4/5 branch generated by Consurf
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Figure 12.21 represent a section of the whole phylogenetic tree generated hy Phylip o f 
yeast UBC4/5 and its homologues in different species. Figure 12.22 represents the 
sections o f the whole phylogenetic tree generated by Consurf o f yeast UBC4/5 and its 
homologues in different species. Here in Consurf the yeast UBC4/5 and its homologues 






_  r osUBC4 
r atUBC4b




Yeast UBC4 and yeast UBC5 peptide sequences are quite similar to each other (93% 
identity & 97% similarity) and its homologues are the same. There are peptide 
sequences' of organisms like Homo sapiens, M as musculus and Arabidopsis thaliana, 
which appear more than once. All the UBC4/5 homologues have appeared in the same 
phylogenetic branch in the tree generated by Phylip, but the tree generated by Consurf 
has the yeast UBC4/5 and its homologues in separate branches.
Table 12.12 Gene duplication in the UBC4/5 family
Different UBC4/5s Number of genes Different splice /start variants
Homo sapiens 7
Oryza sativa 1











P. yoelli yoelli 0
Table 12.12 above shows that there are seven genes in Homo sapiens, three genes of A. 
thaliana, three of M. musculus, but all other organisms have appeared only once.
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Figure 12.23 UBC1 branch generated by Phylip
12.3.11. Yeast U B C la n d  its homologues







Figure 12.23 represent a section of the whole phylogenetic tree generated by Phylip the 
branch o f yeast UBC1 and its homologues in different species, whereas Figure 12.24 is 
a section o f the phylogenetic trees generated by Consurf the branch o f yeast UBC1 and 
its homologues.
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As can be seen from the phylogenetic sub-branches from the two trees generated by 
Phylip and Consurf, all species have evolved only once. This is further illustrated in the 
Table 12.13. What is evident from the phylogenetic tree branches of the two trees is that 
yeast UBC1 and its homologues have segregated very well, distinct from all other 
UBCs.
Table 12.13 Gene duplication in the UBC1 family














P. yoelli yoelli 1
Table 12.13 shows that all homologues of yeast UBC1 have appeared only once without 
any gene duplication.
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Figure 12.25.1 MMS2 and UBE2Vs branches generated by Phylip
12.3.12. U B C s  and U B E 2 V s, TSG101
Figure 12.25 shows that the yeast MMS2 and human CROC-1 (UBE2EV1) are very 
distantly related to all other UBCs as obtained in the Phylip tree.
Figure 12.25.2 TSG101 and UBC9 branch generated by Phylip
Figure 12.25.2 indicates that TSG101 may be a distant structural relative o f the UBC9 
family, as represented by the Phylip tree.
Figurel2.26 MMS2, TSG101 and UBE2V branch generated by Consurf
Figure 12.26 indicates that TSG101 and the MMS2/UBE2Vfamily may be more closely 
related than all other UBCs, as represented by the Consurf tree.
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The distant UBC like TSG101 and MMS2/UBE2V families, completely lack a UBC 
active site i.e. no cysteine or conserved amino acids from either UBC6 or non-UBC6 
PROSITE signatures. It is therefore not surprising that Consurf analysis has placed both 
families on separate adjacent UBC evolutionary sub branches (Figure 12.2). From these 
Consurf results, this suggests that the TSG101 and the MMS2/UBE2V families had a 
common ancestor.
Surprisingly the Phylip tree (Figure 12.1) suggests that TSG101 is more closely related 
to the UBC9 family, than to any member of the MMS2/UBE2V family.
12.3.13. An overall view of the phylogenetic analysis
As can be seen from the constructed phylogenetic trees (Figure 12.1 & 12.2), functional 
members of the UBC family have been clearly separated into approximately 15 distinct 
functional branches. As the function of all 13 UBC’s in yeast is known, the constructed 
phylogenetic trees makes it possible to predict the putative function of other plant and 
animal species that are on the same branch of the tree as their yeast homologue. For 
example human UBE2J1 and UBE2J2 are on the same phylogenetic branch as yeast 
UBC6, and which have all been shown to have similar cellular functions (Lenk et al.,
2002). Another possible use of this UBC phylogenetic tree is that it can serve to 
simplify the task of the different eukaryotic nomenclature committees, whereby 
appropriate names can be ascribed to these branches of related enzymes. This analysis is 
of particular importance as it has been found that many of the UBC enzymes submitted 
to the database have either multiple or inappropriate names (see Table 12.14). By using 
a unified approach based on well constructed phylogenetic trees (Figure 12.1 & 12.2) 
for all UBC’s, it is hoped that the subsequently generated trees will greatly aid scientists 
in investigating genome function, structure and/or nomenclature in their chosen 
organism.
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12.4. Revised nomenclature of human UBCs
Table 12.14 Table of yeast human UBC nomenclature
YEAST UBCs Yeast misnomers Human names and Misnomers
UBC1 HIP2 (UBE2K) (UBCl_Human)
UBC2 RAD6 UBE2A (RAD6A, HHR6A) 
UBE2B(ubc2b, RAD6B, HHR6B)
UBC3 CDC34, DNA6 CDC34 (UBE2R1) 
UBE2R2







No yeast orthologues UBE2L3(UBCE7, UBCH7) 
UBE2L6 (UBCH8)





UBC8 UBE2H (UBCH, UBC8)
UBC9 UBE2I (UBC9, UBCE9)
UBC 10 PEX4, UBCX, PAS2 UBE2S (E2EPF)
UBC 11 UBE2C (UBCH 10)
UBC12 UBE2M (hUbcl2)
UBC13 OBE2N (UbcH-ben, MGC8489, 
BLU)
MMS2 UBE2V1 (UEV1A, CROC-1) 
UBE2V2 (UEV-2, DDVit-1, EDPF- 
1, MMS2)
No yeast orthologues TSG101
Table 12.14 illustrates all 13 yeast U BCs in the first column, the misnomers of yeast in 
the second column, and in the third column are all the H G N C  nomenclature approved 
human names of corresponding yeast U BCs in bold, and its misnomers in brackets. All 
human nomenclature approved names have the prefix UBE2, followed by the alphabets 
specific to each 13 UBCs.
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12.4.1. Yeast UBC1 and HIP2 (UBE2K)
From the phylogenetic trees shown in Figures 12.1 and 12.2, it can clearly be seen that 
as yeast UBC1 and the human HIP2 (human interacting protein 2) are on the same 
branch of the UBC tree they are therefore very likely to be orthologues. This was 
confirmed by using the Sacchromyces cerevisiae option in the Ensembl database 
(www.ensembl.org), which also identifies HIP2 as the predicted orthologue of yeast 
UBC1. The Human genome organisation (HGNC) nomenclature committee 
(http://www.gene.ucl.ac.uk/nomenclature/) still uses the name HIP2 and not its 
previously recommended name UBE2K or UBC1JHUMAN as it is known in 
UNIPROT (http://www.ebi.uniprot.org/index.shtml). The persistent use of HIP2 (Lee, 
et al. 2001) is particularly confusing as it bear no sequence or functional resemblance to 
Huntingtin interacting protein 1 HIP1 (Wanker et al., 1997) and the human intraparietal 
area 2 (HIP2) (Choi et al., 2006).
12.4.2. Yeast UBC2 and human UBE2A and UBE2B
From Figures 12.1 and 12.2, it can be seen that both human UBE2A and UBE2B are on 
the same branch as yeast UBC2 and are therefore likely to be orthologues. Again the 
Ensembl entry for yeast UBC2 agrees with this prediction. Unfortunately the HGNC 
nomenclature database calls UBE2A and UBE2B as RAD6 and not as a yeast UBC2 
orthologues.
12.4.3. Yeast UBC3 (CDC34), human CDC34 (UBE2R1) and UBE2R2
From Figures 12.1 and 12.2, it can be seen that both human CDC34 (UBE2R1) and 
UBE2R2 are on the same branch as yeast UBC3 and again are likely to be orthologues. 
Again the Ensembl entry for yeast UBC3 agrees with this prediction.
Like HIP2, HGNC calls human CDC34 as the proper nomenclature name and does not 
mention its yeast homologue. In addition the HGNC database calls UBE2R1, as an alias 
of CDC34 which is confusing as the related human protein UBE2R2 is also a functional 
orthologue of yeast UBC3. An example of the confusion caused by this nomenclature is 
a recent paper entitled “Ubiquitin-conjugating enzyme 3 delays human lens epithelial 
cells in metaphase” (Liu et al., 2006), which fails to distinguish which Human 
orthologue of yeast UBC3, CDC34 (UBE2R1) or UBE2R2, they were investigating.
12.4.4. Yeast UBC4/5, Human UBE2D’s and Human UBE2E’s
From the phylogenetic trees it can clearly be seen that yeast UBC4, yeast UBC5 and 
four different human UBE2D proteins (1-4) are on the same branch of the UBC tree
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(see Figures 12.1 and 12.2) and are therefore very likely to be orthologues. In support of 
this assumption the Ensembl database has all four human UBE2D’s are quoted as 
predicted orthologues of both yeast UBC4 and yeast UBC5. Unfortunately the Consurf 
phylogenetic analyses (Figure 12.2) places two of the UBE2D’s (UBE2D1 and 
UBE2D2 ) on a different branch from yeast UBC4, yeast UBC5 , human UBE2D3 and 
human UBE2D4. Consurf phylogenetic analysis is however a less rigorous statistical 
package designed more to look for structural rather than actual sequence homology. 
Although the human UBE2E’s (1-3) appear on the same evolutionary sub-branch 
(Figure 12.2) as yeast UBC4, yeast UBC5 they appear not to be as closely related to 
these yeast proteins as the UBE2D family and are therefore probably not true 
orthologues of yeast UBC4 and UBC5.
Unfortunately protein biochemists have been especially slow to change over to the 
(HGNC) UBE2D names and are currently still using the very ambiguous UBCH5a 
(UBE2D1), UBCH5b (UBE2D2), UBCH5c (UBE2D3) names (Brzovic et al., 2006; 
Lopez-Avalos et al., 2006; Buchwald et al., 2006). Even more confusingly scientists 
are still using UBCH6 for UBE2E1 (Buchwald et al., 2006; Karaczyn et al., 2006), 
UBCH8 for UBE2E2 (Takeuchi, Inoue, and Yokosawa, 2006), and UBCH9 for 
UBE2E3 (Woods et al., 2004). The use of UBCH8 (UBE2E2) is particularly confusing 
as the name UBCH8 is currently wrongly being used for the human UBE2L6 protein 
(Tripathi, and Chaudhuri, 2005)!
12.4.5. Human UBE2L3 and UBE2L6
From the phylogenetic trees shown in Figures 12.1 and 12.2, it can clearly be seen that 
the related human UBE2L3 (UBCH7) and UBE2L6 (UBCH8) proteins are on their own 
branch of both the Phylip and the Consurf trees. There appears to be no known yeast 
orthologues to these proteins. UBE2L6 has been shown to be involved in the 
ubiquination of the cell cycle control protein P53 (Huang et al., 2006). Again many 
protein biochemists are still currently using the highly confusing names UBCH7 and 
UBCH8 for UBE2L3 and UBE2L6 respectively (Fortier and Kombluth, 2006; 
Takeuchi, Inoue and Yokosawa, 2006; Wong et al., 2006; Takeuchi et al., 2005).
12.4.6. Yeast UBC7 and human UBE2G
From the phylogenetic trees shown in Figures 12.1 and 12.2, it can clearly be seen that 
as yeast UBC7 and the two human UBE2G’s (1 and 2) are on the same branch of the
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UBC tree they are therefore very likely to be orthologues. This was confirmed by using 
the Sacchromyces cervisiae option in the Ensembl database
(www.ensembl.org). Unfortunately many biochemists confusingly still insist on using 
the yeast UBC7 name to describe UBE2G2, clearly ignoring the fact that another human 
orthologue, UBE2G1, also exists for yeast UBC7 (e.g. Briggman et al., 2005).
12.4.7. Yeast UBC8 and human UBE2H
The phylogenetic trees shown in Figure 12.1 and 12.2, clear identifies yeast UBC8 and 
the human UBE2H in the same phylogenetic sub branch, which signifies that they are 
most likely to be orthologues, which is further confirmed by the Ensembl database 
(www.ensembl.org).
12.4.8. Yeast UBC9 and UBE2I
The phylogenetic trees shown in Figures 12.1 and 12.2, identifies yeast UBC9 and the 
human UBE2I in the same phylogenetic sub branch. This signifies that UBE2I is most 
likely to be an orthologue of yeast UBC9, which was further confirmed by the 
Ensemble database (www.ensembl.org).
12.4.9. Yeast UBC10 and human UBE2S
The yeast UBC 10 (Alias UBCX, Pex 4, and Pas2) and the human UBE2S appears in the 
same phylogenetic sub branch as in Figures 12.1 and 12.2, which specifies that it is 
most likely an orthologue. Although the human UBE2S name is now widely used and 
accepted unfortunately yeast UBC 10 is also known as several other names e.g. UBCX, 
Pex4 and Pas2. Disappointingly the Ensembl database uses Pex4 as the recognised 
name for yeast UBC10 and has not yet named human UBE2S as its orthologue. The 
persistent use of the name pex4 is not logical and can be confusing e.g. Eckert and 
Johnsson’s (2003) paper is entitled “PexlOp links the ubiquitin conjugating enzyme 
Pex4p to the protein import machinery of the peroxisome.” this could be written more 
simply and accurately as “PexlOp links UBC10 to the protein import machinery of the 
peroxisome.”!
12.4.10. Yeast UBC11 and human UBE2C
From the phylogenetic tree it could be said that human UBE2C is probably a yeast 
UBC11 orthologue as they appear in the same phylogenetic sub branch. This is further 
confirmed by the Ensembl database (www.ensembl.org). which quotes human UBE2C 
as a predicted orthologue for yeast UBC11. Unfortunately the, old and confusing, alias
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name UBCH10, and not human UBE2C, is currently still being used by biochemists 
(e.g. Fortier and Kombluth, 2006).
12.4.11. Yeast UBC12 and human UBE2M
Once again both the yeast UBC12 and the human UBE2M are in the same phylogenetic 
sub branch as in Figures 12.1 and 12.2, and is further confirmed by the Ensemble 
database (www.ensembl.org). From this it could be said that UBE2M is most likely an 
orthologue of yeast UBC12.
12.4.12. Yeast UBC13 and human UBE2N
Yeast UBC13 and the human UBE2N are on the same phylogenetic sub branch shown 
in Figures 12.1 and 12.2, and which is further confirmed by the Ensemble database 
(www.ensembl.org). Hence it is most likely that UBE2N is an orthologue of yeast 
UBC13. UBE2N has its aliases mentioned in the HGNC database as (UbcH-ben, 
MGC8489, BLU).
12.4.13. Yeast MMS2 and the human UBE2V, and the TSG101
The yeast MMS2 and the human UBE2Vs (UBE2V1 and UBE2V2) are on the adjacent 
sub branches of the phylogenetic tree. The aliases of the human variants of yeast MMS2 
(UBE2V1 and UBE2V2) are UBE2V1 (UevlA, CROC-1) (Andersen et al., 2005), and 
UBE2V2 (UEV-2, DDVit-1, EDPF-1, MMS2) (Lewis et al., 2006). The TSG101 
appears in the sub branch on its own in the phylogenetic tree as in Figures 12.1 and 
12.2.
12.4.14. Yeast UBC6 and the human UBE2J
My supervisor Dr. Lester previously identified two potential human orthologues of 
yeast UBC6 (Lester et al., 2000), which he and his co-workers named NCUBE1 (now 
UBE2J1) and NCUBE2 (now named UBE2J2). Weissman et al. (2001) later identified a 
mouse orthologue of yeast UBC6, which he named MmUBC6 (now named UBE2J2). 
The next year Lenk et al. (2002) proved experimentally that two human proteins UBC6 
(now named UBE2J2) and UBC6e (now named UBE2J1) were the true functional 
orthologues of yeast UBC6. To try and clear up the possible future confusion over the 2 
human yeast UBC6 orthologues my supervisor and I contacted Hester Wain of the 
HGNC, who in 2003, deemed that NCUBE was not a suitable nomenclature name, but
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offered us an option of several UBE2 names. As the letter J was still available for 
UBCs, and being the initial of my first name Joy, my supervisor and I chose UBE2J1 
for NCUBE1 and UBE2J2 for NCUBE2. Unfortunately many authors still insist on 
using the old, redundant and confusing nomenclature (e.g. Oh et al., 2006).
12.4.15. Conclusions from HGNC approved UBC nomenclature
As can be seen from the above section there are still many anomalies for both the yeast 
and human nomenclature committees to resolve. Where there is possible ambiguity it 
would be preferable if authors used both their preferred nickname and in brackets the 
approved HGNC nomenclature e.g. HIP2 (UBE2K) and CDC34 (UBE2R1). These 
examples immediately show that as well as being either a hutington interacting protein 
(HIP2) or a cell cycle protein (CDC34), these proteins are also ubiquitin conjugating 
enzymes! Moreover the nomenclature UBE2R1 suggests that another closely related 
paralogue exists, namely UBE2R2, which is likely to be also a cell cycle control 
protein.
12.5 Structural Conservation results from Consurf analysis
The results of the UBE2J2 Consurf analysis are given in three sections. Firstly the 
Consurf phylogenetic tree (Figure 12.2), secondly the three dimensional structure of the 
protein UBE2J2 (PDB ID- 2F4W), with its conservation parameters in respective 
colours (Figure 12.27A and Figure 12.27B) and finally the same conservation of the 
protein UBE2J2, shown on the peptide sequence of UBE2J2 (Figure 12.27C). The 
significance of the conservation results from the Consurf analysis (Figure 12.27C) is 
that it mostly correlates with the highly conserved amino acids in our proposed UBC6 
PROSITE signature (Figure 12.27D).
As was said previously, Consurf could be used to identify conserved surface features of 
homologous proteins. Figure 12.27 was generated by using the human homologue of 
yeast UBC6 (UBE2J2), as a template onto which all other UBC structural conservations 
were projected. In this way conserved structural features among all UBC homologues 
was identified.
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Figure 12.27 Evolutionary conservation on the 3D structure the UBE2J2 
protein (2F4W)
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*
1 2 3 4 7 8 ^ C O
G LY 85B A R G 86B PH E87B C Y S94B
G R F C
Figure 12.27C
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Colour codes at different 
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Figure 12.27D Pairwise alignment of UBC6 (UBE2J2) with a non UBC6 
[UBC9]
Our proposed PROSITE signature of UBC6:
T-[PAR]-[NS]-G-R-F-x(3)-[KTE]-[RK]-[LIV]-C*-[LMS]-[ST]-[IMF]-[ST]-x(2)-H-[PK]
9 2  9 8 9 7  -5 8 5 8 9  8 These are the conservation
“score 5” is not coloured white as otherwise scores of corresponding amino
it would not be visible acids in the PROSITE signature
hs2J2 VI: HYVVRGPEMTPYEGGYYHGKLIFPREFPFKPPSIY--- MITPNGRFKCN
hsUBE2l : ecaipgkkgtpwegglfklrmlfkddypssppkckfepplfhpng-vpfg 
hs2J2 VI :TRLCLSITDFHPDTWNPAWSVSTILTGLLSFMVEKGPTLGSIETSDFTKR
hsUBE2l : t-vclsileedkd-wrpaitikqillgiqellne--pni
The PROSITE signature of all other UBCs [e.g.UBC9 (UBE2I)] except UBC6--
[FYWLPS]-H-[PC]-[NH]-[ LIV]-x(3,4)-G-x- [LIV]-C*-[LlV]-x-[LIV]
Figures 12.27 (A-D), shows the various levels o f conservation o f the amino acid 
sequence mapped on the 3D structure o f the protein UBE2J2. Figure 12.27A and 
12.27B are the same, as they are the conservation o f amino acids onto the 3D structure 
o f UBE2J2. Figure 12.27A shows the overall conservation o f UBCs onto the 3D 
structure o f UBE2J2 with the active site residue Cysteine, and 3 other amino acids o f its 
PROSITE signature region highlighted. Figure 12.27B also shows the overall 
conservation o f amino acids, but with a better view o f conservation. Figure 12.27C 
shows the same conservation o f amino acids at the sequence level. There is a gap at the 
region o f the PROSITE signature o f the peptide sequence, just after the active site 
residue Cysteine. This is because, although those amino acids exist, their coordinates 
could not be obtained from the X-ray diffraction o f the crystal structure o f 2F4W. Also 
represented is the index o f the different colour codes o f conservation at various 
conservation levels from 1 to 9 that are projected onto the 3D structure. Figure 12.27D 
shows a pairwise alignment o f UBC (UBE2J2) and a non-UBC6 [UBC9 (UBE2I)], 
illustrating the differences in their PROSITE signatures.
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From Figures 12.27 (A, B, C), it can clearly be seen that the invariant UBC active site 
cysteine, that is present in both the non-UBC6 and our UBC6 PROSITE signature is 
not surprisingly in the highest conserved category (coloured maroon, conservation 9) on 
both the 3D structural diagrams and the 2D Consurf results. Surprisingly the GRF 
motif, which is only found in UBC6 like enzymes, and not non-UBC6s, appears also to 
be in the highly conserved categories (between conservation 7-9). This result appears to 
indicate that although the amino acids around the cysteine active site are very different 
between the UBC6 and non-UBC6 families, the amino acid properties and therefore 
possibly the structure of the two families active sites, have remained similar.
In support of this hypothesis our UBC6 PROSITE signature states that after the 
conserved amino acids G, R, F, there can be any three amino acids (e.g. KCN in 
UBE2J2). Interestingly these amino acids are grouped in less conserved categories 
(conservation 3-5). This result is consistent with these amino acids being less important 
for determining the structure and function of the UBC6 family active site.
The adjacent highly conserved [KTE] of the UBC6 PROSITE signature, again appears 
to comply with the Consurf results, as the T (tyrosine) in UBE2J2 is also in the highly 
conserved category 8.
From Figure 12.27C it can therefore be seen that generally the more conserved an 
amino acid is (e.g. between 1 and 3 options), in our UBC6 PROSITE signature it is also 
likely to be in the highly conserved category following our Consurf analysis using all 
UBC’s. There are however two notable exceptions. Firstly in UBE2J2 the proline 
residue, which is part of the [PAR] part of the UBC6 PROSITE signature, has a very 
low conservation 2 from the Consurf analysis. This would suggest that the structure of 
the active site of UBE2J2 is therefore likely to differ considerably from other UBCs, 
due to this proline residue, which is known to introduce distortions in structures. The 
second notable exception is the highly conserved positively charged amino acids 
arginine that forms part of the UBC6 PROSITE signature [RK]. These positively 
charged amino acids are completely absent from non UBC6 UBCs PROSITE signature. 
A low conservation score of 5 is therefore found for this arginine residue in UBE2J2. 
The presence of a positively charged amino acid near the active site of (UBE2J2) UBC6 
like enzymes, that is absent from other UBCs, may also produce a difference in its 
structure and therefore in their substrate specificity.
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12.6 Conclusion
To conclude it can clearly be seen from the Phylip 3.6 generated phylogenetic tree that 
the 13 yeast UBCs and the UBC-like protein yeast MMS2, with their homologues have 
been resolved into 15 individual orthologous branches. Two of the 15 branches contain 
no yeast orthologues. One of these branches contains human UBE2L3 and UBE2L6, 
while the other branch contains the UBC like protein TSG101 that lacks a cysteine 
active site. From the distinct divergence of the 15 branches it is likely that all the UBC 
and UBC like proteins have evolved from a common ancestor, by gene duplication. 
Following gene duplication these genes have mutated and have evolved different 
functions. These results indicate that any new putative UBCs can be assigned to the 
correct orthologous group by using these phylogenetic approaches. This approach 
should be particularly useful in assigning correct nomenclature in plant species that 
have undergone considerable gene duplication of most ancesteral UBCs (see gene 
duplication tables in previous sections) e.g. yeast UBC7 appears to have 5 different 
orthologues in Arabidopsis thaliana (Table 12.6).
Finally these phylogenetic trees should help in the revision of the nomenclature for non­
yeast UBCs.
12.7 Future prospects
The phylogenetic tree developed in this study can now be taken as a reference tree, 
acting as a backbone for any future analysis. With the increasing number of eukaryotic 
genomes being sequenced many new UBC and UBC-like peptides of unknown function 
will be identified, so by adding these newly identified sequences to the sequences used 
in this phylogenetic analysis and carrying out a new phylogenetic analysis, the new 
UBC sequences should appear in branches, where the functional and evolutionary 
relationships can be deduced. This analysis should also help in assigning the correct 
and less confusing names to new UBC peptides.
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CHAPTER THIRTEEN
RESULTS & DISCUSSION OF 
PHYLOGENETIC ANALYSIS OF
TAF„250
13.1. Results and discussion of phylogenetic analysis of TAFn250
Pham and Sauer (2000) previously showed that the Drosophila transcription factor 
TAFn250 possesses both E l Ubiquitin-activating and E2 ubiquitin conjugating activity 
and is able to mono-ubiquinate histone HI in chromatin. From this paper the amino acid 
positions on the TAFn250 protein for the El active site were demonstrated 
experimentally using previously identified Drosophila mutants (Pham and Sauer, 2000; 
Wassarman et al., 2000). The exact position of the E2 active site on TAFn250 was not, 
however, elucidated from these experiments, but was shown to lie between amino acids 
612 and 1140. Therefore in order to try and identify the exact location of the UBC (E2) 
active sites in the Drosophila TAFn250 protein a search was carried out for a UBC 
PROSITE signature in this and other regions of the protein (Pham and Sauer, 2000).
All UBC’s contain a cysteine residue in their active site, which binds ubiquitin before it 
is added to a specific protein substrate (Passmore and Barford, 2004; Lester et al.,
2000). In addition, with the notable exception of yeast UBC6 and its homologues 
(Lester et al., 2000), most UBCs have the PROSITE signature [FYWLPS]-H-[PC]- 
[NH]-[LIV]-x(3,4)-G-x-[LIV]-C-[LIV]-x-[LIV] at their active sites. Any putative 
Drosophila TAFn250 UBC active site is therefore likely to also contain both a cysteine 
residue and similar surrounding amino acid residues to known UBC’s. For example 
most UBCs have, an invariant Glycine, 2 amino acids upstream to the active site 
cysteine residue.
Of the 2065 amino acids in Drosophila TAFn250 only 20 were found to be cysteine 
residues. Of these 20 cysteine residues only one cysteine, at position 742, has a Glycine 
residue in close proximity, two amino acids upstream (at position 740). Using both 
protein sequences from TAFn250 and selected UBCs [including CROC1 (UBE2V1)], 
from different species, clustalW was used and manually aligned to create a multiple 
sequence alignment (see Figures 13.1.1 & 13.1.2), in order to see if this putative UBC 
active site was conserved in other metazoan orthologues of Drosophila TAF250.
As can be seen from Figure 13.1.1, approximately 70% of the conserved UBC 
PROSITE amino acids (indicated by an asterix) are also conserved in the putative 
TAF250 UBC active sites for both Drosophila and Apis mellifera. It is highly likely 
therefore that the area surrounding and including cysteine 742 in drosophila and 
cysteine 631 in honeybee TAFn250 are the functional UBC active sites, in these species. 
Partial TAFn250 sequences were obtained for the Red flour beetle and silkworm, which
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also showed similar homology. Surprisingly the essential cysteine in the putative E2 
active site for TAFn250 in these insect species appeared to be absent in all other known 
TAFn250 orthologues including human and mosquito. This suggested that UBC activity 
is probably absent from TAFn250 in most species. Interestingly the sequence 
surrounding and including the only cysteine located between 1080 and 1137, where 
Pham and Sauer (2000) previously predicted a UBC active site, in Drosophila 
TAFn250, showed no homology to the UBC PROSITE signature.
Using the multiple sequence alignment shown in Figure 13.3, a phylogenetic tree was 
constructed, using Phylip 3.6 (see figure 13.2). From this tree it can be hypothesised 
that both UBCs and UBC like enzymes such as CROC1 (UBE2V1) shared a common 
structural ancestor with the TAFn250 family. In support of this hypothesis it has been 
previously shown that CROC 1 (UBE2V1), which lacks a UBC active site, possesses 
both transcriptional activity and a homologous TAFn250 like domain (Rothofsky and 
Lin 1997), (see Figure 13.1.1). Assuming that TAFn250 and the UBC family do indeed 
share a common structural ancestor, convergent evolution probably occurred later 
when the UBC family of enzymes and the TAFn250 protein in several different insect 
species, independently evolved a functional UBC active site. This UBC active site in 
TAFn250 appears not to have evolved in mosquitoes, vertebrates or plants (data not 
shown). Mono-ubiquitination of histone HI in most eukaryotic species is therefore 
probably carried out by other UBC (E2) and possibly E3 ubiquitin ligases. For example 
it has recently been shown that human testis Histones including HI, have been shown to 
be ubiquitinated by the UBCs: UBE2D2, UBE2L3 and an ubiquitin ligase, E3 Hlstone 
(Liu, Oughtred and Wing, 2005; Hass, Bright and Jackson, 1988).
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Figure 13.1.1 Figure 13.1.2










































































































[FYWLPS]-H-[PC]- [NH]- [LIV]-x(3,4)-G-x-[LIV]- C - [LIV]-x-[LIV]
The PROSITE signature of UBCs, cysteine (C] being the ubiquitin active site residue.
Figure 13.1.1 Shows a clusta lW  multiple sequence alignment of the putative UBC active 
site block in TAFn250 and selected UBCs [including the UBC like enzyme 
CR0C1(UBE2V1)]. It can be seen that there is a conservation of approximately 70% of 
the UBC PROSITE signature (shown by *), including the cysteine active site in the 
drosophila and honeybee TAFn250 in this region. The cysteine active site is however, 
absent in all other species in this alignment. Figure 13.1.2 shows the conservation of the 
TAFn250 like motif in the human CROC1 enzyme compared to the TAFn250 protein 
sequences of several different animal species.
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Figure 13.2 Unrooted phylogenetic tree generated from the M S A  of TAFn250,
U B C  &  C R O C 1  (UBE2V1)
Figure 13.2 Shows a phylogenetic tree based on the larger clustalW generated multiple 
sequence alignment (see Figure 13.3 on the next page for the whole alignment), using 
Phylip3.6 neighbour joining method and 100 bootstrap replicates.
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Figure 13.3 The whole M S A  of TAF„250, U B C  &  C R O C l(U B E 2 V l)  continued:
acc. nos.
Btaurus pHm m q v
Pcynocephal pBm m q v
Mfascicula pI m m q v
Mmusculus pBm m q v
Rnorvegicus pBm m q v
Mauratus pBm m q v
Cfamiliaris pI m m q v
Hsapiens pBm m q v
Hlar p i m m q i
Ppygmaeus P IMMQV
Ptroglodytes PIMMQV
Ggorilla p I m m q v
Tnigroviridi pB f m q v
Ggallus pI m m q v
Drerio pB h m q v
hsCROCl gI n s s n
celegans 'HLSQP
Cbriggsae v B l g q p
Agambiae fB m n q v
A . ageypti p| m n q v
Dmelanogast FilNQV
Dpseudoobs pBm n q v
Amellifera pBm n q v
silkworm pB l s q v
redflourbe pBm n q v
scUBC4 .8:4-AN
scUBC13 NMD-RL
scUBCl i iB s s v t
AtUBCl Hi-AD
SCUBC2RAD6 nB y - a n
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Figure 13.3 is a clustalW (http://www.ebi.ac.uk/clustalw/index.html) and manually aligned 
(using GENDOC http://gendiapo.sourceforge.net/) multiple sequence alignment of selected 
TAFji250, UBC and UBC like proteins CR0C1 (UBE2V1). The Cysteine in the UBC active site 
is underlined (Q . The red flour beetle and silkworm TAF//250 were excluded from the 
phylogenetic analysis as only partial predicted genomic translations were available.
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13.2. Conclusion
Previous laboratory experiments have shown that the Drosophila, transcription factor, TAFn250 
has ubiquitin conjugating (UBC) enzyme activity, however, these experiments, failed to identify 
the exact location of this UBC active site. A putative UBC active site was identified, in the 
Drosophila TAFn250 amino acid sequence. Interestingly this UBC active site was found to be 
absent from most other species studied, with the notable exceptions of Drosophila melanogaster 
and Apis mellifera. These results suggest that the UBC active site in these species is likely to 
have occurred due to convergent, rather than divergent evolution.
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CHAPTER FORTEEN
RESULTS AND DISCUSSION OF 
STRUCTURE DETERMINATION BY X- 




14.1. Results of the expression of UBE2J1 for X-ray crystallography
14.1.1. PCR of UBE2J1 fragment
As described in the materials and methods section (chapter 9), a PCR reaction of the 
UBE2J1 fragment was carried out with the normal brain cDNA, and ligated into an 
expression vector. This plasmid was then successfully transformed into E. coli. The 
expressed protein was then purified and attempts were then made to crystallise this 
protein fragment.
Figure 14.1 Gel electrophoresis of PCR reaction products and the plasmids




Primer dimers GST HIS-TEV( ~6800bp)
HIS-TEV (5365bp) the two bands are either linearised or supercoiled
Figure 14.1 is a gel electrophoresis o f  the PCR reaction. Lane 1 on the gel d iagram  is 
the lOObp DNA ladder, lane 2 is the b lank control, lane 3 is the PC R reaction p roduct 
o f  the UBE2J1 fragm ent. In lane 4 is the G ST  H IS-TEV30A plasm id, which is show n in 
the m aterials and methods. In lane 5 is the H IS-TE V 30A plasm id.
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14.1.2. Digestion by the restriction enzymes
The PCR reaction product of the UBE2J1 fragment, and also the two plasmids as 
mentioned previously, were then subjected to digestion before ligation into the plasmid 
vector, by the restriction enzymes B a m H l and E c o R l, procedure described in the 
materials and methods.
The digested products were later run on an agarose gel as shown in Figure 14.2.
Figure 14.2 Gel electrophoresis of the digested products
500bp GST HIS-TEV30A HIS-TEV30A(5365bp) 
(~6800bp).
Figure 14.2 is the gel elecrophoresis o f  the d igested  products in d ifferent lanes. In  lane  
1 is the lOObp D NA ladder, lane 3 is the B a m H l + E co R l d igest o f  the P C R  product, 
lane 5 is the B a m H l + E co R l digest o f  G ST  H IS-TE V30A  plasm id, and  lane 7 is the  
E co R l + B a m H l digest o f  H IS-TEV30A plasm id. The gel was m ade o f  agarose (1% ) 
with 10 pi of 0.0005% w/v ethidium bromide and was run a t 4 0 -6 0 V fo r  1 hour.
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14.1.3. Digestion by the restriction enzymes of the digested UBE2J1 fragment 
and HISTEV30A plasmid
Following ligation of UBE2J1 fragment into HISTEV30A and GST HISTEV30A 
plasmids, a B am H l and E co R l digestion was carried out to prove that the UBE2J1 PCR 
fragment had been successfully ligated. As can been seen from Figure 14.3, that the 
UBE2J1 fragment was present in several HISTEV30A samples, unfortunately no 
ligation of the UBE2J1 fragment was achieved with the GST HISTEV plasmid (data not 
shown).
Figure 14.3 Gel electrophoresis of the digestion by the restriction enzymes






Figure 14.3 illustrates the appearance o f  the two bands, the p la sm id  vector (H IS -T E V ) 
and the UBE2J1 fra g m en t in each o f  the lanes, clearly sta ting  that the desired  ligation  
has occurred, and has no t s e lf  ligated. Fane 1 is the m arker and  lanes 3 to 7 are the  
ligations which have been digested by the restriction enzym es w here it c lear show s the 
p lasm id  H IS-TE V  and the UBE2J1 fragm ent.
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Table 14.1.1 Quantity of standard BSA and its O.D. at 595nm






Table 14.1.1 shows the quantities of standard (BSA) sample taken and its absorbance at 
595 nmfor determining the standard curve.
Table 14.1.2 Quantity of test sample taken and its O.D. at 595nm
Quantity of test Absorbance of Concentration
sample taken test sample Of the protein
2pl 0.703 6.6 mg/ml
5pl 1.326 -
10(xl 1.876 -
Table 14.1.2 shows the quantities of the protein sample taken and its absorbance at 595 
nm, fo r the determination of its concentration. From the standard curve the 
concentration of protein sample was obtained by extrapolating on the graph the 
absorbance of protein sample to its corresponding concentration. Here 0.703 was 
considered as the absorbance is less than 1 and its concentration was estimated from  
the standard curve.
From the standard graph plotted, the corresponding concentration of the protein sample 
from its absorbance of 0.703 is 13.2pg/2pl. So the final concentration is 6.6 mg/ml.
Theoretically lpg of TEV protease cleaves 1 mg of protein.
Hence various concentrations of TEV protease was mixed with the protein samples and 
incubated at room temperature for 4 -5 hours and then run on the gel to estimate which 
concentration of TEV protease cleaved the best. The result is illustrated in Figure 14.4.
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1 2 3 4 5
UBE2J1
dimers
V. _ _ _ _ J Cleaved
Fragment (19671 Daltons)
Uncleaved protein
Cleaved portion after the UBE2J1 
fragment had been cut out by TEV protease
Figure 14.4 illustrates TEV  protease cleavage a t various concentration. Lane 1 is the 
protein  marker, lane 2 is the uncleaved protein  which is a control, lanes 3, 4, 5 are the 
TEV protease cleave o f  the protein  in concentrations o f  10 ng/pl, lOOng/pl, and  Jpg /p l. 
It was fo u n d  that the lane 5 o f  the T E V  protease concentration o f  lp g /p i  is the best 
concentration fo r  com plete cleavage o f  the H istidine tagged protein .
Hence the TEV protease concentration of lpg/jil was used to cleave the whole eluted 
protein fraction. The TEV protease was added in required amount to the whole eluted 
protein fraction, and allowed to incubate for 5 hours at room temperature.
The cleaved protein fraction was then incubated with 10 ml of the nickel beads for 30 
minutes, 30 mM of imidazole was added to it and the whole mixture was poured into a 
column, where the required protein was collected as a flow through and the nickel beads 
along with the attached histidine tag was retained in the column.
182
The gel electrophoresis of all the fractions collected at every step was carried out as 
shown in Figure 14.5.
Figure 14.5
Gel electrophoresis of the eluted protein fractions in different stages
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Fraction o f  the elutes w here the pro tein  
UBE2J1 has e lu ted  m axim um .
Figure 14.5 is the gel electrophoresis o f  the e lu ted  protein fra c tio n  a t d ifferen t stages. 
Lane 1 is the pro tein  marker, lane 2 is the supernatant before binding with the nickel 
beads, lane 3 is the supernatant a fter b inding with the n ickel beads (p ro te in s  that 
initially fa ile d  to bind to the nickel co lum n), lane 4  is the f ir s t  wash, lane 5 is the second  
wash, lane 6 is the third wash with the wash bu ffer  o f the n ickel colum n to rem ove any  
unbound protein. The lanes 7 to 14 are the d ifferent stages o f  the e lu ted  UBE2J1  
protein  fro m  the nickel colum n by passing  through the elution bu ffer through the nickel 
column.
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Figure 14.6 Gel electrophoresis of the T E Y  protease cleaved protein sample





Purified fraction of 
the cleaved UBE2J1 fragment
Uncleaved UBE2J1 fragment
Cleaved UBE2J1 fragment
Figure 14.6 is the gel electrophoresis o f  the uncleaved fra c tio n  in lane 1, T E V  p ro tea se  
cleaved UBE2J1 frac tion  in lane 2, and the pu r ified  UBE2J1 pro tein  fra c tio n  in lane 3.
14.1.4. Gel purification (by gel permeation chromatography)
The protein was further purified by gel permeation chromatography. The buffer used as 
detailed in the methods section 9.24. The chromatograph obtained from the gel 
permeation chromatography, is as shown in Figure 14.7.
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Figure 14.7 The chromatogram of gel permeation chromatography
(mAU)Absorption at 280nm
Figure 14.7 is the result o f  the gel purification o f  the protein sample collected in 2ml 
fractions. There are 2 peaks where peak 1 is the dimerised form o f the protein 
UBE2J1 fragment. Peak 2 is the monomeric form o f UBE2J1 protein; the fractions o f  
the purified protein under peak 2 were collectedfor crystallization.
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As can be seen, there are 2 peaks, among which the main protein are in the fractions 
under the second big peak. All the fractions of peak 2 were collected separately and gel 
electrophoresis was carried out before pooling them.
The gel electrophoresis result is as illustrated in Figure 14.8.
Figure 14.8 Gel electrophoresis of gel purified fractions
1 2 3 4  5 6 7  8 9  10
Starting from lane 5 to lane 8 are the gel purified fraction of peak 2 of the 
chromatogram shown in figure 14.9.
Figure 14.8 is the g e l electrophoresis o f  the g e l p u r ifie d  fractions. Lane 1 is the p ro te in  
marker, lane 2 is the unbound nickel colum n supernatant. Lane 3 is the e lu ted  p ro te in  
w ithout the TE V  pro tease digestion, lane 4 is the T E V  pro tease  cleaved  p ro te in  w hich  is 
elu ted  fro m  the n ickel column. Lanes 5 to 8 are the d ifferent g e l p u r ified  fra c tio n  o f  the 
big p ea k  in the g e l purifica tion  chrom atogram  as show n Figure 14.7 and  lanes 9  & 10 
are the fra c tio n s  o f  the f ir s t  sm all peak, w hich is the d im erised  fo r m  o f  UBE2J1.
As can be seen from the gel bands, the majority of the protein is retained in the second 
big peak and as there are no impurity bands for these four fractions, it was considered 
best to pool the four fraction of the second big peak.
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14.1.5. Mass spectrometry
To further confirm that only the required protein was present in the pooled fraction from 
the gel purified sample and no other contaminated proteins were present, the mass 
spectrometric analysis was carried out. The sample was given in a volume of 20 pi 
whose concentration was 20pmol/pl. The result of the mass spectrometric analysis is as 
shown in Figure 14.9.
Figure 14.9 Mass spectrometric result
Figure 14.9 show s the m ass spectrom etric analysis result, fr o m  which it can be sa id  that 
there is only one pro te in  o f  the m olecular w eigh t o f  19671.0 Daltons, w hich is the 
correct size fo r  the UBE2J1 fragm ent.
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Figure 14.10 A suspected crystal growth in one of the crystal trial plates
1
Ammonium sulphate salt crystal
Figure 14.10 is a crystal fo rm ation  in one o f  the crysta l tria l p la tes  set fo r  
crystallization, p ic ture  taken by the crysta llography machine.
Below is the diffraction pattern obtained of the salt crystal and the actual diffraction 
pattern of a protein as an example, so as to show how a diffraction pattern of a salt 
crystal is different from that of the diffraction pattern of a protein.
Figure 14.11.1
Diffraction pattern of the crystal 
obtained
Figure 14.11.2
An example of a typical diffraction 
pattern of a protein crystal
Figure 14.11.1 is the diffraction pattern  o f  the crysta l that was obtained which actually  
is a sa lt crystal (am monium  sulphate crystal); a n d  to the right o f  it is F igure 14.11.2  
which is an exam ple o f  a typical diffraction pa tte rn  o f  a pro tein  crystal, so as to g ive a 
visual com parison o f  the two diffraction patterns.
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14.2. Results of Circular Dichroism (CD) spectrum analysis
After four months of incubation under all conditions (see appendix), no crystal was 
obtained for the UBE2J1 protein fragment. In order to try and understand why this 
UBE2J1 fragment did not crystallise, a Circular Dichroism (CD) spectroscopic analysis 
was carried out, to get more information of the secondary structural composition of the 
UBE2J1 fragment that had been unsuccessful to crystallise.
The CD spectrum analysis was carried out for both the far UV and the near UV.
The CD spectrum obtained for the far UV ranging from 190 to 260 nm is as below:
Figure 14.12 Far UV CD spectrum of the protein UBE2J1
190 200 220 240 260
Wavelength [nm]
F igure 14.12 is the graphical representation illustrating the spectrum  o f  the UBE2J1 
fra g m en t in the fa r  U V region. (Mol. Ellip.) as seen in the Y-axis, represen ts m olar  
ellipticity, and H T[V] represents high tension voltage. The upper p a n e l show s the CD  
spectrum  and the lower p a n e l shows the corresponding high tension voltage.
Different CD instruments have different HT operating values, like the J-600 has a 
maximum HT value of 574 (with a fluctuation of 5) V. The J715 has a maximum value 
of 587V (with a fluctuation of 5). Hence for these instruments around 600V is 
considered maximum safe operating HT voltage.
Molar ellipticity (0)m is measured in degrees decilitres mol'1 decimeter1.
The CD spectrum obtained for the near UV range from 250 to 320nm is as follows:
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Figure 14.13 Near UV CD of the protein UBE2J1
Wavelength [nm]
Figure 14.13 is the graphical representation illustrating the spectrum o f the UBE2J1 
fragment in the near UV region.
These two spectral results obtained above were used in the DICHROWEB server for 
further structural analysis.
The CD spectral data was then analysed with the help of “DICHROWEB” an online 
analysis server where the secondary structural properties were estimated. The result 
obtained was the secondary structural content of the protein fragment UBE2J2. The 
output o f the analysis obtained is as stated below:
Table 14.2 Result obtained from Dichroweb of the secondary structural 
component, which has been calculated from the CD spectrum of Figure 14.15
NRMSD:0.031
Helix segments per 100 residues: 2.793 
Ave helix length per segment: 7.640
Strand segments per 100 
residues: 3.948
Ave strand length per 
segment: 5.284
Helix 1 | Helix2 | Strand 1 Strand2 Turns Unordered Total
0.10 | 0.11 | 0.13 0.08 0.18 0.39 0.99
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From the results of the DICHROWEB, that had analysed the CD spectrum which had 
been obtained, the sum total o f the two fractions of each of helix and sheet were, the 
protein contained around 21% helix (sum of Helix 1 and Helix2), 21% sheet (sum of 
strandl and strand2), 18% turns and 39-40% unordered.
The normalised root mean square deviation (NRMSD) obtained here was 0.031. The 
different percentages o f the secondary structure content were calculated from the CD 
spectral data by the Dichroweb as shown in Table 14.2. The NRMSD parameter is 
actually a measure o f how well the theoretical CD spectrum calculated from the derived 
secondary structure composition matches the experimental data over the entire length of 
wavelength of interest. A low value of the NRMSD (<0.1) considers a good result, but it 
does not mean that it is accurate. As the NRMSD result obtained in this experiment was
0.031, it was considered to be a good result. The fact that there was a particular 
percentage of secondary structure, adds to the correctness of the UBE2J1 that was being 
used to crystallise. Hence from the far UV CD spectrum the secondary structural 
properties of the protein UBE2J1 were derived.
The near UV spectral analysis result was used to monitor the tertiary structure of the 
protein. The spectral bands in this region o f 240 -  320 nm wavelength were of the 
aromatic residues, like mostly Tryptophan. The spectral bands in the wavelength of 240 
to 320nm were o f the aromatic residues, which are very sensitive to the tertiary 
structural changes. Tryptophan is the only aromatic residue that has a significant 
contribution to the near UV CD spectrum analysis. There are two tryptophan residues 
around the active site residue Cysteine of the UBE2J1 fragment. A list of percentage of 
the amino acids in the protein UBE2J1 as given by the CD spectral analysis by the 
Dichroweb server is given in the appendix section.
From the circular dichroism spectral analysis it was concluded that the fragment of the 
protein UBE2J1 that was tried to crystallise, had the secondary structural contents of 
around 21% each of a-helices and p-sheets, but around 40% of the peptide sequence 
was unordered. This could be the possible reason why the fragment o f UBE2J1 did not 
crystallise. The disadvantage in CD spectral analysis is that it does not provide 
information that which residues are disordered. Hence other methods have been tried 
that would predict the globular part and the disordered part in the peptide sequence.
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14.3. Conclusion and future research
From the UV CD spectral analysis it was concluded that, although the protein contained 
around 21% helix, 21% sheet and 18% turns, there is a 39-40% unordered region in the 
protein. Hence this unordered region contributes to the improper folding of the protein. 
This required to design a new set of primers by taking a different domain or fragment of 
the protein, but due to time and resource constraint, it was not possible to carry out the 
analysis again. Some ideas have been put forward for future research to crystallise the 
same UBE2J1 protein, considering the globular and disordered regions in the protein. 
The programs that predict the globularity and disorder in the peptide sequence are 
discussed as follows:
14.4. To check the globularity and disorder domains in the UBE2J1 fragment
To check whether the protein UBE2J1 has any predicted “globular” and “disordered” 
domains, tools like GLOBPLOT and RONN were used.
Another technique that is often used, is limited trypsin proteolysis; after running the 
trypsin treated protein on SDS-PAGE, any bands containing the core domains (which 
tend to be more stable to proteolysis) can be analysed by mass spectrometry and N- 
terminal sequencing to ascertain which region o f the protein they correspond to. This 
information could be then used to clone that region.
The other problem may be with protein aggregation - this can be checked by light 
scattering or by running a native gel. It would give an indication of how homogeneous 
the protein sample is, which, is an important factor for the crystallization of a protein. 
Purity is the other important reason. It has been found that even if a protein looks clean 
on SDS PAGE, a gel filtration polishing step at the end can make the difference 
between a protein crystallizing and not crystallizing.
14.4.1. Globplot
GLOBPLOT is a web based tool accessible at (http.7/globplot.embl.de), used to find out 
the disorder and globular segments o f a protein. It is known that many functionally 
important segments of a protein lie outside the globular domain that is classified as 
disordered. Globplot is a computational tool which helps to find out domains of order or
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disorder in a peptide sequence. The disorder of a protein may be termed as a lack of 
regular secondary structures or it could be that the protein is not properly folded. The 
result of the globplot analysis is as shown in Figure 14.16. The resulting Globularity/ 
non-globularity is named Russell/Linding, which combined both the random coil and 
secondary structure of the protein (Linding et al., 2003; Linding, 2004).
Figure 14.14 Result of globplot
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Figure 14.14 is a graphical representation o f  the ordered  or the d isordered  region o f  
the w hole pro tein  UBE2J1. The region m arked  in green is the g lobu lar (ordered) 
region, whereas the region m arked in blue is the d isordered  region. The transm em brane  
dom ain region is shaded  in red  and  the region shaded  in ye llow  is recogn ised  by the 
G lobplot server as the UBCs. The g lobu lar and  d isordered  region is fu r th e r  illustra ted  
along the pep tide sequence as in Table 14.3.
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Table 14.3 is a interpretation of the graph in Figure 14.17, predicting the ordered and 
disordered regions of UBE2J1 by Globplot, by Russell/Linding.
Table 14.3
Globular and disordered region of UBE2J1 protein
>none_Disorder 23-28, 45-57, 65-73, 94-103, 119-132, 148-154, 163-170, 190-195,211- 
217,223-230,238-251,266-286
metrynlksp avkrlmkeaa elK D PT D H yh aqplednlfe w hftV R G PPD  SD F D G G V yhg  
rivlPPEYPM  KPPsiillta ngrfevgkki C lsISG H H P E  TWQpswsirt allaiigfMP 
T K G E G A IG S L  DYtpeerral akksqdfCCE GCGSamkdvl lpL K S G S D S S  qadqeakela 
rqisfkaevN SSG K Tisesd lnhsfsltdl Q D D IP T T fqg a tA S T S Y G L Q  nssaasfHQP 
T Q P V A K N T S M  Sprqrraqqq sqrrlSTSPD V IQ G H Q P R D N  H T D H G G savl 
iviltlalaa lifrriylan eyifdfel
The result show n in Table 14.3, show s the o rdered  and  the d isordered  reg ions o f  the 
w hole protein  UBE2J1. The am ino acids in low er case are the g lobu lar am ino acids, 
w hereas those that are in uppercase a n d  in bo ld  are the d isordered  am ino acids.
From the result as shown above it is clear that the active site residue Cysteine (shown as 
“Cv above) and some residues around it is globular, but there are also some amino acids 
that are disordered.
This is further supported by the GLOBPLOT of the recently crystallised protein 
UBE2J2 as shown below:
Table 14.4 Globular and disordered regions o f the protein UBE2J2
>none_Disorder 1-9, 35-39, 50-61, 70-76, 82-87, 99-107, 125-131, 178-185 
MSSTSSKRAp ttatqrlkqd ylrikkdpvp yicaEPLPSn ilewhyvvrG 
PEMTPYEGGY YhgklifprE FPFKPPsiym iTPNGRFkcn trlclsitDF 
HPDTWNPaws vstiltglls fmveKGPTLG Sietsdftkr qlavqslafn lkdkvfcelf 
pevveeikqk qkaqdelSSR PQTLP
Show n in Table 14.4 are the ordered  and  the d isordered  region o f  the fra g m e n t o f  
UBE2J2 that had  recently been crystallised. The am ino acids in low er case are the 
globular proteins, w hereas those that are in uppercase and  in bo ld  are the d isordered  
am ino acids.
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As can been seen in Table 14.4, UBE2J2 also have the active site residue cysteine 
(shown as “CT above) and some of the other amino acids in the globular region, but 
there are some amino acids that are disordered as well.
Though GLOBPLOT is one o f the most recommended tools to predict regions of 
globularity and disorder in the protein, here it can be seen from the GLOBPLOT 
analysis of both the proteins UBE2J1 and UBE2J2, that there is not much significant 
difference between the two UBE2J1 and UBE2J2 disorder prediction. Both show almost 
the same regions o f globularity and disorder; although very recently UBE2J2 has been 
crystallised.
14.4.2. RONN: to predict the disordered region of a protein
RONN is another tool for predicting the disorder in a protein 
(http://www.strubi.ox.ac.uk/cgi-bin/disorder_resultsjan2005.cgi). The result is a 
graphical representation showing the ordered and disordered regions of the protein 
(Yang et al., 2005)
Figure 14.15 Disorder prediction of UBE2J1 by RONN prediction server
Probability of Disorder for >hsBE2J1
Residue Position
Figure 14.15 is the graph o f the globularity and disordered region o f  the protein 
UBE2J1. The region below the line marked 0.5 is the globular region, whereas the 
region above the threshold value is the disordered region o f the protein UBE2J1.
This graph has been interpreted on the amino acid level as shown in table 14.5, to show 
the globular and disordered region o f the protein UBE2J1.
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Table 14.5
Continuation of the disorder prediction of UBE2J1 by R O N N  prediction server
1 METRYNLKSP AVKRLMKEAA ELKDPTDHYH AQPLEDNLFE WHFTVRGPPD 50* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
51 SDFDGGVYHG RIVLPPEYPM KPPSIILLTA NGRFEVGKKI CLSISGHHPE 100
101 TWQPSWSIRT ALLAIIGFMP TKGEGAIGSL DYTPEERRAL AKKSQDFCCE 150* * * * * * * * * * ******
151 GCGSAMKDVL LPLKSGSDSS QADQEAKELA RQISFKAEVN SSGKTISESD 200** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
201 LNHSFSLTDL QDDIPTTFQG ATASTSYGLQ NSSAASFHQP TQPVAKNTSM 250* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
2 51 SPRQRRAQQQ SQRRLSTSPD VIQGHQPRDN HTDHGGSAVL IVILTLALAA 3 00* ** * * * * * * * **★ *★ *★ *★ * * * * * * * * * * * * *****
301 LIFRRIYLAN EYIFDFEL
From the result of the disorder prediction by RONN, it is found that the disordered 
regions are 1- 34, 131- 146, 159- 286. In this RONN analysis tool, the cut off limit is
0.5, where any amino acid having a probability of disorder value greater than 0.5 is 
considered to be disorder. Hence it can be seen that most o f the region of the protein 
UBE2J1 is disordered except for around 100 amino acid residues in the region of amino 
acids ranging from 35 -  130, which also consists the active site residue Cysteine.
Figure 14.16 Disorder prediction of UBE2J2 by RONN prediction server
Probability of Disorder for unknown protein
20 40 60 80 100 120 140 160 160
Residue Position
Figure 14.16 is the graph o f  the glohularity and disordered region o f the protein 
UBE2J2. The region below the line marked 0.5 is the globular region, whereas the 
region above the threshold value is the disordered region o f the protein UBE2J2.
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The region of disorder and of the globular part o f the protein UBE2J2 whose graphical 
representation is as shown in the previous page in figure 14.16, is shown below at the 
amino acid level.
Table 14.6
Continuation of the disorder prediction of UBE2J1 by RONN predicion server
1 M SSTSSK RA P TTATQRLKQD Y LR IK K D PV P Y IC A E P L P S N ILEW H Y W RG 5 0
★  ★
5 1 PEMTPYEGGY Y H G K L IFPR E F P F K P P S IY M ITPN G R FK C N T R L C L S IT D F 1 0 0
1 0 1 HPDTWNPAWS V S T IL T G L L S FMVEKGPTLG S IE T S D F T K R QLAVQSLAFN 1 5 0
1 5 1 LKDKVFCELF P E W E E IK Q K QKAQDELSSR PQ T L P
★ ★ ★ ★ ★
From the RONN result o f the protein UBE2J2 above, it is very clear that UBE2J2 as a 
whole is a globular protein, with the majority o f the portion o f the protein is globular. A 
very minor portion o f disordered is between amino acid 1-12,  and 167 -  185.
From the RONN result of UBE2J1, various regions of the protein could be used to 
design primers, and try to crystallise them. Short fragments o f the UBE2J1, like amino 
acid 35- 130, or 35 -  158, could be the used to design primers.
14.4.3. Trypsin proteolysis
The other method is to do a trypsin digest o f the protein and try to find out the regions 
of the protein that are not folded or loosely hanging on the surface. By the trypsin 
proteolysis, the trypsin cleaves at the amino acids lysine-X and agrinine-X bond. These 
amino acids are abundantly available in the protein, but the trypsin proteolysis is only 
possible on the surface region of the protein, as it cannot penetrate at the compact core 
region. Trypsin cleaves at the particular sites, and this trypsin digested protein is then 
run on the SDS PAGE to separate all the cleaved regions. Each region can be cut out 
from the gel bands, protein extracted and either sequenced or done a mass spectrometric 
analysis, to find out the regions that are in the core domain. That core domain fragment 
could then be considered for crystallisation (Beynon and Bond, 1989).
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14.4.4. Protein purification
The final stage o f protein preparation is to purity the protein UBE2J1. An affinity 
chromatography could be carried out from ubiquitin-affinity-gel followed by the size 
separation (Gel filtration) of the protein, or an alternative purification procedure could 








15.1.1. Modelling, using DeepView
The modelling steps in DeepView were as follows:
Model Building: To generate the backbone of the model, the templates are evaluated by 
their sequence similarity to the target sequence, where significantly deviating atom 
positions are excluded. The template coordinates are then used to model the regions of 
insertions and deletions in the target-template alignment. These parts are generated by 
the “constraint space programming” (CSP). The best loop is selected using the scoring 
scheme, which looks for favourable interactions like hydrogen bond formation, steric 
hindrance, and force field energy.
Side chain modelling: The side chain modelling is also based on the evaluation of the 
corresponding residues in the template structures. The model side chains of the 
conserved residues, are built by replacing the template structure side chains. The 
backbone dependent rotamer library gives a selection of the possible side chain 
conformations.
Energy minimizations: The protein model is regularised in the last step, by the steepest 
descent energy minimization, using the GROMOS96 force field (Schwede et al., 2003).
15.1.2. Obtaining the model of UBE2J1 by DeepView
The domain information of the protein sequence (UBE2J1) was needed to be found first 
before homology modelling was carried out. There are various tools for protein domain 
search like the PfamA, InterPro, ProDom, SBASE. The tool that was used here in the 
analysis was PfamA, and the result of the domain search is in Figure 15.1.
15.1 Results and discussion of computational structure prediction
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Figure 15.1 Results obtained from  Pfam  dom ain prediction
Model Alignment Description
(JO c o n  1 4  1 4 9  9 5 . 8  g lo b a l
U b iq u i t i n -
c o n ju g a t in g
e n z y m e
F igure 15.1 show s the range o f  the UBE2J1 pep tide  sequence tha t w as fo u n d  su itable  
f o r  carrying out hom ology m odelling. W hat P fam  had done is, it had  carried  ou t a 
m ultip le  sequence a lignm ent o f  the UBE2J1 p ep tide  sequence with a ll U BC s and  had  
pred ic ted  the m ost conserved  regions in the alignm ent, w hich is fro m  am ino acid  14 to
It was found that the sequence region of amino acid 14 to amino acid 149 was the best 
region, as it had the greatest homology, with a significant E-value, which is < 0.05. 
Hence the peptide sequence around that region was taken to do the homology 
modelling.
E-value is the Expectation value. The number of different alignments with scores 
equivalent to or better than S that are expected to occur in a database search by chance. 
Lower the E value, the more significant the score. The S score is a measure of the 
similarity of the query to the sequence shown. The E-value is a measure of the 
reliability of the S score
(littp://www.ncbi.nlm.nih.gov/Education/BLASTinfo/glossary2.html).
The actual equation is E=Kmn(e"XS) , where K and X represent natural scales for the 
search space and the scoring system respectively. The rest of the equation represents the 
size of the query (m), the size of the database (n), and of course the S score.
The typical threshold for a good E-value from a BLAST search is e'5=(10'5) or lower.
149.
2 0 1
The reason for such low values is that an E=0.001 in a million entry database would still 
leave 1000 entries due to chance. An E=e 6 would only leave one entry due to chance 
(http://www.osc.edu/research/bioinformatics/FAQ/evalue.shtml).
The secondary structural components of the protein UBE2J1 was required to be 
predicted, which was carried out by the GOR4 secondary structure prediction server 
(Gamier, Gibrat and Robson, 1996) as shown in Figure 15.2.
Figure 15.2 Secondary structural contents of UBE2J1












Sequence length : 318
Alpha helix (Hh) 84 is 26.42
3io helix (Gg) 0 is 0.00
Pi helix (Ii) 0 is 0.00
Beta bridge (Bb) 0 is 0.00
Extended strand (Ee) 66 is 20.75
Beta turn (Tt) 0 is 0.00
Bend region ( ) 0 is 0.00
Random coil ( ) 168 is 52.83
Ambigous states (?) 0 is 0.00
Other states 0 is 0.00
Figure 15.2 show s the secondary structura l com ponent o f  the pep tide  sequence U BE2J1  
obtained fro m  G O R4
(h ttp ://npsa-pbil.ibcp .fr/csi-b in /npsa  autom at.p l?pase= /N P SA /npsa  so r4 .h tm l).
The knowledge of the secondary structural components was necessary when selecting a 
range of amino acids for modelling. This gave an idea of the secondary structural 
components, so that when selecting a range of amino acids for modelling, a complete 
range of the secondary structural component is selected.
A template that was found to be the closest homologue of UBE2J1 peptide sequence, 
was the recently found UBE2J2 (pdb file-2F4WB) crystal structure.
2 0 2
This template (2F4WB) was then retrieved in Deepview from the PDB.
In the structure of 2F4WB, there is a gap after leucine (which is just after the active site 
residue cysteine), where 9 amino acids are missing. It is often the case in structures 
solved by X-ray crystallography that there are residues that cannot be modelled due to 
their high mobility or disorder. In 2F4WB the amino acids are indeed present in the 
crystal, but no electron density has been observed. The pairwise alignment of UBE2J1 
with the template 2F4WB is as in Figure 15.3.
Figure 15.3 Alignment of UBE2J1 with the template (2F4WB)
# Identity: 60/139(43.2%)
# Similarity: 90/139 (64.7%)
# Gaps: 6/139(4.3%)
h s B E 2 J 1 : rlmkeaael-kdptdhyhaqplednlfewhftvrgppdsdfdggvyhgri  
II •• • Ill . 1 . II I . Ill- 1 1 II . ..II III..
2F4WB : rlkqdylrik k d p v p y i c a e p l p s n i l e w h y w r g p e m t p y e g g y y h g k l
h s B E 2 J 1 : vlppeypmkppsiilltangrfevgkkiclsisghhpetwqpswsirtal  
. 1 1 . 1 1 1 1 1 1 . . 1 I N I .  . . I N I .  II . 1 l | . | | . | |
2F4WB : • • 1 ■ 1 • 1 • 1 II 1 1 • • M  • II 1 1...... 1 1 1 1 • • • 1 1 • 1 1 • 1 • 1 1 • • 1 • 1ifprefpfkppsiymitpngrfkcntrlclsitdfhpdtwnpawsvstil
h s B E 2 J 1 : laiigfmptkge--gaigsldytpeerralakksqdfcc  
• • I I  II | . | . | . | . | | | . | |
2F4WB :
..... II * * 1 1 ‘ 1 * 1 * * " 1 * 1 * 1 ' 1 1 ' ' 1 ' • 1 ' *
tgllsfmvekgptlgsietsdft---krqlavqslafnl
F igu re
1 5 .3  sh o w s the p a irw ise  a lign m en t o f  U BE2J1 w ith  the tem p la te  2F 4W B . The 
p e rc e n ta g e  id en tity  is  a ro u n d  43% .
The aligned UBE2J1 and the template have the percentage identity of around 43% and 
similarity of around 65%. Theoretically 30% sequence identity is the lowest limit to 
carry out homology modelling. The pairwise alignment of these two sequences were 
carried out in “L-align” (http://www.ebi.ac.uk/emboss/align/index.html), to try to 
increase the percentage identity by aligning various segments of the sequences, but it 
was found that although some trials gave an increased percentage identity, there were 
large gaps introduced. Hence the alignment that was generated by the DeepView 
software was taken to carry out the homology modelling. Shown in Figure 15.4 is the 
pairwise sequence alignment of UBE2J1 with that of the template (2F4WB), generated 
by DeepView.
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Figure 15.4 Pairwise sequence alignm ent generated by DeepView
C: \Doc ume nts a n d Setti ngs\JO Y\Deskto p\dee pview\D E EPVIE W\SPD VB\tem p\A lign...
U B E 2J1 £ 1 PAVKRLMK EAAELKDPTD HYHAQPLEDN LFETOHFTVRG PPD SDFDGGV
2 f 4wb 11 TTATQRLKQD YLRIKKDPVP Y IC A EPLPSN ILEWHYWRG PEMTPYEGGY
■ - - * * ■*■ ★  *■ * ■* * * *  * * * *
U B E 2J1 S 49 YHGRIVLPPE Y PM K PPSIIL LTANGRFEVG K K IC L SISG H HPETWQPSIiIS
2 f4 w b 61 YHGKLIFPRE FPFK PPSIY H ITPNGRFKCN TRLGJiFJUPAW SV STILTG LL★  * * * * * * ■ *■ *•*•■ *■ * * *
U B E 2J1 S 99 IR T A L L A IIG FMPTKGEGAI GSLDYTPEER RALi KKSQDF CCE
2 £ 4 u b 1 2 0 SFMVEKGPTL GSIETSDFTK RQLAVQSLAF NLKE KVFCEL F P E W E E IK Q
■ . . . ■ * * *
U B E 2J1 £
2 f4 w b 1 7 0 KQ
< H
Active site residue cysteine
Figure 15.4 is an a lignm ent generated  by D eepview . 2F 4W B  is the tem pla te  based  on  
which the query sequence UBE2J1 was m odelled.
In the template UBE2J2 (2F4WB), there are 9 amino acids missing. Although the actual 
protein has those 9 amino acids, no diffraction patterns have been obtained from the 
UBE2J2 crystal. Hence gaps were then introduced in the peptide sequence of the 
template, in the region were there are 9 amino acids missing when carrying out the 
homology modelling, so that the model of UBE2J1 will also have that region 
highlighted. Finally the alignment had been submitted to DeepView to generate the 
model is as in Figure 15.5.
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Figure 15.5 The alignment that was generated by DeepView and the gap 
introduced manually at the region of missing 9 amino acids
U B E 2 J 1 £ 1
2 f 4 u b 1 1
U B E 2 J 1 S 4 9
2 f  4 u b 6 1
U B E 2 J 1 £ 9 9
2f4x.Tb 1 1 1
U B E 2 J 1  




TTATQRLKQD Y L R IK K D P V P
Y H G R IV L P P E  Y P M K P P S IIL  
Y H G K L IF P R E  F P F K P P S IY M  *  * * * * * * *
I R T A L L A II G  FM PTK G EG A I 
V S T IL T G L L S  FM V EK G PTLG .
HYHAQPLEDN L F E ¥ H F T V R G  PPD SD FD G G V  
Y IC A E P L P S N  ILEXiJHYW RG PE H T PY EG G Y
* *  *  • * ■ * *  *  * * ■
LTA H G RFEV G  K K IC L S IS G H  H P E T ¥ Q P S ¥ S
IT PW G R FK C N  T R I ^ L —v - — ---------¥ N P A ¥ S
★ * * * *  ** T * * **
G S IJ> Y tP E E R  RALAKK3QDF CCE
E T S D F T K R  Q L A V Q S lA F N  L K D K V FC ELF
P E W E E
Active site residue cysteine 9 gaps introduced
Figure 15.5 is an a lignm ent generated  by D eepview . 2F 4W B  is the tem pla te  based  on  
which the query sequence UBE2J1 was m odelled. 9 gaps were in troduced  m anually  in 
the 2F4W B sequence in the D eepV iew  a lignm en t a s  there are 9 am ino a cid s m issing  in 
the structure o f2 F 4 W B  in the region arrow  m arked.
This aligned sequence of UBE2J1 was then sent to SwissPDB to be modelled. Stated as 
follows, is the discussion of the model of UBE2J1 that was obtained from Swiss Model.
15.1.3. Evaluating and optimising the model sent by SWISS PDB
The model of UBE2J1 received from the Swiss Model, along with a geometric check 
report (What Check report) was viewed in DeepView. The modelled UBE2J1 obtained 
from the SwissPDB was first coloured by B-factor to look for high or low B-factor 
values or to identify areas of structural uncertainty. The model of UBE2J1 colouring by 
B-factor is as in Figure 15.6.
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15.1.3.1. Colour by B-factor
Figure 15.6 Model of UBE2J1 coloured by B-factor
Low B-factor
Active site residue 
cysteine
High B-factor
Figure 15.6 is the m odel o f  UBE2J1 coloured  by B-factor w hich is a m ea su re  o f  how  
m uch structura l in form ation the m odelling  program  was able to transfer fr o m  the  
tem plate. A s  could  be seen fro m  the fig u re  above, that the m odel com plies w ith  the 
criteria, w here it could  be said  that it has hom ology a long the w hole len g th  o f  the 
pep tide  sequence, except fo r  the region in red where the 9 am ino  acids are m issing  in 
the tem plate and hence there is no hom ology in that region.
The next step of evaluation was to check the Ramachandran plot, the details of which 
and all other details of the What Check report are illustrated as follows:
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The most powerful and important tool to check the stereochemical quality of a protein 
structure, is the Ramachandran Plot (Ramachandran, Ramakrishnan and Sasisekharan, 
1963). The plot is of a Phi versus Psi (main chain torsion angle) for every amino acid 
residue of the protein with the exception of two terminal residues, because the N- 
terminal residue does not have Phi and the C-terminal residue has no Psi. The resulting 
scatter plot is a cluster of points (of amino aids) in certain favourable regions, and some 
points tend to be excluded into the disallowed regions due to steric hindrances of the 
side chain atoms. Glycine is an exception as it has no side chains, and therefore can 
adopt phi and psi angles in all four quadrants of the Ramachandran plot. Hence it 
frequently occurs in turn regions of proteins where any other residue would be sterically 
hindered, showing slightly different distributions on the plot. The Ramachandran plots 
of the model UBE2J1 (Figure 15.7.1), and the template 2F4WB (Figure 15.7.2) are as 
follows:
15.1.3.2. T he R am achandran  p lot
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F igures 15.7.1 show s the R am achandran p lo t o f  the m odel o f  U BE2J1 p ro te in . The  
sm all p lu s indicates any am ino acid  o ther than glycine and  the square sign  ind ica ting  
glycine in the d ifferen t regions. There is the favo ura b le  region w here regular secondary  
structures like helices, beta sheets and  even residues in loops a lso lie in this region, a nd  
there is a lso the d isallow ed region w here am ino acids are loca ted  w hich is due to steric  
hindrances or clashes betw een atoms, w ith the exception o f  glycine.
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F igures 15.7.2 show s the Ram achandran p lo t o f  the tem plate 2F4W B. U BE2J2 has m ost 
am ino acids in the ” m ost favo ura b le  ” region.
It can be seen from the Ramachandran plots of both the template UBE2J2 and the model 
UBE2J1 that most amino acids are in the “most favourable” region; very few amino 
acids are in the “additionally allowed” regions. There are two amino acids of the 
UBE2J1 model (GLU91 & THR92) that are in the generously allowed region.
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The next step was to calculate the average energy for each group within a structure, 
based on its confirmation and interaction with its neighbours. This gave a list of the 
energy states of each amino acid in the model, shown in Figure 15.8.
15.1.3.3. Force field energy
Figure 15.8 Force field energy of UBE2J1 model
RESIDUES RES. NO. FORCE FIELD RESIDUE RES. NO. FORCE FIELD
ENERGY ENERGY
PRO 1 E = -17.198ALA 2 E = -19.268VAL 3 E = -2.627LYSH 4 E = -17.644ARC 5 E = -221.073LEU 6 E = -28.644MET 7 E = -36.208LYSH 8 E = 1.653GLU 9 E = -21.272ALA 10 E = -21.741ALA 11 E = -27.932GLU 12 E = -0.372LEU 1 3 E = -20.606LYSH 14 E = -5.675ASP 15 E = 120.714PRO 16 E = -0.440THR 17 E = 5.559ASP 18 E = 0.197HIS A 19 E = -28.501TYR 20 E = 47.852HIS A 21 E = -19.472ALA 22 E = -21.770GLN 23 E = -166.574PRO 24 E = -27.051LEU 25 E = -27.751GLU 26 E = 5.574ASP 27 E = 16.196ASH 28 E = -200.650LEU 29 E = 20.971PHE 30 E = -19.934GLU 31 E = -41.806TRP 32 E = -32.248HIS A 33 E = -56.421PHE 34 E = -52.709THR 35 E = -37.963VAL 36 E = -12.361ARG 37 E = -247.172GLY 38 E = 36.025PRO 39 E = -4.606PRO 40 E = -2.541ASP 41 E = 0.976SER 42 E = -28.019
ASP 43 E = 20.097PHE 44 E = 39.791ASP 45 E = 26.476GLY 46 E = 68.074GLY 47 E = 10.378VAL 48 E = -21.374TYR 49 E = 66.534HIS A 50 E = -19.339GLY 51 E = -1.521ARG 52 E = -244.666ILE 53 E = -8.810VAL 54 E = -24.652LEU 55 E = 36.636PRO 56 E = -3.421PRO 57 E = -4.978GLU 58 E = -17.588TYR 59 E = -26.173PRO 60 E = -28.091MET 61 E = 6.050LYSH 62 E = -7.121PRO 63 E = 5.316PRO 64 E = -28.052SER 65 E = -27.675ILE 66 E = 35.991ILE 67 E = 89.223LEU 68 E = 17.130LEU 69 E = -26.907THR 70 E = -22.627ALA 71 E = 9.577ASN 72 E = -99.180GLY 73 E = 31.416ARG 74 E = -276.236PHE 75 E = 34.272GLU 76 E = -17.460VAL 77 E = 38.154GLY 78 E = 48.077LYSH 79 E = 21.875LYSH 80 E = -28.933ILE 81 E = 26.377CYSH 82 E = -4.041LEU 83 E = 72.207SER 84 E = -9.086
Force f ie ld  energy o f  UBE2J1 m odel continued  to the next page
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Figure 15.8 Force field energy of UBE2J1 model continued
RESIDUE RES. NO. FORCE FIELD 
ENERGY
ILE 85 E = 26.523SEP. 86 E = 4.349GLY 87 E = 36.139HIS A 83 E = 31.156HIS A 39 E = 30.609PRO 90 E = 9.666GLU 91 E = 18.901THR 92 E = 102.200TRP 93 E = 142.671GLN 94 E = -150.632PRO 95 E = 16.796SEP. 96 E = -0.143TRP 97 E= 31.435SEP 98 E = 6.329ILE 99 E = 25.426ARG 100 E = -162.579THR 101 E = -17.243ALA 102 E = -30.387LEU 103 E = -12.578LEU 104 E- -5.792ALA 105 E = -32.999ILE 106 E = 32.973ILE 107 E = 197.139GLY 108 E = 30.154PHE 109 E = -1.069MET 110 E = 2.240PRO 1 1 1  E = 56.796THR 112 E = -1.191LYSH 113 E = 44.301GLY 114 E = 44.236
RESIDUE RES. NO. FORCE FIELD ENERGY
GLU 1 1 5 E = 4 0 . 7 0 4
GLY 1 1 6 E = 3 3 . 5 2 7
ALA 1 1 7 E = 3 4 . 6 4 0
IL E 1 1 8 E = 1 6 2 . 8 0 0
GLY 1 1 9 E = 1 8 . 9 5 0
SEP. 1 2 0 E = - 3 2 . 3 2 5
LEU 1 2 1 E = - 2 . 5 7 7
ASP 1 2 2 E = - 7 . 9 7 6
TYR 1 2 3 E = - 6 7 . 0 9 2
THR 1 2 4 E = 8 . 2 0 3
PRO 1 2 5 E = - 0 . 2 9 0
GLU 1 2 6 E = - 1 4 . 8 7 9
GLU 1 2 7 E = - 4 8 . 2 4 8
ARG 1 2 8 E = - 2 7 7 . 9 3 0
ARG 1 2 9 E = - 2 7 0 . 6 6 1
ALA 1 3 0 E = - 1 7 . 0 4 3
LEU 1 3 1 E = 9 1 . 3 9 3
ALA 1 3 2 E = - 1 9 . 7 5 7
LYSH 1 3 3 E = - 3 6 . 3 8 5
LYSH 1 3 4 E = 1 4 7 . 4 4 3
SER 1 3 5 E = - 2 8 . 7 1 9
GLN 1 3 6 E = - 1 8 3 . 4 7 6
ASP 1 3 7 E = - 2 4 . 0 7 3
PHE 1 3 8 E = - 2 4 . 1 2 7
CYSH 1 3 9 E = - 1 8 . 6 7 7
CYSH 1 4 0 E = - 1 2 . 4 9 0
GLU 1 4 1 E = 5 6 . 1 5 0
OXT 1 4 1 E = 1 1 . 3 3 6
K J /m o l  E= - 1 4 6 3 . 0 2 3
Figure 15.8 show s the list o f  energy sta tes o f  a ll am ino acids o f  the m odel U BE2J1  
genera ted  by D eepView . The low er the value, the m ore stab le the in teractions a m o ng  
residues, w here large positive  values indicate unstable in teractions a m o ng  residues. 
Very fe w  am ino acids have high fo rc e  f ie ld  energy like THR92, TRP93, ILE107, IL E 118  
a n d  LYS134. M ost other am ino acids have fo rc e  f ie ld  energy w ith in  accep table  lim its.
2 1 1
Here it can be seen that the overall energy state of the model UBE2J1 is low (around 
-1463 KJ/mol) and hence the model is stable.
The different force fields are the GROMOS, AMBER, CHARMM, and SYBYL. 
“GROMOS” was developed by Van Gunsteren. GROMOS was used in DeepView to 
calculate force fields, which can calculate force fields, perform energy minimization 
and molecular dynamics simulation (constant energy or temperature, constant volume or 
pressure), in vacuo, in crystals or in aqueous or any other solutions.
The equation for GROMOS force field calculations is as follows:
The above equation was adapted from (MacKerell [No date] 
http://www.wiley.com/legacv/wilevchi/ecc/samples/sampleQ7.pdf)
This equation could be separated into the internal terms, which would include the bond, 
angle, dihedral contributions, and the nonbonded or external terms that include the 
electrostatic and van der Waals terms, bo and 0o represents the equilibrium bond and 
angle terms, Kb, Kq, and Kx represents the bonds, angles, and dihedral force constants, n 
represents the multiplicity or periodicity of the dihedral term, A represents the phase of 
the dihedral term, and b, 0, and x are the bond, angle, and the dihedral angle 
respectively that define r. The dihedral term is a fourier series, indicating an accurate 
description of torsional surfaces, qj and qj are the partial atomic charges on atoms i and 
j. eo is the dielectric constant, rjj is the distance between atom i and j. Sjj and Rmin i j are 
the well depth and minimum interaction distance describing the van der Waals 
interaction between atoms i and j. (Clark, 1997;
http://amrit.ittc.ku.edu/tclark/bio97/node 1 .html; Gunsteren, 2001;
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http://www.igc.ethz.ch/gromos-docs/index.html).
The different force fields are as follows:
AMBER- (Assisted Model Building and Energy Refinement)- widely used for proteins 
and DNA.
CHARMM- originally developed at Harvard, widely used for both micro molecules and 
macro molecules.
GROMOS- A force field that comes as part of the GROMOS (GROningen MOlecular 
Simulation package) a general-purpose molecular dynamics computer simulation 
package for the study of biomolecular systems. GROMOS force field (A-version) has 
been developed for application to aqueous or apolar solutions of proteins, nucleotides 
and sugars. However, a gas phase (B-version) for simulation of isolated molecules is 
also available.
SYBYL- This force field was developed for the calculation of internal geometries and 
conformational energies.
(Cornell et al., 1995;
http://www.molvis.indiana.edu/app guide/Insightll/forcefields.html)
GROMOS, CHARMm force fields are the category of simple diagonal force fields. 
These force fields incorporate a simple harmonic diagonal representation for the bond 
and angle terms. GROMOS and CHARMm incorporate the Van Der Waals parameters 
derived from crystal data, whereas the Van Der Waals parameters in the AMBER force 
field are derived from liquid simulations. The AMBER and GROMOS force fields 
specify values for A (repulsive coefficients), and B (attractive coefficients), whereas 
CHARMm specify values for R* and e. CHARMm uses arithmetic mean combining 
rules for R*, and geometric mean combining rules for s. By using different values for A 
and B for a particular atom type, GROMOS makes a further distinction, depending on 
the second atom involved in the interaction. While all force fields incorporate a simple 
fourier expansion to represent the dihedral energy, some variations are also seen in the 
assignment of the energy. GROMOS reduces the NBF computational workload by
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excluding interactions beyond a (user input) cut off radius, an important fact in parallel 
algorithm selection. A pair list indicating which non-bonded interactions are computed 
every t steps, where t is typically in the range from 10 to 50. The data structures 
representing the pair list tend to be the most space consuming in the program, with 
hundreds of interaction partners for each atom (Cornell et al., 1995).
It has been seen from the force field energy of UBE2J1, that there are no such high 
values which could create a problem in the structure.
15.1.3.4. Colour by force field energy
The energy parameters of a protein can predict many features of interaction within it. 
Potentials of mean force derived from the statistical analysis of interaction regularities 
in proteins, can recognise misfolded structures or assess the quality of models prepared 
by homology modelling and capture changes to protein structure model during 
refinement (Godzik, 2003).
As it takes a long time to go through the energy states of each residue, it is easier to 
colour the model by force field energy to see the energy states of the residues. So the 
next step was to colour the structure by force field energy, where in general long 
stretches of warm colours are indications that the model is not stable. The structure of 
UBE2J1 as coloured by force field energy is as shown in Figure 15.9.
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Figure 15.9 M odel of U BE2J1  coloured by force field energy
ALA102(-37.9 KJ/mol)
ILE107 (197.1 KJ/mol)
GLU127 ARG128 ILE118 THR35
(-48.2 KJ/mol) (-277.9 KJ/mol) (162.8 KJ/mol) (-37.9 KJ/mol)
F igure 15.9 show s the m odel o f  UBE2J1 co loured  by fo rc e  f ie ld  energy. A m ino  acids  
with d ifferen t fo rc e  f ie ld  energies have been illustrated  in the fig u re . A m in o  acids like  
IL E 107 and  IL E 118 has h igher fo rc e  f ie ld  values o f  197.1 and  162.8 K J/m ol 
respectively, w hereas am ino acids like A L A  102 has fo rc e  f ie ld  energy o f  -37 .9  KJ/mol, 
TH R35 -37.9 KJ/mol, A R G 128  -277 K J/m ol and  G LU 127 -48.2 K J/m ol has fo rc e  f ie ld  
values in the negative range indicating con tribu ting  to the stability  o f  the protein . H ere 
it can be seen that m ost o f  the regions o f  the m odel is having low  fo rc e  f ie ld  energies, 
clearly stating  that the m odel generated  is stable.
From the Figure 15.9 it can be seen that although some of the regions in the model 
shows instability, overall the model is stable as can be seen from the Figure 15.9.
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Hence from all the above checks it was found that the model of UBE2J1 is stable which 
is further confirmed by the following results illustrated as follows:
15.1.3.5. Model of UBE2J1 coloured by RMS (root mean square)
Figure 15.10 Colour by RMS
Regions having 
homology of 
the model with 
the template
Region of the 
model where 
the template 9 





F igure 15.10 show s the root m ean square devia tions (R M SD ) o f  the m odel UBE2J1  
fro m  the tem plate (2F4W B) structure. The only  region tha t show s the m odel to he 
d ivergen t fro m  the tem plate is the region m arked  in red, as the 9 am ino  acids in that 
region o f  the tem plate structure are no t available.
The model UBE2J1 and the template structure (2F4WB) were compared to find regions 
which are similar or divergent, by colouring by root mean square (RMS). As can be 
seen from Figure 15.10, except for the region of the missing 9 amino acids in the 
template which shows divergence, most other regions of the model and template have 
similarity. The deviation of the model from the template is further illustrated by 
alignment diversity as in figure 15.11.
216
15.1.3.6. M odel of U BE2J1  coloured by alignment diversity




close to similar dissimilar
Figure 15.11.1 illustrates the m odel o fU B E 2 J l  coloured  by a lignm ent d iversity, o f  the  
level o f  sim ilarity  o f  UBE2J1 with the tem plate structure 2F4W B. It can be seen  fro m  
the m odel coloured by a lignm ent d iversity  that, m ost o f  the reg ions o f  the m o d e l has  
sim ilarity  with the tem plate, except fo r  very short regions which show s d ivergence  
betw een the m odel and  the template.
The alignment diversity is further illustrated by the sequence alignment of the model 
and the template as in Figure 15.11.2.
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The line indicates 
highest similarity
F igure 15.11.2 show s the sam e colouring by a lignm ent d iversity  o f  the m od el o f  F igure
15.11.1, bu t a t the sequence a lignm ent level. A s  can be seen the line betw een  th e  am ino  
acids co loured  in blue indicates the h ighest sim ilarity, w ith  a double  d o t b e tw een  two  
am ino acids coloured  in green indicating  sim ilarity  bu t n o t as m uch as a m in o  acids 
coloured  in blue. This is fo llo w ed  by the single dot betw een am ino  acids co lo u red  in 
yellow  indicating  even less sim ilarity.
When a model and its template are compared and their peptide sequences been aligned, 
the option of colour by alignment diversity helps to colour the sequences by the degree 
of conservation in their primary sequence. The different levels of conservation as can be 
seen in the alignment Figure 15.11.2, indicates that the amino acids are completely 
conserved, conserved, close to conserved and not at all conserved.
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15.1.3.7. M ode l of U BE2J1  coloured by secondary structure
Figure 15.12 Colour by secondary structure
p sheets loops
Figure 15.12 show s the m odel o f  UBE2J1 co loured  by secondary structure . H ere it 
show s all the (3 sheets coloured  in green, a helices coloured  in yellow ish  b row n  and  the 
loops in grey.
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15.1.3.8. M ode l of U B E2 J1  coloured by solvent accessibility
Figure 15.13.1 Figure 15.13.2
Colour by solvent accessibility Colour by solvent accessibility
of the UBE2J1 model of the UBE2J2(2F4W) structure
RP105
/  * \ / ^ ^ ^ tYSH82 4
/(dark blue) buried residues \  / \  \
Active site region (light blue) buried residues \  
is in the intermediate stage/
(green) intermediate stage Active site is in an intermediate stage
(yellow) intermediate stage
Figure 15.13.1 show s the m odel o f  U BE2J1, and  F igu re-15.13.2 show s the tem plate  
(2F4W B), coloured  by residues according  to their so lven t accessib ilities. The m ore  
exposed am ino acids to the solvent are in red (no t p resen t in e ither U BE2J1 m odel or in 
the UBE2J2 structure), the interm ediately exposed  am ino acids in g reen  and  yellow , 
and the buried  residues in blue. H ere there are no am ino acids o f  both  U BE 2J1 and  the  
tem plate UBE2J2 that are exposed to solvent.
2 2 0
Solvent accessibility can be used as a criterion towards 3D structure prediction, the 
principle goal of which is to predict the extent to which a residue embedded in a protein 
structure is accessible to solvent (Lee and Richards, 1971; Chotia, 1976; Connolly,
1983). The volume of a residue embedded in a structure that is exposed to solvent, 
where different residues has different accessible surface areas. Residues that are buried 
have a relative solvent accessibility of less than 16%, whereas those that are exposed 
have solvent accessibility 16%.
The accessibility option will colour the residues according to their solvent 
accessibilities. This is calculated as a percentage of theoretical surfaces of the amino 
acid which is accessible to water. Buried residues are coloured blue (not accessible) 
whereas more exposed amino acids become green and then red.
From the Figures 15.13.1 and 15.13.2, of the UBE2J1 model and the template 2F4WB, 
it can be seen that both the model and the template, have their active sites CYS exposed 
to the solvent, as it is appears green in colour. Although an amino acid should appear 
red in colour so as to show its complete exposure to the surface, still the green colour of 
the active site CYS indicates that although it is not completely exposed, but still it tends 
towards the surface.
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15.1.3.9. What check report comparison of the template (2F4WB) and the 
model of UBE2J1
Table 15.1 Whatcheck report of the template 2F4WB and the UBE2J1 model
Structure Z-scores. positive is better than average:
Template (2F4WB) model of UBE2J1
1st generation packing quality : -0.225 -1.658
2nd generation packing quality 0.176 -2.071
Ramachandran plot appearance : -0.890 -0.321
chi-1/chi-2 rotamer normality -0.515 2.026
Backbone conformation 0.912 0.159
RMS Z-scores, should be close to 1.0:
Bond lengths : 0.742 0.780
Bond angles : 0.803 1.468
Omega angle restraints : 1.072 0.991
Side chain planarity : 1.005 2.250 (loose)
Improper dihedral distribution : 0.964 1.972 (loose)
B-factor distribution : 1.008 —
Inside/Outside distribution : 1.073 1.170 (unusual)
T able 15.1 is  a  co m p a ra tive  s tu d y  o f  the W hatcheck re p o r ts  o f  the tem p la te  U B E 2J2  
(p b d  ID  2F 4W B ) a n d  the m o d e l o f  U BE2J1 g en era te  b y  D e e p  View. The va lu es  o f  the  
a b o ve  ta b le  a re  the Z -sco re s  o r  the n u m ber o f  s ta n d a rd  d ev ia tio n s  a w a y  fr o m  the m ean. 
The term s m en tio n ed  “lo o s e ” a n d  “u n u su a l” a g a in s t the va lu es  in d ic a te d  th a t th ey  
d ev ia te  f r o m  the s ta n d a rd  value.
The measured value minus the mean value, divided by the standard deviation is the Z- 
score which is represented by the equation as below:
Z = X -  mu/ sigma.
If the value of “X” is less than the mean then the Z-score value is negative, but is 
positive if the value of “X” is greater than mean. The Z-score value should be around 0, 
and when it is positive, it is greater than the average, but when it is negative it is worse 
than the average.
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The RMS-Z score is calculated as per the equation as given below:
RMS-Z = V sum (Z2)/ number of bonds.
The RMS-Z score value should be around 1.0.
15.1.3.10. Feature of the Whatcheck report:
Packing quality: In the analysis of protein packing quality, the threading potential is 
made use of, which expresses how well the peptide sequence sits in the structure. 
Whatif calculates whether a configuration is favourable or not, by making use of the 
database densities. The occurrence of all possible atoms in all possible positions around 
the fixed fragment (any largest group of atoms that does not contain a torsion angle, is a 
fixed fragment) is counted.
Ramachandran plot: Also known as the Phi/Psi plot, is the first verification tool for 
protein structures. The Ramachandran plot has the alpha helix and the beta strand area 
and also some loop conformations area. The Ramachandran plot allows very few 
residues to lie outside these areas as mentioned. The exception is glycine, as it does not 
have a side chain, and hence has not restriction.
chi-l/chi-2 rotamer: As all amino acids have their different preferences for the 
chil/chi2 rotamers, Whatif calculates the chil/chi2 conformation Z-scores.
Backbone conformation: Whatif checks for the number of times a similar backbone 
conformation exists in its database. If the number of times the conformation exists is 
less than 3, then the amino acid residue is said to have a unique backbone conformation. 
The structural average score, that describes how well the hits in the backbone database, 
fits the structure, referred to as the backbone normality of the query structure.
Bond lengths: As bond lengths are very well known entities, there are standards, set in 
proteins which includes average and standard deviations for all different bond types. 
Using these standards, the Z-scores for each of the bonds in the protein structure are
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calculated by Whatif. All Z-scores of (Z < -4 or Z > 4) are listed in the Whatcheck 
report.
Bond angles: Similar to the bond lengths, the average and standard deviations of bond 
angles are obtained and used to calculate the Z-scores for all bond angles.
Omega angle restraints: In theory omega angles are restrained to 180 degrees, with a 
small amount of flexibility for small molecular structures. Variation in the omega angles 
is determined by Whatif, and noted in the report.
Side chain planarity: Residues that have large planarity deviations could cause strain 
in the structure, which could be caused by incorrect backbone or side chain positioning. 
All residues that deviate more than 4 times the normal value from planarity are listed.
Improper dihedral distribution: The measure of the chirality or planarity of the 
structure at a specific atom is called Improper dihedral. 0 degree will be obtained if the 
planar atoms, and for non-planar configurations (chiral atoms), values are around +35 
and -35 degrees. The mean value and standard deviation for the corresponding Improper 
dihedral, for each of the atom types in the protein, is calculated by Whatif from its 
database of 500 X-ray structures.
Inside/Outside distribution: As all hydrophobic residues like to sit on the “inside” and 
the hydrophilic residues on the “outside” of the globular protein, Whatif calculates an 
overall RMS Z-score to show how all residues are located in protein. Ideally for 
globular proteins the RMS Z-score is close to 1.
Listed above is an overall comparison of the Whatcheck report, of the template structure 
(UBE2J2), with that of the model of UBE2J1 obtained by homology modelling in 
DeepView. From the whatcheck reports it can be said that the structure of UBE2J2, has 
all its geometric parameters within permissible limits. The model of UBE2J1 has some 
of the geometric parameters whose values are within permissible limits, like the 
Ramachandran plot, the bond length, bond angles, and the omega angle restraints. 
There are few geometric parameters of the model of UBE2J1, whose values are not 
within the permissible limits. For example, the side chain planarity, and the improper
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dihedral distribution values of the model of UBE2J1 are termed as “loose” by the 
whatcheck report. Also, the Inside/Outside distribution value is also termed as 
“unusual” by the whatcheck report whose normal values are between 0.84 and 1.16. The 
second generation packing quality value is also -2.929, which is not suitable whatcheck 
value criteria. Generally, a second generation packing quality value below -3.0 is 
considered a poor model and a value of below -5.0 is definitely a wrong model.
15.1.4. Homology modelling by 3D-JIGSAW
To compare the prediction of the 3D model of UBE2J1 initially obtained by Deep View, 
another online homology modelling had been tried to predict the model of UBE2J1 by 
an online server called 3D-JIGSAW, results of which is as shown and discussed as 
follows:
The UBE2J1 peptide sequence had been modelled by 3D-JIGSAW, by using UBE2J2 




Model of UBE2J1 obtained by homology modelling from 3D-JIGS AW, coloured 
By secondary structure
Active site residue cysteine
Figure 15.14 is the m odel o f  UBE2J1, ob ta ined  by hom ology m odelling  fr o m  3D - 
J1G SAW  online hom ology m odelling  server. This m odel is coloured  by B -factor  
indicating a high degree o f  conservation  o f  am ino acids o f  the m odel generated, w ith  
that o f  the tem plate structure (2F4W B).
In order to see the possible conformations of the Phi and Psi angles of amino acid 
residues in the modelled UBE2J1 structure, the Ramachandran plot of the model of 
UBE2J1 obtained from 3D-JIGS AW is shown in Figure 15.15.
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Figure 15.15
The Ramachamdran plot of the model of UBE2J1, obtained from 3D-JIGS AW 
homology modelling
Left handed a helices
F igure 15.15 show s the R am achandran  p lo t o f  the m odel o f  U BE2J1 obta ined  by  
hom ology m odelling  in 3D -JIG SA W  online hom ology m odelling  server. The sm all p lu s  
indicates any am ino acid  o ther than glyci?je a nd  the square sign ind ica ting  g lycine in 
the d ifferen t regions.
From the Ramachandran plot shown in Figure 15.15 of the model of UBE2J1 generated 
by 3D-JIGSAW, it can be seen that most amino acids lie in the most favourable region, 
very few lie in the additionally allowed and the generously allowed regions.
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15.1.4.1. What check report comparison of the model of UBE2J1 obtained by 
homology modelling by DeepView, with that of the UBE2J1 model obtained from 
3D-JIGSAW.
Each reported fact has an assigned severity, one of:
* error: severe errors encountered during the analyses. Items marked as errors are
considered severe problems requiring immediate attention.
* warning: Either less severe problems or uncommon structural features. These still 
need special attention.
* note: Statistical values, plots, or other verbose results of tests and analyses that have
been performed. If no error was found, this will also be listed as a note.
1) Bond angle variability 
Model of UBE2J1 by DeepView
Note: Normal bond angle variability. Bond angles were found to deviate normally from 
the mean standard bond angles. The RMS Z-score given below is expected to be around
1.0 for a normally restrained data set, and this is indeed observed for very high 
resolution X-ray structures. More common values are around 1.55 
RMS Z-score for bond angles: 1.468 
RMS-deviation in bond angles: 2.849
Model of UBE2J1 by 3D-JIGSAW
Warning: High bond angle deviations
Bond angles were found to deviate more than normal from the mean standard bond 
angles. The RMS Z-score given below is expected to be around 1.0 for a normally 
restrained data set, and this is indeed observed for very high resolution X-ray structures. 
More common values are around 1.55. The fact that it is higher than 2.0 in this structure 
might indicate that the constraints used in the refinement were not strong enough. This 
will also occur if a different bond angle dictionary is used.
RMS Z-score for bond angles: 2.116 
RMS-deviation in bond angles: 4.194.
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2) Ramachandran Z-score
Model of UBE2J1 by Deep View
Note: Ramachandran Z-score OK
The score expressing how well the backbone conformations of all residues are 
corresponding to the known allowed areas in the Ramachandran plot is within expected 
ranges for well-refined structures.
Ramachandran Z-score : -0.321
3D-JIGSAW model
Warning: Ramachandran Z-score low
The score expressing how well the backbone conformations of all residues are 
corresponding to the known allowed areas in the Ramachandran plot is a bit low.
Ramachandran Z-score : -3.040
Interpretation: The overall impression of the Ramachandran plot is the Ramachandran 
Z-score, where the negative value of the Z-score is worse than the average and positive 
is better than the average. As the negative value gets lower than 
-3, Whatif starts giving an indication that it is low.
The model obtained from Deepview has the Ramachandran Z-score just below the 
average, but the model obtained from 3D-JIGSAW has low Z-score value.
Table 15.2 gives a comparison of Whatcheck reports of the model of UBE2J1 generated 
by Deepview and that generated by 3D-JIGSAW.
Interpretation: The model obtained by Deep V iew  has normal bond angle variab ility ,
whereas the model obtained from  3D -JIG SA W  have high bond angle variab ility .
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3) Overall comparison of the Whatcheck reports of the models of UBE2J1 
obtained by Deepview and 3D-JIGSAW
Table 15.2 Whatcheck report comparison of the models of UBE2J1 
generated by Deepview and 3D-JIGSAW
Structure Z-scores, positive is better than average:
model of Deep View 3D-JIGSAW model
1st generation packing quality : -1.658 -2.434
2nd generation packing quality : -2.071 -3.259 (poor)
Ramachandran plot appearance :-0.321 -3.040 (poor)
chi-1/chi-2 rotamer normality : 2.026 -1.817
Backbone conformation : 0.159 -2.538
RMS Z-scores, should be close to 1.0:
Bond lengths 0.780 2.237 (loose)
Bond angles 1.468 2.116 (loose)
Omega angle restraints 0.991 2.427 (loose)
Side chain planarity 2.250 (loose) 8.141 (loose)
Improper dihedral distribution 1.972 (loose) 3.600 (loose)
Inside/Outside distribution 1.170 (unusual) 1.120
Table 15.2 is a comparative study o f  the Whatcheck reports o f the model o f  UBE2J1 
and the model generate by 3D-JIGSA W. The terms indicated as “poor ”, “loose ” and 
“unusual ” along with some o f the values are the values which deviate very much from  
the required value. The Z-score should be around 0 and the RMS-Z score should be 
around 1.0.
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15.1.4.2. Interpretation of the Whatcheck report of the model generated 
by DeepView and the model generated by 3D-JIGSAW :
Whatcheck criteria had been used to check the model of UBE2J1, generated by 1) 
deepview, and 2) 3D-JIGSAW, it can be said that the model of UBE2J1 generated by 
Deepview, is better than the model generated by 3D-JIGSAW. The value of second 
generation packing quality of the UBE2J1 model generated by 3D-JIGSAW is 
represented as “poor” by whatcheck. The Ramachandran plot appearance of the 
UBE2J1 model generated by 3D-JIGSAW is also represented as “poor”. The bond 
lengths, bond angles, and omega angle restraints values of the UBE2J1 model generated 
by 3D-JIGSAW, are all represented as “loose” by the whatcheck report. Hence, from 
the above mentioned quality checks it can clearly be said, that the model of UBE2J1 
generated by Deepview, is better than that generated by 3D-JIGS AW.
Although the model generated by DeepView complies with almost all criteria of a good 
model, this model will not be ideal for predicting the substrate binding site, at the region 
where there is no homology around 9 amino acids as illustrated in Figure 15.6. The 
substrate binding site in this model could however be predicted at other regions of the 
active site, especially the regions where other amino acid residues like G, R, F which 
are unique in the UBC6.
15.2. Structural comparisons of UBE2Js (UBE2J1 & UBE2J2) with UBC9 
protein
The following section gives the results of the structural superimposition of UBE2J1 and 
UBE2J2 with UBC9.
The two human orthologues of yeast UBC6 are the UBE2J1 and UBE2J2. As 
Avvakumov et al. (2006) predicted the structure of one of the human homologues of 
yeast UBC6, UBE2J2 (pdb ID- 2F4W) from the co-ordinates obtained from X-ray 
crystallography. The UBE2J2 structure had been compared to yeast UBC9 (pdb ID 
1U9A) so as to see how the UBC6 family PROSITE signature (active site region) fit in 
to that of UBC9. The PROSITE signature obtained for the UBC6 family is quite 
different from that of all other UBC.
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The reason for choosing UBC9 as an example for the structural comparisons mentioned 
before is as follows:
More information on the active site, of UBC9 has been known than any other UBCs. 
Again from the prosite signatures of UBC6 and non-UBC6 UBCs it is quite evident that 
cysteine in the PROSITE signature is the most important catalytic residue. As 
previously implicated by Pickart (Pickart, 2001) and recently shown by Yunus & Lima, 
and Knipscheer & Sixma (Yunus and Lima, 2006; Knipscheer and Sixma, 2006), that 
Asparagine ASN85 of UBC9 is also important in the catalysis. In addition to 
Asparagine, Tyrosine TYR87 and aspartic acid ASP 127 of UBC9 has also been said to 
have catalytic activity. This is illustrated in Figure 15.16.
Prosite signature of all U BCs except UBC6: [FYW LPSJ-H -[PC ]-[N H ]-[ LIV]-x(3,4)- 
G-x-[L IV ]-C *-[L IV ]-x-[L IV ].
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Figure 15.16 The catalytically active amino acids in UBC9
Target









reaction taking place is 
illustrated below:









Active site residue 
cysteine
[ ubiquitin ]— C — S — C y s —E2 + H2 N — L y s —protein to be degraded 
E3 (Ubiquitin-Protein Jg a se )
O
f ubiquitin]— C — N — L y s — protein to be degraded + H S— C y s —E2
I
H
F igure 15.16 show s three residues in the U BC9 active site, Asn85, Tyr87  and  A sp  127  
having the catalytic activity, o ther than the active site residue cysteine. These three 
residues (Asn85, Tyr87 and  A sp  127) in addition  to the cata ly tic  cysteine are loca ted  in 
a p o cke t that helps to position  the target (p53) lysine (the only titra table residue). 
Illustra ted  in the fig u re  is the reaction betw een the target p ro te in  and  the E 2-SU M O  
th ioester complex. The fig u re  show s the activa tion  o f  the lysine residue o f  the target 
protein, with a decrease in its p K  value by Asn85, Tyr87  a nd  A sp  127 (figure w as  
adap ted  fro m  K nipscheer and  Sixma, 2006). The ubiquitination  reaction taking p lace  
illustrated  in the above fig u re  was adap ted  fro m
(http.V/www. rpi. edu/dept/bcbp/m olb iochem /M B  W eb/m b2 /oartl/p  ro tea se .h tm ).
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No clear picture of the E2 mechanism has been identified so far. Asparagine residue 
(Asn85) was identified by Pickart and coworkers but no catalytic acid or base had been 
found so far. Recently Yunus and Lima has effectively used a screening experiment in 
yeast, in which the human UBC9 complements the essential yeast UBC9 (Yunus and 
Lima, 2006). A number of UBC9 residues had shown to have an effect on the growth 
rate, but none of them, in contrast to the catalytic cysteine is essential for yeast survival. 
Asn85, Tyr87, and Asp 127, has shown to affect the rate of conjugation reaction, but not 
affect the affinity for the substrate. Cysteine together with these three residues are 
located in a pocket from where it helps in the interation with the lysine, but any 
mutation of the three amino acids Asn85, Tyr87, and Asp 127 causes the destabilization 
of the lysine side chain conformation. (Knipscheer and Sixma, 2006). Several kinetic 
studies were carried out where it showed that the decrease or increase in the pK of the 
target lysine was affected by these there amino acids Asn85, Tyr87, and Asp 127 along 
with the active site residue cysteine.
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15.2.1. Superimposition of UBE2J2 with UBC9 
Figure 15.17






Figure 15.17 illustrates the superim position  o fU B E 2 J2  (coloured  in ye llow ) w ith U BC 9  
(coloured  in light blue). Illustra ted  in the fig u re  are the C YS94 (o f  U BE2J2) a nd  C YS93  
(o fU B C 9 ) coloured in pink. Three non-superim posing  regions n earest to the active  site  
residue cysteine o f  UBE2J2 and U BC9 are m arked  in red and  m arked  in the f ig u re  as 
R E G IO N  1, R E G IO N  2 and R E G IO N  3. The R M S o f  the superim position  o f  UBE2J1 to  
U BC9 is 1.151.
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Figure 15.18.1
Structural superimposition of UBE2J2 and UBC9 of Figure 15.17, shown at its 
amino acid residue level.
Non-UBC6 UBCs PROSITE signature:
[FYWLPS]-H~[PC]-[NH]-[LIV]-x(3,4)-G-x4LIV]-C*-[LIV]-x-[LIV]
no superimposition ◄ — ►  ◄ -------- ►
Asn85 superimposition \T y r8 7
Proposed UBC6 PROSITE signature:
T-[PAR]-[NS]-G-R-F-x(3)-[KTEJ-[RK]-[LIV]-C*-[LMS]-[ST]-[IMF]-[ST]-x(2)-H-[PK]
Figure 15.18.2
Structural superimposition of UBE2J2 and UBC9 shown at its amino acid residue 
level, continued from the previous Figure 15.18.1.
Q D P A  Q A  E A  T T I Y C Q N R V  E
T G L L S F M V E K G P T L f r E T 8 D F T K R Q L A
Asp127
Figure 15.18.1 show s a short region a t the am ino  acid level (around the active site) o f  
the superim position  o f  the UBC9 (pdb ID - 1U 9A ) structure w ith the U BE2J2 (pdb ID - 
2F4W B) structure (illustrated  in F igure 15.17). The reason to show  the structura l 
superim position a t the am ino acid residue level is to illustrate better  which am ino  acids 
do not superim pose as it was not possib le  to show  all o f  them  in the structure in F igure
15.17. The P R O SIT E  signatures o f  both U BC 6 and N on-U B C 6 U BC s P R O S IT E  
signature has a lso been shown.
A lso  show n in F igure 15.18.1 are the ca ta ly tica lly  active am ino  acids o f  U BC 9 which  
are asparagine (A sn85) and  tyrosine (Tyr87). The third  ca ta ly tica lly  active  am ino  acid  
o f  UBC9 which is A spartic  acid  (A sp l2 7 ) is show n  in F igure 15.18.2. From  both the  
Figures 15.18.1 & 15.18.2, it can be seen tha t these cata ly tica lly  active  residues o f
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U BC 9  do not superimpose with UBE2J2, hence indicating that these residues are 
catalytically important fo r U BC9 only and not to UBE2J2 nor any other UBCs.
It can be seen from the structural superimposition of UBE2J2 with UBC9 that 
surprisingly the active site residue cysteine of both the structures superimposes. This 
was an unexpected result as UBE2J2 and UBC9 have very different substrate 
specificities. Therefore other amino acids surrounding the active site cysteines must be 
responsible for changing the substrate specificity. As can be seen from figure 15.17 and
15.18, there appears to be three areas of non-superimposing amino acids near the active 
sites of UBE2J2 and UBC9 that may be responsible for the different substrate 
specificities. The first and nearest area to the active site cysteine of UBE2J2 at amino 
acid 94, is the sequence from amino acids 87 to 90, namely F, K, C, N, where F is the 
invariant phenylalanine in our proposed UBC6 PROSITE signature. The second region 
that does not superimpose on the UBC9 structure, near the active sites are the UBE2J2 
amino acids from 82 to 84 namely T, P, N, where T is the invariant threonine of the 
proposed UBC6 PROSITE signature. To the other side of the active site cysteine 
(towards the C-terminal) as there are 9 amino acids missing in the 2F4WB structure, 
there is this region of non-superimposition with the structure of UBC9. This is 
highlighted in Figure 15.17 as “REGION 1”.
Also, as the catalytically active residues Asn85, Tyr87 and Asp 127 of UBC9 do not 
superimpose with UBE2J2, it could be hypothesised that these three residues are only 
catalytically important for UBC9, but may not have any substrate specificity for any 
other UBCs.
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15.2.2. Superimposition of UBE2J1 and UBC9 
Figure 15.19 Superimposition of UBE2J1 and UBC9
/C ysteine 82 C ysteine 93
Figure 15.19 show s the 3D  structure o f  hum an UBC9 (pdb ID  1U 9A) co lo ured  in ligh t 
blue, consists o f  158 am ino acids have been superim posed  w ith the m odel o f  UBE2J1  
coloured  in green consisting  o f  141 am ino acids.
From the superimposition of UBE2J1 with UBC9 it can be seen that both superimposes 




Conservation of UBE2J1 and UBC9 along the whole length o f the peptide sequence
F igure 15.20 illustrates the conservation  o f  U BE2J1 w ith  U BC 9 (pdb ID  1U 9A) along  
the whole length o f  its p ep tide  sequences.
As can be seen from Figure 15.19, both the UBE2J1 model and UBC9 structure is 
completely superimposed. This is in contrast to the structural superimposition of 
UBE2J2 with UBC9 where there are various regions of non-superimposition, especially 
along the active site region as illustrated in Figure 15.17 & 15.18. These differences in 
the structural superimpositions of UBE2J1 with UBC9 and UBE2J2 with UBC9 states 
clearly that the DeepView generated model of UBE2J1 is unique and its structural 
findings will have a strong impact for further studies, except the region where there is 
no homology with the template (2F4WB), where the 9 amino acids are missing.
239
15.3. Conclusion
The model obtained by homology modelling of UBE2J1 is in a good agreement with the 
practical approach of homology modelling. Using the approach described above, the 
model of UBE2J1 was built based on the coordinates of 2F4WB structure. The Z-score 
& RMS Z-scores obtained from analysis by WHATIF (Whatcheck report), showed that 
the model obtained is acceptable.
The best available template that had been used here which had a low percentage identity 
(around 43%) but within acceptable limits (as theoretically the percentage identity 
should be 30% and above). By doing the alignment corrections, and various other 
optimization steps, the model obtained had been checked and verified and had been 
found to have satisfied most of the evaluation criteria.
The superimpositions of UBE2J2 with UBC9 had shown that the UBC6 family differs 
from all other UBCs, especially with respect to the active site and have different 
substrate specificities. There were no diffraction patterns obtained for the 9 amino acids 
of the crystal of UBE2J2 (2F4WB) by Avvakumov et al. (2006), as these 9 amino acids 
are highly mobile or disordered. It could be hypothesised from this that this mobility 
and disorder of amino acid of UBE2J2 could be the same as in UBE2J1. This could be 
also one of the reasons why the UBE2J1 failed to crystallize.
15.4. Future research
The future research would be to carry out a docking analysis, to find out a suitable 
substrate that would specifically bind to the active site of human UBE2Js (UBE2J1 and 
UBE2J2), and not to any other UBCs. This would be required to inhibit the degradation 
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16.1 Overall conclusion and future research
Sequences of homologous proteins from related organisms are very similar. The 
difference grows with an increase in the evolutionary distance between species. The 
observation has led to the development of sequence alignment methods (Doolittle, 
1996) where the optimum alignment can be found between the sequences of two or 
more proteins being compared. Following the sequence alignment, the phylogenetic 
analysis is carried out of those aligned sequences, so as to draw a evolutionary and 
functional relationship of the sequences and the species from which the sequences were 
derived. By carrying out the phylogenetic analysis of all the 13 yeast UBCs and their 
respective homologues from eleven selected species, an evolutionary and functional 
relationship was inferred. Another important use of the phylogenetic tree was the 
proposal for the correct nomenclature of all wrongly named UBCs. The HGNC 
nomenclature system needs to assign unique names to proteins, on the basis of well 
established phylogenetic relationships. We have successfully renamed the NCUBE1 and 
NCUBE2 as UBE2J1 and UBE2J2 respectively, and would propose a system of 
nomenclature for all UBC (E2s) on the basis of the interpretations of the phylogenetic 
tree of the 193 peptide sequences.
Results of the Consurf analysis has produced a phylogenetic tree of the same peptide 
sequences used for phylip in the studies. This phylogenetic study has investigated the 
structural relationship of UBE2J2, to all its homologues in UBC (E2s). The plot 
represents different levels of conservations (Figure 12.3) and provides a better 
understanding of the conservation of UBC (E2s).
The identification of the previously unidentified UBC (E2) active site of the D ro so p h ila  
TAFn250 has opened up a new area of further research. Moreover the identification of 
the active site residue Cysteine in only the A p is  m ellifera  has led to the assumption of 
convergent/divergent evolution where again future research could be carried out in the 
laboratory to confirm the finding of the UBC (E2) active site region in D ro so p h ila  
TAFn250.
Proteins are described and classified into families and analysed for patterns of mutations 
at various positions along the sequence. The sequence similarity between proteins from
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different species forms the basis of molecular phylogenetics. Protein structures have a 
complex shape defined by specific interactions between amino acids along the chain. 
Different sequences adopt similar folds. For closely related proteins, it is possible to 
build reliable evolutionary trees and analyze the relationships between the organisms 
from which they came. For studying the dynamics of side chain movements in proteins 
or for predicting the results of a point mutation, it may not be thought of as a necessity 
of how enzymes evolved. But there are problems that require insight from both 
perspectives. Why does proteins performing different functions have very similar 
structures and the vis-a versa (Godzik, 2003)? The homology modelling, protein fold 
assessment and ab initio protein structure prediction are the very important 
bioinformatics tools, which brings mechanistic insights to biology, chemistry and 
medicine. A significant evolutionary change in the gene sequence is easily noticed at the 
level of an individual protein functional unit or domain. Structural biologists can 
contribute enormously to protein structure, of which homology modelling can be 
distinguished from all other methods for analysing relationships among protein 
sequences, because it produces atomic co-ordinates suitable for direct comparisons with 
X-ray and NMR structures (Burley and Bonanno, 2003).
We have tried to predict the tertiary structure of the protein UBE2J1 by X-ray 
crystallography. This approach has proved so far, to be unsuccessful because of the 
failure to grow usable protein crystals. We have used an alternative strategy to generate 
a tertiary structure for UBE2J1 using computational structure prediction (homology 
modelling). UBE2J1 and UBE2J2 are the two human homologues of yeast UBC6, 
which has a sequence identity of around 43%. Although the crystal structure of UBE2J1 
could have given a more confident prediction, the structure obtained by homology 
modelling could give valuable insights into the structural similarity of UBE2J1 with 
UBE2J2. The future research could be to design primers of the UBE2J1 protein (as 
mentioned in sections 14.3 and 14.4), by taking other suitable regions of the UBE2J1 
protein, as predicted by Globplot and RONN (globular or disordered region prediction 
program). By carrying out various trials, could possibly lead to crystal growth in at least 
one of the UBE2 J1 designed primers.
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16.2 The use of Grid to identify specific UBE2J inhibitors
As the X-ray crystallographic structure of UBE2J2 is now known (Avvakumov et al., 
2006), another area of future research would be to find a substrate that would bind 
specifically to the yeast UBC6 homologues, i.e. human UBE2J1 and UBE2J2, and not 
bind to any other UBCs of all the 13 yeast UBC family. Such inhibitors may prove to be 
of therapeutic value in the treatment of cystic fibrosis. The inhibition of ERAD using a 
UBE2J1/J2 inhibitor should stop the degradation of AF508 CFTR protein, thus making 
functional AF508 CFTR proteins available for use into the plasma membrane. The 
design of suitable inhibitors can be helped by using the very recently available GRID 
system (http://www.grid-support.ac.uk/) comprising programmes such as “AutoDock 
(Morris et ah, 1998; 1996; Goodsell and Olson, 1990) or flexX” (Lengauer and Klebe, 
1996).
Autodock is a software that runs under the grid agent which tries to determine how 
small molecules, such as substrates or drugs, can bind to a receptor of a known 3D 
structure. There are three separate programs in Autodoc: The docking of the ligand to a 
set of grids describing the target protein is performed by Autodoc; These grids are pre­
calculated by AutoGrid; and finally the AutoTors program sets up which bonds will be 
treated as rotatable in the ligand
(http://www.scripps.edu/mb/olson/doc/autodock/; http://www.grid-support.ac.uk/).
One of the first success’s achieved by AutoDock was called WISDOM (Wide In Silico 
Docking On Malaria http://wisdom.eu-egee.fr/malaria/). This system enables the 
relatively rapid identification of compounds that bind specifically to 3D protein 
structures using “ZINC”, which is a free database of commercially available compounds 
(Irwin and Shoichet, 2005).
The Zinc database contains over 3.3 million compounds available for docking 
experiments. Hence from the database the compound that best fits to the receptor of the 
3D structure is found, with the help of computers running the analysis at various nodes 
in various parts of the world, hence increasing the CPU capacity that is required for 
such a high capacity of space for the analysis.
Our structural superimposition of human UBE2J2 on UBC9 (UBE2I) shows that using 
GRID programmes such as Autodoc, with the ZINC database, it would be possible to 
identify molecules that bind specifically to the active sites of UBE2J’s but not to other 
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atUBCl Q9FI61 ceUBC8a vl AAF60891 mmHIP2 P27924
atUBC2a P42745 ceUBC8a v2 NP 500245 mmUB2D4 73318
atUBC2b vl P42746 ceUBC9 Q95017 MmUBE2B P23567
atUBC2b v2 Q8H1P1 ceUBC13 Q95XX0 MmUBE2R2 Q8VDE5
atUBC2b v3 Q94AD2 MmUBE2D2 P51669
atUBC4a vl Q9SLE4 dmUBCl P91633 MmUBE2Jl Q9DC92
atUBC4a v2 P35132 dmUBC2 P25153 MmUBE2J2 Q9QX58
atUBC4b P35131 dmUBC3a vl Q8IQM5 MmUBE2G2 Q9QX59
atUBC4c P35132-2 dmUBC3a v2 Q9VUR4 MmUBE2I P50550
atUBC6a Q9FK29 dmUBC4 P25867 MmUBE2a Q9Z255
atUBC6b Q9SHI7 dmUBC6 Q9VEJ4 MmUBE2C Q9D1C1
atUBC6c Q9LSP7 dmUBC7a Q9VXE8 MmUBE2M 076069
atUBC7a P42747 dmUBC7b Q8IH42 MmUBE2N Q16781
atUBC7b Q42540 dmUBC7c Q9N9Z5 MmCDC34 Q8CFI2
atUBC7c Q42540 dmUBC7d Q8SYG3 MmUBC3 BAC35904
atUBC7d AT5G59300 dmUBC8a Q9W3K7 mmTSGlOl Q61187
atUBC7e Q42541 dmUBC8b Q9VGD6 MmUBE2V2 Q8CE99
atUBC8a vl AAG52444 dmUBC9 062622 MmUBE2S Q921J4
atUBC8a v2 P42749 dmUBCll Q9VTY6 MmUBE2E3 P52483
atUBC8b P42748 dmUBC12 Q9VSF3
atUBC9 Q42551 dmUBC13a P35128 ncUBCl Q9P725
atUBCIO Q8LGF7 dmUBC13b Q9VJS5 ncUBC2 P52493
atUBClla vl Q9LPS2 dmUBC13c Q9NKC1 ncUBC3a vl Q7S7Z9
atUBClla v2 Q9C6Q4 ncUBC3a v2 Q8X0N3
atUBClla v3 Q8L7T3 hsHIP2 P27924 ncUBC6a Q7S6X1
atUBCllb Q9LJZ5 hsUBE2A Q9Z255 ncUBC6b Q7S7C4
atUBC12a Q9SDY5 hsCDC34 P49427 ncUBC7 Q9C2A5
atUBC12b Q9ZU75 hsUBE2R2 Q9NX64 ncUBC8 Q7S086
atUBC13a vl Q94A97 hsHBUCEl Q9Y2X8 ncUBC9 Q871H3
atUBC13a v2 Q9ZVA6 hsUBE2D2 P51669 ncUBCIO Q7SDB0
atUBC13b Q9FZ48 hsUBE2D3 BAC04632 ncUBC12 Q8X0I8
hsUBE2Dl P51668 ncUBC13 Q7SDM1
agUBCl Q7PHN5 hsUBE2El P52483 osUBCl Q8S1Y5
agUBC2a Q7QFT1 hsUBE2Jl Q9NY66 osUBC2a vl Q7XIC8
agUBC2b Q7PFQ9 hsUBE2J2 Vl Q96T84 osUBC2a v2 NP 911360
agUBC4 Q7PFW9 hsUBE2J2 V2 Q96N26 OsUBC2b Q8SBC1
agUBC6 Q7Q6A2 hsUBE2V2 Q15819 osUBC4 Q94DA8
agUBC7a Q7QK63 hsUBE2Vl Q13403 osUBC7 Q943L1
agUBC7b Q7PTL6 hsUBE2S Q16763 osUBC8 Q7XDX9
agUBC8 Q7PJL8 hsUBE2E3 Q969T4 osUBC9a Q7XCN3
agUBC9a Q7QH85 hsUBE2E2 Q96LR5 osUBC9b Q8H8G9
agUBC9b Q7PZV4 hsUBE2G2 vl AAP35560 osUBC9c CAD41164
agUBClla Q7Q5S2 hsUBE2G2 v2 AAC32312 osUBCll Q9LIY1
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NAMES ACCESSION NO. NAMES ACCESSION NO. NAMES ACC. NO.
agUBC12 Q7Q6C9 hsUBE2Gl Q99462 osUBC12 Q8LMK7
agUBC13 Q7Q9K0 hsUBE2L3 P51966 osUBC13 Q8W0I1
hsUBE2I P50550
ceUBCl NP 497174 hsQ9BQ25 Q9BQ25 pfUBCl Q8IDD9
ceUBC2a vl Q9TZ69 hsUBE2B P23567 pfUBC2a vl 077397
ceUBC2a v2 P52478 hsUBE2C 000762 pfUBC2a v2 T18512
ceUBC3 Q95XN7 hsUBE2H P37286 pfUBC2b Q8IAW2
ceUBC4 P35129 hsUBE2L6 014933 pfUBC4 Q8I607
ceUBC6a NP 871922 hsUBE2M 076069 pfUBC7 Q8I2U3
ceUBC6b Q9N490 hsUBE2N Q16781 pfUBC8 Q8IJ70
ceUBC6c vl T34195 hsTSGlOl Q99816 pfUBC9 Q8I301
ceUBC6c v2 NP 495566 pfUBCIO Q8ICV3
ceUBC7a Q9U1Q1 pfUBC12 Q8I4X8
ceUBC7b P34477 pfUBC13 Q8I3J4
scUBCl P21734 scUBC9 P50623 pyyUBCl Q7RP52
scUBC2 P06104 scUBCIO P29340 pyyUBC2a Q7RNM4
scUBC3 P14682 scUBCll P52492 pyyUBC2b Q7RQW9
scUBC4 P15731 scUBC12 P52491 pyyUBC8 Q7RS94
scUBC5 P15732 scUBC13 P52490 pyyUBCIO Q7RJU9
scUBC6 P33296 scMMS2 P53152
scUBC7 Q02159
scUBC8 P28263
spUBCl 074810 spUBC8 Q9P7R4
spUBC2 P23566 spUBC9 P40984
spUBC4 P46595 spUBCIO Q9P6I1
spUBC6 042646 spUBCll 000103
spUBC7a 000102 spUBC12 074549
spUBC7b Q9Y818 spUBC13 013685
T able 18.1 illu s tra tes  a l l  the p e p tid e  seq u en ces o f  the p h y lo g e n e tic  tree, w ith  th e ir  a ccess io n  
num bers. F rom  the a ccess io n  num bers, the p e p tid e  seq u en ces  can b e  r e tr ie v e d  fro m  an y  o f  the  
d a ta b a se s  like N CBI, E M B L  a n d  ENSEM BL.
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F ig ure  18.1
h s U B E 2 V 2 / l  
m m U B E 2V 2 / l 
h s U B E 2 V l/ l  
S C M M S 2 /1 -1  
s c U B C 6 / l - 2  
C e U B C 6 a / l-  
s p U B C 6 / l- 2  
h s 2 J 2 _ V l / l  
mmU2j 2 / 1 - 2  
h s 2 J 2 _ V 2 / l  
D m U B C 6 / l-2  
A g U B C 6 / l- 2  
A t U B C 6 a / l -  
A t U B C 6 b / l -  
C e U B C 6 b / l-  
h s B E 2 J l / 1 -  
m m U b e 2 j1/1  
C e U B C 6 c / l-  
C e U B C 6 d / l-  
A t U B C 6 c / l -  
A t U B C 8 a / l -  
A t U B C 8 b / l -  
A t U B C 8 c / l -  
O s U B C 8 / l - l  
s p U B C 8 / l - l  
n c U B C 8 / l - l  
s c U B C 8 / l - 2  
P f U B C 8 / l - l  
P y y U B C 8 / l -  
C e U B C 8 a / l-  
C e U B C 8 b / l-  
D m U B C 8 a / l-  
a g U B C 8 / l - l  
h s U B E 2 H / l-  
D m U B C 8 b / l-  
s c U B C l/ 1 - 2  
s p U B C lb / 1 -  
n c U B C l/ 1 - 2  
O s U B C l/ 1 - 1
The  whole m ultip le sequence alignm ent that had been used to generate the phylogenetic trees:
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H V K F F | P T E --------------------------------------------- S Pi E G '
C V K F E  PRG --------------------------------------------I p iE G -
H F T | R | P - - -
h f t S r I p —  
h f t | r | |T—  
h f t I r I t —  
|Qf a 1r § p _ - '
|FVEFS|PKD-
F V E F S lP K D -
Y V EFN | P K D -
iF V E F R jp T E -
y v r f h I p s e -
|YVRFK| PAE- 
IHVKFL-'PKD-
A ' EG- 
A  EG-
■ Rl! SLAG EC G S]
IECGPI
-R: S L S  -DCGPNS
- Q HGT T F P S D
| Q iH G T | IF P P E
| Y | H G K | IF P R E
| y | h g k | i f p r e  
| y | h g k | i f p r e
• Y |HGt | l FP R E  
| y | h g t ||l f t k e
P | a G ------------------------------------------------- F g Y G K >:K F P P E
Y G K B K F P P E
| V V K F Y | P Q G --------------------------------------------- g P H E G
l n v c | e | p l g ---------------------------------------------
l k g t f l | p - p ------------------------------------------- g I p I e g
L K G M F R S P -E ------------------------------------------- G lp p E G










|y k !  
Sy
■ |I|KVH |ELPSEI
: :-:v e  e l p d q
■ ;;V;,;"RLH"'ELPDNi 
I  i l  KVH T LP D D i
Ii I k v h I t l p d d i
DMPDI 
DMPDI 
Y LPD N i 
HLPEHI 
1DLPDI
| l| T V N iT M fQ D |
kgV v d P e v p m e S 
1 y 8 v v d | e  I p  i  d |

















































Th e  whole m ultip le sequence alignm ent that had been used to generate the phylogenetic trees continued
a t U B C lb / 1 -  
d m U B C l/ 1 -1  
a g U B C l/ 1 - 1  
h s H I P 2 / l - 2  
m m H I P 2 / l-2  
c e U B C lb / 1 -  
P f U B C l/ 1 - 2  
P y y U B C l/ 1 -  
a g U B C 4 / l - l  
D m U B C 4 / l- l  
C e U B C 4 / l - l  
h s U B E 2 D 2 / l  
m m UBE2D2/1 
h s U B E 2 D 3 / l  
h s H B U C E l/ 1  
h s U B E 2 D l/ l  
mmUB2D4/ 1 -  
S C U B C 4 / 1 —1 
S C U B C 5 / 1 -1  
s p U B C 4 / l - l  
A t U B C 4 c / l -  
A t U B C 4 d / l -  
A t U B C 4 b / l -  
0 s u b c 4 a / l -  
A t U B C 4 a / l -  
P f U B C 4 / l - l  
h s U B E 2 E l/1 
h s U B E 2 E 3 / l  
m m U B E 2 E 3 / l 
h s B E 2 E 2 / l -  
D m U B C 1 3 b / l 
D m U B C 1 3 c/ l 
d m U B C 1 3 a / l 
A g U B C 1 3 / l-  
h s U B E 2 N / l-  
m m U B E 2 N / l-  
c e U B C 1 3 / l -  
a t U B C 1 3 a / l  
0 s U B C 1 3 / l-
Q A S l  
|QAS 
■ CAT
Sq a t | m | p - s - 
| Q A T jM jf- S -  
|q a t ! m | | - a - 
>-s-
I iP -N -
|QAT 
QAT I
VG------------------------------------------------- i v i F L S
RST
Ir s t !
L I P - P -  
- P -
R S T iL | P - P -
r s t I l i p - p -
-K -
t 1 p -K -  
t | p - n -
F | P - E -  .
| P -Q -  
| P -D -  
N V M | L | P -T -  
iN V M lL | P -A -
-------------------------------------------------I V I F l
:G------------------------------------------------- iv ^ K L E
Ik l e I
TMPDG
K V P E T
K - P E T
K I P E T
K I P E T
K IP D Q
T IP N D


















K FP P D
T F S S D
T F S S D
T F S S D
T F S P D
F L P E D
F L P E D
F L P E D
F L P E D
F L P E E
F L P E E
F L P E E
F L P E E
















































































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
a t U B C 1 3 c / l  
a t U B C 1 3 b / l  
n c U B C 1 3 / l-  
s p U B C 1 3 / l-  
s c U B C l 3 / 1 -  
P f U B C 1 3 / l -  
h s U B E 2 S / l-  
m m U B E 2 S / l-  
c e U B C la / 1 -  
c e U B C 2 / l - 2  
h s U B E 2 A / l-  
m m U B E 2 A / l-  
m m U B E 2 B / l-  
h s U B E 2 B / l-  
a g U B C 2 a / l-  
d m U B C 2 / l- l  
a g U B C 2 b / l-  
0 s U B C 2 a / l-  
O s U B C l la / 1  
O s U B C 2 b / l-  
a t U B C 2 a / l -  
a t U B C 2 b / l -  
a t U B C 2 c / l -  
A t U B C 9 c / l -  
n c U B C 2 / l - l  
s p U B C 2 / l - l  
s c U B C 2 / l - l  
p y y U B C 2 a / l  
P f U B C 2 b / l -  
P f U B C 2 a / l -  
P f U B C 2 c / l -  
p y y U B C 2 b / l  
s p U B C 9 / 1 -1  
N c U B C 9 / l - 1 
A g U B C 9 a / l-  
d m U B C 9 / l- l  
A g U B C 9 b / l-  
c e U B C 9 / l - l  
m m U B E 2 I / l-
INVM|L| P - T -
!n v m | l | p - t -
jD V E | H | P -S -
5k i t | e }!p - q - 
q v t Se | p - e - 
i n i l I n  p - d -
c| p -E -  
L Q V T | E | ;P -E -
5p - q -
IP-Q -
e g ------------------------------------------------ | v | k l e | f l p e e |
E G ------------------------------------------------ I v I k L e I f LPEES
Se g -------------------------------------------------S v I k l e I f l p d d H m
■ QiApEG  
-q | p I e d
;«jK|HLE|FLPDE  
i I e l e I y l p d d
p p E G ------------------------------------------------ ;;t | k l e | f l p e q
A G ------------------------------------------------| l | r MI<®LLGKD
|a g ------------------------------------------------| l | r m k 1 l l g k d
E D ------------------------------------------------| T | K L S j E F T  E E
E D ------------------------------------------------| t | K L s | e F T E E
GD------------------------------------------------1 t | K L t | e F T E E
E D ------------------------------------------------| t | K L t | e F T E E
E D ------------------------------------------------| t | K L v | e F S E E
IPSED ------------------------------------------------B t S k L  V H E F  S E E
-| t | k l t | e f t e e  
- | t | k l t | e f t e e  
- I t | k l t | e f t e e
- | t | K L T iQ F T E D l
- I t I k l t I q f t e d I
-E A V M Q F K A T H H C E A G H L G L C D R L S A IR L N N L | T | K L T lQ F T E D j
|t 1 k l s 1 q f s e d |
H F T E D i
P i K - K ------------------------------------------- G!
P | K - K ------------------------------------------- s
E C A | P | K - K ------------------------------------------- G!
e g a I p I r - k
| E C a 1 p 1 k - K ------------------------------------------- G
| t |
-| T | K L T | H F T E D S
|DG------------------------------------------------ | t | k L T | H F T E d |
iP iE D ------------------------------------------------ | t | r l v | h f e e q [
jsFD EQ I  
R L L rfE F D E E jTiQLElLFGNE!
lT | H L E iL F G N E ;  
| i | h l i | h f s e e  
* i 1 h l i | h f s e e
H L l lN F S E E i
| l | k l t | a f p e e | 









In k  
In k  
In k !  
| I
| N lJ









































Sg E C A g P g K -K -  
®ECAgP| K -K -
„ i c k | p | k - k - 
I h c t I p I k - q - 
| h c t | p ! k - q - 
§ H C t | p :;e K -A -  
g R C I g P g K - E -
! e a g | p | k - e -
g R FG g M V IN P -
§ r f g | m v i n p -
jMVLNE-
iF l p - p -
Sf I p - p -
j E V A iF i P - P -
!e v ; m
l p -p -
jE V A iF p P - P -  
|EVA|F P -P -
iT V # | p - p -
|DCl |q | p - 





p | e g ------------------------------------------------ | l | k l r 1 l  f k d d |
E G -------------------------------------------------L  |KLRj LFK D D i
------------------------------------------------ ! E :' 'P L T ';E F T E d !
------------------------------------------------ | Y i PLT '"'H FSED i
------------------------------------------------ v .- ? L T:G iFSED 8
-F'F;;PLT-GHFSEDS
---y |[p l t  Iq f t e d ! 
-|v J:;;p i t | e y p n e [ 
■ Iy S r a e | v f s d e |
C iV FS D E I
J E G -
■g | d | e g - 
- - : f.g - 
■ g | d  e g -
-G D EG- 
- G lN iA G -
■D| L p -
The  whole m ultiple sequence alignm ent that had been used to generate the phylogenetic trees continued
h s U B E 2 I / l -  
h s Q 9 B Q 2 5 / l  
P fU B C 9 / 1 - 1  
O s u b c 9 a / l -  
O s U B C 9 b / l-  
A t U B C 9 b / l -  
O s U B C 9 c / l-  
S C U B C 9 / 1 -1  
n c U B C 3 a / l-  
n c U B C 3 b / l-  
s c U B C 3 / l- 2  
d m U B C 3 a / l-  
D m U B C 3 b / l-  
h s C D C 3 4 / l-  
m m C D C 3 4 / l-  
h s U B E 2 R 2 / l  
m m U B C 3 / l-2  
m m U B E2R 2/l 
C e U B C 3 / l- 3  
s p U B C 7 a / l-  
n c U B C 7 / l - l  
D m U B C 7 a / l-  
D m U B C 7 c / l-  
A g U B C 7 a / l-  
h s 2 G 2 _ v l/ l  
m m U B E2G 2/l 
h s U 2 G 2 _ v 2 /
C e U B C 7 a / l-  
s c U B C 7 / l - l  
A g U B C 7 b / l-  
d m U B C 7 d / l-  
h s 2 G l / l - 1 7  
D m U B C 7 b / l-  
C e U B C 7 b / l-  
s p U B C 7 b / l-  
A t U B C 7 b / l -  
A t U B C 7 c / l -  
a t U B C 7 e / l -  
O s U B C 7 / l - l
• -
- G | P p G -
C EG-1J  ...
. EG-
2E A L | M fe P -E --------------------------------------m
i l P - E --------------------------------------
H
| P - E --------------------------------------
J1T1P “ E --------------------------------------
|d c l |q | p - p --------------------------------------
|e v l | i | p - p --------------------------------------
|e v l | i | p - p --------------------------------------
| EV L| l|  P - P -------------------------------------------d I l I e G
1
■ E-------------------------------------------D i L i E G
I e v v  | i | p -  p -------------------------------------------D i L l E G
| e V l | i | p - P -------------------------------------------D' L  ; EG
| e v m | i | p -
i s v T | i l p - P -  
J S V T .  I | P - P -
a
* s v T | i  I p - p -
" i Yl
- iY S K A H i
KAH jKFPH D i 
|YSKAH-y K FPH D i 
P YG'KAR K F P ID i
k a r | k f p i d [
KFP1D I  
Iy S k A h S k F P  ID*
E G -------------------------------------------------|Y| KAH KFPID|




p a e I k f p n d  
p a r I i f p t d  
p a r J i f p t d  
t a k I i f p p d
P A I -SFP LD  
j P A l l s F P L D  
I V I P A I  'S F P L D  
JTFPQD
Ie f p k d  
Sh f p k e
l | e g ------------------------------------------------- I f S k a h S y f p k e H S l r I
1KAH
iVi|KAH |TFPKD|
Sk a h I i f p k e  
k a i I d f p r d i
• iF iH A T | S F P Q D
Sn a i I t f p q n
| F | N A I| T F P Q N
d I l I e g ------------------------------------------------ i Fl Y A I l s  FPQN
DG------------------------------------------------ 3 y | n A i | s FPQN
l r ^











































Th e  whole m ultip le sequence alignm ent that had been used to generate the phylogenetic trees continued
A t U B C 7 a / l -  
A t U B C 7 d / l -  
P fU B C 7 / 1 - 1
s c U B C l l / 1 -  
s p U B C l l / 1 -  
d m U B C ll/ 1 -  
a g U B C l la / 1  
h s U B E 2 C / l-  
m m U b e 2 c / l-  
a t U B C l l b / 1  
a t U B C l l d / 1  
a t U B C l l c / 1  
a t U B C l l a / 1  
O s U B C l lb / 1  
P y y U B C 1 0 / l  
P f U B C 1 0 / l -  
A t U B C la / 1 -  
s p U B C la / 1 -  
S C U B C 1 0 / 1 -  
n c U B C 1 0 / l-  
s p U B C 1 2 / l-  
n c U B C 1 2 / l-  
d m U B C 1 2 / l-  
a g U B C 1 2 / l-  
h s U B E 2 M / l-  
m m U b e2 m /l-  
a t U B C 1 2 a / l  
a t U B C 1 2 b / l  
O s U B C 1 2 / l-  
S c U B C 1 2 / l-  
P fU B C 1 2 / 1 -  
h s U B E 2 L 3 / l  
h s U B E 2 L 6 / l  
h s T S G 1 0 1 / l  
m m T S G lO l/ 1  
n c U B C 6 a / l-  
n c U B C 6 b / l-
S svsfe M  P -P -  
. : : p - p -
| N V C F e |;P-K- 
5p - k -JVGY ITS 
|AGT |TV'P-S-
|VGT
j v g t  |h ; 
Ik G T 1T i S
IG T | S | P -D -  
i v g t I h I a - a -
-A -  
-K -
K G Ti T i s _ K '
KGT T | S - K -  
|KGT | T i  S -K -
1v g t |a | s - a -
3-R -
Se a i  
Q A VB l
a® TAL|K |  P -S -  
K A v j;E | P - T  
I e a i J S I P - S
| e A v |n | k G V -------------------------------------------GGGj
l h l e I r p d - 
[i l y I e p d -
1K L I  IsP D -  
| K L l| cP D -  
|KLV|CPD
Ik l v I c p d  
i e v s I k p d
lE V T H K P D -----------------------------------------------EGYi
•DGYLKD-------------------------------------------------K
E I I jjR P D  
L E V l lR P D  
I Y L S I K P T
âQGL| V P D ----------------------------------------------- N P P jD K
^h a l J l p d ------------------------------------------------q p p | h l ------------------------------------------------- k a | n b :
E S Q L K K M V S K Y K Y R D L T V R E T V N V IT L Y K D L K P V L D S Y V F N D G S S R E L M N L T G T IP V P Y R G N T Y N IP IC  
E S Q L K K M M S K Y K Y R D L T V R Q T V N V IA M Y K D LK P V LD S Y V F N D G S S R E L V N LT G T IP V R Y R G N IY N IP IC i 
R A A H K R A R P E--------------------------------------------N g p g H G -------------------------------------------------g Q jW G T
| h f t | r | p ----------------------------------------------p n | v | a d -------------------------------------------------| i | h g r
S F P E N  
^ F jN A IjT F P Q N
i I n a t I s f p s d
KFPQN  
SFP A N  
DFPNS  
E FP N S  
E F P S G  
E F P S G  
SFSN D  
SFSN D  
TFSN C  
SFS N C  
FPG E  
K C K ST  
K C K ST  
Q L A F S V P E F  
iVLDpHVHEG
r i l I e v p s s
L L H iT L P P T
!k f r | q i d d n
S F T F N I T P K  
jVFNFRVGSK  
FN FK VG PK  
FSFK VG Q G  
FSFK VG Q G  
V F T F Q V S P V  
iVFSFQ VSN P  
F T F Q V S P S
Y P M > P
y p B B I p
f p H | p
Y F f f l| p
y p M p p
DFNEVI
KFKE^
| a | r i e | n f p a e
” ~H ” ' ~ " S F P PE 
L L D T  
iW L L D T  

























I E l 
IT|
FKI










































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
h s U B E 2 V 2 /1 
m m UBE2V2/1  
h s U B E 2 V l/ l  
s c M M S 2 / l- l  
s c U B C 6 / l- 2  
C e U B C 6 a / l-  
s p U B C 6 / l- 2  
h s 2 J 2 _ V 1 /1  
mmU2j 2 / 1 - 2  
h s 2 J 2 _ V 2 / l  
D m UBC6/1 -2  
A g U B C 6 / 1 -2  
A t U B C 6 a / l -  
A t U B C 6 b / l -  
C e U B C 6 b / l-  
h s B E 2 J l / 1 -  
m m U b e 2 j1/1  
C e U B C 6 c / l-  
C e U B C 6 d / l-  
A t U B C 6 c / l -  
A t U B C 8 a / l -  
A t U B C 8 b / l -  
A t U B C 8 c / l -  
O S U B C 8 / 1 -1  
s p U B C 8 / l - l  
n c U B C 8 / l - l  
s c U B C 8 / l- 2  
P fU B C 8 / 1 - 1  
P y y U B C 8 / l-  
C e U B C 8 a / l-  
C e U B C 8 b / l-  
D m U B C 8 a / l-  
a g U B C 8 / l - l  
h s U B E 2 H / l-  
D m U B C 8 b / l-  
s c U B C l/ 1 - 2  
s p U B C lb / 1 -
S l R l --------- V T K -
S | r | --------- V T K -
F j R l --------- V T K -
k | t !|----------i s k -
A  RM----------I T P -
A § L M --------- L T P -
A  RM----------I T P -
S YM----------I T P -
S ! YM----------I T P -
S I YM----------I T P -
S j YM--------- L T P -
S [ YM--------- T T P -
G| TM--------- T T P -
G TM--------- T T P -
A  TM----------I T P -
s l l L --------- L T A -
S I L --------- L T A -
N I L --------- L T P -
N | l L --------- L T P -
S F M L --------- L T P -
s | g | ----------I T K -
s i Gl — I T K ~
1 ----------I T K -
'--------- V N K -
I--------- V N R -
1--------- V N R -




G{ j--------- L N K -
G| --------- L N K -
G | --------- V N K -
G| ----------IN K -
g L?--------- MNK-
A — VTK_
K Q .--------- D T K -
k | n ! --------- D T K -
NM NG|NNSS|M fflDARS|PVLA-
n m n g | n n s s | mB d a r s | p v l a -
n m n g | n s s n | v | d p r a | s v l a -
n l ! c ! n p t t I e B q t - d f h t l r - ■ D[
■ -n g r f k p n - t :
■ -NGRFQTN-T  
--S G R F Q T N -T  
--N G R F K C N -T  
--N G R F K C N -T
- - n g r f k c n - t :
--N G R F K T N -T R E  
--N G R FK TN -K ]
— NGRFVTQ-K1  
--N G R F M TQ -K K  
--N G R FQ TN -TR|i 
- - n g r f e v g - k :
--N G R F E V G -K K fi
--N G R F E L N -K K
--N G R FELN -K 1
- - n g r f e t n - t : 
1DEMS SI
jS lS D Y H P --------------------- DT
S g S D Y H P --------------------- DT
JS F S D F H P --------------------- KS
I s iT D F H P --------------------- DT
’D FH P--------------------- DT
ITD FH P--------------------- DT
jS D F H P --------------------- DT
H s i S D F H P --------------------- DT
I S iS D F H P --------------------- ES
I s D F H P --------------------- ES
J s D Y H P --------------------- ES
S s g S G H H P --------------------- E T
g S| JsG H H P --------------------- ET
I l s l s G Y H P --------------------- ET
:d r s s  t B 3  D
jDEVSi 
:D E A S| Tj
Ie f i t I l i
S S V T l
s s q t I/
p y
fN Q V G IG G R S-------V w
In --------------------------- q .
J N --------------------------- Q




|q n s y -------------------------s I k v H q e -
Ik r a y -------------------------t S e t B l d -
In I g W-------------------------Sj STgjjN G -
Jn | a w -------------------------t | s t  |t g -
|n | s w -------------------------m I s t B v g -
In I a W-------------------------s i s T g g T G -
------------------------- S s .S T .;"CTG-
jN iT W -------------------------C | G T | T G-
L - ' m w ------------------------ s | s A g -
Il J s w ------------------------ s I r t a ^ l a -
L|SW ------------------------ s | r T A | L A -
Q|SW------------------------ s i;R T  M V A -
Ss I m f ------------------------ d ''; v n I f e t -
J M F ------------------------ D ‘V n I f E T -
jSlCMF------------------------ D |v N | F E T -
s | m f g e i t l v l v i - i s t d / v n ; f e v -
s I m f ------------------------ d It n I f e v -
s | m f ------------------------ d ';;IN |FEV-
|t | l Y ------------------------ s| vN -/FEV -
Jt | l y ------------------------ s | v n | f e v -
Jt a l y ------------------------ d I t n I f d t -
It a l y ------------------------ d I s n I f e s -
t a l y ------------------------ d I t n I f e s -
jS S S Y ------------------------ d 1 v n | f ET-







































S | Y L --------- I T K - SS V T |a |
K g Q i---------I T K - SSQN a  J
# 1 ---------S T K -
k3 r | ---------I T R - P
SSQS






r | k § ---------V T K - S S V T
k S r I ---------I T K - S S V T
K g R g ---------I T K - S S V T
N | K § ---------S T K - SSQ T VII1
G T -------------- ------------ a h s ;
KD -------------- ------------ q | s |
lA L -
K f lK i -------- N f K - g
m m -------- V T K -g
# 1 -------- t t r - |
k I a i j -------- t t r -|
k | a | --------T T R - j
k | a | -------- t t r -1
K | A j--------T T R  |
K A --------T T R - j
k | a | --------T T K - 1
K A ' --------T T K -|
J e B --------T T R - I ^
K § S § --------T T K -
K : : --------t t k -
k | n 1 --------T T  s
i— r t k " B
------ R T K — ■ "
j--------R T K -
j--------R T K -
j — RTK~I0
K | t |-------- R T R - ' I
k | t | --------R T R -
k S t | --------R T R -
K p l j --------R T R -
k I r I --------L T K -
K 1R & ------
K jR g -  
K R A  
K  R - 
K R 1- 
Kg R -
SSQ Tj
B H s s q t I 
Q H | n s n - | s B  
n s x - v s  
b M n s n - I s
Ilf
N SN - S 
N SN - S 
N S N - S 
X S N - S 
j N S N - ls  
N SX -: S 
. N AN - X
Jn s s - | n
X S X -  SI  
jN S N - iS  
N S X - S 
N S N - S 
N S N - S 
X S N -| N
|n t a - | a  I
r
lC f f iN S Q - | V  
N S Q -| V  
X S Q - via 
N S Q - fV
d r v - I r  
drv-Ir 
d r l - I r o  
d r l -  
d k l - I r Owk r  
D K L-S R I
apM BK D --------■ m
f D l f lK D --------
I D « K N -------- SI
The  whole m ultip le sequence alignm ent that had bcenused  to generate the phylogenetic trees continued
n c U B C l/ 1 - 2  
O s U B C l/ 1 - 1  
a t U B C lb / 1 -  
d m U B C l/ 1 -1  
a g U B C l/ 1 - 1  
h s H I P 2 / l - 2  
m m H I P 2 / l-2  
c e U B C lb / 1 -  
P fU B C 1 / 1 - 2  
P y y U B C l/ 1 -  
a g U B C 4 / l - l  
Dm UBC4/ 1 - 1  
C e U B C 4 / l - l  
h s U B E 2 D 2 / l  
m m U B E2D 2/l 
h s U B E 2 D 3 / l  
h s H B U C E l/1 
h s U B E 2 D l/1 
m m U B 2 D 4 / l-  
S C U B C 4 / 1 -1  
S C U B C 5 / 1 -1  
s p U B C 4 / l - l  
A t U B C 4 c / l -  
A t U B C 4 d / l -  
A t U B C 4 b / l -  
O s u b c 4 a / l -  
A t U B C 4 a / l -  
P f U B C 4 / l - l  
h s U B E 2 E l / l  
h s U B E 2 E 3 / l  
m m U B E 2 E 3 / l 
h s B E 2 E 2 / l -  
D m U B C 1 3 b / l 
D m U B C 1 3 c/ l 
d m U B C 1 3 a / l 
A g U B C 1 3 / l-  
h s U B E 2 N / l-  
m m U B E 2 N / l-
c e U B C 1 3 / l -  : i l --------M T K - DKL-1
■ T|KTA»L-
•t I k t a I l -
------------ N
8 d s s k d -------------------------- N
H o f f iK D -------------------------- Q
--------------Qj
--------------E
M K N -------------------------- E
r l l i R S -------------------------- Q I S g A L --------------------
h IdmB r s -------------------------- Q | S iA L
Ir s -------------------------- Q l S l A L
R S -------------------------- Q\~
Ir s --------------------------c p s i A L
Ir s -------------------------- q
Ir s -------------------------- q I
-------------Q
-------------Q|
Id E k D--------------------------Q
-TB R Tjp|L -  
- T S R T ^ L -
-tIr tB l - 
-tIr tB l ----:' vs;-tIrt aI l ----\
Si ■
- T iR T A l l -------!
-S QA
■ s{ QA
-S/Q A  
-S 'Q A  
-S QA
-s IQA
- T iS K W L -
m  RS
[d S k d
S l A L ------------------------ TgiSK jjpL-
s | a L ------------------------ T iS K f e L -m fe
S A A L ------------------------ T 1 SK E L ‘
s ISa l ------------------------ t | s k B l -
1RD-------------------------- Ql Si A L ------------------------- t | s k S l -
K E -------------------------- Q ^ S p A L ------------------------- T | S K S | l -
s I a l ------------------------ t m s k B I l -p i g K E -------------------------- Q|_
IdH k E -------------------------- Q l S i A L -------------------------- T|
-QiS||AL-
iK D ---------------------------q J s  A x ------------------------- Tj
s | a L -------------------------TJ






I s I a L  
Is J a l  





s S a lI
]sj|AL






-Q R Tj 
-q I r t I
,------- S iQ A
J-------S | Q A
j SH QA
i------- s ! q a
l------- s | q a









































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
a t U B C 1 3 a / l  
O s U B C 1 3 / l-  
a t U B C 1 3 c / l  
a t U B C 1 3 b / l  
n c U B C 1 3 / l-  
s p U B C 1 3 / l-  
s c U B C l 3 / 1 -  
P f U B C 1 3 / l-  
h s U B E 2 S / l -  
m m U B E 2 S / l-  
c e U B C la / 1 -  
c e U B C 2 / 1 - 2  
h s U B E 2 A / l-  
m m U B E 2 A / l-  
m m U B E 2 B / l-  
h s U B E 2 B / l-  
a g U B C 2 a / l -  
d m U B C 2 / l- l  
a g U B C 2 b / l-  
O s U B C 2 a / l-  
O s U B C l la / 1  
0 s U B C 2 b / l -  
a t U B C 2 a / l -  
a t U B C 2 b / l -  
a t U B C 2 c / l -  
A t U B C 9 c / l -  
n c U B C 2 / l - l  
s p U B C 2 / l - l  
S C U B C 2 / 1 -1  
p y y U B C 2 a / l  
P f U B C 2 b / l -  
P f U B C 2 a / l -  
P f U B C 2 c / 1 -  
p y y U B C 2 b / l  
s p U B C 9 / l - l  
N c U B C 9 / l - l  
A g U B C 9 a / l-  
d m U B C 9 / l- l  
A g U B C 9 b / l-
K | R | -------- L | K -  '
k S r |?-------- L T K - B
K. R -------- L T K -
m m -------- l t k -
KjgR§|-------- L T K -
Nj|R>{---------L T K -j
K | R j -------- L T K -
K R -------- L T K -
K G Y | -------- L T K -
KGY| -------- L T K - l H
t | J ® -------- I S K -
t J f s — V S K -
m m -------- v s k -
T j R g -------- L S K -
t | r | --------V S K -
t | r k --------VSK-
T||r | --------V!
| r | --------V S R --
T§Ir ||--------V S R - S
t I r K --------V S R - S 11# P  :
’  ----------------------- V S R _im
i U ---------VSR--
II
K D K L -S R H
*  p  I1 d k l - 1 r 0
M D K L - I  
| D K L -| R i  
ijDKL-iRr
I d k l - | r  
Jd r l - I r  
S d k l - | r |
GAN - E  r  
: ;GPN- E
H y a d - I s 
H y A D - B e
| Y A D -| s  
| y a d -  S 
M Y A D - lS
H y a d - | s 1 
S y a d - S g  
1 y a d - 1 g
llj Nt 
Y A P - G
■ u
j -------- L T K -
l K | -------- LTK-
| r | -------- L S
k I r I -------- L S K -;  '




Y S D -S N
KgK| ---------L S K - Y T D -  
■ TX’3 Y P S -KCR ---------T P P -
KC K  /---------V P P - Y P S -
KCR/ --------- E P P - ..... Y ? S -
KCK> ---------E P P - Y PS -  
Y P S -KCKg --------- E P P -
jS | A L ------------------------ Q llR T H  L - -
p f f t L ------------------------ q| rtS L-
|S§A L------------------------ q s r t |m l - -
Js I a l ------------------------ q I r t S l r -
s | a l ------------------------ q | r t | | l -
Js I a l ------------------------ q 1 r t |1|l - -
D M K T ---------------------------N I S i A L ------------------------- Q l R T « L - - -
;D ,KD---------------------------1 ------------------------ Q g R T|ggL-.
------------------------ g m r h K l --
------------------------ g I r h B l --
JSfgAL- 
-D |TAEL- 
- D I T A E L -
S l T Y ------------------------ D iA A l f iT - -
«  18 WM
S | T Y ------------------------ d I a * -
iS g T Y ------------------------ d I s s S I t -
s f lT Y ------------------------ D SSI T --
DfflSSS ! t -
--S  QA 
- S '  .QA
— s | q a  
- s | q a  
— s | q a  
- s | q a
— S QA  
--S  QA


















I q K --------------------------- H
JQ N --------------------------- Q
8QN--------------------------- Q
iQ N --------------------------- Q
N E E E ----------------------- G
Pn e e e
Jd e e k ----------------------- Di Rl A I
I D E E K ------------------------ Dl Ri A I --------------------
D EQ K------------------------c S f^ A I
D j S S j J  
dhsaB t-- 
D SA
D p S A  QT--
dSaaBIt- -■ .
D g A A B S T --
f -
ESI
S I I Y -------------------------d i t s w t -M mm®
S l l Y ---------------------- DHTS|J|T—  
:  KQ L - -
I
T K Q j g L -














































E E D K -----------------------D|
E E D K -----------------------D i R l A I
E E D K -----------------
INEDE-----------------
N E D S -----------------------G| RHA I
N E D S -----------------------g I r I a I■ Hi
N ED Y -----------------------Gi R| A I
S _ _ T -----------------------a B k I s i
INEDQ-----------------------D|
H T P G E D L M S -G E Q A S E  
H T P G E D L M S -G E Q A S E  
H Q S G -D P M T -D E P D A E T
The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
c e U B C 9 / l - l  
m m U B E 2 l/ l-  
h s U B E 2 l / l -  
h s Q 9 B Q 2 5 / l  
P f U B C 9 / l - l  
O s u b c 9 a / l -  
O s U B C 9 b / l-  
A t U B C 9 b / l -  
O s U B C 9 c / l-  
s c U B C 9 / l - l  
n c U B C 3 a / l-  
n c U B C 3 b / l-  
S C U B C 3 / 1 -2  
d m U B C 3 a / l-  
D m U B C 3 b / l-  
h s C D C 3 4 / l-  
in m C D C 3 4 / l-  
h s U B E 2 R 2 /1 
m m UBC3/1 -2  
m m UBE2R2/1 
C e U B C 3 / l- 3  
s p U B C 7 a / l-  
n c U B C 7 / l - l  
D m U B C 7 a / l-  
D m U B C 7 c / l-  
A g U B C 7 a / l-  
h s 2 G 2 _ v l/ l  
m inU B E2G 2/l 
h s U 2 G 2 _ v 2 / 
C e U B C 7 a / l-  
S C U B C 7 / 1 -1  
A g U B C 7 b / l-  
d m U B C 7 d / l-  
h s 2 G l / l - 1 7  
D m U B C 7 b / l-  
C e U B C 7 b / l-  
s p U B C 7 b / l-  
A t U B C 7 b / l -  
A t U B C 7 c / l -
K|SI------------- Sll
R i M -------------------------T
— T I _
- —  T IKOp iT , -
- —  T
k q } H i -
k q § | l -
K Q » -
K Q v a -
KQPiPV-
m iv -
H P P V D D P Q S -G E L P C E  
H P P V D D P Q S -G E L P C E  
H P P V D D P Q S -G E L P S E R 1 N  
H P P V D D P Q S -G E L P S E R | N  
H P P V D D P Q S -G E L P S E R 1 N  
| S ^ H P P V D D P Q S -G E L P S E R | N  
: "SH P P V D D P Q S -G E L P S E R 1 N  
H S P ID D P Q S -G E L A C E  
H A P G D D P N M -Y E SSS E  
;H P PG D D PN H -YETASE  
H A P G D D P M G -Y ELS A E  
H A P G D D P M G -Y ELSA E  
H A P G D D P L G -Y E L S A E  
H A P G D D P M G -Y ES SA E  
IH H A P G D D P M G -Y E S S A E  
H A P G D D P H G -LR EQ P E  
H A P G D D P T G -Y E LS N E  
H S P G D D P N M -Y E LA E E  
H EPG D D K W G -Y EK ASE  
H EPG D D K W G -Y EK ASE  
H E P G E D K Y G -Y E K P E E  
SHEPGDDKW G-YEKAEE  
H D PG D D K W G -YERPEE  
H P P G D D K Y G -Y E D A G E  
H P P G D D P S G -Y E L A S E  
H P P G D D P S G -Y E L A S E
------------ GAESi
------------ GAES
-------------------------T i E S |
------------------------- N p R T g L -
T Q ------------------------n S r T W L -
T Q ------------------------N Rt H l -
T Q ------------------------n ||Rt H l -




- J f i s  
- s i  i s  
- s f c s  -m is  
-s A
-s ,;MS 













































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
a t U B C 7 e / l -  
O s U B C 7 / l - l  
A t U B C 7 a / l -  
A t U B C 7 d / l -  
P f U B C 7 / l - l  
s c U B C l l / 1 -  
s p U B C l l / 1 -  
d m U B C ll/ 1 -  
a g U B C l la / 1  
h s U B E 2 C / l-  
n u n U b e2 c/1 -  
a t U B C l l b / 1  
a t U B C l l d / 1  
a t U B C l l c / 1  
a t U B C l l a / 1  
O s U B C l lb / 1  
P y y U B C 1 0 / l  
P f U B C 1 0 / l-  
A t U B C la / 1 -  
s p U B C la / 1 -  
S C U B C 1 0 / 1 -  
n c U B C 1 0 / l-  
s p U B C 1 2 / l-  
n c U B C 1 2 / l-  
d m U B C 1 2 / l-  
a g U B C 1 2 / l-  
h s U B E 2 M / l-  
m m U b e2 m /l-  
a t U B C 1 2 a / l  
a t U B C 1 2 b / l  
0 s U B C 1 2 / l-  
S c U B C 1 2 / l-  
P f U B C 1 2 / l -  
h s U B E 2 L 3 / l  
h s U B E 2 L 6 / l  
h s T S G 1 0 1 / l  
ira n T S G lO l/ 1  
n c U B C 6 a / l-  
n c U B C 6 b / l-
|--------- T S D -
lA --------- T S E -J
|t | ----------T S E -]
Ir I --------- T S D -
Q |k| --------- T Q E -
i p  — L S P i  




m --------- L T S - C
---ITP-Cjl
t|k§---- l t p -cM d t q-
■  m ft
k : K . --------- E T C _ C |
k | k § -------- E T C  -  c f e lM S D V Y - i
---------1
k ‘ K ;,-------- E T C - C iim g g jD V Y -
R -------- r.TF-c;.
V 7 :>-------- j T K -  N F T T
T -------- V T K - F  ■ N EVTj
Q i R i ----------L T K - Bs ™  m
------ MQNN|
(g -------- I T P -
p C -------- L N K -
|QC-------- R E K -
p C -------- A T Q -
 ̂J c -------- E T Q -
|C-------- E T M -
CC-------- E T M -
CC-------- K T K -
CC-------- K T K -
CC-------- K T K -
--------- L K K -j
1IC-------- L S K -
------ KTK-SM M  1
M |K|--------T T K - j
IC F V K P T S S M T IK T G K H V D A N --J
IC F V K P T S S M T IK T G K H V D A N — §§K
AgRM --------H T P ------ S G R F T P S -S R
S F R i --------V T P ------ S G R F E A N -R E
H P P G D D P S G -Y E L A S E
h p p g d d p n g - y e l a s e : 
I h p p g d d p h g - y e l a s e : 
h p p g d d p s g - y e l a s e :












Jt ; V H -------------------------T 1 E S ^
St I v H-------------------------T I E S
j l i V H -------------------------T j|ES
Jr § IW -------------------------S EG
js A V Y -------------------------N1 E T
9SAVY-------------------------N QT
jS A L Y -------------------------D |RT
jS A L Y -------------------------D|Jr T
8S A L Y -------------------------D IRT1
MSALY------------------------ D
BSSAY-------------------------DjjRT
js S A Y ------------------------ D |RT
SSSAY------------------------ D IR T
SSSAY------------------------ D ;RT
9SSAY------------------------ DgRT
!s ||a w ------------------------ T
L -------S | I S
L -------s l i s
|l -------s | i s
I  ------------s' i s
v -------s i  'IS
|l ------ s i  QS
L ------ SgjQS
II ------------S pQS
L ------ S. QS
I ------ s I q s
|l ------ s | q s
(I------ S QS
| ------ s | q s
L ------ S|Q S
|L------ S QS
L ------ S QS
SAW-
Ia w - 
JT JVW- 
It S a y -
------------------- Na N
------------------- p i p s
g iS v L -------------------------T| NS
7L------------------------- T IN S
rL ------------------------- T IN S
rL ------------------------- N |N T
-------------------N| NT
S vL------------------------- N |N T
jS A L ------------------------- D I QS




HD----------------------------- IK H P R -
S D F H P --------------------- KS|








































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
h s U B E 2 V 2 / l  
m m UBE2V2/1 
h s U B E 2 V l/1 
s c M M S 2 / l- l  
s c U B C 6 / l- 2  
C e U B C 6 a / l-  
s p U B C 6 / 1 -2  
h s 2 J 2 _ V l / l  
mmU2j 2 / 1 - 2  
h s 2 J 2 _ V 2 / 1  
D m U B C 6 / l-2  
A g U B C 6 / 1 -2  
A t U B C 6 a / l -  
A t U B C 6 b / l -  
C e U B C 6 b / l-  
h s B E 2 J l / l -  
m m U b e 2 j1/1  
C e U B C 6 c / l-  
C e U B C 6 d / l-  
A t U B C 6 c / l -  
A t U B C 8 a / l -  
A t U B C 8 b / l -  
A t U B C 8 c / l -  
O S U B C 8 / 1 -1  
s p U B C 8 / l - l  
n c U B C 8 / l - l  
s c U B C 8 / l- 2  
P f U B C 8 / l - l  
P y y U B C 8 / 1 -  
C e U B C 8 a / l-  
C e U B C 8 b / l-  
D m U B C 8 a / l-  
a g U B C 8 / l - l  
h s U B E 2 H / l-  
D m U B C 8 b / l-  
s c U B C l/ 1 - 2  
s p U B C lb / 1 -  
n c U B C l/ 1 - 2
| t ,
' : ■:
iS K E | M K L | Q P P E G Q T Y
J s k e | m k l J q p p e g q t y  
P S k e I m k l I q p p e g q c y  
a t p a | k k l r q p k e g e t f
T S D -E A T T G S I T T S D H Q  
N D N -Q P T L G S L V T S E S E  
T S D - E I T T G G I V T S E S T  
E K - G P T L G S I E T S D F T  
E K - G P T L G S I E T S D F T  
E K - G P T L G S I E T S D F T  
E S - T P T L G S I E S S N Y D  
E S -T P T M G S C E T T P A E  
D N -S P T T G S V N T S V A E  
ID T -S P T T G S V N T T V IE  
N E N -S P A A G S IA G T P Q D  
P T K G E G A IG S L D Y T P E E  
P T K G E G A IG S L D Y T P E E  
G G A L G S L D Y P P K E  
G G A L G S L D Y P P K E  
G A LG SV D Y P K D E
|p s d | l n g e a a a l  
p s d I l n g e a a a l  
p s d I l n g e a a a l  
p s d I l n g e a a a l  
s d I l n g e a a a l  
p t d I l n g e a a a m  
g s d I l n n e a a t l  
p s d I l n s d a a s l  
p s d I l n s d a a s l  
d I l I g e a a r l  
d I l n g e a a r l  
p v d | l n r d a |a l
PVDjlLNGDAAAM  
PID gLN G D AA AM  
P H D SLN H R A AA I
|q s |:Ep n d | q d a e v a q h  
c t I e p s n  q d a q v a q v








































The whole multiple sequence alignment that had been used to generate the phylogenetic trees continued
O s U B C l/ 1 - 1  
a t U B C lb / 1 -  
d m U B C l/ 1 -1  
a g U B C l/ 1 - 1  
h s H I P 2 / l - 2  
m m H I P 2 / l-2  
c e U B C lb / 1 -  
P f U B C l/ 1 - 2  
P y y U B C l/ 1 -  
a g U B C 4 / l - l  
Dm UBC4/ 1 - 1  
C e U B C 4 / l - l  
h s U B E 2 D 2 / l  
m m U B E2D 2/l 
h s U B E 2 D 3 / l  
h s H B U C E l/1 
h s U B E 2 D l/1 
m m U B 2 D 4 / l-  
S C U B C 4 / 1 -1  
S C U B C 5 / 1 -1  
s p U B C 4 / l - l  
A tU B C 4  c / 1 -  
A t U B C 4 d / l -  
A t U B C 4 b / l -  
0 s u b c 4 a / l -  
A t U B C 4 a / l -  
P f U B C 4 / l - l  
h s U B E 2 E l / l  
h s U B E 2 E 3 / l  
m m U B E 2 E 3 / l 
h s B E 2 E 2 / l -  
D m U B C 1 3 b / l 
D m U B C 1 3 c / l 
d m U B C 1 3 a / l 
A g ( J B C 1 3 / l-  
h s U B E 2 N / l-  
m m U B E 2 N / l-  
c e U B C 1 3 / l -  
a t U B C 1 3 a / l
s a | a p  d d | q DAVVAQQ  
Is a H e p k d J ’q d a v v a e q  
e p d d I q d a v v a y q
E P D DSQ D AVVAT Q 
EPDDj q d a v v a n q  
e p d d S q d a v v a n q
C T iE P K D ;Q D A V V A K Q  
S D jQ P  D d | q DAEVAKM
s d | q p d d | q d a e v a k m
•cdS pddI l v p e ia r i
c d B p d d I l v p e i a r i  
p d d I l v p e i a r i  
p d d B l v p e i a r i
jP D D iL V P E I A R I
p d d I l v p e i a r i  
p d d I l v p e i a h t
iP D D | L V P D IA Q !  
PD D |LVPEIAQ :I: 
PDD' 'L V P E I A H I
p d d ; l v p e i a q i  
Ip d d L'l v p e i a h v  
p d d I l v p e i a h m
iP D D | LV P E IA H M  
p d d S l v p e i a h I  
|p d d | l v p e i a h m
P D D | L V P E IB H |
d d I l v p e i a h v  
1t d c | p a d | l v g s i a t q  
t d c | p a d | l v g s i a t q  
t d c B p a d H l v g s i a t q  
t d c I p a d I l v g s i a t q
,PDD:.,;:LA N D V A E L
"p d d I l a n d v a e l  
Jp Dd I l A N D V A E L
i p d d I l a n d v a e l  
Ip d d I l a n d v a e q  
’ p d d  l a n d v a e q  
j p e d I l a t d v a e q  










It  d | 
t d |
lTD 
















































































!n e  
!n h
jPD D g'LSD N IAKH
p̂ d o I l s e n i a k h  
;p d d | l s e n i a k h  
|PD d I l A P DVAKT
p d d I l d n d v a k i
:PND gLAN D VAED  
lE P D D g LD SK V A EH  
IjPESA LN EEAG R L  
IP ESA LN EE A G R L
T h e  whole m ultip le sequence alignm ent that had been used to generate the phylogenetic trees continued
O s U B C 1 3 / l-  
a t U B C 1 3 c / l  
a t U B C 1 3 b / l  
n c U B C 1 3 / l-  
s p U B C 1 3 / l-  
S C U B C 1 3 / 1 -  
P fU B C 1 3 / 1 -  
h s U B E 2 S / l-  
im n U B E 2 S / l-  
c e U B C la / 1 -  
c e U B C 2 / l - 2  
h s U B E 2 A / l-  
m m U B E 2 A / l-  
m m U B E 2 B / l-  
h s U B E 2 B / l-  
a g U B C 2 a / l-  
d m U B C 2 / l- l  
a g U B C 2 b / l-  
O s U B C 2 a / l-  
O s U B C l la / 1  
O s U B C 2 b / l-  
a t U B C 2 a / l -  
a t U B C 2 b / l -  
a t U B C 2 c / l -  
A t U B C 9 c / l -  
n c U B C 2 / l - l  
s p U B C 2 / l - l  
s c U B C 2 / l - l  
p y y U B C 2 a / l  
P f U B C 2 b / l-  
P f  U B C 2 a / l-  
P f U B C 2 c / l -  
p y y U B C 2 b / l  
s p U B C 9 / l - l  
N C U B C 9 / 1 -1  
A g U B C 9 a / l-  
d m U B C 9 / l- l  
A g U B C 9 b / l-  


















|n a s |





It a s I
I1 AS! 
PES  









































































The whole m ultip le sequence alignm ent that had been used to generate the phylogenetic trees continued
m m U B E 2 I / l- ;'-;,NE IQ D p A Q A E A Y T I  : 96
h s U B E 2 I / 1 - W N E 1 I Q D iA Q A E A Y T I  : 96
h s Q 9 B Q 2 5 / l B n e IQ D | A Q A E A Y T I  : 96
P fU B C 9 / 1 - 1 B dn PN s I a Q A E P F L L  : 96
0 s u b c 9 a / 1 - ■ d q W P A d | a Q TD G YH I : 96
0 s U B C 9 b / l - PA D |AQ TD G YH L : 96
A t U B C 9 b / l - P DT PAD |AQ TD G YH L : 96
0 s U B C 9 c / l - I f DD P N S A A Q N IS Y E L 94
S C U B C 9 / 1 -1 ! ds |I||P N S iA Q EP A W R S 96
n c U B C 3 a / l- S d d |e i n s | a n v d a g v m 108
n c U B C 3 b / l- ■ D D I e i n s B a n v d a g v m 108
s c U B C 3 / l- 2 B e d i n s I a n v c a a v d 107
d m U B C 3 a / l- S n e t f s I a I v d a s v I 107
D m U B C 3 b / l- S n e
. . . . . . .
TFS" AN VD ASVM 107
h s C D C 3 4 / l- S n e t f s I a n v d a s v m 107
m m C D C 3 4 / l- S I n e t f s S a n v d a s v m 107
h s U B E 2 R 2 / l B n e t f s ; a n v d a s v m 107
m m U B C 3 / l-2 S ne t f s I a n v d a s v m 107
m m UBE2R2/1 B n e t f s I a n v d a s v m 107
C e U B C 3 / 1 -3 H n e i| ||TSSgA N V D A SV M 107
s p U B C 7 a / l- H a e D ESG AN ID ACKM 107
n c U B C 7 / l - l B a e 1 d e s | a n v e a a k m 107
D m U B C 7 a / l- H a e D ESG AN VD AAIM 107
D m U B C 7 c / l- H a e 'D ESG AN VD AAIM 107
A g U B C 7 a / l- H a e • : D ESG AN VD AAIM 107
h s 2 G 2  v l / 1 .: Ia e I f DESGANVDASKM 107
m m U B E2G 2/l H a e DESGANVDASKM 107
h sU 2 G 2  v 2 / H a e DESGANVDASKM 107
C e U B C 7 a / l- B a e d e s | a n v s a a k m 107
S C U B C 7 / 1 -1 B s e I E S G A N I D A C I L 107
A g U B C 7 b / l- IIIa d d e s I a n v d a a k e 107
d m U B C 7 d / l- S a d 1!d e s | a n v d a a k e 107
h s 2 G l / l - 1 7 S ad ffG D SgAN VD AAK E 107
D m U B C 7 b / l- S td D ESAA N VD A AK E 107
C e U B C 7 b / l- H td f e s I a n v d a a k m 107
s p U B C 7 b / l- I s s DES ^ANIDAAKE 107
A t U B C 7 b / l - fflsG DES A N V EA A K E 107
A t U B C 7 c / l - S s G litd e s I a n v e a a k e 107
a t U B C 7 e / l - I S G •D E S g A N V E A A K E 107
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C R Y S T A L L O G R A P H Y
All the crystallization conditions used: (Salts and Buffers); its corresponding precipitants are illustrated in the later pages as it was not 
possible to fit in all together.
Table 18.2
Hampton Research Crystal Screen formulation - Copyright 2001
Reagent [Salt]number [Salt] units Salt [Buffer] [Buffer] units Buffer pH
1
2
0.02 M calcium chloride dihydrate 0.1 M sodium acetate trihydrate 4.6
3
4 sodium citrate tribasic
0.1 M Tris hydrochloride 8.5
5 0.2 M dihydratemagnesium chloride
0.1 M Hepes sodium 7.5
6 0.2 M hexahydrate 0.1 M Tris hydrochloride 8.5
7 sodium citrate tribasic
0.1 M sodium cacodylate 6.5
8 0.2 M di hydrate 0.1 M sodium cacodylate sodium citrate tribasic
6.5
9 0.2 M ammonium acetate 0.1 M dihydrate 5.6
10 0.2 M ammonium acetate 0.1 M sodium acetate trihydrate sodium citrate tribasic
4.6
11 magnesium chloride 0.1 M di hydrate
5.6
12 0.2 M hexahydrate sodium citrate tribasic
0.1 M Hepes sodium 7.5
13 0.2 M di hydrate 0.1 M Tris hydrochloride 8.5
14 0.2 M calcium chloride dihydrate 0.1 M Hepes sodium 7.5
15 0.2 M ammonium sulfate 0.1 M sodium cacodylate 6.5
16 0.1 M Hepes sodium 7.5
17 0.2 M lithium sulfate monohydrate magnesium acetate
0.1 M Tris hydrochloride 8.5
18 0.2 M tetrahydrate 0.1 M sodium cacodylate 6.5
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crystallization conditions continued
Reagent no. Salts salt units salts Buffer
19 0.2 M ammonium acetate 0.1
20 0.2 M ammonium sulfate 
magnesium acetate
0.1
21 0.2 M tetrahydrate 0.1
22 0.2 M sodium acetate trihydrate 
magnesium chloride
0.1
23 0.2 M hexa hydrate 0.1
24 0.2 M calcium chloride dihydrate 0.1
25 0.1
26 0.2 M ammonium acetate 
sodium citrate tribasic
0.1
27 0.2 M dihydrate 0.1
28 0.2 M sodium acetate trihydrate 0.1
29 0.1
30 0.2 M ammonium sulfate











42 0.05 M potassium phosphate monobasic
43
44
Buffer units Buffer pH
M Tris hydrochloride 8.5
M Sodium acetate trihydrate 4.6
M sodium cacodylate 6.5
M Tris hydrochloride 8.5
M Hepes sodium 7.5
M Sodium acetate trihydrate 4.6
M imidazolesodium citrate tribasic
6.5
M dihydrate 5.6
M Hepes sodium 7.5
M sodium cacodylate 6.5
M Hepes sodium 7.5
M sodium acetate trihydrate 4.6
M Hepes sodium 7.5
M Tris hydrochloride 8.5
M sodium acetate trihydrate 4.6
M Hepes sodium 7.5




M Hepes sodium 7.5
crystallization conditions continued:
Reagent no. Salts salt units salts Buffer Buffer units Buffer pH
45 0.2 M zinc acetate dihydrate
46 0.2 M calcium acetate hydrate
47
48
49 1 M lithium sulfate monohydrate
50 0.5 M lithium sulfate monohydrate
crystallization conditions used: (Precipitants)
0.1 M sodium cacodylate 6.5
0.1 M sodium cacodylate 6.5
0.1. M sodium acetate trihydrate 4.6
0.1 M Tris hydrochloride 8.5
Reagent no. [Precipitant 11 [Precipitant 11 units Precipitant 1 [Ppt 2] [Ppt 2] units Ppt 2
1 30 %v/v 2-methyl-2,4-pentanediol
2 0.4 M potassium sodium tartrate tetrahydrate
3 0.4 M ammonium phosphate monobasic
4 2 M ammonium sulfate
5 30 %v/v 2-methyl-2,4-pentanediol
6 30 %w/v polyethylene glycol 4000
7 1.4 M sodium acetate trihydrate
8 30 %v/v iso-propanol
9 30 %w/v polyethylene glycol 4000
10 30 %w/v polyethylene glycol 4000
11 1 M ammonium phosphate monobasic
12 30 %v/v iso-propanol
13 30 %v/v polyethylene glycol 400
14 28 %v/v polyethylene glycol 400
15 30 %w/v polyethylene glycol 8000
16 1.5 M lithium sulfate monohydrate
17 30 %w/v polyethylene glycol 4000
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crystallization conditions used: (Precipitants)
Reagent # [Precipitant 1] [Precipitant 1] units Precipitant 1 [Precipitant 2] [Ppt 2] units Precipitant 2
18 20 %w/v polyethylene glycol 8000
19 30 %v/v iso-propanol
20 25 %w/v polyethylene glycol 4000
21 30 %v/v 2-methyl-2,4-pentanediol
22 30 %w/v polyethylene glycol 4000
23 30 %v/v polyethylene glycol 400
24 20 %v/v iso-propanol
25 1 M sodium acetate trihydrate
26 30 %v/v 2-methyl-2,4-pentanediol
27 20 %v/v iso-propanol
28 30 %w/v polyethylene glycol 8000
29 0.8 M
30 30 %w/v polyethylene glycol 8000
31 30 %w/v polyethylene glycol 4000
32 2 M ammonium sulfate
33 4 M sodium formate
34 2 M sodium formate
35
0.8 M
sodium phosphate monobasic monohydrate 0.8 M
Potassium phosphate monobasic
36 8 %w/v polyethylene glycol 8000
37 8 %w/v polyethylene glycol 4000
38 1.4 M sodium citrate tribasic dihydrate
39 2 %v/v polyethylene glycol 400 2 M Ammonium sulfate
40 20 %v/v iso-propanol 20 %w/v Polyethylene glycol 4000
41 10 %v/v iso-propanol 20 %w/v Polyethylene glycol 4000
42 20 %w/v polyethylene glycol 8000
43 30 %w/v polyethylene glycol 1500
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